The role of apoptosis in <i>in vitro</i> and <i>in vivo</i> models of amyotrophic lateral sclerosis by Bigini, Paolo
Open Research Online
The Open University’s repository of research publications
and other research outputs
The role of apoptosis in in vitro and in vivo models of
amyotrophic lateral sclerosis
Thesis
How to cite:
Bigini, Paolo (2005). The role of apoptosis in in vitro and in vivo models of amyotrophic lateral sclerosis.
PhD thesis The Open University.
For guidance on citations see FAQs.
c© 2005 The Author
Version: Version of Record
Copyright and Moral Rights for the articles on this site are retained by the individual authors and/or other copyright
owners. For more information on Open Research Online’s data policy on reuse of materials please consult the policies
page.
oro.open.ac.uk
LJ 2C°, 
THE ROLE OF APOPTOSIS IN in vitro AND in vivo 
MODELS OF AMYOTROPHIC LATERAL 
SCLEROSIS 
Paolo Bigini 
+ 
, ýý ". 
Thesis submitted for the degree of Doctor of Philosophy 
The.. Open. 'University 
Laboratory of Receptor Pharmacology 
Department of Biochemistry and Molecular 
Pharmacology 
Mario Negri Institute for Pharmacological Research 
Milano, Italy 
September 30th, 2004 
a, ý`ý-tsrr, > Jr 
J70 
/64 
, qu, ", ýz , _L : 1A +3 o2 cE? 
c1 si r-2Q4 
ei) (), lt; 3I 005 
1 
02909 
1 
VIII I11IIVNIIII14IDNIIIIIIýIINý LIST OF CONTENTS 
ACKNOWLEDGMENTS Pag. 10 
COLLABORATIONS Pag. 12 
ABSTRACT Pag. 14 
LIST OF TABLES AND FIGURES Pag. 16 
LIST OF ABBREVIATIONS Pag. 23 
CHAPTER 1 HUMAN AMYOTROPHIC LATERAL SCLEROSIS 
1.1 Clinical hallmarks: symptoms and diagnosis Pag. 31 
1.1.1 Epidemiology (incidence, prevalence, onset) Pag. 31 
1.1.2 Symptoms Pag. 33 
1.1.3 Diagnosis Pag. 35 
1.1.3.1 Clinical criteria Pag. 35 
1.1.3.2 Neuropathological and hystopathologycal criteria Pag. 36 
1.2 Neuropathological and hystopathological alterations Pag. 37 
1.2.1 Upper motor neurons and corticospinal tract Pag. 37 
1.2.2 Lower motor neurons Pag. 37 
1.2.2.1 Neurofilament alterations Pag. 38 
1.2.2.2 Intracellular inclusions Pag. 39 
1.2.2.3 Mitochondrial alterations Pag. 40 
1.2.2.4 Axonal alterations Pag. 40 
1.3 Aetiopathological hypotheses Pag. 41 
1.3.1 Genetic involvement Pag. 41 
1.3.1.1 fALS1 (SOD1) Pag. 41 
1.3.1.2 fALS2 (ALSIN) Pag. 42 
1.3.2 Glutamate-induced excitotoxicity Pag. 43 
1.3.3 Oxidative stress and mitochondrial abnormalities Pag. 46 
1.3.4 Neurofilaments disorganization and axonal strangulation Pag. 48 
1.3.5 Intracellular aggregates and/or failure of protein folding Pag. 48 
1 
1.3.6 Reactivegliosis-inducedneuroinflammation Pag. 49 
1.4 Pharmacotherapy Pag. 53 
1.4.1 ALS and clinical trials Pag. 53 
1.4.2 Antiexcitotoxic drugs Pag. 56 
1.4.2.1 Riluzole Pag. 56 
1.4.2.2 Dextromethorphan and L-threonine Pag. 57 
1.4.2.3 Ca channels blockers Pag. 57 
1.4.3 Neurotrophic factors Pag. 58 
1.4.3.1 BDNF Pag. 59 
1.4.3.2 CNTF Pag. 60 
1.4.3.3 TRH Pag. 61 
1.4.3.4 IGF-1 Pag. 62 
CHAPTER 2 APOPTOSIS IN NEURONS 
2.1 Principles of neuronal death in embryonic and adult brain Pag. 63 
2.1.1 Morphological changes in neuronal apoptosis Pag. 64 
2.2 Molecular mechanisms of neuronal apoptosis Pag. 67 
2.2.1 Extrinsic pathway Pag. 70 
2.2.1.1 Death receptors Pag. 70 
2.2.2 intrinsic pathway Pag. 72 
2.2.2.1 Neurotrophic factors withdrawal Pag. 72 
2.2.2.2 Ca overloading Pag. 73 
2.2.3 Antiapoptotic and proaptotic molecules Pag. 75 
2.2.4 The role of mitochondria Pag. 76 
2.2.4.1 Mitochondrial membrane potential Pag. 76 
2.2.4.2 The permeability transition pore Pag. 77 
2.2.4.3 Cytochrome-c release Pag. 78 
2.2.4.4 Apoptosis-initiating factors Pag. 78 
2.2.5 Caspases Pag. 80 
2.2.6 Caspases substrates Pag. 82 
2.2.6.1 Nuclear substrates Pag. 82 
2.2.6.2 Cytoskeletal substrates Pag. 83 
2.3 Apoptosis and neurodegenerative diseases Pag. 85 
2.3.1 Positive evidence Pag. 85 
2 
2.3.2 Controversial evidence Pag. 86 
2.3.3 ALS and apoptosis Pag. 87 
2.4 Neuroprotective and anti-apoptotic effects of erythropoietin Pag. 90 
2.4.1 EPO and erythropoyesis Pag. 90 
2.4.2 EPO and neuroprotection Pag. 91 
CHAPTER 3 In vitro AND in vivo models of ALS: 
ADVANTAGES AND PITFALLS 
3.1 Cellular models Pag. 93 
3.2 Animal models Pag. 94 
3.2.1 mnd mouse Pag. 95 
3.2.2 pmn mouse Pag. 96 
3.2.3 Wasted mouse Pag. 96 
3.2.4 SOD1 transgenic mouse Pag. 97 
3.2.5 Wobbler mouse Pag. 97 
CHAPTER 4 PRIMARY CULTURES OF MOTOR NEURONS 
4.1 Purified and mixed cultures Pag. 100 
4.1.1 Purified cultures of motor neurons Pag. 100 
4.1.2 Mixed glia/neurons cultures Pag. 101 
4.2 Primary cultures of motor neurons and ALS-associated toxicity Pag. 101 
4.2.1 Cu/Zn SOD1 mutation and Fas-L activation Pag. 101 
4.2.2 Glutamate-induced excitotoxicity Pag. 103 
4.2.2.1 AMPA and Kainate overstimulation Pag. 103 
4.2.2.2 Ca influx and the role of GluR 2 subunit Pag. 104 
4.2.2.3 The role of astrocytes Pag. 106 
4.2.3 Free radicals exposure Pag. 108 
4.2.4 Mitochondrial inhibition Pag. 109 
4.2.5 Proteasome inhibition pag. 109 
4.2.6 Neurotrophic factors withdrawal Pag. 111 
4.2.6.1 BDNF Pag. 111 
4.2.6.2 CNTF Pag. 112 
3 
CHAPTER 5 THE WOBBLER MOUSE 
5.1 Genetic Pag. 113 
5.2 Symptoms Pag. 114 
5.3 Neuropathological and hystopathological alterations Pag. 117 
5.3.1 Motor neurons Pag. 117 
5.3.1.1 Hystometry and histology Pag. 117 
5.3.1.2 Cytology Pag. 119 
5.3.2 Axons Pag. 120 
5.3.3 Muscles Pag. 121 
5.4 Aetiopathological markers Pag. 122 
5.4.1 Glutamate-induced excitotoxicity Pag. 122 
5.4.2 Oxidative stress Pag. 122 
5.4.3 Mitochondrial abnormalities Pag. 124 
5.4.4 Neurofilaments accumulation Pag. 124 
5.4.5 Intracellular aggregates and/or failure of protein folding Pag. 125 
5.4.6 Reactive gliosis Pag. 127 
5.5 Pharmacological trials Pag. 130 
5.5.1 Growth factors Pag. 130 
5.5.1.1 BDNF and CNTF Pag. 130 
5.5.1.2 IGF-1 Pag. 130 
5.5.1.3 T-588 and cardiotrophin 1 Pag. 131 
5.5.1.4 LIF Pag. 132 
5.5.1.5 IL-6 Pag. 132 
5.5.2 Antiglutamatergic agents Pag. 134 
5.5.3 Mitochondrial agents Pag. 134 
5.5.4 Antioxidants Pag. 135 
5.6 Wobbler and apoptosis Pag. 136 
CHAPTER 6 AIM OF THE STUDY 
CHAPTER 7 MATERIALS 
4 
CHAPTER 8 In vitro EXPERIMENTAL PROCEDURES 
8.1 Primary cultures of motor neurons Pag. 147 
8.1.1 Animals Pag. 147 
8.1.2 Motor neurons cultures Pag. 147 
8.1.3 Pharmacological treatments Pag. 148 
8.2 Immunocytochemistry Pag. 148 
8.2.1 SM132 for non-phosphorylated neurofilaments Pag. 149 
8.2.2 EPOr Pag. 151 
8.2.3 GluR 1-4 Pag. 151 
8.2.4 Active Caspase 3 and Caspase 9 Pag. 153 
8.2.5 Cytochrome-c Pag. 154 
8.3 Hoechst 33258 staining Pag. 154 
8.4 Mito-Tracker staining Pag. 154 
8.5 Propidium Iodide and SYTO 59 staining Pag. 155 
8.6 Mitochondrial trans membrane potential measurement Pag. 155 
8.7 Laser scanning confocal microscopy setting up Pag. 156 
8.8 Statistics Pag. 157 
CHAPTER 9 In vivo EXPERIMENTAL PROCEDURES 
9.1 Genotyping Pag. 158 
9.2 Pharmacological treatments Pag. 159 
9.2.1 EPO treatment Pag. 159 
9.2.2 RPR 119990 treatment Pag. 160 
9.2.3 Riluzole treatment Pag. 161 
9.3 Behavioural scores recording Pag. 162 
9.3.1 Paw and walking abnormality Pag. 162 
9.3.2 Running time Pag. 163 
9.3.3 Grip strength Pag. 163 
9.4 Haematocrit measurement Pag. 163 
9.5 Spinal cord perfusion and slices preparation Pag. 164 
9.6 Immunohystochemistry Pag. 166 
9.6.1 ChAT Pag. 166 
9.6.2 CdI1b Pag. 166 
9.6.3 TNF-a and TNF receptors Pag. 167 
5 
9.6.4 Active caspases 3,7,8 and 9 Pag. 168 
9.6.5 G1uR 1-4 Pag. 169 
9.6.6 BDNF Pag. 170 
9.6.7 EPOr Pag. 171 
9.6.8 Densitometric analysis Pag. 171 
9.7 Hystological staining Pag. 172 
9.7.1 NISSL staining Pag. 172 
9.7.2 In Situ End Labelling (ISEL) colorimetric assay Pag. 173 
9.7.3 Mitochondrial complex I staining Pag. 174 
9.8 Immunoblotting Pag. 175 
9.8.1 AMPA receptor subunits (GluR 1-4) Pag. 175 
9.8.2 Glutamate transporters (GLAST and GLT1) Pag. 176 
9.8.3 Densitometric measurement Pag. 176 
9.9 Glutamate determination in plasma Pag. 176 
9.10 [3H] uptake experiments Pag. 177 
9.11 Mitochondrial activity measurement Pag. 178 
9.11.1 Oxygen consumption rate Pag. 178 
9.11.2 Spectrophotometric assays Pag. 178 
9.12 ChAT activity determination Pag. 179 
9.13 Statistics Pag. 180 
CHAPTER 10 In vitro RESULTS 
10.1 BDNF/serum withdrawal induces apoptosis in primary cultures of 
motor neurons Pag. 182 
10.1.1 Introduction Pag. 182 
10.1.2 Experimental design Pag. 183 
10.1.3 Results Pag. 184 
10.1.4 Discussion Pag. 190 
10.2 Chronic treatments with AMPA and Kainate induce cell death 
in primary cultures of motor neurons by different mechanisms Pag. 192 
10.2.1 Introduction Pag. 192 
10.2.2 Results Pag. 193 
10.2.2.1 AMPAr subunits expression Pag. 193 
10.2.2.2 AMPA and kainate toxicity: time-course Pag. 198 
6 
10.2.2.3 Nuclear fragmentation and membrane permeabilization Pag. 200 
10.2.2.4 Caspases 3-9 activation Pag. 203 
10.2.3 Discussion Pag. 209 
10.3 EPO selectively protects primary cultures of motor neurons from 
apoptosis Pag. 211 
10.3.1 Introduction Pag. 211 
10.3.2 Results Pag. 212 
10.3.2.1 EPO receptor is expressed in embryo rat spinal motor neurons Pag. 212 
10.3.2.2 Serum/BDNF deprivation and EPO Pag. 212 
10.3.2.3 EPO protects motor neurons exposed to kainate but not to AMPA Pag. 217 
10.3.2.4 EPO reduces nuclear fragmentation in kainate treated motor neurons Pag. 218 
10.3.2.5 EPO inhibits caspases 3 and 9 activation in kainate treated 
motor neurons rag. hey 
10.3.3 Discussion Pag. 221 
10.4 EPO exerts its anti-apoptotic effect on primary cultures of motor neurons 
by inhibiting the mitochondrial depolarization produced by kainate treatment Pag. 223 
10.4.1 Introduction Pag. 223 
10.4.2 Results Pag. 224 
10.4.2.1 Cytochrome-c release Pag. 224 
10.4.2.2 Mitochondrial membrane potential Pag. 226 
10.4.2.3 AMPA, kainate and the mitochondrial PTP Pag. 229 
10.4.3 Discussion Pag. 230 
CHAPTER 11 MECHANISMS OF MOTOR NEURON DEATH IN THE 
CERVICAL SPINAL CORD OF WOBBLER MICE 
11.1 Motor neuron loss: time-course in wobbler mice Pag. 233 
11.1.1 Introduction Pag. 233 
11.1.2 Experimental design Pag. 234 
11.1.3 Results Pag. 235 
11.1.3.1 Genotyping Pag. 235 
11.1.3.2 Motor neuron counting Pag. 236 
11.1.4 Discussion Pag. 244 
11.2 Neuroinflammation and apoptosis Pag. 246 
11.2.1 Introduction Pag. 246 
7 
11.2.2 Experimental design Pag. 246 
11.2.3 Results Pag. 247 
11.2.3.1 Microglial staining Pag. 247 
11.2.3.2 TNF-a immunostaining Pag. 249 
11.2.3.3 TNF receptors immunohystochemistry Pag. 251 
11.2.3.4 Active caspase 8 immunohystochemistry Pag. 253 
11.2.4 Discussion Pag. 255 
11.3 Excitotoxicity and wobbler mouse motor neuron disease Pag. 257 
11.3.1 Introduction Pag. 257 
11.3.2 Experimental design Pag. 257 
11.3.3 Results Pag. 258 
11.3.3.1 Glutamate determination in plasma Pag. 258 
11.3.3.2 Glutamate transporters Pag. 258 
11.3.3.3 AMPAr expression and localization Pag. 261 
11.3.4 Discussion Pag. 270 
11.4 Mitochondria and apoptosis Pag. 271 
11.4.1 Introduction Pag. 271 
11.4.2 Experimental design Pag. 271 
11.4.3 Results Pag. 272 
11.4.3.1 Mitochondrial activity Pag. 272 
11.4.3.2 Active caspase 3, -7, -9 immunohystochemistry Pag. 275 
11.4.3.3 ISEL staining Pag. 279 
11.4.4 Discussion Pag. 282 
CHAPTER 12 PHARMACOLOGICAL TREATMENTS 
12.1 EPO fails to arrest neuromuscular impairment and motor 
neurons loss in wobbler mice Pag. 285 
12.1.1 Introduction Pag. 285 
12.1.2 Experimental design Pag. 286 
12.1.3 Results Pag. 287 
12.1.3.1 Behavioural scores Pag. 287 
12.1.3.2 Neuropathological estimation Pag. 291 
12.1.3.3 EPOr immunohystochemistry Pag. 292 
12.1.3.4 Haematocrit measurement Pag. 294 
8 
12.1.4 Discussion Pag. 295 
12.2 Riluzole, unlike the AMPA antagonist RPR119990, reduces 
motor impairment and partially prevents motor neurons death in wobbler mice Pag. 296 
12.2.1 Introduction Pag. 296 
12.2.2 Experimental design Pag. 298 
12.2.3 Results Pag. 299 
12.2.3.1 Behavioural scores Pag. 299 
12.2.3.2 Neuropathological estimation Pag. 307 
12.2.3.3 BDNF immunostaining Pag. 309 
12.2.4 Discussion Pag. 312 
CHAPTER 13 APOPTOSIS AND ALS: A LESSON FROM CELLULAR 
AND ANIMAL MODELS OF MOTOR NEURON DEGENERATION 
13.1 Neurotrophic factors starvation and apoptosis Pag. 319 
13.2 Glutamate-induced excitotoxicity and apoptosis Pag. 323 
13.3 Glial-induced neuroinflammation and apoptosis Pag. 326 
REFERENCES 
9 
ACKNOWLEDGEMENTS 
" First, I would like to acknowledge my head of laboratory and director of studies, 
Tiziana Mennini, for always being a point of reference during the development of 
my thesis. 
I would like to thank my second supervisor, Vincenzo Crunelli, for critically 
reading the manuscript and for giving me advice in the structuring of this thesis. 
91 wish to express my gratitude for the support of the Mario Negri Institute, in 
particular the director Silvio Garattini and my head of Department and director of 
academic activities, Mario Salmona, for giving me the opportunity to do this PhD. 
"I also would like to acknowledge Daniela Curti, Ettore Beghi, Pietro Ghezzi and 
Antonio Migheli for their critical analyses and for their cultural contribution. 
"I wish to thank all my colleagues, in particular Elena Fumagalli and Sara Barbera, 
for their indispensable collaboration, Ilario Mereghetti and Massimo Farina for 
their informatics support and Alfredo Cagnotto, an important point of reference for 
the lab activities. Moreover I would like to thank the "motor neurons' team" 
(Simona, Claudio, Francesca and Massimiliano). Many thanks to Rita Campi for 
statistical advices. 
" I'm grateful to Felice De Ceglie and Alessandro Soave for the graphic assistance. 
"I am very grateful to Noeleen De Angelis and Gary David Odd for 
10 
giving me precious advice in English writing. 
9A special thanks to Massimo Tortarolo, a sparring partner, a source of help and 
calmness and, above all, a dear friend. 
" Many many thanks, once again, to my parents and their powerful PC, which 
allowed me to see the sea and the beach through the window, while I was writing 
this thesis on summer holydays. Next time, I will advice them to buy a lap top! 
" Last, but not least, I wish to express my total and unconditioned gratitude, and not 
only, to Antonella for putting with me over these last stressful months. 
11 
COLLABORATIONS 
The measurement of mitochondrial membrane potential in cultures of motor 
neurons, the evaluation of mitochondrial respiration and mitochondrial enzymes 
activity in mice were performed in collaboration with Prof. Daniela Curti, Dr. 
Giovanna Levandis and Dr. Barbara Santoro, Department of Cellular & Molecular 
Physiological & Pharmacological Sciences, University of Pavia, Italy. 
" The measurement of protein levels of AMPA receptor subunits, G1uR 1-4, in the 
mice cervical spinal cord homogenates were carried out in collaboration with Prof. 
Monica De Luca and Dr. Fabrizio Gardoni, Department of Pharmacological 
Sciences, University of Milan, Italy. 
" In situ end labelling (INSEL) experiments in the mice cervical spinal cord of 
wobbler mice and in cerebellar sections of weaver mice were done in collaboration 
with Prof. Antonio Migheli and Dr. Cristiana Atzori, Department of Anatomy, 
Pharmacology and Forensic Medicine, University of Torino, Italy. 
" The measurement of plasmatic aminoacids levels in mice were performed in 
collaboration with Mr. Antonio Bastone, Laboratory of Biochemistry and Protein 
Chemistry, Department of Biochemistry and Molecular Pharmacology, Mario 
Negri Institute of Milan, Italy. 
12 
The experiments of [3H]glutamate uptake in the mice cervical spinal cord 
homogenates were carried out in collaboration with Dr. Marco Gobbi, Dr. Marcella 
Funicello and Dr. Lorenza Pirona, Unit of Synaptic Transmission, Laboratory of 
Receptor Pharmacology, Department of Biochemistry and Molecular 
Pharmacology, Mario Negri Institute of Milan, Italy. 
13 
ABSTRACT 
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease leading to motor 
neurons death. Although many studies were performed, the aetiology and the features of 
cellular death occurring in ALS are poorly understood, and studies carried out from 
autoptic samples do not allow to clarify early events occurring in ALS. To understand the 
basic mechanisms leading to motor neuronal death in ALS and to detect the different steps 
involved in motor neuron degeneration, alternative models are required. 
The wobbler mouse is one of the most reliable models of human motor neurodegenerative 
diseases. In the wobbler mouse neuromuscular deficits that are related to a selective 
vulnerability of cervical spinal cord motor neurons have an early onset and progress 
rapidly. 
In my project of thesis I first characterized apoptosis in primary cultures of motor neurons 
exposed to detrimental stimuli, and then I evaluated the possible involvement of apoptosis 
in the cervical spinal cord neurons of early symptomatic wobbler mice. 
In primary cultures of motor neurons I found that: I) BDNF deprivation produced apoptotic 
cell death, II) AMPA and kainate induced apoptotic or non apoptotic cell death depending 
on the experimental conditions utilized, III) EPO selectively protected motor neurons 
committed to dye apoptically. 
In wobbler mice I found that: I) mitochondrial activity is reduced but caspase 9-mediated 
apoptosis does not seem involved, II) glutamate induced excitotoxicity does not seem 
involved in motor neuron degeneration, III) markers of neuroinflammation, such as 
activated microglia and TNF-a, appeared highly increased in the cervical region of early 
symptomatic wobbler mice but this process does not seem to induce the activation of 
caspase 8-mediated apoptosis. 
Pharmacological treatments confirmed that an antiglutamatergic agent (RPR 119990) and 
an antiapoptotic agent (EPO) were ineffective, while riluzole showed protective effects. 
14 
Although alternative cell death pathways should be investigated, my study excludes 
apoptosis as the mechanism of death in cervical motor neurons of wobbler mice. 
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CHAPTER 1 
HUMAN AMYOTROPHIC LATERAL SCLEROSIS 
1.1 Clinical hallmarks: symptoms and diagnosis 
1.1.1 Epidemiology (incidence, prevalence, onset) 
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder involving 
primarily motor neurons in the spinal cord, brainstem and cerebral motor cortex and leading to 
denervation, muscular atrophy and paralysis (Fig 1.1 Rowland) [Brooks, 1994]. 
Motor cortex 
Oropharv-ngeal 
muscles 
IN: 71 ý 
Bulbar 
motor 
neurons 
Lumbar 
spinal cord 
Figure 1.1 Pattern of cellular districts that are more affected in ALS. Upper and lower motor 
neurons loss produce a marked denervation and a consequent atrophy of skeletal muscles. Paralysis 
and respiratory failure are the main symptoms that lead to the death of ALS patients 
Limb i 
muscles 
Medulla 
Cervical 
spinal cord 
Thoracic 
spinal cord 
ALS is a progressive disease and the prognosis is negative. The average of survival from 
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symptoms comparison is <5 years. Worst prognoses are associated with a younger age at 
symptoms onset and a limb onset symptoms in contrast to early bulbar dysfunction [Eisen, 
1993; Jablecki, 1989; Strong, 1991]. 
ALS affects between 1.2 and 1.8/ 100,000 individuals [Eisen, 1993; Jablecki, 1989 ; Strong, 1991]. 
This age-dependent disorder is increasing in incidence at a rate, which cannot be accounted for 
by population aging alone. 
Three variants of ALS are generally considered: 1) the Pacific type (often associated with 
dementia); II) the familial form (fALS) (the majority of which are autosomal dominant in 
their inheritance) [Rosen, 1993] and; the sporadic ALS. The disease is sporadic in approximately 
90% of cases [Rowland, 1998]. Familial cases show a typical pattern of autosomal dominant 
inheritance, but only in a few percentage of familial cases (20%) the correlation between the 
pathology to a well known gene mutation is known [Cudkowicz, 1997]. 
Environmental factors are considered of interest as pathological factors of ALS [Chou, 
1992; Arvidson, 1992; Kapaki, 1997]. Unfortunately the identification of such specific triggers is 
very difficult. Anecdotal case reports and retrospective views have indicated trauma, stress or 
environmental exposure as possible factors that lead to motor neuron degeneration [Provinciali, 
1990]. However, a correlation between these factors and the disease remains to be verified. 
A higher incidence of ALS was observed among factory workers, domestic staff, athletes and 
labourers involved in heavy manual work [Bracco, 1979]. Exposure to areas of major chemical 
industry has also been suggested to account for a greater risk for the disease. Chemical agents, such 
as lead, mercury and solvents, seem to increase the level of risk for ALS. However, these studies 
are limited in the number of patients [Abarbanel, 1985 ; Strickland, 1996]. 
Epidemiological studies have suggested an increased rate of ALS cases among workers in the 
plastics industry, people whose have had recent trauma or significant electrical injury [Strong, 
1991] , and among professional Italian footballers [Beretta, 2003 ]. 
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1.1.2 Symptoms 
The clinical onset of ALS is characterized by asymmetrical spread of symptoms that involves 
multiple levels of the neuraxis [Brooks, 1994 ; Munsat, 1988]. Although there is a formal separation 
between sporadic and familial groups, both forms show similar clinical and pathological features 
and seem to share common pathophysiological mechanisms [Andersen, 1997]. 
The low frequency and the late onset of the disease suggests that sporadic ALS may have a 
preclinical phase. During the preclinical phase it is thought that a series of events create a state of 
susceptibility that leads to the development of symptoms. No clear evidence of neuropathological, 
neurophysiological or biochemical markers are as yet available to identify a patient as potentially 
susceptible for ALS before symptom onset [de Carvalho, 2003]. 
During the early symptomatic period there are neuropathological alterations (involving motor 
neuron size, corticospinal tract alteration and motor axonal conduction modification), that are sub- 
pathological changes in ALS. The onset of the clinical phase is revealed by functional changes in 
ALS patients and possible abnormalities in isokinetic muscle tests at time when isometric strength 
is not yet reduced in these patients [de Carvalho, 2003]. 
Symptomatic phase produces a rapid evolution at the same level of neuroaxis, in horizontal 
direction, prior to rostral or caudal spread throughout the neuraxis. In patients with a distinct 
anatomical onset of symptoms, usually the progression of the disease follows a different pattern of 
evolution [Rowland, 1991]. 
The early phase is followed by a symptomatic stage in which sub clinical alterations diffuse from 
focal to more symmetrical generalisation. At this point ALS patients show changes in isokinetic 
strength as well as early changes in isometric strength. During this phase, pathology is usually 
reported to be more severe in regions where ALS had initially started but progressively increases 
even in regions in which the symptoms had spread [Ince, 1998]. 
Nevertheless the clinical involvement of other systems is not considered in ALS diagnosis, recent 
studies have revealed the concomitant presence of unrelated symptoms, including sensory 
dysfunction, autonomic nervous system abnormalities mood alterations and cognitive abnormalities 
[Mulder, 1983; Daube, 2000]. 
Respiratory failure is the most common cause of death in ALS patients. Respiratory deficits are 
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due to the progressive atrophy of respiratory muscles. Very often, in ALS patients, the diaphragm 
appears to be particularly vulnerable to atrophy [Brooks, 1994]. Measurements of forced vital 
capacity are useful to identify early respiratory problems [Borasio, 1997]. Dyspnea at rest is the 
earlier hallmark of respiratory failure. As the respiratory difficulty increases, attacks of sleep apnea 
do not permit to patients to sleep supine. During the development of the disease, when respiratory 
forced activity is completely lost, patients need to use accessory ventilation. Respiratory failure 
finally leads to the death of most ALS patients [Gelanis, 2001]. 
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1.1.3 Diagnosis 
1.1.3.1 Clinical criteria 
The early diagnosis of ALS is based on the recognition of a clinical pattern of symptoms, aided by 
electrophysiological determination [Swash, - 
2000]. The loss of muscular strength has been 
considered as a surrogate marker for the loss of motor neurons. However, the even more pressing 
requests for a universal and precise diagnostic criterion led to a classification in 1990. This 
determination was called "El Escorial" scale. "El Escorial" scale is based on different parameters, 
clinical features that allow distinguishing ALS from other motor neuron diseases. 
The "El Escorial" scale classifies the probability of a patient having ALS, according to the degree 
of clinical certainty in relation to other pathologies, such as multiple sclerosis, cervical myelopathy 
and other similar neuromuscular disorders [Brooks, 1994]. 
The "El Escorial" scale includes four degrees of certainty for the diagnosis of ALS. They can range 
from "clinically definite" to "clinically suspected". The four different levels of certainty are 
reported below. 
-Definite ALS: is defined by upper motor neuron (UMN) and lower motor neurons (LMN) signs 
in bulbar and in two spinal regions, or UMN and LMN signs in three spinal cord regions. 
-Probable ALS: is defined by UMN and LMN signs in at least two regions and UMN signs in a 
region rostral to LMN signs. 
-Possible ALS: is defined by UMN and LMN signs in one region or UMN signs in two or three 
regions. 
-Suspected ALS: is define by UMN and LMN signs in two or three regions. 
Table 1.1 Clinical criteria included in the El Escorial diagnostic scale. 
Although the "El Escorial" scale represents a valid criterion to diagnoses ALS, this approach can 
not evaluate the progression of symptoms. To determine a more efficient protocol to score the 
progression of symptoms, an alternative series of tests (the Amyotrophic Functional Rating Scale 
(ALS FRS)) have been undertaken. The ALS FRS is a ten-item scale with five different scores for 
each item. The total score is obtained by the sum of scores for each single item and increases 
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proportionally to the symptomatological worsening. The evaluation of three bulbar functions 
(speech, salivation and swallowing), one respiratory function (breathing), three upper-extremity 
(handwriting, cutting food and dressing), one truncal function (turning in bed) and two lower- 
extremity (walking and climbing stairs) are included in ALS FRS (ALS CNTF Treatment Study 
group-no authors listed). 
The aim of this scale is: I) to provide an unique, simple, reproducible, sensitive and specific 
protocol to test the possible efficiency of drugs during clinical trials; II) to better characterize and 
separate the evolution of symptoms among the different forms of ALS; III) to define the different 
stages of disease for a population of patients who might have all types of onset. 
1.13.2 Neuropathological and hystopathological criteria 
In 1994 neuropathological analyses were included in the "El Escorial" diagnostic criteria (World 
Federation of Neurology Research Group on Neuromuscular Disease Subcommittee on Motor 
Neuron Disease). The guidelines to make neuropathological diagnoses of ALS are listed below. 
Features that support the diagnosis: 
Selective atrophy of the motor cortex 
Greyness and atrophy of anterior spinal nerve roots compared with normal roots 
Grains of the lateral columns of the spinal cord 
Atrophy of skeletal muscles 
Features that rule out the diagnosis of ALS or suggest the presence of additional disease 
" Plaques of multiple sclerosis 
"A focal cause of myelopathy 
Table 1.2 Neuropathological parameters of diagnosis included in the El Escorial scale 
Because of the inadequacy to confirm a diagnosis of ALS exclusively by gross examination of the 
brain and spinal cord tissues, light and electron microscopy analyses are needed. 
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1.2 Neuropathological and hystopathological alterations in ALS patients 
In the study of neurodegenerative diseases, knowledge of the descriptive neuropathology is 
essential to clarify the clinical pattern of the disease, to differentiate among distinct pathologies 
sharing similar symptoms and to understand if neuropathological observations found in animal 
models are similar to human condition. For this reason a short description of most important 
hysto/cyto-pathological alterations characterizing can be very useful to better understand clinical 
aspects of the disease. 
1.2.1 Upper motor neurons and corticospinal tract 
In the cerebral cortex a marked decrease of large pyramidal motor neurons has been predominantly 
observed in the motor area. However, neuronal abnormalities are not confined in the motor cortex; 
a lesser extent of damage is also reported in the premotor areas, sensory cortex and temporal 
cortex. Quantitative histological studies of cortical motor neurons revealed changes in size with 
shortened and fragmented dendrites. Accumulation of neurofilaments and ubiquinated proteins are 
common before motor neurons death [Kiernan, 1991]. 
Demyelination, due to axonal degeneration of descending large myelinated fibers of cortical motor 
neurons, is a common feature in the corticospinal tract of ALS patients. Moreover, corticospinal 
fibres show a marked axonal swelling and spheroids containing packed neurofilamentous material 
and other cellular debris are found [Chou, 1992]. 
1.2.2 Lower motor neurons 
A marked loss of large anterior horn cells has been observed by Nissl stained cell counting, this 
pattern of lower motor neurons loss in the anterior horn of ALS patients is to be patchy and focal 
[Tsang, 2000]. Quantitative histological studies have shown that large motor neurons are 
selectively involved. In these cells neuronal shrinkage or atrophy precedes neuronal death and also 
involves alterations to axons and dendrites. Loss of Nissl substance (chromatolysis), vacuolization 
and lipofuscin deposits are sometimes detectable in the remaining anterior horn motor neurons 
[Kiernan, 1991]. 
Since spinal motor neurons represent the best- studied and characterized group of motor 
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neurons in ALS, a detailed description of ultrastrutural alterations found in spinal motor neurons is 
reported below. 
1.2.2.1 Neurofilament alterations 
The cytoskeleton plays a pivotal role in several processes of eukaryotic cells. Mitosis, cell motility, 
endocytosis, and the maintenance of cellular shape are allowed to cytoskeletal components. 
Moreover, in neurons, cytoskeletal organisation is fundamental to connecting the cellular body to 
the periphery, axons and dendrites, and to regulating the transport of a large amount of molecules 
by an extensive network of microtubules and filaments [Bloom, 1998]. Neurofilaments are the 
most abundant filamentous component in neurons. They are divided in three different classes, light 
neurofilaments (NF-L) medium neurofilaments (NF-M) and heavy neurofilaments (NF-H) 
depending on their molecular size [Al-Chalabi, 2003]. In healthy motor neurons neurofilaments are 
expressed in the perikarya and are then transported to the periphery in a not-phosphorylated form. 
When neurofilaments reach their targets they are phosphorylated, the phosphorylation is a crucial 
event to the assembly of singles neurofilaments. This mechanism of assembling is essential for the 
extension of axons and to maintain the integrity of neuronal morphology [Shea, 2003]. 
In the recent years a growing body of evidence suggests that various neurodegenerative diseases 
share a similar process in which neurofilaments are phosphorylated and accumulated in the cell 
body of dying neurons [Taylor, 2002; Zhao, 2001]. 
A common pathological feature, observed in autoptic samples of ALS patients, is the presence of a 
marked accumulations of intermediate filaments in the perikaryon of motor neurons and in their 
axons [Gambetti, 1983; Hirano, 1984]. Immunostaining experiments with monoclonal antibodies 
directed against the three different form of neurofilaments showed levels 5 to 10 times higher of 
immunopositivity in motor neurons from ALS patients compared to non ALS motor neurons 
[Rouleau, 1996]. Abnormal neurofilaments accumulation in the perikaryon occurs in two distinct 
patterns: homogeneously diffuse or focally accumulated in various shapes. 
Neurofilaments are not the unique category of cytoskeletal components present in ALS inclusion 
bodies. Peripherin is another protein detected in the majority of inclusions in motor neurons of ALS 
patients [Sterneck, 1996; Migheli, 1993; Corbo, 1992]. Peripherin is normally expressed in 
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peripheral sensory neurons but is almost absent in the motor neurons [Escurat, 1990; Troy, 1990]. 
However, peripherin gene expression can be up regulated by nerve injury and inflammatory 
cytokines [Wong, 1990]. 
1.2.2.2 Intracellular inclusions 
Several types of inclusion bodies that have been found in the perikarya of anterior horn motor 
neurons are immunoreactive to ubiquitin [Leigh, 1989]. 
Ubiquitin is a 76-amino-acid protein that is involved in an ATP-dependent nonlysosomal 
proteolysis of abnormal or short-lived proteins [Leigh, 1991]. Although ubiquitin inclusions in 
lower motor neuron are unique to ALS tissues, ubiquitin-immunoreactive intraneuronal inclusions 
are often observed in the upper motor neurons [Morris, 2001; Noda, 1997] and are not specific to 
this disease [Wilson, 2001]. By immunoelectron microscopy observation, it has been shown that 
these ubiquitin-reactive inclusions are composed of small 10-15 A linear fragments whose the 
exact identity remains undiscovered [Okamoto, 1991]. 
Lewy-body-like hyalin inclusions were originally described as a characteristic feature of posterior 
columns and spinocerebellar tracts in ALS patients, but furthermore they have been also found in 
the soma and in the proximal axons of anterior horn motor neurons [Murakami, 1990]. These 
inclusions measure 7 to 20 pm in diameter and are surrounded by a lighter, slightly basophilic halo 
and contain a dense eosinophilic core of granules associated with a patchy shaped aggregate of 
filaments. These filaments are not immunoreactive to any cytoskeletal components such as 
neurofilaments, tubulin, microtubule-associated protein 2, and phosphorylated tau protein. These 
inclusions are similar to those described in the Lewy bodies in Parkinson's disease. 
Bunina bodies are hystologically described as small, eosinophilic, irregularly shaped, 2 to 3 pm in 
diameter and exclusively found in the perikaryon. Ultrastructurally, they are electron dense 
amorphous structures surrounded by lysosomial vesicles, endoplasmic reticulum fragment, 
lipofuscin granules and other debris. 
An intriguing relationship between bunina bodies and Golgi apparatus fragments has been 
hypothesised because of the presence in the bunina bodies of marked immunoreactivity for anti- 
cystatin C antibody, a protein highly expressed in Golgi apparatus [Okamoto, 1991]. 
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1.2.2.3 Mitochondrial alterations 
In recent years, observations of mitochondrial morphological alterations in the central nervous 
system (CNS) of ALS patients have accumulated. A fine ultrastructural examination of the 
synapses in ALS patients showed mitochondrial alterations in the anterior horn motor neurons 
(lumbar spinal cord) not only in degenerated neurons, but, to a lesser extent, in neurons that appear 
normal. Mitochondrial abnormalities include dense conglomerates of aggregated, dark 
mitochondria and presynaptic vesicles, and also bundles of neurofilaments, and a marked increase 
of presynaptic vesicles. These observations suggest that a substantial synaptic alteration, including 
mitochondrial changes, occurs in the early stages of anterior horn neuron death process in ALS 
patients [Swerdlow, 1998]. 
Hirano showed that, in dendrites and in the axon hillock of degenerating motor neurons, 
mitochondria are swollen and highly vacuolized, and it was also reported that abnormal 
mitochondrial morphology in the nerve terminal and in other peripheral tissues of ALS patients 
[Hirano, 1984]. Abnormal mitochondrial morphology is found in ALS patients may be related to a 
many factors, as oxidative injury, increased cytosolic calcium concentration and mtDNA mutations 
[Beal, 2003; Swerdlow, 2000]. 
1.2.2.4 Axonal alterations 
As in other neurodegenerative diseases, axonal swelling represents a common event detectable in 
ALS. In ALS patients the axons are swollen and typically show well-defined structures that are 
identified as spheroids [Carpenter, 1968]. These structures are eosinophilic bodies and are usually 
greater than 20 µm in diameter. They contain packed 10-nm-thick neurofilaments. Like 
intraneuronal neurofilament accumulations, spheroids are phosphorylated. However, spheroids 
have not been found exclusively in ALS tissues and many other neurological diseases are 
characterized by the presence of phosphorylated neurofilaments and neurofilamentous 
conglomerates [Manetto, 1988; Chou, 1992]. 
Interestingly, axonal swellings are more frequent in younger than in older ALS patients and in the 
patients with shorter as opposed to longer clinical course [Kurosumi, 19791. 
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1.3 Aetiopathological hypotheses 
1.3.1 Genetic involvement 
Genetic risk factors for ALS have been studied extensively. Familial Amyotrophic Lateral 
Sclerosis (fALS) forms, are a clinically and genetically heterogeneous class of pathologies with 
multiple autosomal-dominant and recessive forms [Rosen, 1993]. Molecular genetic analysis of 
fALS has led to the discovery of several genes involved in ALS. 
1.3.1.1 f ALS! (SOD! ) 
In 1991 the first ALS gene (ALS 1), for an autosomal-dominant form of fALS, was mapped to 
chromosome 21q [Siddique, 1991]. Two years later the cytosolic copper-zinc superoxide dismutase 
(SODJ) gene was shown to be the ALS1 gene [Rosen, 1993]. SOD1 is a 153-amino acid 
metalloenzyme with high expression in nervous tissue, liver and erythrocytes. The enzyme 
catalyzes the conversion of the superoxide radical anion (O2-) to molecular oxygen (02) and 
hydrogen peroxide (H202). Presently, more than 90 different mutations in all five exons of this 
gene have been identified [Cudkowicz, 1997]. 
The majority of mutations in SOD] are missense mutations and there is no clear correlation with 
the clinical expression of the disease (genotype-phenotype correlation) [Andersen, 1997]. This 
inter- and intrafamilial variability precludes precise predictions on the course of the disease. 
Clinical characteristics, age at onset, and survival vary greatly between and among specific 
mutations. The phenotypic variability extends from rapidly progressive disease with only lower 
motor neuron signs to a very slowly progressing disease with upper and lower motor neuron signs 
[Camu, 1999]. 
It is unclear how mutations in SOD] cause ALS. As the level of residual SOD1 enzyme activity 
does not correlate with disease expression in ALS patients, the loss of function of SOD1 is not a 
probable cause of motor neuron degeneration [Ratovitski, 1998]. Other toxic effects of SOD] 
mutations may involve increased vulnerability to excitotoxic mechanisms by selective inactivation 
of the glutamate transporter, EAAT2/GLT1 [Trotti, 1999], or by mitochondrial degeneration 
[Jaarsma, 2000]. 
Neurofibrillary depositions and Lewy body-like inclusions belong to the pathological spectrum 
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of ALS1 [Shaw, 1997]. Immunohystochemical co-localization of SOD1 in neuronal Lewy body- 
like hyaline inclusions (LBHIs) in the spinal cords of ALS1 patients indicates that SODI is a 
component of LBHI [Kato, 2000]. 
1.3.1.2 f ALS2 (ALSIN) 
Autosomal-recessive fALS was first described in a large inbred family in Tunisia showing linkage 
to the chromosomal region 2q33-34. Symptoms occurred in the first or second decade of life, and 
included progressive spasticity of the limbs and the facial and pharyngeal muscles. Survival is 
relatively long (15 to 20 years) [Hentati, 1994]. 
Recently, the gene for ALS2 was identified in Tunisian and Kuwaiti families and named alsin or 
als2 [Hadano, 2001]. Alternative splicing of this gene produces a short and a long transcript. 
Deletions affecting both transcripts result in the ALS2 phenotype, whereas homozygous deletions 
in exon 9 and affecting only the short form of the protein, cause juvenile primary lateral sclerosis 
(JPLS). JPLS is even rarer than ALS2, and its phenotypic presentation consists of slowly 
progressive spastic paraparesis and muscle weakness of the oro-facial and ocular muscles. 
Expression of the mouse ortholog of alsin was found in neuronal cells throughout the brain and the 
spinal cord. Because Alsin has protein domains with similarities to pleckstrin and guanine- 
nucleotide exchange factors (GEFs) known to activate GTPases, Alsin may act as a 
regulator/activator of GTPases, and modulate microtubuli assembly, membrane organization and 
trafficking in neurons [Kanekura, 2004]. 
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1.3.2 Glutamate-induced excitotoxicity 
Glutamate-induced excitotoxicity is the best-characterized factor in the ALS pathogenesis. 
Excitotoxicity is basically due to an overstimulation of postsynaptic glutamate receptors. This 
overstimulation can generate an excessive influx of Ca++ and Na+ into the neurons and the 
following activation of damaging pathways ultimately leading to cell death [Choi, 1987]. Both glial 
and neuronal glutamate transporters play a pivotal role in avoiding excitotoxicity stimuli by 
removing the excess of glutamate released into the synaptic cleft from presynaptic neurons and, 
consequently, by preventing the overstimulation of postsynaptic glutamate receptors. The evidence 
of an abnormal glutamate metabolism and an impaired expression of the glial glutamate transporter 
GLT-I, known as (EAAT2 in humans) in ALS patients suggests that glutamate-induced 
excitotoxicity plays a key role in generating ALS disease [Rothstein, 1993]. 
Different studies have reported a significant increase of glutamate levels in cerebrospinal fluid and 
serum of sporadic ALS and a selective local loss of EAAT2 in the anterior horn of affected spinal 
cord regions in ALS patients. In addition, a significant decrease of glutamate uptake from cerebral 
and spinal homogenates in about two-thirds of sporadic ALS patients has been measured 
[Rothstein, 1994]. 
Glutamate overstimulation produces its neurotoxic effect acting through both the N-methyl-D- 
aspartate (NMDA) receptors and the alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate 
(AMPA)/kainate ionotropic receptors. However, while NMDA receptors seem to mediate most 
acute neuronal injury, AMPA/kainate receptors seem to be associated to detrimental effects 
produced following a slower and prolonged overstimulation. This latter mechanism appears to be 
more related to chronic processes, such as neurodegenerative diseases and ALS [Weiss, 1991]. 
AMPAr are cation-conducting complexes, the receptors are composed of four subunits (GIuR1-4) 
and are always constituted as an heteromeric protein. The alternative assembly of the different 
subunits produces important differences in the electrophysiological properties of AMPAr [Jonas, 
1995]. 
A possible mechanism of excitotoxicity due to a post-transcriptional editing of the calcium 
impermeable subunit (GluR2) of AMPAr has been postulated [Takuma, 1999]. Ca permeability is 
largely determined by the GluR2 subunit, receptors incorporating edited G1uR2 subunit 
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show a limited Ca permeability in comparison with G1uR2-lacking channels or containing the 
unedited form of G1uR2. This effect is attributable to the presence of an arginine in its pore- 
forming segment in GluR2, in a position occupied by a glutamine in the other AMPAr subunits 
[Hume, 1991; Burnashev, 1992]. 
This critical arginine residue is formed at the pre-mRNA stage by RNA editing [Sommer, 19911. 
The relative Cam permeability of native AMPAr in neurons is inversely correlated with the rate of 
edited GluR2 and the divergence in relative Cam permeability of AMPAr between different 
neuronal cell types could be an important constituent of selective vulnerability [Pellegrini- 
Giampietro, 1997]. It has been widely demonstrated that different neuronal cell types can diverge 
in G1uR2 expression, in the rate of GluR2 editing and in the desensitisation properties of their 
AMPAr [Raman, 1994] and such differences may be related to the selective vulnerability of motor 
neurons that occurs in ALS. In figure 1.2 are summarized the main events involved in glutamate- 
induced excitotoxicity. 
44 
Chapter 1 Human ALS 
PHYSIOLOGICAL CONDITION 
GLT 40 
GL LU 
3A 
UPPER MOTOR NEURON A 2A® ®Cä +LOWER MOTOR NEURON 
UA 
3A T dar, 
ASTROCYTE 
GLUTAMATE OVERSTIMULATION 
DEATH 
PROCESSES 
UPPER MOTOR NEURON IPArB 
GLU µ CL GLU ® 
ý3'' 
L ? A. 4C-1 LOWER MOTOR NEURON 
Ae. 
ý 1B 
-AAT2 
4STROCti"CE 
Figure 1.2 Important alterations of glutamate metabolism that are found in ALS patients can 
account for a glutamate-induced excitotoxicity in motor neurons. The possible concomitant effects 
produced by decreased amount and reduced functional expression of the main glial glutamate 
transporter (EAAT2) leading to increased liquoral levels of glutamic acid. An augmented Cä 
permeability, due to a reduced process of editing for G1uR2 mRNA, could induce a Ca++ 
overloading thus activating a series of different cell death pathways in lower motor neurons (see 
Chapter 2). 
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1.3.3 Oxidative stress and mitochondria( abnormalities 
The hypothesis that oxygen free radical-mediated neurotoxicity may contribute to pathogenesis of 
ALS originated from the discovery of the human Cu++/Zn superoxide dismutase-1 (SOD1) 
mutation in a group of fALS patients and the demonstration of reduced enzyme activity in affected 
individuals [Rosen, 1993]. 
A major source of free radicals production can be due to a defective flux of electrons through the 
mitochondrial membrane, during the process of oxidative phosphorylation. Mitochondria produce 
ATP via the creation of an electrochemical gradient across the mitochondrial inner membrane. This 
gradient is obtained by the pumping of H+ ions through protein complexes that form the electron 
transport chain (ETC). As electrons are transported through the ETC they undergo a series of redox 
reactions. These steps are required to produce the electrochemical gradient to transport H+ ions 
across the membrane. This H+ flux through the H+ ATP pore is the driving force to transform ADP 
into ATP. The final electron acceptor is molecular oxygen that is transformed in 02% 02 usually 
reacts with H2O thus producing H2O2, In physiological conditions the large amount of reactive 
oxygen species (ROS), principally superoxide anions (02) and hydroxyl radicals (OH"), produced 
from reduction of O2 by electrons, is readily converted to H202 from superoxide-dismutase and 
further convereted to H2O and 02 by catalase. 
The ROS produced by mitochondria can react with a wide series of substrates, such as lipids and 
NO, thus generating catastrophic effects for the cell [Cassarino, 1999]. 
A large body of evidence indicates oxidative damage as one of the most probable aetiological 
factors to initiate ALS pathology. An increase of protein carbonyl content has been reported in 
frontal and motor cortex and in spinal cord of ALS patients [Oteiza, 1997]. Increased level of 
immunopositivity for 3-nitrotyrosine and neuronal nitric oxide synthase (nNOS) has been found in 
the spinal cord motor neurons of both sporadic and fALS patients [Abe, 1997]. On the other hand, 
further studies did not reveal nNOS alteration in motor neurons, but showed an increase of nNOS 
activity in astrocytes of spinal cord and sub cortical white matter in ALS patients [Sasaki, 2000]. 
As in other neurodegenerative diseases, a relevant source of risk in ALS disease is constituted by 
ageing and, consequently, with the processes have implicated in ageing. A classic feature of ageing 
is represented by ROS overproduction induced through a loss of function of mitochondria. 
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Several mitochondrial abnormalities have been found in ALS patients [Beal, 2000; Cassarino, 
1999]. The first evidence of involvement of mitochondria in ALS arose from electron microscopy 
studies, in which an abnormal mitochondrial morphology in muscles of ALS patients was shown. 
Moreover, in the same study, a decrease in mitochondrial number was also reported in 
intramuscular nerves of ALS patients [Hirano, 1984]. 
Using a metabolic assay, a significant reduction in cytochrome oxidase activity and an increase of 
either complex I activity alone [Bowling, 1993] or both complex I and II was found in ALS 
patients [Browne, 1998]. This study also showed that others enzymatic activities of ETC 
(complexes II-III and N) were not altered. 
The increased activity of complex I in ALS patients may be due to a compensatory mechanism in 
response to the oxidative damage of the inner mitochondrial membrane components that may cause 
electron leakage and the uncoupling of oxidative phosphorylation. 
A further study reported a decreased activity of complex IV. In this work mitochondrial activity 
was evaluated by staining spinal cord sections from post post-mortem tissues obtained from ALS 
and no neurological patients [Borthwick, 1999]. Complex IV deficiency has been also described in 
muscles of sporadic ALS patients, in which complex N negative muscles fibres were found 
[Chung, 2002]. A detailed comparison of mitochondrial activity obtained from lymphocytes of 
fALS patients and healthy humans, clearly showed an impaired response of fALS mitochondria to 
uncouplers of oxidative phosphorylation, an altered mitochondrial ultrastructure and an abnormal 
electron transport chain functioning [Curti, 1996]. 
Finally, it is important to report as drugs, acting primarily on energy metabolism, were effective to 
delaying muscle atrophy and to reducing degeneration of spinal motor neurons in animal models of 
motor neuron diseases [Klivenyi, 1999; Ikeda, 2000]. 
The results obtained in the last few years suggest that, although there is no evidence that ALS is a 
mitochondrial cytopathy and the temporal and causal role of mitochondria in motor neuron 
degenerative process have not yet been clarified, mitochondrial alteration must be considered as a 
possible aetiological factor in ALS pathology. 
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1.3.4 Neurofilaments disorganization and axonal strangulation 
Both in sporadic and in familial forms of ALS, neurofilament alterations seems to play an 
important role in the pathogenesis of the disease [Julien, 2000]. 
Since neurofilaments are heavily expressed in motor neurons it has been suggested that the level of 
neurofilaments may be an important factor in determining the selective vulnerability of motor 
neurons. The direct involvement of neurofilaments in the pathogenesis of ALS was suggested by 
the evidence of mutations, in a subset of ALS patients, in a gene that encodes for the heavy 
neurofilament subunit [Bomont, 2000]. However, how this aberrant expression of neurofilament 
can lead to a selective damage for motor neurons is still unclear. 
About the role played by neurofilaments in ALS pathology it is important to note that the formation 
of intraneuronal aggregates, highly enriched in phosphorylated neurofilaments, is a peculiarity of 
motor neurons in ALS patients. This increase of highly phosphorylated neurofilaments could also 
suggest that the failure in the metabolism of neurofilaments may be the first step of a series of 
processes leading to neurofilament accumulation, axonal strangulation and neuronal cell death. 
However, it has been also suggested that upstream defects, such as, axonal transport deficit, 
glutamate induced excitotoxicity, SOD I mutation, inflammatory response, might cause the 
disorganisation of neurofilaments in the cell body; in that case neurofilament alteration would 
represent more an effect than a cause of the disease [Ackerley, 2000; Asahara, 1999]. 
1.3.5 Intracellular aggregates and/or failure of protein folding 
As reported for other neurodegenerative diseases, like Alzheimer's disease, prion disease, Kennedy 
and Hungtinton's disease, protein accumulation in motor neurons of ALS patients may be caused 
by the formation of aggregates due to an alteration of the process of misfolded proteins degradation 
[Ross, 2004]. The mutant SOD I protein was reported to sequester chaperones that are required for 
promoting the correct folding of many proteins, whereas ubiquitin-mediated protein degradation 
might be inhibited by those aggregates. Aggregates intensely immunoreactive for SOD 1 are found 
in the motor neurons of fALS patients carrying SOD1 mutations, and ubiquitin deposits have been 
reported in lower motor neurons in both sporadic ALS and fALS patients. The evidence of a large 
amount of ubiquitin positive aggregates in motor neurons of ALS patients strengthens the 
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hypotheses that a failure in ubiquitin-proteasome system can be responsible for protein 
accumulation [Valentine, 2003; Migheli, 1999; Valentine, 2003; Migheli, 1999]. 
1.3.6 Reactive gliosis-induced neuroinflammation 
Although the CNS has been considered for many years as an immune privileged organ, a well- 
characterized repertoire of inflammatory responses are observed in different types of brain injury. 
Many different types of neurodegenerative diseases share a common pattern of events in which, not 
only the dying neurons undergo cellular changes, but also the morphological and functional 
properties of neighbouring cells are affected. These cellular changes are common in different 
species and likely reflect an evolutionarily conserved program which plays an important role in the 
protection against infectious pathogens and the repair of the injured nervous system. The group of 
cells that more actively participate to this response are microglial cells and astrocytes, for this 
reason this response is often indicated as reactive gliosis [Raivich, 1999]. 
Although a marked reactive gliosis in anterior horn and motor cortex from ALS patients was 
already described several years ago, the interest of microglial activation as pathogenetic factor in 
ALS is recent and reflects previous experimental evidence showing that microglial activation plays 
a relevant role in motor neuron degeneration [Turner, 2004]. 
Microglial cells are functionally related to peripheral tissue macrophages and, like macrophages in 
other tissues, resting microglia appears to participate in the immune surveillance of the nervous 
system [Eglitis, 1987]. Resting microglia are characterized by a stellate morphology composed by 
thin and ramified processes. Resting microglial cells are unable to migrate and are characterized by 
low level of metabolic activity [Compston, 1997]. In response to injury, microglial cells modify 
their physiology and rapidly produce a transformation from a resting into an activated state. 
Activated microglial cells markedly increase their size; cell bodies swell and acquire a round shape, 
together with a decrease in the ramification of distal branches. During this phase of morphological 
changes, microglial activation proceeds through a series of steps characterized by a conspicuous 
expression of molecules for cell adhesion, cytoskeletal organization, antigen presentation and cell 
membrane receptors [Streit, 1989]. 
Once activated microglial cells migrate to the injured side, this step is identified as homing 
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process. The homing of activated microglia permits the adhesion to damaged structures like 
lesioned neurons or degenerating neurite terminals [Angelov, 1996]. 
The presence or absence of cell death and phagocytosis determines the further development of the 
microglial response after the process of homing. When neuronal damage declines without a 
massive neuronal death, microglial number is progressively reduced and activated cells switch off 
their metabolic machinery reducing the expression of many proteins and reverting to a resting state. 
Interestingly, during this latter phase microglial cells return to their original state characterized by a 
territorial distribution, highly ramified morphology and moderate levels of complement receptors, 
Fc-receptors and IgG immunoreactivity [Raivich, 1999]. 
On the other hand, neuronal cell death produces an additional modification of microglial cells 
toward a phagocytotic phenotype. This transformation guarantees the clearance of tissue by 
removing neural debris from injured area. Phagocytotosis is not only important to remove neuronal 
fragments but it is often required for the removal of disconnected neuntes in both natural occurring 
axonopathy and in experimental axotomy [Bauer, 1995]. Removal of large cellular structures like 
dead pyramidal cells or degenerating motor neurons frequently leads to the formation of microglial 
nodules consisting of microglial phagocytes [Streit, 1988]. 
Another important component of the neuroinflammatory response is represented by astrocytes. 
Astrocytes represent about 75-80% of glial cells in the CNS. Astrocytes can be divided in two main 
groups: stellar-fibrillary astrocytes and protoplasmatic astrocytes. Fibrillary astrocytes are generally 
found in the white matter whereas protoplasmatic astrocytes are located in the grey matter and 
exhibit numerous short and thicker highly ramified processes with many membranous extensions 
[Bignami, 1972]. 
The cellular modifications occurring in reactive astrocytes play an important role in neuroglial 
response. As for microglia, the astrocyte response to injury can be divided into different serial 
steps. A rapid increase of GFAP synthesis, related to a glial hypertrophy, is evident in the early 
phase of neuroinflammatory response [Tetzlaff, 1988]. This early morphological transformation 
from protoplasmic to fibrillary astrocytes in the neural parenchyma can be tightly controlled by 
several factors, including cytokines, which regulate different steps in this activation response 
[Lucas, 1995]. 
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The release of these cytokines, often accompanied by an increase of their receptors on motor 
neurons surface [Mennini, 2004], can activate cellular pathways that lead to the death of motor 
neurons. In addition diffusible factors released from dying neurons can activate protoplasmatic 
astrocytes and increase both the GFAP levels and the expression of a series of distinct molecules 
[Vivian, 2000]. 
A schematic representation of the complex processes between activated microglia/astrocytes and 
motor neurons is reported in figure 1.3 
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Figure 1.3 The main processes likely involved in the glial-dependent motor neuron toxicity are 
shown in this drawing. 1-Diseased motor neurons release some factors that stimulate resting 
microglia, 2-microglial cells are activated, 3-activated microglia releases factors interacting with 
other cells, 4- release of soluble molecules from upper and lower motor neurons activate astrocytes, 
5-astrocytes release further molecules able to interact to motor neurons, 6-the factors released from 
glial cells stimulate intracellular pathways in motor neurons that, 7-induce motor neuron death. 
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1.4 Pharmacotherapy of ALS 
1.4.1 ALS and clinical trials 
The history of clinical trials in ALS can be divided into four separate phases. Prior to 1940, other 
than anedoctal and subjective past experience, there were essentially no organised therapeutic 
trials. The first identifiable phase of trial design encompasses roughly the period from 1940 to 
1970, before the use of placebo as a internal control in studies. This period was characterised by 
observational, ' descriptive trials without any controls. The second phase comprised the studies 
reported from 1971 to 1990 and was characterised by the increasing use of placebo controls in a 
double-blinded schedule of treatment. The third phase, since early 90s, signed an improvement of 
trial design resulting from a better understanding of natural history and statistical techniques. It is 
now ten years, since the publication of riluzole the trial in ALS that firstly showed improved 
survival [Bensimon, 1994] of Rilutek® (Aventis Pharma, France), that the fourth phase of clinical 
trials has taken place. 
To date, in all pharmacological trials, riluzole is the reference drug, in spite of a modest effect it 
significantly prolongs the survival of ALS patients. Since riluzole effect was confirmed by 
following studies [Miller, 2001], it has been established that alternative placebo-controlled trials 
are unethical [Ford, 2001]. 
Since 1993, no relevant improvement in ALS pharmacotherapy has been obtained and all the 
clinical trials performed so far have been ineffective. It has been postulated that the efficacy of 
riluzole is due to its antiglutamatergic effect and that the reduction of excitotoxic glutamate- 
mediated stimulus could partially counteracts the progressive motor neuron degenerative process. 
However, further clinical trials, by treating the patients with others glutamate antagonists, 
completely failed both in prolonging survival and in decreasing the slope of clinical worsening 
[Miller, 1999]. The actual therapeutical effect of riluzole in ALS disease is not yet fully understood 
and several studies to elucidate alternative mechanisms of action played by this drug are still under 
investigation. 
As reported in section 1.3, several aetiological hypotheses to account for ALS disease have been 
postulated and different pharmacological strategies to arrest or, at least, to slow the progression of 
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symptoms have been proposed. 
In the last decade the rationale to define a therapy for ALS was to plan clinical trials by agents that: 
I) have been shown to be effective in in vitro or in in vivo models of motor neuron degeneration, 
such as neurotrophic agents, compounds that support mitochondrial activity, or anti-apoptotic 
agents; II) have been reported to counteract the detrimental effect caused by stimuli that have been 
postulated to be involved in ALS, such as antiglutamatergic agents, anti-inflammatory agents, 
calcium regulators, antiviral drugs. 
To provide a clear description about the most relevant clinical trials in ALS, it is possible to include 
the different drugs tested in accordance with their specific pharmacological activities (see table 
1.3). 
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AGENT EFFICACY 
Antiglutamaiergic 
Riluzole 
L- hreonine ° 
Branched amino acids ° 
Gababpentin ° 
Lamotrigine ° 
Dextromethorphan ° 
0 
Ca-channel blockers 
VerapamiI 
Nimodipine ° 
° 
Antioxidants 
Acetyicysteine 
Vitamin E ° 
rhSOD1 (intrathecal) ° 
Neurotrophicfactors 
CNTF 
TRH ° 
rhIGF-1 ° 
BDNF ° 
° 
Immunomodulatory 
Cyclophosphamide 
Plasmapheresis 
Cyclosporine ° 
CE-interferon 
Dopaminergic pathway 
L-Dopa ° 
Deprenyl ° 
Cholinergicpathway 
Physostigmine ° 
Neostigmine ° 
3,4-Diarninopyridine ° 
Tetrathyroaminoacridine ° 
Antiviral 
Tilorone ° 
Modified snake venom ° 
Miscellanous 
Gangliosides ° 
Amantadine ° 
Guanidine ° 
Table 1.3 CLINICAL TRIALS IN ALS 
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1.4.2 Antiexcitotoxic drugs 
1.4.2.1 Riluzole 
Riluzole is, at present, the only drug approved from the Food and Drug Administration (FDA) for 
the treatment of ALS. Riluzole is considered to exert its protective effect in ALS patients by acting 
as an antiexcitotoxic agent [Lacomblez, 1996]. Riluzole treatment can block different processes 
inducing the release of glutamate from presynaptic neurons and therefore can inhibit the glutamate- 
mediated overstimulation of postsynaptic glutamate receptor [Pratt, 1992; Zona, 1998]. In the last 
fifteen years several findings have confirmed the well-known antiglutamatergic properties of 
riluzole. It has been reported that riluzole inhibits the release of glutamate in the rat caudate 
nucleus [Cheramy, 1992], blocks sodium channels in their inactivated state in myelinated fibers 
[Benoit, 1991], modulates Na+ currents and the late component of outward K+ currents in cultured 
cortical neurons [Zona, 1998], activates a G-protein-dependent process that inhibits glutamate 
release [Doble, 1996] and modulates the kainate-induced Na+ currents in rat cortical neurons [Zona, 
2002]. 
In two distinct therapeutic trials, riluzole prolonged the survival by three to six months [Bensimon, 
1994; Lacomblez, 1996]. In one of these trials the treatment slightly slowed the decline in the 
strength of limb muscle but failed to reduce others considered clinical parameters. In one 
retrospective analysis [Riviere, 1998] patients who received riluzole remained in a milder state of 
the disease longer than placebo-treated ALS patients. More recent evidence, by utilizing proton 
density magnetic resonance spetroscopy, has demonstrated that patients, treated with riluzole, had a 
less marked progression of neuronal loss compared to placebo treated group [Kalra, 1999]. The 
effect of riluzole reinforced the hypothesis that glutamate-induced excitotoxicity was related to 
ALS and prompted the scientific community to plan several clinical trials using more specific 
antiglutamatergic agents. The most relevant treatments including antiexcitotoxic agents are 
reported below. 
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1.4.2.2 Dextromethorphan and L-threonine 
Dextromethorphan is a NMDA antagonist utilized in experimental models of ischemia [Steinberg, 
1991]. Dextromethorphan was tested in ALS patients for 12 weeks in a double-blind crossover 
trial. Thereafter surviving patients protracted the treatment for 6 months but clinical and 
neurophysiological tests did not show any positive effect in the treated group [Askmark, 1993]. 
Glycine is an inhibitory neurotrasmitter in the mammalian CNS. In 1980 it was shown that L- 
threonine administration increases glycine concentration in the rat CNS [Maher, 1980]. Based on 
this finding, L-threonine was administered in ALS patients to reduce the excess of excitatory 
neurotrasmission. 
Several studies were performed using different doses of L-threonine [Blin, 1992; Hugon, 1996]. 
Although a functional improvement was recorded at the initial phase of the treatment, modulation 
of the glicinergic transmission does not seem to alter the clinical evolution of ALS. However, it is 
important to note that the glycine not only works as an inhibitory neurotransmitter in the spinal 
cord but also acts as an allosteric agonist of the NMDA glutamate receptor and greatly facilitates 
its activation [Johnson, 19871. This dual role in neurotransmission may in part account for an 
explanation of the failure of L-threonine treatment in ALS patients. 
1.4.2.3 Ca'+ channels blockers 
Two different aetiologycal hypotheses of ALS disease (the toxicity produced by Ca++ overload 
following postsynaptic glutamate receptor overstimulation, and the over expression of IgG 
antibodies against L-type calcium channels) may be blocked by a common strategy of treatment 
passing through calcium-channel blockage. In light of this suggestion two classical drugs classified 
as calcium antagonist, verapamil and nimodipine, were tested in two distinct clinical trials. 
The slopes of declining respiratory function and the limb weakness were not significantly different 
in the verapamil treated group compared to placebo treated patients. Verapamil was ineffective in 
slowing the clinical progression in ALS patients[Miller, 1996]. 
The effect of another Cam'' channels blocker, nimodipine, was studied in ALS patients. The scores 
of isometric muscle strength and respiratory function were used to compare the nimodipine treated 
and the placebo treated group. No difference in adverse events occurred in placebo vs. drug- 
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treated patients, but diarrhoea and nausea were more common with nimodipine. Moreover, there 
was no significant difference in the rate of decline of pulmonary function or limb strength during 
treatment with drug or placebo. Nimodipine was ineffective in slowing the progress of ALS 
[Miller, 1996]. 
In summary, all antiglutamatergic agents tested until now did not produce significant clinical 
improvement. This evidence suggests that the mechanism of action of riluzole is not exclusively 
related to the reduction of the glutamate-induced toxicity and that additional mechanisms may 
contribute to the actual effectiveness of this drug in ALS care. 
1.4.3 Neurotrophic factors 
Because of the landmark discovery that the nerve growth factor (NGF) rescued sympathetic 
chicken neurons after axotomy and that its withdrawal markedly reduces the neuron survival 
[Levi-Montalcini, 1987] in the 80s and 90s, the use of neurotrophins as potential therapeutical 
factors in neurodegeneartive diseases had a massive and sometimes uncontrolled development. 
In ALS studies, these investigations included trials with the brain-derived neurotrophic factor 
(BDNF), the ciliary neurotrophic factor (CNTF), the thyrotropin-releasing hormone (TRH) and the 
insulin-like growth factor 1(IGF-1). 
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1.4.3.1 BDNF 
BDNF has been shown to have a protective role in preventing cell death in several experimental 
models of neurodegenerative diseases. In embryonic rat spinal cord motor neurons [Henderson, 
1993] and in neonatal rat facial motor neurons' following axotomy [Yan, 1992] BDNF was highly 
protective in reducing the percentage of mortality. In addition, BDNF has been found to reduce 
motor impairment and the motor neuron loss in a murine model of motor neuron degeneration, the 
wobbler mouse [Ikeda, 1995]. In a first series of treatments BDNF was effective on increasing 
survival and on delaying the loss of pulmonary function in ALS patients. In contrast, in a phase III 
study, the survival in patients treated with BDNF was identical to placebo. Although the treatment 
failed, post hoc analyses showed that those ALS patients with early respiratory impairment and 
those developing altered bowel functions showed statistically significant benefit. In further clinical 
trials, performed by intrathecal delivery of a recombinant methionyl human BDNF (met-BDNF) 
the majority of patients reported mild sensory symptoms. They included paraesthesias or a sense of 
warmth, which were usually confined to the lower limbs and were frequently exacerbated by neck 
flexion. In most instances these symptoms decreased or even disappeared over several weeks. 
However, both small number of patients and the design of the study did not permitted conclusions 
about the efficacy of the treatment. 
Immunohystochemical studies, in neuronal somata and proximal processes of large-sized anterior 
horn cells of non-ALS patients, revealed a punctate staining for BDNF, the same immunostaining 
pattern was found in the spared anterior horn cells detected in ALS patients. These findings suggest 
that BDNF expression in ALS patients is unchanged, and that motor neurons would be sufficiently 
supplied with endogenous BDNF from other neuronal subpopulations in the spinal cord. 
Interestingly, immunochemical experiments revealed that the tyrosine kinase receptor-B (TrkB), 
the high affinity functional receptors for BDNF, is less phosphorylated on tyrosine residues in ALS 
patients spinal cord samples than in controls and therefore less active [Mutoh, 2000]. These 
findings would suggest an abnormality in TrkB-mediated intracellular signalling in ALS spinal 
cord and open the possibility of an alternative therapeutic intervention with agents that have the 
possibility to increase this intracellular signalling (i. e. Acetyl-L-carnitine). 
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1.4.3.2 CNTF 
CNTF is a neuroactive cytokine having a potent survival effect in spinal motor neurons of 
embryonic chicken and rat, and demonstrating to be active in decreasing the clinical worsening in 
wobbler mice. Moreover, mice lacking the CNTF gene develop mild but progressive motor neuron 
loss, and CNTF contents in the lateral corticospinal tract were markedly lower in ALS patients than 
in controls [Albrecht, 2002; Gatzinsky, 2003; lkeda, 1995; Ono, 1999]. These results suggest that: 1) 
motor neuron survival requires high levels of CNTF and; II) the under-threshold level of CNTF, 
which was measured in ALS patients, could generate motor neuron toxicity. 
Based on these hypotheses, clinical trials with CNTF were designed. First clinical trials, in which 
CNTF was systemically administered, were highly toxic and all treatments were interrupted. More 
recently the "ALS CNTF Treatment Study Group" has reported that the administration of 
recombinant human CNTF subcutaneously, markedly decreased the appearance of side effects but 
did not produce any significant improvement in slowing disease progression [ALS CNTF 
Treatment Study Group, 1996]. Later on, a phase I trial of CNTF delivered intrathecally was 
designed to determine the safety of this new route of administration as well as the 
pharmacokinetics and the drug distribution. With intrathecal administration no clinical signs of 
meningeal irritation, no asthenia, fever, nausea, weight loss, were seen, and it was also reported 
that the CNTF was well distributed along the spinal canal. Although CNTF was well tolerated and 
well distributed into the spinal cord region, this treatment did not reduce the gradual decline in 
motor strength and performance of standard skills [Penn, 1997]. Further studies are thus required to 
well establish the pharmacological prospective of CNTF treatment. 
1.433 TRH 
TRH receptors are localized in different anatomical regions of CNS, including the ventral horn of 
the spinal cord and several data seem to support the idea of this hormone in ALS care. In fact TRH 
has been reported to increase extracellular levels of acetylcholine and accelerate acetylcholine 
turnover in brain [Giovannini, 19911, to have a neurotrophic effect on cultures rat embryonic 
ventral spinal cord cells of rat embryo [Iwasaki, 1989] and to protect against spinal cord motor 
neuron degeneration in a murine model of ALS (the wobbler mouse) [Kozachuk, 1987]. 
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However, no positive effect was recorded from different clinical trials previously performed and 
semi quantitative and quantitative neurological functions were similar in TRH-treated and in 
placebo-treated group [Brooke, 1989; Munsat, 1992; Brooks, 1987]. 
In ALS patients a temporary increase in the strength of some muscles following the administration 
of TRH has been reported, but no change in functional performance was noted and the course of 
the illness was not altered [Kozachuk, 1987]. 
1.4.3.4 IGF-1 
IGF-1 receptors are highly expressed in muscular surface, in brain and in spinal cord [Daughaday, 
1972; Lund, 1986]. By in vitro studies it was demonstrated that supplementation of IGF-1 in the 
culture media promotes neurite formation and increases survival of peripheral and central neurons 
[Bothwell, 1982; Recio-Pinto, 1986; Bothwell, 1982; Recio-Pinto, 1986]. The beneficial effect of 
IGF-1 was also observed after in vivo administration. IGF-1 stimulated neurogenesis after nerve 
sciatic axotomy [Vergani, 1999]. In addition, it prolonged the lifespan by slowering the disease 
progression in two murine models of ALS, the SOD! transgenic mouse and the wobbler mouse 
[Kaspar, 2003; Gorio, 2002]. 
Three distinct clinical trials were carried out. The first produced convincing results, by slowing the 
progression of the disease [Vaught, 1996]. However this outcome was not confirmed in two further 
clinical trials performed by treating ALS patients with recombinant human IGF-1. These studies 
did not show clinical improvement and the therapeutic evidence provided from this compound was 
not considered sufficiently reliable to obtain the FDA approval for IGF-1 in ALS care [Borasio, 
1998; Lai, 1997]. 
Many other clinical trials were conducted using antioxidant compounds [Desnuelle, 2001; 
Louwerse, 1995], immunomodulants agents [Brown, 1986; Gourie-Devi, 1997; Haverkamp, 1994; 
Beghi, 2000; Meucci, 1996; Mora, 1986], agents modulating the dopaminergic [Lange, 1998; 
Mendell, 1971] and the cholinergic activity [Norris, 1993; Aquilonius, 1992], antiviral agents 
[Olson, 1978; Rivera, 1980; Bradley, 1984; Lacomblez, 1989] and gangliosides [Olson, 1978; 
Rivera, 1980; Bradley, 1984; Lacomblez, 1989]. 
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Unfortunately all the clinical trials performed in ALS patients, produced negative results. New 
strategies as antiapoptotic agents, stem cell implantation, and VEGF administration are now under 
investigation and preclinical studies in animal models of motor neuron degeneration are still in 
progress. 
The striking dichotomy between the efficacy of many agents in animal models of motor neuron 
degeneration (see Chapter 5) and their ineffectiveness in the care of ALS patients induces a crucial 
reflection. What is the relevance of pharmacological treatments, both in in vitro and in in vivo 
models of ALS, without a clear comprehension about the basic cell death mechanisms occurring in 
these models of study? 
For the development of disease-specific therapies, both in in vitro and in in vivo studies, better 
information that clarifies the specific cell death mechanism(s) leading to motor neuron death is 
needed. 
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CHAPTER 2 
APOPTOSIS IN NEURONS 
2.1 Principles of neuronal death in embryonic and adult brain 
In contrast to other cells, neurons are permanent cellular population and they do not undergo 
turnover and self-renewal. For this reason, neurons have to be preserved against detrimental stimuli 
produced by environmental injuries and external perturbations. In order to maintain the rate of 
neuronal death as low as possible, during the evolution, several protective mechanisms have 
enforced. 
It is possible to distinguish two main events characterizing neuronal death an early physiological 
and a pathological cell death. 
The first is identified as the programmed cell death (PCD). PCD is characterized by the loss of a 
high percentage of neurons that are generated from neural precursors during the early phase of 
CNS formation. This type of death is indicated as "naturally occurring neuronal death" (NOND). It 
is generally believed that a correct balance between cell proliferation and NOND during 
development is fundamental to determine the ultimate structure, architecture, size, and shape of 
tissues in the CNS. The existence of naturally occurring cell death was first described more than 50 
years ago in the neuroepithelial tissue at the beginning of neurulation [Glucksmann, 1951]. 
PCD is a highly phylogenetically conserved mechanism by which eukaryotic cells die following a 
stereotyped series of molecular events [Glucksmann, 1951; Clarke, 1976; Saunders, 1966]. The most 
important process of death in PCD, is universally identified as apoptosis. During brain 
development apoptosis is responsible for the control of the final numbers of neurons in the central 
and peripheral nervous system [Glucksmann, 1951]. 
Although neuronal apoptosis is a typical feature of development, several toxic stimuli, associated 
with pathological conditions, have been shown to be able in inducing apoptosis [Sastry, 2000]. 
Among these agents it is worthwhile to mention oxidative stress, nitric oxide (NO), excitatory 
aminoacids neurotransmitters and related agonists (glutamate, NMDA, AMPA, kainic and 
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quisqualic acids), neurotoxic drugs, peptides and proteins ((3-amyloid, HIV-1 gp120), and lipids 
(ceramide, retinoic acid, phosphatidylinositol-3-phosphate). 
Although physiological and pathological apoptosis are two completely distinct events, both 
processes are characterized by similar morphological and biochemical features [Sloviter, 2002]. 
2.1.1 Morphological changes in neuronal apoptosis 
In an ultrastructural study performed in several embryonic tissues Schweichel and Merker 
proposed three main types of cell death occurring during the development, on the basis of the role 
of lysosomes in cell disruption [Schweichel, 1973]. In the first type, cell death occurs without any 
detectable activation of endogenous lysosomes, but phagocytosis and secondary lysosome 
activation induced by macrophages destroy the cells. This process was identified as 
heterophagocytosis. In the second type of cell death (autophagocytosis) cells are eliminated after 
activation of their own lysosomal enzymes. In the third type there is no obvious lysosome 
intervention. 
Although this original view was then revised and improved, it is possible to recognize 
ultrastructural features of type 1 cell death in the current definition of apoptosis, while at least a 
variant of type 3 shares several features with necrosis. An exhaustive description and classification 
of morphological alterations that diversify the different types of cell death, was described by Clarke 
in 1990 [Clarke, 1990]. In this study Clarke described in detail the morphological diversity and the 
multiple mechanism involved in developmental cell death of neurons and proposed its well-known 
threefold classification. This classification was published in "Anatomy and Embriology: number 
181, year 1990". In the following pages it will be exactly reported the explanation of 
morphological alterations during apoptosis. 
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"Morphological types of dying cells... 
... Type 1: Apoptosis 
(condensation, fragmentation, phagocytosis) 
Schweikel and Merker's (1973) first type begins with condensation of both the nucleus and the 
cytoplasm. In the nucleus, dense chromatin masses appear and increase in number until the 
nucleus has become frankly pyknotic (i. e., condensed). Under high magnification, the DNA 
fragments can be seen to be packed together more closely in the regions of dense chromatin. 
Outside the nucleus, the most striking change is that cell membrane becomes convoluted, being 
drawn deep to the cytoplasm, which may give the cell a starlike appearance. Subsequently, the 
processes of the star constrict proximally and detach from the cell. They are then phagocytosed 
and their contents degraded in heterolysosomes.. Most of the cytoplasmatic organelles are initially 
normal, although they become abnormally closely packed, reflecting a loss of cytosol (Bellairs 
1961). However, there is a loss of ribosomes from polysomes and rough endoplasmic reticulum, 
and the polysomes may even disappear (Schweichel and Merker 1973; O'Connor and Wyttenbach 
1974; Pilar and Landmesser 1976)[Schweichel, 1973; O'Connor, 1974; Pilar, 19761. 
Scweichel and Merker found that this type of cell death occurred in almost all isolated dying cells, 
but never in region of wholesale destruction. They observed it in many different regions including 
the apical ectodermal ridge (Schweichel 1972 )[Schweichel, 1972(l); Schweichel, 1972(2)] and 
parts of the nervous system. However, the identification of the dying cells in the apical ectodermal 
ridge as type I does not agree with an earlier report (Jurand 196) [Jurand, 1975] in which they 
had many of the properties of type 2 (autophagic) dying cells (see below). In some cases free 
ribosomes crystallize (Bellairs 1961; Mottet and Hammar 1972; O'Connor and Wyttenbach 1974) 
[Bellairs, 1961; Mottet, 1972 #; O'Connor, 1974], which probably reflects a cessation of their 
protein synthetizing capacity. 
Many workers have described this kind of cell death sequence of condensation followed by 
fragmentation and phagocytosis occurs not only in development (Wyllie et al. 1973; Kerr et al. 
1974) [Wyllie, 1973; Kerr, 1974], but in physiological tissue turnover in adults, in various tissues 
exposed to cytotoxic agents or immunological attack, in tumours, and in hormone-induced 
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atrophy(for reviews, see Kerr et al. 1972,1987; Wyllie 1981; Wyllie et al. 1984 a) [Kerr, 
1972; Kerr, 1987; Wyllie, 1981; Wyllie, 1984]. 
Following an initial designation as "shrinkage necrosis"(Kerr 1965,1971) [Kerr, 1971; Kerr, 
1965], Kerr et al(1972). coined the term "apoptosis"; which in Greek denotes the dropping of 
petals from flowers or leaves from trees, and recalled to these authors the role of this kind of cell 
death in tissue kinetics, which they wished to emphasize. The term has caught on, particularly in 
the pathological literature (see below), and I shall therefore use it, although its connotation of cell 
death in tissue kinetics is inappropriate in our present context of development. This type of cell 
death has also been described as `primary or precoucious pycnosis" [Beaulaton, 1982](Beauloton 
and Lockshin 1982), but I would be reluctant to use this terminology because the autophagic kind 
of cell death (type 2; see below) sometimes also involves early pyknosis. 
The "nuclear" (as opposed to "cytoplasmatic"- see below) type of neuronal death described by 
Pilar and Landmesser (1976) [Pilaf', 1976] is clearly of type 1, since according to these authors the 
nucleus become electron-opaque and its chromatin becomes clumped, followed by cytoplasm 
changes, notably the freeing of ribosomes from polysomes andRER. ". 
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2.2 Molecular mechanisms of neuronal apoptosis 
Our current knowledge on the gene regulation involved in apoptosis is mainly achieved from 
studies on the nematode worm Caernobitidis elegans [Yuan, 1995; Meier, 1998; Liu, 
1999; Hengartner, 2001]. In C. elegans, in which 131 out of 1090 somatic cells undergo 
developmental apoptosis, four genes named ced-3, ced-4, ced-9 and egl-1 form the "death 
machinery" which is responsible for the execution of the cells undergoing PCD [Hengartner, 1997]. 
In mammals, apoptosis is mainly regulated by two group of molecules: I) the classes of molecules 
belonging to "BCL2 family" and apoptosis protease activating factor-1 (Apaf-1), that corresponds 
to CED-3/4 and that act as adapter, and; 11) the caspases, a family of aspartyl-specific cysteine 
proteases possessing a cleavage property, that correspond to CED-9 associated proteins and that act 
as executor of apoptosis [Putcha, 2004]. 
Apoptotic processes can be roughly confined in two main pathways termed "extrinsic" and 
"intrinsic". Although they show profound differences both pathways are able to activate caspases 
and both require the formation of large multi-protein complexes [Bratton, 2000]. 
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The extrinsic pathway utilises a specific class of receptors identified as "death receptors". Death 
receptors are members of the tumor necrosis factor (TNF) receptor superfamily. They, once 
coupled to their cognate TNF family ligand, rapidly activate a series of processes leading the 
cleavage of different caspases typical of apoptosis [Ashkenazi, 1998]. A schematic representation 
of the mechanism involved in death receptor activation is shown in figure 2.1. 
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Figure 2.1 Death receptors and extrinsic apoptotic pathway 
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By contrast, the intrinsic pathway is triggered in response to a variety of stress conditions, such as 
cytotoxic drugs or growth factor withdrawal. The cascade of events produced by the intrinsic 
pathway selectively induces a mitochondrial perturbation and the release of cytochrome-c. In the 
cytoplasm cytochrome-c interacts with Apaf-1 and procaspase-9 to form a 700 kDa complex 
known as the 'apoptosome' which results in autocatalytic processing of caspase-9 and initiation of 
the caspase cascade [Zou, 1999]. Importantly, both pro- and anti-apoptotic members of the BCL2 
family, which act on mitochondria, can regulate this pathway [Green, 1998]. A schematic 
representation of the mechanism involved the intrinsic apoptotic pathway is shown in figure 2.2. 
Figure 2.2 Intrinsic apoptotic pathway activated by trophic factor withdrawal 
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2.2.1 Extrinsic pathway 
2.2.1.1 Death receptors 
Death receptors are cell surface receptors that are able to trigger apoptosis. Among the members of 
the TNF receptor (TNFR) Fas (CD95/Apo-1) and the p75 neurotrophin receptor (p75NTR) family 
are recently demonstrated to be involved in neuronal death [Raoul, 2002]. 
The Fas apoptotic pathway has been extensively investigated as a model system for mammalian 
apoptosis. Fas molecules preassemble into homotrimers via the preligand-binding assembly 
domain in the extracellular regions [Chan, 2000; Siegel, 2000]. Upon binding to the trimeric Fas 
ligand (Fas-L), Fas recruits a cytosolic adapter protein, Fas-associated death domain (FADD), 
through an interaction between the Fas intracellular death domain and the FADD C-terminal death 
domain [Boldin, 1995]. FADD contains a death effector domain (DED) in its N-terminal region. 
DED interacts with the prodomain of procaspase-8 and recruits procaspase-8 to Fas forming a 
multimeric complex [Boldin, 1996]. This complex, formed by Fas, FADD, procaspase-8, and 
possibly other proteins, is known as death-inducing signalling complex (DISC) [Kischkel, 1995]. 
The formation of DISC, after the recruitment of procaspase-8 leads to zymogen activation, likely 
occurring through autoproteolytic processing. This process activates the signalling of procaspase 8, 
which eventually activates the effector caspase 3 [Blatt, 2001]. The activation of these complexes 
elicits a wider series of events leading to the involvement of the c-Jun amino-terminal kinase 
(JNK), the second protein kinase (PKB or AKT), the nuclear factor-xB (NF-, KB) and other targets. 
Two other death receptors can be included in the extrinsic apoptotic pathway. They are classified 
as death receptors 4-5 or DR4 and DR5, and they are structurally and functionally similar to Fas. 
They mediate apoptosis upon activation by their ligand, the TNF-related apoptosis-inducing ligand 
(TRAIL) [Wiley, 1995]. In contrast to other members of the TNF family, whose expression is 
tightly regulated and is often only transiently expressed on activated cells, TRAIL mRNA is 
expressed constitutively in a wide range of non neural tissues. Similarly, DR4 and DR5 transcripts 
are expressed in many normal tissues [Wiley, 1995]. In neurons, the activation of TRAIL receptors 
induces the cleavage of procaspase-8 [Griffith, 1998]. Caspases-8 activation can be detected within 
minutes after the addition of TRAIL to target cells, suggesting that caspase-8 is one of the proximal 
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TRAIL signalling. Studies using 
experiments have also shown that the TNF-receptor-associated death domain (TRADD) may be 
recruited by both TRAIL-RI and -R2 [Chaudhary, 1997]. In addition it was found that both 
TRAIL-RI and -R2 can induce NF-KB activation, but are also capable of inducing JNK kinase 
activity [Hu, 1999]. TRAIL induces NF-KB activation by a caspase-sensitive event and cannot 
produce apoptosis by inhibiting NF-KB activation. This process implicates the presence of a 
protein, whose cleavage by caspäses precedes NF-KB activation [MacFarlane, 2000]. 
TNFR1, together with TNFR2, mediates the pleiotropic effects of TNF-a, a primary inflammatory 
cytokine whose activation is thought to be involved in different diseases associated to neuronal 
injury or an inflammatory response. TNFR1 is expressed ubiquitously, while TNF-a is produced 
mainly by activated macrophages, T cells and microglial cells. Upon binding to TNF-a, TNFR1 
associates with an adapter protein, TRADD [Hu, 1999], which then recruits FADD to activate 
caspase-8 and tumor necrosis-associated factor 2 and receptor-integrated protein 1 (TRAF2/RIP1) 
to activate JNK and NF-KB, respectively [Stanger, 1995; Ting, 1996]. 
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2.2.2 Intrinsic Pathway 
While the extrinsic pathway seems to be activated by a relatively small number of structurally 
related ligands, intrinsic, or mitochondrial-apoptosome associated apoptosis, can be triggered by a 
wide variety of structurally unrelated agents. This implies that intrinsic apoptosis can be induced 
by more than one single mechanism [Sastry, 2000]. 
2.2.2.1 Neurotrophic factors withdrawal 
During development the neurons that fail to establish proper connections with their respective 
postsynaptic targets die to the lack of a sufficient trophic support. Intrinsic apoptosis caused by 
trophic factors withdrawal, represents the primary source of neuronal apoptosis in embryo CNS. 
This is an active process that involves the release of cytochrome-c and requires synthesis of 
proteins. 
It was initially proposed that trophic factors exert a tonic inhibition by inactivating apoptotic 
pathway and consequently their removal activated the cascade of events inducing cytochrome-c 
release and caspases activation. To date, an alternative hypothesis has been proposed [Sanchez, 
2001] and the current picture of sympathetic neuronal death pathway is as follows. 
Consequently to the lack of NGF, neurons express and activate proteins that may play critical roles 
in apoptotic signal transduction, including two transcription factors of the activator protein-1 (AP- 
1) family, c-jun and c-fos. c-jun and other factors may act together to regulate the expression of 
different proapoptotic molecules. The phosphorylation of c-Jun by JNK and the consequent 
activation of a molecule belonging to the proapoptotic adapter proteins, the "BCL2 interacting 
mediator" of cell death (BIM) [Yuan, 1995], are considered as the critical step for development of 
competence-to-die in sympathetic neurons deprived of NGF [Whitfield, 2001]. Following its 
phosphorylation c-jun promotes BIM activation and the consequent translocation of BAX, from 
cytosol to mitochondrial outer membrane close to mitochondrial megapore known as the 
permeability transition pore (PTP). Translocation of Bax to mitochondria lead to mitochondrial 
depolarization and cytochrome-c release finally activating the caspases cascade cell signalling 
[Sartorius, 2001]. 
The possible contribution of trophic factor (serum and BDNF) withdrawal in inducing 
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apoptotic cell death in primary cultures of motor neurons will be widely investigated as object of 
this thesis (see chapter 10). 
2.2.2.2 Ca++ overloading 
Ca' overloading can be important factor, principally in excitable cells, to activate intrinsic 
apoptotic pathways. The induction of apoptosis by Caoverloading depends on the intensity of 
Cam influx [Orrenius, 1994]. 
Although excitotoxicity and the resulting imbalance of neuronal Ca' homeostasis have been 
extensively studied, the downstream mechanisms generated from increased [Ca++ ]; are still poorly 
understood. Potential targets of Cam include kinases, phosphatases, proteases, phospholipases, NOS 
and mitochondrial deficits [Choi, 1995; Nicotera, 1997; Leist, 19971. 
In in vitro experiments, by using rodent cerebellar granule cells (CGC), it has been demonstrated 
that high doses of glutamate produce a typical necrosis identified by the disruption of membrane 
integrity, the collapse of mitochondria, the membrane potential decay and the swelling of nuclei. In 
contrast, by maintaining a milder excitotoxic stimulation, by lower but longer lasting exposure to 
glutamate or glutamate agonists, a great percentage of neurons did not die by necrosis but 
following an apoptotic pattern [Ankarcrona, 1995]. These results suggested that, depending on the 
selective alteration in the different targets, due to the intensity of Ca+' entry, neurons can shift from 
apoptotic to necrotyc/lytic cell death [Ankarcrona, 1995; Nicotera, 1997]. 
In agreement with previous results, in different experiments carried out in CGC cultures exposed to 
low doses of excitotoxins, Leist confirmed the typical pattern of apoptosis in which the nuclear 
fragmentation, proteolysis of cc-fodrin and the translocation of phosphatidylserine to the outer layer 
of plasmatic membrane, were seen prior to any loss of cell integrity and membrane impermeability. 
All these events were prevented both by glutamate receptor antagonists and by caspase inhibitors. 
In contrast, in CGC exposed to higher concentration of glutamate, caspase inhibitors resulted 
weakly protective [Leist, 1997]. 
This evidence suggested a possible coexistence of two different processes of death. The authors 
proposed that the two distinct pathways are differentially activated depending on the intensity of 
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cell death signal. 
When Cam influx is slow and relatively moderate the pathway involving protease activation is 
activated. This pathway is likely related to a delayed loss in Ca++ homeostasis and its effect is 
almost completely prevented by agents that inhibit the cleavage of caspases. On the other hand, 
stronger glutamatergic stimulation can produce a massive Ca++ influx. In this latter condition In 
order to maintain the physiological ratio [Ca ]oý[Ca ]ýyýsoi = 104, free Cam is first readily 
inactivated by calcium binding proteins, (i. e. calbindin, calretinin, parvalbumin). If calcium 
binding protein activity is insufficient to restore physiological levels of free Ca++, the excess is 
removed from the cytoplasm and stored in different sub cellular components, such as mitochondria 
and ER, by a process of uptake. This rapid accumulation of Ca' reduces the functionality of these 
organelles thus provoking a so fast decay in cellular activity that the cells, that are triggered to 
undergo to apoptosis, are instead forced to die by necrosis [Volbracht, 1999]. 
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2.2.3 Antiapoptotic and proaptotic molecules 
Mammalian B-cell lymphoma-2 (BCL2) proteins [Hengartner, 1994], are constituted of at least 15 
proteins structurally related to CED-9 and grouped in the so-called BCL2 protein family [Adams, 
1998 ; Chao, 1998 ; Newton, 1998]. All members of the family posses at least one of the four 
conserved BCL-homology (BH) domains (BH1, BH2, BH3, and BH4). Besides to BCL2, some of 
these proteins (such as BCL-XL and BCL-W) act as survival factors, whereas others (such as BAX, 
BAK, BAD, and BID) are pro-apoptotic agents. BCL2 and BCL-XL can prevent the release of 
cytochrome-c from mitochondria, avoiding assembling of the apoptosome, and thereby protecting 
cells from being killed [Li, 1998 ; Luo, 1998]. In addition, BCL-XL in mammals interacts with 
Apafl. This interaction results in inhibition of the association of Apafl with procaspase 9 and with 
consequent blockage of apoptosome formation and caspase 9 activation [Adams, 1998]. 
Some of the BCL2 family members can interact with each other by forming homo- or 
heterodimers. Although the subcellular location of each component of the BCL2 family differs 
slightly, most of them are found in the outer mitochondrial and in nuclear membranes. In normal 
conditions, BCL2 is concentrated in the outer mitochondrial membrane, while BAX is largely 
confined to the cytosol and translocate to the mitochondrial outer membrane once apoptotic 
pathway is activated [Hsu, 1997]. 
BID is normally cytoplasmic and apparently inactive; following proteolytic activation, BID 
translocates to the mitochondria and triggers the mitochondrial death pathway, as evidenced by the 
release of cytochrome-c. 
On the other hand, BAD has been shown to be regulated by protein phosphorylation, which allows 
its sequestration by chaperone protein 14-3-3 and inhibition of its proapoptotic activity [Zha, 
1996]. 
While BCL2 is placed in the intermembrane space the pro-apoptotic family members (BAD, BAX, 
BID) may be either cytosolic or present on the cytoplasmic surface of the outer mitochondrial 
membrane [Zimmermann, 2001 ]. 
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2.2.4 The role of mitochondria 
2.2.4.1 Mitochondrial membrane potential 
The importance of mitochondria in the initiation of apoptosis is illustrated by the finding that 
mitochondrial factors can induce chromatin condensation and nuclear fragmentation typical of 
apoptosis in cell free Xenopus egg extracts [Newmeyer, 1994]. In many cases mitochondrial 
apoptosis is associated with a sequence of events that includes the PTP opening, the decrease of 
mitochondrial membrane potential (ATM) and the release in the cytoplasm of small mitochondrial 
proteins responsible for the initiation of caspase mediated apoptosis, the apoptotic-initiating factors 
(AIFs). Depending on different physiological effectors, the PTP complex can adopt an open or a 
closed conformation but physiologically, most if not all PTPs are closed [Zoratti, 1995; Bernardi, 
1996]. 
The '`1 M is dependent on the capacity of mitochondrial complexes I, 111, and IV to use electron 
energy in the carrier molecules nicotinamide adenine dinucleotide (NADH), ubiquinone, and 
cytochrome-c to pump protons out of the mitochondrial matrix by transporting them across the 
inner mitochondrial membrane. The ATm and the ipH contribute to a proton electromotive force 
(Sp). Since 0`PM is the greatest contributor to Sp, it can be assumed that ATm varies almost linearly 
with the ATP/ADP ratio and provides an estimate of the ATP/ADP ratio within individual 
mitochondria [Tager, 1983]. 
In most experimental conditions in which apoptosis is induced, L'PM decay is one of the earliest, if 
not the earlier, detectable event to discriminate this type of cell death [Wadia, 1998]. In neuronal 
apoptosis induced by NGF withdrawal A I'M was found significantly reduced 3-6 h prior to nuclear 
DNA fragmentation and chromatin condensation [Sasaki, 2000]. 
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2.2.4.2 The permeability transition pore 
Opening of the PTP dissipates any remaining proton gradient across the mitochondrial membrane 
and further reduces the EI'PM. In addition, PTP opening allows to free exchange between the 
mitochondrial matrix and the extramitochondrial cytosol of solutes and proteins smaller than 1500 
Da. This exchange of soluble factors can produce mitochondrial swelling, the rupture of the outer 
mitochondrial membrane and the consequent release of AIFs components, in particular 
cytochrome-c, from the intermembrane space of the mitochondria into the cytoplasm [Goldstein, 
2000]. 
Several factors are known to influence opening or closure of the PTP, one of the elements that 
favours pore closing and acts as anti-apoptotic agent is Cyclosporin A. Cyclosporin A binds to the 
PTP and maintains it in a closed position. Moreover it also promotes pore closure by binding 
cyclophilins that otherwise induce PTP opening in the presence of Ca+' [Bernardi, 1996]. 
The anti-apoptotic protein BCL2 maintains closure of the PTP in a manner similar to cyclosporin 
A. In fact BCL2 resides on the mitochondrial outer membrane close to the peripheral 
benzodiazepine receptor (PBR) and form a blockage for the ion flux between the outer and the 
inner membrane. On the other hand, the anti-apoptotic proteins BCL2 and BCL-XL work to prevent 
cytochrome-c release from mitochondria, and thereby protect cells from death [Kluck, 1997]. BCL- 
XL similarly regulates A'PM and matrix volume within mitochondria. Thus, opening of the PTP is a 
critical step in many forms of apoptosis and is proposed to constitute an irreversible step in the 
process [Mignotte, 1998]. 
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2.2.4.3 Cytochrome-c release 
Because in physiological condition, cytochrome-c does not move through the PTP, it can be 
released into the cytoplasm through fractures in the mitochondrial membrane. 
Cytochrome-c normally resides in the space between the outer and the inner membrane of 
mitochondria. During apoptosis the pro-apoptotic molecules are activated and translocate to the 
mitochondria where they induce the release of cytochrome-c (and other proteins) from the 
intermembrane space. It has been previously mentioned (see section 2.2.2) that a key event in the 
intrinsic pathway is constituted by the release of cytochrome-c into the cytosol [Neame, 19981. 
At high and medium levels of 0'YM cytochrome-c content in mitochondria varies randomly with 
ABM thus maintaining its level over a physiological threshold. At low 0`I`M levels, 
intramitochondrial cytochrome-c levels fall dramatically and nearby cytoplasmic cytochrome-c 
levels increase reciprocally [Gorman, 2000]. Once diffused into the cytosol cytochrome-c is able to 
initiate the processing of multiple caspases activation. In different experiments performed on cell- 
free extracts, depletion of caspase 9 rendered all the other caspases unresponsive to cytochrome-c, 
suggesting that all of these caspase activation events lie on the same pathway, with caspase-9 at the 
apex of the cascade [Garrido, 1999; Garrido, 1999]. 
2.2.4.4 Apoptosis-initiating factors 
AIFs represent an important class of cytosolic proteins which are normally located in the 
intermembrane space of mitochondria and which promote the propagation of apoptotic cascade 
once cytochrome-c is released from mitochondria in response to a fall in LW'M and of PTP opening 
[Newmeyer, 1994]. 
Apafl is a part of a large protein complex, the apoptosome [Adams, 1998]. Upon binding to 
cytochrome-c (also indicated to as Apaf2), which is released from mitochondria at the onset of 
apoptosis, a series of conformational changes lead to Apafl multimerization and association with 
procaspase-9 (or Apaf3) with the generation of the about 1 MDa molecular weight, the apoptosome 
[Adams, 1998]. 
In addition to cytochrome-c, another protein, with the dual name Smac/DIABLO is released 
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together with cytochrome-c during early phase of apoptosis. Smac/DIABLO has been identified as 
adapter molecule from mitochondria and caspases activation [Verhagen, 2000]. It promotes 
caspases activation both by associating with the apoptosome and inhibiting a family of proteins that 
function as inhibitors of apoptosis (IAPs). 
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2.2.5 Caspases 
Caspases are known to cleave a number of structural targets as well as RNA splicing and DNA 
repair-associated proteins but can also process other caspases [Casciola-Rosen, 1994; Tewari, 
1995]. Caspases can serve both as transducers and executioners of cell death [Reed, 2000]. 
To date the 14 members of the caspase family can be divided into three subfamilies on the basis of 
the peptide-sequence preferences of their substrates: I) the ICE-protease subfamily (caspases 1,4, 
5,13 and 14, and murine caspases 11 and 12); II) the CED-3 subfamily (caspases 3,6,7,8,9 and 
10) and; III) the caspase 2 subfamily. Each of the 14 different mammalian caspases may be 
responsible for cleavage of several different molecules, reflecting the more complex structural 
morphology of apoptosis. Each caspase is initially synthesized as a zymogen and requires 
processing at specific cleavage sites to generate the active enzyme. Different subsets of caspases 
are activated depending on the different pro-apoptotic stimuli [Li, 1997]. 
In the intrinsic apoptotic pathway caspase 9 seems to be the first caspase to become activated, 
almost certainly due to clustering of this protease via Apaf-1. Apaf-1 and procaspase 9 form a 
complex at a 1: 1 ratio (Zou H 1999). Thus, procaspase 9 molecules are brought into close 
proximity by Apaf-1 and activated by autocleavage. Active procaspase 9 then cleaves and activates 
procaspase 3 [Li, 1997]. There may be a positive feedback loop between these two caspases, as 
active caspase 3 cleaves partially processed caspase-9 to generate the final form of the mature 
caspase 9 [Roth, 2001]. Cytochrome-c is able to initiate the process of activation for several 
caspases (-2, -8, -9 and -10) but all these events were blocked by removal of caspase 9 from 
extracts, confirming that this protease is indispensable for cytochrome-c-initiated program of death 
and occupies an apical point in the caspase cascade [Garrido, 1999]. 
Caspase 3 and -7 were activated downstream of caspase 9 and these caspases propagate the caspase 
cascade by activating caspase 2, -6, -8, and -10 alternatively. 
The pattern of caspase 3 breakdown suggests that caspase 9 attacks this molecule between the large 
and small subunits and that caspase 3 subsequently removes its own prodomain by autocatalysis. 
The pattern of immunostaining for cleaved caspase 3 indicated that caspase 3 is cleaved in the 
cytosol and then rapidly translocated into the nucleus. It is well known that activated caspase 3 is 
responsible for proteolytic cleavage of several proteins in apoptosis [Tsutsumi, 2001]. 
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Activated caspase 3 in turn activates caspase 2 and -6 [Chang, 2000]. 
An independent activation of apoptotic pathway in which caspase 9 seems preferentially interact 
with procaspase 7 is observed in different apoptotic pathways in neurons. Although the 
contribution of caspase 7 activation in apoptosis is controversial, in neurons exposed to 
staurosporine, a different timing and a distinct subcellular over expression of caspase 7 with respect 
to the classical profile of caspase 9/caspase 3 cleaved substrates was found. This evidence suggests 
that some differences could exist between caspase 3 and caspase 7-mediated cell signalling [Deas, 
1998]. Interestingly immunohystochemical studies carried out to characterize the type of motor 
neuron death occurring in SOD 1 transgenic mice (see section 3.2.4) revealed a marked and 
selective immunoreactivity for caspase 9 and caspase 7 was observed in degenerating motor 
neurons following BAX translocation and cytochrome-c release [Guegan, 2001 ]. 
In contrast, activation of caspases 1, -4 and -5 was not observed in response to cytochrome-c 
release. This evidence suggests that these caspases participate at the upstream level of the release 
of cytochrome-c into the cytosol [Liu, 1996; Pan, 1998]. On the other hand, caspases 3,6, and 8 are 
preferentially activated by the Fas/TNF-mediated death pathway [Zimmermann, 2001]. 
Caspases often function in cascades; an upstream caspase (initiator caspase) is activated by its 
interaction with a caspase adapter(s). Once activated, the initiator caspase processes and activates 
one or more downstream caspases (effector or executioner caspases). The activated effector 
caspases then cleave various cellular proteins, leading to apoptotic cell death. 
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2.2.6 Caspases substrates 
To date, more than 60 proteins have been shown to be substrates of one or more caspases in 
mammalian cells, and the list is still growing. These substrate proteins contain one or more caspase 
cleavage sites in interdomain linker sequences [Stroh, 1998]. 
2.2.6.1 Nuclear substrates 
Well-documented targets for the activated caspases are nuclear elements. 
During apoptosis, nuclear DNA is condensed and degraded into large bodies (50 to 300 kb) and 
subsequently into small oligonucleosomal fragments of several hundred base pairs, for this reason a 
standardised assay to determine apoptosis is the typical observation of DNA laddering following 
electrophoresis in agarose gel. 
Historically, one of the first proteins identified as being cleaved during apoptosis by diverse stimuli 
was the poly (ADP-ribose) polymerase-1 (PARP-1). PARP-1 cleavage activity was in fact used to 
identify and purify caspase3 as an effector caspase [Nicholson, 1995; Tewari, 1995]. PARP is a 
nuclear enzyme that senses DNA nicks and catalyzes the ADP-ribosylation of hystones and other 
nuclear proteins in order to facilitate DNA repair. PARP is cleaved at a single site by caspase-3, 
which separates the N-terminal DNA-binding domain from the catalytic domain and inactivates the 
enzymatic activity [Lazebnik, 1994]. 
Biochemical purifications have led to the discovery of a caspase-regulated DNAase complex 
termed DFF (DNA fragmentation factor) that is composed of a DNase termed CAD (caspase- 
activated Dnase) and its inhibitor ICAD [Liu, 1997]. In healthy cells, CAD is complexed with 
ICAD and functionally inactive. In apoptotic cells, ICAD is cleaved by caspase 3 and -7. The 
cleavage provokes the release of CAD and the degradation of nuclear DNA [Sakahira, 1998]. DFF 
induces both chromatin condensation and DNA fragmentation in vitro [Liu, 1997], and cells from 
mice deficient for DFF activity exhibit neither of these classic apoptotic features when induced to 
die [Zhang, 1998]. 
Interestingly, another caspase 3-activated factor, named acinus, induces chromatin condensation 
without affecting DNA fragmentation [Sahara, 1999]. 
Although there are multiple sensors that record and transduce DNA damage within mammalian 
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cells, one of the most important is the p53 tumor suppressor protein. p53 plays a critical role as a 
transducer of damage to genomic integrity into growth arrest and/or apoptosis. DNA damage 
triggers stabilization and accumulation of p53, which then initiates either a Gl cell cycle arrest or 
apoptosis [Fraser, 1996]. It seems that, in response to appropriate stimuli, p53 translocates to the 
nucleus and plays a regulatory role in directing primary neurons toward differentiation or apoptosis 
[Caelles, 1994 ; Wagner, 1994]. p53 can induce apoptosis even after treatment with translational or 
transcription blockers, indicating that p53 can induce apoptosis through pathways that do not 
require de novo protein synthesis [Haupt, 1996]. 
Several lines of evidence converge to indicate that neurons undergo to apoptosis by p53-dependent 
or -independent pathways, depending on the stimulus responsible for the death. 
2.2.6.2 Cytoskeletal substrates 
The cytoskeleton is another important target for active caspases Apoptotic cells do not exclusively 
undergo to nuclear fragmentation, but also show shrinkage, and, in non neuronal tissues, cells 
become detached from surrounding cells and from the basal membrane. The molecular logic 
behind these changes appears more evident after the biochemical identification of many 
cytoskeletal proteins that are cleaved by caspases [Cotter, 1992]. 
Caspases attack multiple targets in the cortical actin architecture, a-fodrin and focal adhesion 
kinase, two components of the focal adhesion complex, which links cortical actin filaments, plasma 
membrane, and transmembrane proteins to the extracellular matrix, are cleaved by caspases and 
this process can lead to cell body shrinkage [Martin, 1996]. Actin itself is cleaved by effector 
caspases and the caspase-generated fragments may contribute directly to apoptotic changes of cell 
shape [Stroh, 1998]. 
Given some morphological similarities between apoptosis and mitotic catastrophe it is important to 
note that, in presence of active caspase 3 the cyclin-dependent kinase (Cdk) activity increases, and 
that the inhibition of Cdk activity attenuates apoptosis in several experimental systems [Shi, 1994]. 
A number of proteases, including cysteine proteases and calpains have been shown to contribute to 
apoptosis. Specific calpains have been shown to contribute to the cleavage of the cytoskeletal 
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protein actin that occurs during apoptosis and calpain inhibitors have shown to block actin cleavage 
in apoptosis. Interestingly, it has been also reported that calpains, once activated by caspases, can 
cut and inactivate the active form of caspase 3, thus producing a negative feedback [Jordan, 
1997; Nath, 1996; Jordan, 1997; Nath, 1996]. 
Many other proteins found to be caspase substrates are cleaved by effector caspases in the late 
phases of apoptosis. The kinetic data imply that this group of proteins may not have primary roles 
in regulating the decision to undergo cell death but they are activated to produce subsequent events 
of apoptosis, such as phagocytosis of apoptotic bodies or recycling of the cellular constituents. For 
instance, phosphatidylserine externalization at the plasma membrane facilitates phagocytosis of 
apoptotic bodies. Its externalization requires caspase activity. In this view, the activation of 
signalling cascades by caspases can be considered a "message from the dead". 
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2.3 Apoptosis and neurodegenerative diseases 
2.3.1 Positive evidence 
In adult neurons, apoptosis can be caused by exposure to excitatory amino acids [Mitchell, 
1994; Bonfoco, 1995], 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) [Tatton, 1997] and 
its metabolite MPP+ [Dipasquale, 1991; Mochizuki, 1994], 6-hydroxydopamine, the 25-35 fragment 
of (3-amyloid protein and prion protein [Chiesa, 2000; Forloni, 1996; Chiesa, 2000; Forloni, 1996], 
mutated presenilin 2 [Wolozin, 1996], mitochondrial complex I inhibitors [Hartley, 1994], high 
levels of dopamine [Ziv, 1994] or levodopa [Walkinshaw, 1995], the AIDS protein gp120 [Muller, 
1992] and overexpression of the mutant superoxide dismutase (SOD-1) gene [Rabizadeh, 1995]. 
In recent years, apoptosis has been described in a variety of human neurodegenerative diseases, 
primarily based on the use of in situ end labelling (ISEL) or dUTP nick and-labelling (TUNEL) 
techniques to detect neuronal nuclei with apparent DNA cleavage. ISEL-positive nuclei have been 
found in the brain of patients with Parkinson's disease [Mochizuki, 1996 ; Cotman, 1994], 
Alzheimer's disease [Dragunow, 1995], Huntington's disease [Thomas, 1995] and TUNEL positive 
cells were found in spinal motor neurons of ALS patients [Tews, 1997]. 
In different inherited neurodegenerative diseases, including Huntington's disease and 
spinocerebellar ataxia, a marked involvement of apoptosis was observed in distinct regions of the 
brain, and, interestingly, several polyQ proteins have been found to be substrates for caspase 3 
[Martin, 1999]. 
BCL2, was found to be decreased in neurons of Alzheimer's patients with neurofibrillary tangles, 
still resulting unchanged or increased in nearby unaffected neurons [Vyas, 1997]. 
In Alzheimer's disease post-mortem brains, an increase of c-Jun immunostaining has been reported. 
c-Jun positive immunostaining was observed in cells without ISEL-positive nuclei. This evidence 
suggested that these neurons may have entered the early stages of the apoptotic process but had not 
yet progressed to the point of nuclear DNA cleavage [Anderson, 1996; MacGibbon, 1997]. 
Increased levels of BAX and c-Jun were further found in cortical neurons from Alzheimer's 
patients, but without evidence of nuclear DNA cleavage. This apparent controversy could also 
suggest an activation of these molecules thus lacking the progression of apoptotic cell death 
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program [Roth, 2001; Su, 2001]. 
At present, it is not possible to determine a direct correlation between the decrease in L'I'M and its 
contribution in human neurodegenerative diseases. Evidence of mitochondrial impairment was 
reported in Parkinson's, Alzheimer's, and Huntington diseases [Bertoni-Freddari, 2004; Beal, 
2003]. This reduction of mitochondrial activity may be responsible for apoptosis through a relative 
failure of proton pumping and a consequent decrease of L`YM. However, as yet, these hypotheses 
are still too weak and more direct correlation between I`FM decay and the following steps of 
apoptosis (i. e. caspase9 and capspase-3 activation) must be produced to account for apoptosis in 
neurodegenerative diseases. 
2.3.2 Controversial evidence 
During the last decade apoptosis has become an appealing aim of study about cell death 
mechanisms in neuropatholgy. Therefore, the concept of apoptotic involvement in neuronal cell 
death has been widely used and abused in these general terms in relation to neurological diseases 
but its experimental demonstration is very problematic. 
Although positive staining of individual neurons with ISEL or (TUNEL) technique has been 
proposed to unambiguously establish the presence of apoptosis [Tatton, 1997], these techniques, if 
not coupled to an accurate ultrastructural study, are not necessarily unequivocal markers for 
detecting of apoptosis. Moreover, several reports have demonstrated that TUNEL positivity is not 
exclusively specific for apoptotic neurons and does not even necessarily label cells that are 
committed to die [Stadelman, 2001]. 
For instance, the high percentage of ISEL positive neurons that were reported in distinct studies 
[Mochizuki, 1996; Cotman, 1994] did not account for the rate of neuronal death that can occurs in 
Parkinson's and Alzheimer's disease, where neurons die asynchronously and over many years. 
This artefact may be due to changes in tissue perfusion and oxygen levels occurring in the period 
prior to death that accelerate the entry of these cells into the final stages of apoptosis. 
There are numerous claims that a postulated apoptotic cell death pathway plays an etiological role 
in Alzheimer's disease. However, although at least 7 different caspases have been implicated in 
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regulating neuronal death in response to (3-amyloid exposure, the direct involvement of caspase- 
dependent neuronal apoptosis in neurons of Alzheimer's patients remains uncertain [Roth, 2001]. 
In the case of Parkinson's disease, distinct groups have consistently failed to confirm previous 
report describing the occurrence of apoptosis in the substantia nigra [Hoglinger, 2004]. 
In addition it has been also reported the presence of caspase 3 positive neurons in the substantia 
nigra of patients with Parkinson's disease, but the correlation between the degree of dopaminergic 
cell loss in Parkinson's disease and the high number of caspase 3 positive neurons in post-mortem 
samples obtained from no neurological patients, utilized as control in this study, these subjects is 
far from convincing [Hartmann, 2001]. 
2.3.3 ALS and apoptosis 
Recent studies have suggested that apoptosis may be responsible for motor neuron degeneration in 
ALS. 
Although there are several observations of chromatin condensation in motor neurons of ALS 
patients, the effective involvement of apoptosis in neuronal cell death still remains to be 
demonstrated. The main source of doubt about apoptotic motor neuron death in ALS arises from 
the absence of DNA fragmentation, reported by Martin in the most cited study in which apoptosis 
is claimed in ALS [Martin, 1999]. 
In order to detect DNA fragmentation in motor neurons from ALS patients many other studies 
were performed. 
In two distinct investigations, TUNEL positivity was reported in the motor cortex, brainstem, 
cervical, thoracic and lumbar spinal cord of ALS patients [Ekegren, 1999]. However, in these two 
studies, TUNEL positive neurons were also found in control patients, thus suggesting a possible 
bias due to changes in tissue perfusion and oxygen levels in the period prior to death. In addition, 
an other group failed to provide evidence of DNA cleavage using in situ nick translation, a 
technique that involves the use of DNA polymerase I, and TUNEL staining both in motor cortex 
and lumbar cord segments [Migheli, 1994]. 
These controversial results suggest that, to ensure proper discrimination between apoptotic and 
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non-apoptotic motor neuronal death, TUNEL/ISEL studies should be supplemented with 
morphological and ultrastructural analyses. 
Although histochemical studies did not provide a clear indication of DNA fragmentation such 
results are supported by the presence of different apoptosis-related markers observed in ALS 
patients tissues. 
In a study conducted at the lumbar spinal cord level, the mRNA content of the antiapoptotic 
molecule BCL2 was found significantly decreased in ALS patients compared to patients that did 
not present neurological disorders. In the same study no significant differences were found, among 
the two experimental groups, by comparing the BCL-2 mRNA in unaffected regions of the lumbar 
spinal cord, dorsal horns and sensory nuclei [Mu, 1996]. 
In a similar study, no difference was found in BCL2 mRNA levels in the thoracic region but an 
increase in BAX was found in ALS patients [Ekegren, 1999]. 
A direct consequence of antiapoptotic/proapoptotic molecules imbalance and mitochondrial 
depolarization is represented by the release of cytochrome-c from the mitochondria to the cytosol. 
In addition to observations indicating a prevalence of the proapoptotic component and an alteration 
in PTP pore in motor neurons from ALS patients [Ekegren, 1999], cytochrome-c positive 
immunostaining was found in the cytosol of spinal motor neurons in sporadic ALS patients 
[Guegan, 2001]. In this study a weak and punctuate cytochrome-c immunostaining was observed in 
controls motor neurons, by contrast, in ALS patients, the remaining motor neurons exhibited a 
homogeneous and intense immunostaining possibly due to cytochrome-c release. However neither 
a double staining (indicating the integrity of mitochondria) nor further confirmations by the 
following steps (APAF I or active-caspase9) were investigated in this work. Thus, it is possible that 
the different pattern of staining of cytochrome-c in motor neurons of ALS patients may be due to a 
mitochondrial collapse and loss of integrity occurring in dying neurons, rather than an actual 
process of active release of cytochrome-c from mitochondria to the cytosol. 
Further evidence implicating caspases activation in the motor neuron death occurring in ALS 
derives from two distinct studies. A significant increase in caspase 3 activity in the spinal cord 
anterior horn and motor cortex of ALS patients was described by Martin [Martin, 1996] and a 
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massive increase, more than 80%, of caspase-1 activity was reported in the spinal cord from ALS 
patients [Li, 2000]. 
Although different results suggesting an apoptotic involvement in ALS motor neuron death are 
reported, these data resulted often weak and controversial. For this reason it is important to remind 
that, in a chronic disease like ALS, conclusive evidence of apoptosis are difficult to obtain given 
the rapidity of the apoptotic cell death process in relation to the relatively long lasting time-course 
of the disease. 
In acute models of neuronal death generated by excitotoxic exposure [Portera-Cailliau, 1996], 
trophic factors deprivation [Al-Abdulla, 1998] and axotomy [Heimer, 1978], evident signs of 
apoptotic involvement are observed from few to a maximum of 24 hours after injury. This short 
range of time to detect apoptosis suggests that, in a chronic disease like ALS, very few cells from 
several thousand motor neurons might be expected to show signs of ongoing apoptosis at any one 
time in temporally static post-mortem sample. Thus, a very large number of sections should be 
examined to obtain a true picture of the involvement of apoptosis in ALS patients: nevertheless 
caution should still be used in interpreting these data because of the late stage of motor neurons 
obtained from autopsy samples. 
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2.4 Neuroprotective and antiapoptotic effects of erythropoietin in different models of 
neurodegeneration 
2.4.1 EPO and erythropoyesis 
Erythropoietin (EPO) is a 30,400-dalton glycoprotein that regulates red cell production [Fisher, 
1971]. In humans, EPO is produced by peritubular cells in the kidney [Jacobson, 1957; Fisher, 
1971], and small amounts of extra-renal EPO are produced by the liver [Zanjani, 1977]. EPO binds 
to an erythroid progenitor cell surface receptor that, when activated, becomes dimerized [Declercq, 
1995]. 
EPO acts primarily to rescue erythroid cells from PCD in an anti-apoptotic manner. Using the 
EPO-dependent human erythroid progenitor cell line HCD-57, Silva [Silva, 1996] showed that 
EPO maintained erythrocytes precursors viability via repressing apoptosis by up regulating Bcl-xL, 
an anti-apoptotic gene of the Bcl-2 family. By culturing erythrocytes in the absence of EPO, Bcl-2 
and Bcl-xL are rapidly down regulated and the cells die apoptically. In support of this link between 
EPO and anti-apoptotic factors it has been reported that knockout mice for Bcl-xL exhibited foetal 
liver haematopoietic defects and had a severe anaemia during embryogenesis [Silva, 1996]. 
EPO acts synergistically with several growth factors (SCF, GM-CSF, IL-3, and IGF-1) to increase 
the survival and to augment the rate of maturation and proliferation of erythroid progenitor cells 
(primarily colony-forming unit-E) [Wu, 1995; Lin, 2004]. Oxygen-dependent regulation of EPO 
gene expression is controlled by a hypoxia-inducible transcription factor (HIF-1) [Semenza, 1991]. 
Other effects of EPO include a haematocrit-independent vasoconstriction-dependent hypertension, 
increased endothelin production, up regulation of tissue renin, change in vascular tissue 
prostaglandins production, stimulation of angiogenesis, and stimulation of endothelial and vascular 
smooth muscle cell proliferation [Smith, 2003; Vaziri, 1997; Nowicki, 1995]. 
Recombinant human EPO (rHuEPO) is currently being used to treat patients with anaemia 
associated with chronic renal failure, nonmyeloid malignancies in patients treated with 
chemotherapeutic agents, perioperative surgical patients, and autologous blood donation [Langston, 
2003]. 
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2.4.2 EPO and neuroprotection 
Over the last ten years, a prominent role for EPO has been defined in the CNS and there is a 
growing interest on the potential therapeutic use of EPO for neuroprotection. It is now widely 
known that EPO does not only affect the haematopoietic system, but it can be considered a 
multifunctional trophic factor with an effect on the general homeostasis of the entire organism 
[Konishi, 1993;. 
Brines et al. [Brines, 2000] reported that rHuEPO crosses the BBB and this passage is increased in 
conditions of neural injury. Although the BBB is considered impermeable to large molecules, 
recent studies clearly demonstrate that some high-molecular-mass molecules can be specifically 
transported into the brain across the capillary endothelium [Chong, 2002; Martinez-Estrada, 2003]. 
Several studies have been directed to evaluate the neurotrophic and neuroprotective function of 
EPO in different conditions of neuronal damage, such as hypoxia, cerebral ischemia and brain 
trauma [Brines, 2000; Agnello, 2002; Siren, 2001; Villa, 2003]. 
In a in vitro model of cerebral ischemia, comprising hypoxia and glucose deprivation, EPO (30pM) 
was shown to protect cultures of neurons from death and, in mixed astrocytes/cortical neurons 
cultures, in which a nonlethal ischemic event was induced, EPO demonstrated to exert its 
neuroprotective/anti-apoptotic action by inhibiting neuronal death via a cascade of phosphorylation 
starting from the dimerization of Jak-2 [Digicaylioglu, 2001]. 
In in vivo studies Sadamoto et al demonstrated that EPO reduces degeneration in rats with 
permanent middle cerebral artery occlusion. Using in situ hybridization technique, they also found 
that EPOr mRNA is up-regulated in the periphery of the cerebrocortical infarction, the so-called 
ischemic penumbra [Sadamoto, 1998]. In 1999, Bernaudin et al. reported the potential role of EPO 
in focal permanent cerebral ischemia induced in mice by permanent occlusion of the left middle 
cerebral artery. Mice treated with intraventricular injection of recombinant mouse EPO produced a 
significant reduction of the infarction volume at the periphery. 
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Because of EPO acts by increasing the neuronal survival only in the penumbra but not in the 
necrotic core, it has been postulated that EPO only protects the penumbra in relation to the 
different type of neuronal death occurring in the ischemic core and in the penumbra area, 
respectively. It would be possible to argue that EPO does not protect against the first type of death 
because the temporal window between the ischemic induction and the cellular death in the core is 
too short to avoid the therapeutical effect of EPO. However, even if EPO is administrated several 
hours before the ischemic injury, this compound results ineffective in reducing the rate of death at 
the ischemic core. This evidence further supports the hypothesis of a selective anti-apoptototic 
effect of EPO [Bernaudin, 1999]. 
Siren et al. showed that rHuEPO administration, in rats with middle cerebral artery occlusion, 
dramatically reduces the infarction area 24h after ischemic induction [Siren, 2001]. 
In addition, EPO not only protects neurons from cell death induced following ischemia, but also 
from a variety of other detrimental stimuli, including excitotoxins exposure and glucose 
deprivation. 
Morishida at al showed that, in cultures of neurons, EPO pre-treatment prevented glutamate- 
induced neurons death in a dose-dependent manner [Kawakami, 2001]. The anti-excitotoxic effect 
of EPO has been further confirmed in cultures of cortical neurons exposed to glutamate or 
glutamate-receptor agonists [Sinor, 2000]. Although a short incubation with EPO (5 min or less) 
has already capable to induce a partial neuroprotection against glutamate toxicity, a relatively long 
incubation period (8h) is required to obtain a consistent neuroprotection. 
Finally, it is important to note that rHuEPO treatment improved brain function, as shown by 
findings from neuropsychological tests and electrophysiological measurements [Nissenson, 1992]. 
Although the discovery of the production of EPO by neuronal cells it is quite recent, treatments 
with rHuEPO have definitively highlighted its neurotrophic and protective effect of the hormone, 
thus opening new frontiers in the treatment of diseases of the CNS, mainly in pathologies where 
apoptosis is involved. 
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CHAPTER 3 
in vitro AND in vivo models of ALS: 
ADVANTAGES AND PITFALLS 
Several aetiopathological hypotheses have been proposed to explain the death of motor neurons that 
occurs in ALS. These hypotheses are generated from different experimental data, clinical and 
biochemical estimations, post-mortem analyses in the spinal cord and brain tissues and by the 
evidence provided from different neurodegenerative processes that leads to neuronal death in other 
types of acute or chronic disorders. However, these approaches lack a well-established pathological 
mechanism occurring in ALS because of their incapability to obtain experimental evidence 
concerning the early events of motor neuron degeneration. In ALS patients the condition of motor 
neurons in post-mortem tissues represents the main limit in studying the early events involved motor 
neuron death. Consequently, alternative models are required in order to bypass the limit of 
investigation deriving from post-mortem samples. 
For this reason, in vivo and in vitro models of motor neuron disorders represent a useful tool to 
obtain more detailed information about the main detrimental processes leading to motor neuron 
death. 
3.1 Cellular models 
Although embryonic spinal cord motor neurons obtained from primary cultures are the best 
characterized model of study in the field of in vitro research, different approaches are available. 
Several tissue culture studies using human CNS tissue have been carried out, but they gave 
insufficient information about spinal cord neurons in culture [Gilden, 1975]. Since the main 
limitations to obtaining human primary cultures motor neurons are represented by the source of the 
tissue ( the embryo), cultures of adult human spinal cord have been reported as explants or 
dissociated cultures [Peterson, 1977; Erkman, 1989; Kim, 1990; Peterson, 1977). Unfortunately, these 
cultures are extremely fragile and their low percentage of viability (even in basal conditions and in 
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presence of serum and trophic factors) did not produce useful results. 
Because of the difficulties in studying human spinal cord cultures, the use of non-human spinal cord 
cultures is considered a reliable alternative of research. Organotypic cultures and cell-lines derived 
from tumours, or-from cells that are dedifferentiated and transformed in vitro, such as the fusion 
product of mouse neuroblastoma with primary mouse embryonic spinal cord neurons [Cashman, 
1992] are widely used in ALS research. 
The use of organotypic cultures, while maintaining reciprocal cell interaction and the presence of 
well-differentiated motor neurons, has two main limitations: the impossibility to perform analyses at 
the single cell level, and the detrimental effects of "experimental axotomy" on motor neurons. This 
form of axotomy is due to the fact that, in early postnatal age, the axons are already connected to 
their specific peripheral targets, and therefore, during the preparation of organotypic slices, the 
proximal stump of axon remains connected to the motor neurons whereas the distal part is lost. 
The possibility to perform a single cell study and to avoid the problems arising from "experimental 
axotomy" is derived from immortalized cell lines. However the use of cell lines as a model of motor 
neuron degeneration has not been entirely successful. This is due mainly to the fact that these cells 
often appear and behave like motor neurons but they are not motor neurons. Moreover, it is 
important to note that, they are frequently obtained by differentiation programs or from tumour cells 
which possess relevant differences both in term of cell biology and in their response to different 
external stimuli. 
For this reason, although such approaches can provide information to the basic mechanisms of 
cytotoxicity, primary cultures of motor neurons (obtained from embryonic rats mice and chickens) 
are the most reliable and direct model to perform more accurate and rapid measurements on different 
cell death pathways and to evaluate the effectiveness of future therapeutic strategies. 
3.2 Animal models 
The development of animal models for human diseases is an important scientific goal since they can 
provide valuable insights into the disease process itself. An ideal animal model of a human disease 
should satisfy a number of criteria; including the recapitulation of the pathogenic process, the 
presentation of the clinical and pathological features of human disease, and the 
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responsiveness to disease-modifying events, such as treatments. 
Several animal models of ALS have been proposed but yet none are thought to be completely 
satisfactory [Pioro, 1995; Price, 1994; Strong, 2000; Gurney, 1994]. The absence of a faithfull animal 
model of ALS is due largely to the paucity of knowledge about the aetiology and the pathogenesis of 
human ALS. 
This reflects the inevitable limitation of accurability reproducing human diseases in species with a 
different physiology and anatomy. Anyway, it is important to remember that all models of motor 
neurodegenerative diseases contribute to the understanding of common detrimental processes that 
lead to motor neuron death. 
The animal models for motor neuron disorders can be classified in three main categories: 
pharmacotoxicological models, animals showing spontaneous motor neuron degeneration and 
transgenic mouse models. 
Below a short description of the most common animal models of ALS is summarized, whereas a 
more detailed characterization of our model of study, the wobbler mouse, will be reported in Chapter 
5. 
3.2.1 mnd mouse 
The mnd mutation is a spontaneous, dominant mutation localised to chromosome 8 [Messer, 1992]. 
The mnd disease, characterized as a model of neuronal ceroid lipofuscinosis [Bronson, 1993; Pardo, 
1994], was initially proposed as a model of motor neuron disease, like ALS [Martin, 1999; Messer, 
1994]. In fact, mnd mouse exhibits adult-onset, progressive spastic paralysis moving from caudal to 
cranial spinal cord levels. The onset of the disease is recognisable at 6 months of age, the motor 
impairment progresses rapidly and lead to premature death at 10-12 months [Messer, 1993]. In spite 
of this rapid symptoms evolution the number of choline acetyltransferase (ChAT) immunopositive 
motor neurons and the ChAT activity in the spinal cord and hind leg muscles of symptomatic mnd 
mice is similar to control mice [Mennini, 2002]. The neuropathological hallmarks of mnd are 
inclusion bodies containing immunoreactive ubiquitin [Mazurkiewicz, 1991], degenerating 
mitochondria [Vance, 1997; Bertamini, 2002], lipofuscin and ATP synthase subunit-c accumulation 
[Pardo, 1994; Faust, 1994], the loss of Nissl substance, displaced neurofilaments [Callahan, 
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1991), and the loss of photoreceptors with degeneration of retinal cells [Messer, 1992; Messer, 
1993]. 
This series of clinical features render the mnd mouse a more appropriate model of human Batten's 
disease than of classical ALS [Battaglioli, 1993]. 
3.2.2 pmn mouse 
The "paralyse natural mutant" (pmn) mouse carries a recessive mutation on the chromosome 13 
[Brunialti, 1995]. Neuropathological and clinical signs have an early onset (2 weeks) and a rapid 
progression of symptoms [Schmalbruch, 1991]. Symptomatic phase begins at two weeks of age and 
evolves rapidly to death at around 40 days. Distal axonopathy is the most relevant sign of this 
pathology. In motor neurons, cell bodies and proximal axons are relatively preserved. Neurogenic 
muscle atrophy and subsequent paralysis are prominent [Kennel, 1996]. In the pmn mouse both 
growth factors and pharmacological agents, including riluzole have been shown to reduce symptoms 
progression [Haase, 1998; Sagot, 1995]. Nonetheless in pmn the mechanism of motor neuron death is 
not yet characterized, the evidence that Bc12 overexpression failed to slow clinical progression and 
to prolong the survival, account for a non-apoptotic cell death process [Blondet, 2002]. 
3.2.3 Wasted mouse 
The wasted mouse carries a recessive mutation that has been identified as a deletion of a sequence of 
DNA on chromosome 2 that prevents the expression of the gene coding for the translation 
elongation factor EG1a2 [Chambers, 1998]. It is still unclear why the disruption of this protein 
involved in protein synthesis should produce such a specific neurological syndrome. 
In the wasted mouse, neuropathological and clinical signs have an early onset, before the second 
week of age, and a very fast progression that leads to death within a month. Pronounced 
vacuolization is observed throughout the anterior horn region and in the brainstem of motor nuclei 
[Lutsep, 1989]. Spinal motor neurons degenerate and are lost, whilst upper motor neurons appear to 
be unaffected. Wasted mice also show lymphoid hypoplasia and other immunological anomalies 
[Kaiserlian, 1986; Libertin, 1994]. 
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Although many neuropathological hallmarks observed in the wasted mouse share with human 
disease, the early onset of symptoms and the short time of survival render extremely difficult to 
determinate the possible effectiveness of pharmacological treatments. 
3.2.4 SOD1 transgenic mouse 
The most characterized transgenic model for studying familial ALS is the transgenic mice for the 
mutation Cu /Zn++ superoxide dismutase (SOD1). Since 1993, when Rosen et al. reported the 
correlation between this mutation and a 20% of familial cases of ALS [Rosen, 1993], several lines of 
transgenic mice, and rats,, carrying different point mutations associated to human mutations, were 
produced [Gurney, 1994; Wong, 1995; Bruijn, 1997]. 
The onset of symptoms differs among the different type of mutation; however, all these mutations 
are able to produce a selective process of motor neuron degeneration. On the other hand, transgenic 
mice expressing the wild type form of human SOD1 (hSODI), thus showing mild 
neuropathological alterations in lumbar motor neurons, do not show neurological disorders, appear 
phenotypically comparable to healthy mice and do not present a "shortened life-span" [Jaarsma, 
2000]. 
The spinal cord motor neurons are mostly affected to the disease, the motor degenerative process 
follows a lumbar/cervical gradient, at the late stage of the disease almost all spinal motor neurons 
are disappeared and the death commonly occurs by respiratory failure. Cytological studies have 
demonstrated that degenerating motor neurons appeared highly vacuolized. At the end stage, the 
cytoplasm of motor neurons is almost empty; Nissl staining is very weak and not homogeneously 
distributed. Moreover, filamentous inclusions immunopositive for ubiquitin and neurofilaments are 
present in some of the surviving neurons [Gurney, 1994]. 
3.2.5 Wobbler mouse 
The wobbler mouse was originally characterized and described by Falconer in 1956. This mutation 
was first observed in some animals belonging to a C57BL/Fa strain and was associated with a 
wobbly gait characteristic of the mice. Mutant mice show a rapid and selective vulnerability of 
cervical spinal cord motor neurons. From the 3`d to the 12th week of age the number of cervical 
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motor neurons is reduced by about 65%. The onset of symptoms and their progression coincide with 
the rate motor neuron loss. Wobbler mice show a progressive atrophy of forelegs muscles 
accompanied to a marked decrease in muscular strength and motor ability. Although the wobbler 
disease was classified for a long time in the group of the spino muscular atrophy (SMA) because no 
neuronal alterations were been detected in the cortex, a result obtained using an in vivo approach by 
proton magnetic resonance spectroscopy confuted this idea. In this study Pioro observed that the cell 
bodies and the neurites of neurons of the neocortex had a strong immunoreactivity for ubiquitin and 
an accumulation of NF-H was observed in neuronal-cell bodies of the cerebral cortex [Pioro, 1998]. 
Although the actual loss of neurons has not yet been demonstrated in the cortex, this result suggests 
that neuronal target in wobbler mice is not restricted to lower motor neurons but may involve the 
brain areas. This finding renders this model more similar to ALS than to SMA [Pioro, 1998]. 
The wobbler mouse is a reliable model to investigate about the symptomatological, 
neuropathological and biochemical alterations leading to motor neuron degeneration. The main 
aetiopathological hypotheses that have been considered responsible for motor neuron death in 
humans, such as excitotoxicity, oxidative stress, deficit of trophic factors and accumulation of toxic 
proteins and aggregates, have been tested in wobbler mice. The results obtained have pointed out 
several defects that are common of human's diseases. 
A summary of the main neuropathological features characterizing the different animal models of 
ALS is summarized in table 3.1. 
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Anterior horn cell 
LYsosomial Chromatolvsi Vacuolization Vacuolization Vacuolizatio 
changes accumulation s 
Anterior horn cell loss lone Limited Extensive Extensive Cerv. sp cord 
Brainstem motor Some Limited Extensive Extensive Present 
neuron loss 
Axonopathy Absent Extensive Present Present Present 
Denervation Unknown Present Present Present Present 
Upper motor neurons Minimal Absent Present Some loss Limited 
Other neuronal groups Absent Brainstem Absent Absent Brainstem 
Table 3.1 Neuropathological alterations in murine models of ALS (modified from Doble 2000). 
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CHAPTER 4 
PRIMARY CULTURES OF MOTOR NEURONS 
4.1 Purified and mixed cultures 
4.1.1 Purified cultures of motor neurons 
In 1981 Schnaar and Schaffner first described the procedure to obtain purified motor neuron 
cultures. In that study, motor neurons were separated from the other cells by centrifugation and, 
using a correct density of neutral substance (metrizamide) a highest percentage of motor 
neurons was obtained [Schnaar, 1981 ]. 
This technique was then modified and adapted from several researchers and in 1993, 
Henderson and colleagues [Henderson, 1993] published a protocol to better purify motor 
neurons. Their method allows to obtain purified cultures of embryonic motor neurons (E14-15) 
by using antibodies specifically directed against the low affinity receptor NGFr, p75, which is 
highly expressed in rat embryo (E 14) motor neuron cell surface. This procedure of purification 
is commonly identified as immunopanning. 
The immunopanning markedly increased the percentage of purified motor neurons and also 
their resistance on plating. 
Unfortunately, although immunopanning increased the survival of purified cultures of motor 
neurons, these cultures are still highly vulnerable and their life span is influenced by several 
external parameters. Because of long term survival is a basic requirement to study a chronic 
disease or evaluate the effect produced by exposure to toxic and/or protective agents, the use of 
alternative condition, such as mixed co cultures, is often more indicated to study motor neuron 
behaviour. 
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4.1.2Mixed glia/neurons cultures 
An alternative source of investigation is represented by mixed glia/neurons cultures. Mixed 
cultures, obtained from anterior horn of embryonic spinal cord without cells purification, allow 
to prolong motor neuron survival and, moreover, to reproduce the physiological condition. 
A further application of mixed glia/neurons cultures involve the purification of a controlled 
layer of glial cells over which purified motor neurons are plated. 
In mixed glia/neurons cultures, glial cells surround motor neurons and maintain a physiological 
supply of trophic factors. This interaction produces an extensive neuntes outgrowth, a higher 
ramification of branched dendritic trees, and a more sustained formation of synapses and, above 
all, a longer life span compared to purified motor neurons that are laid to a simple laminine- 
polyornithine growing substratum on coated plastic. 
Cultures of motor neurons represent a reliable tool to evaluate, at the single cell level, the 
action of different stimuli that have been postulated to be involved in ALS aetiopathogenesis. 
4.2 Primary cultures of motor neurons and ALS-associated toxicity 
4.2.1 Cu/Zn SODI mutation and Fas-L activation 
The cell signalling induced by coupling of Fas-L to their receptors was deeply studied in 
control motor neurons and in motor neurons transfected with different missense mutation of 
human SOD-1 gene [Raoul, 2002]. 
In this study soluble oligomerised Fas-L or an agonistic anti-Fas antibody were administered, 
both in normal and in hSOD-1 transfected cultures. This study was carried to detect whether 
and how the intracellular death domain associated to Fas-L, was able to engage the upstream 
cascade leading to apoptotic activation either in the absence of an additive excitotoxic exposure 
or trophic deprivation. Interestingly, it has been shown that lethal Fas-L associated signalling 
pathway required transcriptional upregulation of neuronal nitric oxide synthase (nNOS) as well 
as the interaction of several proteins (Daxx, ASK1 and p38). The authors also elucidated that 
the mechanisms inducing nNOS transcription is finely tuned by p38 activity and that p38 (a 
kinase that is recently reported to be overexpressed in the ventral horns of h SOD-1 G93A 
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transgenic mice [Tortarolo, 2003]) plays a crucial role in enhancing the production of nitric 
oxide. Moreover the authors measured the toxicity produced by Fas-L administration in motor 
neurons overexpressing SOD-1 mutated gene compared to that in motor neurons 
overexpressing the wild-type form of SOD-1 human gene. They found that the rate of survival 
in "SOD-1 mutated motor neurons" was significantly lower compared "wild-type SOD-1 motor 
neurons". This result confirmed that mutant SOD-1 gene expression significantly enhanced the 
Fas-mediated motor neuron vulnerability. Moreover, they first produced direct evidence about 
the role of hSOD-1 mutated protein in the extrinsic apoptotic pathway involving TNF receptor 
family. A scheme showing the intracellular cascade of events produced by Fas-L in "SOD-1 
mutated motor neurons" is reported in figure 4.1. 
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Figure 4.1 A non cell-autonomous death pathway can be triggered by different detrimental 
stimuli. The overexpression in motor neurons of mutant SOD 1 enhances the toxicity of NO and 
FAS ligand exposure. Moreover, upon this stimulation, astrocytes and microglial cells represent 
a further source of damage for motor neurons (From Raoul, C., et al., Motoneuron death 
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triggered by a specific pathway downstream of Fas. potentiation by ALS linked SOD1 
mutations. Neuron, 2002.35(6): p. 1067-83. ) 
4.2.2 Glutamate-induced excitotoxicity 
The role played by different components of glutamate-induced excitotoxicity, such as 
glutamate receptors, glial glutamate transporters, alteration in glutamate metabolism, has been 
extensively investigated both in ALS patients and in different animal models of ALS. However, 
to better understand the cellular and molecular mechanisms involved in glutamate-induced 
motor neuronal vulnerability, in vitro studies are required. 
Cultures of neurons greatly contribute in understanding the role of glutamatergic neurotoxicity 
and represent a reliable approach to evaluating the effectiveness of several pharmacological 
treatments. 
4.2.2.1 AMPA and Kainate overstimulation 
Excitotoxicity in motor neurons mainly depend on AMPA/Kainate receptors overstimulation 
[Curtis, 1985]. For this reason excitotoxic strategies by treating cultures with AMPA and/or 
kainate are used in many laboratories and neuroprotective approaches using AMPA/Kainate 
receptor antagonists (riluzole and gabapentin) have been shown to be neuroprotective in 
different conditions. 
Initially purified cultures of motor neurons were considered the most indicated tool to study the 
cellular events related to excitotoxicity. However, this experimental condition does not provide 
any information about the role of glial cells in glutamate-induced neurodegenerative process. 
For this reason, mixed glia/neurons cultures are now considered a more appropriate model to 
investigating the mechanisms involved in glutamate-induced excitotoxicity. 
An indirect evidence of the involvement of AMPA/kainate receptors in glutamate-induced 
neuronal death was reported in the rat neurons cultures exposed to ALS patients cerebrospinal 
fluid [Couratier, 1993]. In this study it was observed that the neuronal toxicity produced by 
cerebrospinal fluid of ALS patients was prevented by treating the cells with 6-cyano-7- 
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nitroquinoxaline-2,3-dione (CNQX), a selective antagonist to AMPA/kainate. Contrary to 
NMDA receptor antagonists, CNQX produced a neuroprotective effect by significantly 
reducing the percentage of death. 
Carriedo [Carriedo, 1995; Carriedo, 1996] first reported that: I) embryo cultures of motor 
neurons are selectively vulnerable to AMPA/kainate receptor-mediated injury and; II) the in 
vitro kainate injury is dependent on the influx of Ca'. Motor neurons were preferentially 
injured by brief (40 min) kainate exposure, but not by NMDA exposure and; III) Ca removal 
from the media, during a brief kainate exposure, reduced the toxic effect by maintaining a high 
percentage of motor neurons with large cellular body and a marked SMI-32 immunopositivity. 
On the contrary, at the same doses of kainate, the raising of extracellular Ca++ caused higher 
motor neurons susceptibility. 
By hystochemical techniques, based on kainate-stimulated uptake of Co'-` [Pruss, 1991], it was 
observed that a high percentage of these neurons (about 80%) posses Ca++ permeable 
AMPA/kainate receptors. This evidence suggests that a rapid Cam entry through Ca++- 
permeable AMPA/kainate channels makes motor neurons more vulnerable than other types of 
spinal neurons to excitotoxicity. 
4.2.2.2 Cam influx and GIuR 2 subunit 
Several experiments were performed to evaluate the vulnerability of motor neurons exposed to 
AMPA/kainate compared to other spinal cord neurons. In these studies the role of 
AMPA/kainate receptors in motor neurons and in dorsal horn neurons was widely investigated. 
It was found that 20 minutes of kainate administration produces a dose dependent reduction of 
motor neurons survival but did not decrease dorsal horn neuron survival. Moreover it was also 
reported that this selective toxicity is dependent on [Cal,,,,, and is completely inhibited by the 
specific AMPA antagonist LY300164 and by Joro spider toxin, a selective blocker of AMPAr 
lacking of the edited G1uR2 subunit. 
It has been widely demonstrated that different neuronal cell types can diverge in G1uR2 
expression, in the rate of G1uR2 editing and in the desensitisation properties of their AMPAr. 
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These differences may be related to the selective vulnerability of motor neurons that occurs in 
ALS [Van Den Bosch, 2000; Vandenberghe, 2000]. 
Although GluR2 immunopositivity was observed in almost all motor neurons, double-staining 
experiments demonstrated that GluR2 positive motor neurons were also positive to Co++ uptake 
and sensitive to kainate stimulation. This result indicated that, despite the abundant expression 
of GluR2, a subset of AMPAr lack of the G1uR2 subunit and they are therefore Ca' permeable. 
The relative Cam permeability of AMPAr and the amount in G1uR2 was measured by 
combining whole-cell patch-clamp electrophysiology and single cell RT-PCR and compared 
between motor neurons and dorsal horn neurons. GluR2 resulted almost completely edited in 
both group of neurons. In addition, electrophysiological measurements did not reveal 
differences from motor neurons and dorsal horn neurons in terms of Ca++ conductance, kinetics 
of AMPAr desensitisation, receptor deactivation, and open channel probability. However, when 
the density of functional AMPAr in the whole membrane was measured, the amplitude of 
AMPAr current density (AMPAr current/cell capacitance) was 2.5 higher in motor neurons 
than in dorsal neurons. Finally the authors also demonstrated that AMPAr are responsible for 
the kainate induced inward Ca'' currents. 
These results suggested that the high Cam current density passing through AMPAr might be 
responsible for the selective kainate-induced excitotoxicity observed in motor neurons. 
To better understand the link between the glutamate dependent Cam influx and the excitotoxic 
mechanism proposed in ALS, a series of experiments with a more prolonged time of kainate 
exposure were performed. By treating motor neurons for 24 hours with low doses of kainate (5 
to 20 times lower than in acute treatment) a selective loss of SM132 positive motor neurons 
with a little or no damage in the other spinal neuronal populations was observed [Carriedo, 
1996]. Consistently with previous studies in spinal cord slices [Rothstein, 19931, the toxicity 
seemed to be mediated primarily through activation of AMPA/Kainate receptors, rather than 
NMDAr, as demonstrated by the evidence that the 2,3-dioxo-6-nitro-1,2,3,4, - 
tetrahydrobenzo[f]quinoxaline-7-sulfonamide (NBQX), a selective AMPAr antagonist, was 
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fully protective whereas (+)-5-methyl-10,11-dihydro-5H-dibenzo(a, d)cyclopheten-5,10-imine 
maleate (MK801), a compound that inhibits the NMDAr activity, was ineffective. 
4.2.2.3 The role of astrocytes 
Glial cells can extend the damage produced by glutamate agonists by increasing the stimulation 
of postsynaptic receptors and the consequent Cam wave. This assumption was confirmed by the 
evidence that neuronal vulnerability to kainate was two- to three-fold higher in co-cultures than 
in monoculture, and that this value increased by prolonging the time in co-culture. The increase 
in neuronal kainate vulnerability with time in co-culture was associated to a marked rise in the 
proportion of co cultured neurons expressing Cam''-permeable AMPA/kainate receptors, as 
determined by kainate-activated Con-uptake. Neurons in monoculture had no kainate-activated 
Co'+-uptake. Neurons were immunoreactive to specific antibodies against the AMPAr subunits 
G1uR1 and G1uR2 both in monoculture and co-culture. This study indicated that motor neuron 
differentiation in glialneurons cultures is associated with an increased vulnerability to kainate 
and increased expression of Ca++-permeable AMPA/kainate receptors. In this paradigm glial 
cells support basal survival and differentiation of neurons, but potentiate kainate-induced 
neuronal death [Comoletti, 2001]. 
In addition, astrocytes express a large number of receptors for neurotransmitter, including 
functional AMPA/kainate receptors and metabotropic GluRs. Accumulating evidence indicates 
that such receptors may be a target for the glutamate released from the presynaptic terminals 
[Porter, 1992]. This evidence strongly supports the view that glutamate not only stimulates 
postsynaptic receptors but can also activate receptors located on the nearby astrocyte 
membranes. In two studies performed in mixed glia/neuron cultures the authors independently 
observed that [Cam i elevations induced in astrocytes were followed by [Ca i1 elevations in the 
neighbouring neurons [Parpura, 1994]. Moreover, excitation of neurons following the passage 
of calcium waves in neighbouring astrocytes was observed to be reduced by administration of 
glutamate receptor antagonists [Hassinger, 1995]. 
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These studies indicate that: I) glutamate-stimulated activity can trigger [Ca]; increase in 
astrocytes and; II) [Cam]; elevations in astrocytes can start signalling to neurons. Thus, the 
neuronal calcium response comprised an indirect component mediated by glutamate, most 
likely released from the astrocytes [Pasti, 1997]. The possible role of astrocytes in enhancing 
motor neurons toxicity exposed to excitotoxins can be further reinforced by the direct 
demonstration that astrocytes release glutamate in response to stimulation of mGluRs and, more 
efficiently, in response to coincident stimulation of mGluRs and AMPA/kainate glutamate 
receptors [Bezzi, 1998]. 
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4.2.3 Free radical exposure 
Oxidative stress has been frequently associated to motor neuron degeneration. The experiments 
performed in purified cultures of motor neurons have shown that these cells are vulnerable to 
physiological oxidants. Treatments with radical-generating systems showed that motor neurons 
chronically exposed to low levels of oxidative stress die by apoptosis. By increasing the doses 
of oxidants, apoptogenic factors are still able to induce the upstream events of apoptosis but 
often, during the propagation of apoptotic pathway, the cells undergo a sudden decay of ATP 
levels, and die before apoptotic pathway is ended. Depending on the rate of oxidation it is 
possible to observe a mixed condition in which the characteristic of both apoptosis (shrunken 
nucleus, cleavage of caspases) and necrosis (membrane disintegration, leaky cells) are 
combined. When cells are depleted of energy, they die necrotically and when their energy 
supply is normal and mitochondrial function is undisturbed, they can finish the time- and 
energy- consuming process of apoptosis. 
The exposure of motor neurons to a substance that slowly releases nitric oxide (NO) is a more 
subtle way to expose motor neurons to free radicals [Kaal, 1997]. Under oxidative stress NO, 
that in physiological condition acts as neurotransmitter and neuromodulator agent, can react 
with superoxide to form an aggressive oxidant, the peroxinitrite [Beckman, 1996]. NO, 
possibly through peroxinitrite, is thought to play a role in ALS pathology [Beckman, 1993]. 
The role of oxidative stress on motor neuron degeneration is under investigation in mixed 
glia/neurons cultures, also because many authors have postulated that the detrimental action of 
oxidative stress in ALS patients may be amplified by glial activation. To better understand the 
link between astrogliosis and oxidative stress, a series of experiments were carried out. Cassina 
[Cassina, 2002] reported that the exposure of spinal cord astrocyte monolayers to peroxynitrite 
causes a sustained process of reactive gliosis and that furthermore promotes apoptosis of 
embryonic motor neurons subsequently plated on that monolayer. Interestingly, motor neuron 
death was largely prevented by NOS inhibitors and peroxynitrite scavengers but not by trophic 
factors that otherwise support motor neuron survival in the absence of astrocytes. 
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The role of glial cells in exacerbating the effects of NO was also reported by Comoletti et al. 
[Comoletti, 2001]. They observed that nitric oxide produced from glial cells increased the 
glutamate-induced toxicity and that the application of a nitric oxide synthase inhibitor, the 
nomega-nitro- 1-arginine methyl ester (L-NAME), significantly reduced the percentage of 
motor neurons death in mixed glia/neurons cultures. 
4.2.4 Mitochondrial inhibition 
Evidence is increasing that mitochondrial dysfunction is involved in ALS pathogensis (see 
section 1.2.2.3). 
Since mitochondria represent a preferential target for a plethora of toxic stimuli is quite 
impossible, by performing in vivo studies, to establish whether mitochondrial alterations 
represented a cause or an effect of an earlier defect. For this reason in vitro studies are a reliable 
strategy to evaluate the effects produced by direct alterations of mitochondria in motor neurons 
activity and viability. 
To study the role of mitochondrial dysfunction an in vitro model of chronic motor neuron 
toxicity, based on malonate-induced inhibition of complex II in the mitochondrial ETC chain, 
was developed. Mitochondrial inhibition has been shown to be highly toxic both for motor 
neurons and for dorsal horn neurons. Mitochondrial inhibition was further reproduced 
inhibiting the complex IV by sodium azide. The results, obtained by inhibiting complex IV 
were similar to those obtained by inhibiting the complex II: in both conditions motor neuronal 
death occurred by apoptosis. In this model of mitochondrial dysfunction, several molecules 
were tested. It has been reported that the free radical scavenger alpha-phenyl-N-tert- 
butylnitrone, the AMPA/kainate receptor antagonist CNQX significantly reduced motor neuron 
death induced by malonate [Kaal, 1999]. 
4.2.5 Protcasome inhibition 
Recently, proteasome inhibition has been suggested to be a possible contributor in ALS 
aetiopathogenesis and the effect of two proteasome inhibitors, lactacystin and epoxomicin, was 
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investigated on cultured spinal cord neurons [Kikuchi, 2002]. The incubation of proteasome 
inhibitors in cultures of spinal cord neurons induced neurotoxicity in a dose-dependent manner 
and that motor neurons were more vulnerable than the other spinal neurons. Morphological 
studies revealed that motor neurons treated with proteasome inhibitors showed cell bodies with 
the cytoplasm markedly altered and presenting a characteristic granular pattern. Moreover, 
proteasome-induced neurotoxicity has been accompanied with apoptotic nuclear changes, post- 
translational modification of cellular proteins, generation of intracellular free radicals, 
reduction in the amount of reduced glutathione, and mitochondrial dysfunction. Interestingly, 
the neurotoxic effect was reduced by the administration of low concentration of 
geranylgeranylacetone (GGA), which is widely used as an antiulcer drug. GGA was found to 
induce the expression of heat shock protein 70 as well as thioredoxin, which may partly 
contribute to the protective effect of GGA. These data suggest that the inhibition of proteasome 
may playa role in the mechanism of neurodegenerative processes leading to the motor neuron 
loss. 
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4.2.6 Neurotrophic factors withdrawal 
Purified cultures of motor neurons represent a valid target to evaluate the effectiveness of many 
pharmaceutical strategies and to understand molecular alterations elicited in response to a 
perturbation of the environmental conditions such as a decrease in neurotrophic factors 
concentration. Extensive studies were performed on purified cultures of motor neurons in order 
to better clarify the mechanism of action played by endogenous neurotrophic factors, such as 
NGF, BDNF, NT-4, CNTF, and also to test different drugs reported to have a protective and 
neurotrophic effect in in vivo models. 
4.2.6.1 BDNF 
Henderson et al. [Henderson, 1993] reported that isolated motor neurons are very sensitive to 
BDNF and NT-4, and their withdrawal induces apoptosis [Kaal, 1997]. Further experiments 
indicated that motor neurons in mixed glia/neurons cultures are less vulnerable to BDNF 
deprivation [Comoletti, 2001], likely because of the neurotrophic supply provided by 
astrocytes, which express and release the glial derived neurotrophic factor (GDNF). 
Neurotrophins, such as BDNF and NT-4, cannot replace muscle extract but in the presence of 
muscle extract they have a significant effect on survival preventing apoptotic cell death. 
Although the survival promoting action of BDNF and other neurotrophins has been adequately 
demonstrated (see section 2.2.2.1), the molecular mechanisms that are involved in their anti- 
apoptotic action are not yet completely elucidated. 
In a recent study in chick embryo spinal cord motor neurons, in which BDNF promotes cell 
survival, the intracellular pathways that may be involved in the BDNF-induced motor neurons 
survival was accurately analyzed [Dolcet, 1999]. The authors reported that, downstream the 
binding to its receptors, BDNF activated the extracellular-regulated kinase (ERK), mitogen- 
activated protein (MAP) kinase and the PI3K pathways. To examine the contribution of these 
pathways on the survival they treated cultures of motor neurons in presence of BDNF with PD 
98059, a specific inhibitor of MAP kinase, and LY 294002, a selective inhibitor of PI3K. PD 
98059, at doses that significantly reduced the phosphorylation of ERKs, did not show any 
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prominent effect on neuronal survival. However, LY 294002 at the dose that inhibited the 
phosphorylation of Akt, a down-stream element of the PI3K, completely abolished the motor 
neuron survival effects of BDNF. This result confirmed that the PI3K associated pathway plays 
an important role on the cell survival and that the tonic stimulation provided by BDNF is 
required to avoiding the activation of specific apoptotic pathways. 
4.2.6.2 CNTF 
In addition to the role played by BDNF, GDNF and NT3-4, in the last few years the link 
between CNTF and motor neurons survival has been exploited by different authors both in vitro 
and in vivo studies [Magal, 1991; Ikeda, 1995]. 
CNTF treatment in astrocytes increases their ability to increase the number of ChAT positive 
neurons in ventral spinal cord more than twofold compared to untreated astrocytes [Albrecht, 
2002]. The correlation between neurotrophic factors and ChAT expression in cultures of motor 
neurons was then confirmed by the results obtained in our laboratory by acetyl-L-carnitine 
(ALCAR) treatment [Bigini, 2002]. In mixed glia/neurons cultures we observed that ALCAR 
markedly increased both ChAT and Trk-B immunostaining. We hypothesized that the increase 
in ChAT immunoreactivity observed after ALCAR treatment, was not due to maintenance of 
physiological levels of ChAT, but was likely related to a neurotrophic-like response. It has been 
in fact reported that the stimulation of tyrosine kinase receptors and activation of the 
microtubular associated protein kinase (MAPK) cascade causes extensive phosphorylation and 
activation of the cAMP response element (CRE), in a region involved in the activation of 
ChAT gene transcription (cholinergic locus in rats) [Ginty, 1994]. 
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CHAPTER 5 
THE WOBBLER MOUSE 
5.1 Genetic 
Although many efforts have being done for several years to elucidate the symptomatological 
and neuropathological hallmarks of wobbler motor neuron degenerative process, the genetic 
component associated to this disease is still unknown and since 1992, the year of the mapping 
of locus wr, few progresses have been done in this field of research [Kaupmann, 1992]. 
Falconer provided the first important genetic evidence. Based on statistical analysis of the 
wobbler strain progeny, he showed that the mutated gene responsible for the disease is 
autosomal, recessive and apparently unique. Moreover, it was been reported that the wobbler 
karyotype did not reveal any visible sign of chromosomal deletion or translocation [Andrews, 
1974]. Twelve years ago Kaupman first individuated that the mutation linked to wobbler mouse 
disease is localized on a proximal region of chromosome 11; this region was identified as "wr 
locus". Later on, it has been also reported that the region of interest, identified by 
recombination, covers 4 MB and presents a conversed synteny on human chromosome 2p13-14 
[Kaupmann, 1992; Resch, 1998]. The genes localized in the wr locus correspond to Ugp2 which 
in humans encodes a muscle isoform of UDP-glucose phosphorylase, pelil that is believed to 
be an adaptor protein in different cellular pathways, Otxl a homeobox gene involved in the 
control of brain development, Hcc8 identified as hepatocellular carcinoma antigen, Mort which 
encodes cytoplasmic malate dehydrogenase and three others genes, Homolocl3, Kiaa0903 and 
Homoloc2, which functions are still unknown [Wedemeyer, 1996; Fuchs, 2002]. 
The level of the transcripts of these genes was measured and no differences were reported from 
wobbler mice and healthy littermates [Korthaus, 1996]. In addition a knockout mouse for Otxl 
expressed an epileptic phenotype likely unrelated to the wobbler motor neuron disease. 
113 
Chapter 5 The wobbler mouse 
In order to investigate a potential candidate mutation in a gene located to proximal region of 
"wr locus" on chromosome 11, we have recently collaborated with a group of genetists from 
Edinbourgh University. The gene investigated is a gene corresponding to the Sic 1a4 / ASCT1 
(Alanine, Serine, Cysteine, Threonine transporter 1) and it is another member of the glutamate 
transporter family. In humans it is positioned in a region which maps to 2pl4, and this is a 
region of conserved synteny with the wr locus on mouse chromosome 11. We have successfully 
extracted DNA and RNA from the wobbler and control tissues, and we have measured their 
expression using RT-PCR analysis. We found that Slcla4 / ASCT1 is expressed at similar 
levels (at the RNA level at least) in both wobbler and age matched healthy mice. Then we 
sequenced the coding region, in case, there was a more subtle mutation, but we did not find any 
difference between wobbler and healthy mice (Newberry and Bigini 2002 unpublished). 
These results raised the possibility that the wobbler mutation involves a noncoding sequence 
that could be localized up-stream the wr locus. 
Although the genetic alteration responsible for the wobbler mouse disease has not yet been 
identified, it is possible to individuate homozygous wobbler mice. In fact, by exploiting 
previous observations reporting an inner strain polymorphism between mouse strains new 
Zeeland black NZB mice and C57BL/6 at the Gln psl locus [Augustin, 1997], pre-symptomatic 
diagnosis can be easily performed by genotyping assay [Rathke-Hartlieb, 1999]. 
5.2 Symptoms 
A detailed and still convincing description of the neurological symptoms characterizing the 
wobbler mouse disease was done by Duchen and Strich over thirty years ago [Duchen, 1968]. 
In that study they observed that clinical symptoms are mainly related to the loss of cervical 
spinal cord and, to a lesser extent, of brainstem motor neurons. In spite of the early onset and 
the rapid symptoms progression it is possible to divide the clinical evolution of the wobbler 
neurological syndrome into three phases. 
The presymptomatic phase comprises the first three weeks of postnatal life. Around that period 
the animals that carry the mutation do not show any difference on phenotype compared to 
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healthy littermates, and no clinical signs were recorded. This phase is then followed by a rapid 
worsening, this evolutionary stage lasts from third/fourth to twelfth week of age and produces a 
relevant deficit in motor activity accompanied by a marked muscular atrophy and a loss of 
weight of forelimb muscles [Duchen, 1968]. 
The third phase is characterized by a stabilization of symptoms and is identified as plateau 
stage. During this phase a sustained loss of motor neurons is not observed, also because the 
sub-population of motor neurons selectively involved in this degenerative process, such as the 
cervical spinal motor neurons, are already almost completely disappeared. At the beginning of 
the plateau stage the volume of the spinal cord in affected mice is halved compared to healthy 
littermates. This reduction involves both the dorsal and the ventral horns and appears more a 
result of cell loss, than a side effect of the impaired growth. Indeed, 3 week-old wobbler mice 
are often already smaller than their healthy littermates, although the volume of their spinal cord 
is not yet changed [Boillee, 2001; Bose, 1999]. 
Despite its denomination, the presymptomatic phase may correspond to a subtle alteration of 
motor functions. For example in the strain used in my thesis, the NFR/wr line, an abnormality 
in the righting reflex at three to seven postnatal days of age and an impaired performance 
during grid - walking are reported [Bose, 1999; Bose, 1998]. Although neuropathological 
alterations are widely described at the presymptomatic stage, no clinical signs are observed 
prior to the 3d week of age. 
From 3d week of age, wobbler mice begin to growth slower than healthy littermates and, only 
a week later, they are 40-50% (also depending on the strain) smaller that their age-matched 
control mice. At the 3d/4t' week wobbler mice already show an altered position of fingers, 
wrists and paws. This alteration derives from muscular atrophy and produces unsteady gait with 
a discrete tremor. Afterwards, instability and wobbling of the gait develop progressively thus 
producing alteration in walking that is a typical feature of motor impairment occurring in the 
wobbler mice. As previously proposed'by Kozachuk and colleagues, these two parameters of 
abnormalities can be useful to determine the degree of clinical worsening during this phase of 
the disease [Kozachuk, 1987]. 
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Although the tension in the forelimbs of wobbler mice, recorded by electromyography, 
becomes lower at the 3'h week, muscular strength is unchanged compared to healthy mice until 
4`h week of age [Rathke-Hartlieb, 1999; Smith, 1995]. Later on muscular strength rapidly 
decreases in the following weeks instead of increasing as in control mice [Ikeda, 1995]. In the 
NFR strain, at around the 11th/12`h week of age, wobbler mice have reduced their grip strength 
scores by about 90% passing from --20 grams to -2,0 grams. A progressive decay in the 
muscular strength of the neck and the head was also reported, on the contrary, the hind legs' 
muscles remain spared over this period. At the end of this phase, in three month-old wobbler 
mice, the electromyography recordings of the forelimbs muscles displays characteristics of 
muscular denervation. In contrast the hind limb muscles are eletromyographically unaffected 
[Andrews, 1974]. In the late stage of the disease no remarkable alterations in hind legs muscles, 
diaphragm muscle, muscles deputed to deglutition and mastication are reported. This evidence 
suggests that, in contrast to human condition, the decease in wobbler mice does not seem 
strictly related to a primary motor neuronal involvement. 
Almost all affected animals follow the pattern of symptoms evolution reported above; however, 
few animals exhibit a sudden dramatic worsening of symptoms leading to the death within the 
fourth-fifth week of life. 
Although the wobbler mice are first known for their neurological symptoms, the males also 
suffer from infertility [Heimann, 19911. Wobbler males are unable to reproduce, despite the 
normal morphology of their genital apparatus and normal levels of gonadal testosterone due to 
altered spermatozoa functional motility. In females pregnancy was never reported; however 
direct evidence explaining the origin of this infertility has not yet been described. The wobbler 
mutation may affect the female gametogenesis, but it is also possible that the mind retardation 
and the muscular weakness of mutants are the cause of a deficiency in mating. 
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53 Ncuropathological and hystopathological alterations 
5.3.1 Motor neurons 
5.3.1.1 Hystometry and hystology 
As mentioned before, the polymorphic marker close to the wr locus offers the opportunity of a 
preclinical diagnosis and consequently allows to investigating about the possible morphological 
alterations before the onset of the disease in the wobbler mice. To date few studies have been 
reported by exploiting genotyping assay. A morphometric analysis of cervical spinal cord 
motor neurons (C5-T3) in wobbler and healthy littermates from P10 to P40 showed that: I) 
vacuolar degeneration is present in wobbler mice at just before clinical symptoms in about 10% 
of motor neurons, moreover some interneurons also present vacuolar degeneration; II) no 
difference in motor neuron size is detectable till 2°d week of age while a significant increase in 
dimension appears from 2°d to 3`d week age (interestingly, in the following weeks, the motor 
neurons of healthy mice increased their size while the motor neurons of wobbler mice reduces 
their cell body); III) over the 3'( week of age the size distribution of neurons in healthy mice 
presents a major peak at around 160 µm2 and a second one around 350 µm2, corresponding to 
the appearance of large motor neurons. Motor neurons size distribution in age matched wobbler 
mice has a major peak at around 100µm2. In contrast, a minor peak at around 300 µm2 (that can 
be observed in two weeks old wobbler mice) has disappeared after the 2°d week of life. 
The authors concluded that the loss or absence of differentiation of this particular sub- 
population of large motor neurons, could represent a key event in the course of the disease and 
could have important consequences for the clinical progression observed in the wobbler mouse. 
However, since in wobbler mice spinal cord the cervical region is selectively interested by the 
pathology while thoracic and lumbar motor neurons are spared [Duchen, 1968; Bradley, 1982], 
the choice to evaluate a such a caudal tract (C5-T3) in this study is somewhat questionable. 
Although the preclinical diagnosis by genotyping is a recent discovery, many hystological and 
molecular studies in presymptomatic wobbler mice, particularly in the cervical spinal cord 
region, have been already reported since the early 80s [Mitsumoto, 1982]. 
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Cytoplasmatic vacuolization is the more relevant marker in degenerating motor neurons of 
wobbler mice. However, this typical feature is rare in the spinal motor neurons prior the 
evolutionary phase of the disease [Duchen, 1968; Andrews, 1974]. During the presymptomatic 
stage, morphological alterations of neurons are less evident. An enlarged soma and a weak 
positivity for Nissl staining primarily characterizes. affected motor neurons. Stereological 
measurements have confirmed the enlargement of perikaryon in the cervical spinal cord of P18- 
to P 22-old wobbler mice [Dockery, 1997]. At this stage, cells with diverse anomalies have also 
been reported in the brainstem, in the ventral reticular magnocellular nucleus, and in the motor 
nuclei of the cranial nerve V and VII. In contrast, abnormal neurons were rarely found in the 
red nucleus, substantia nigra, anterior posterior colliculi, and deep nuclei of the cerebellum. 
Sporadic degenerating neurons characterized by a reduced Nissl staining or chromatolysis have 
been also described in thalamic nuclei that belong to the extrapyramidal system and in 
brainstem at two week of age [Rathke-Hartlieb, 1999]. No abnormalities were reported at this 
stage in the cerebral cortex [Duchen, 1968]. 
Despite these morphological changes, the number of motor neurons in the cervical spinal cord 
of three week-old wobbler did not result significantly lower compared to healthy littermates 
[Blondet, 20021. 
The progressive loss of motor neurons starts during at around the 40' week of life, in 
concomitance with the appearance of symptoms, and characterizes the evolution of the disease. 
In the cervical region of affected mice, a massive loss of motor neurons (about 50%) is reported 
from the 3`dto the 6/7`s week of age [Dachen, 1968; Haenggeli, 2002; Mitsumoto, 1982]. Within 
the cervical spinal cord, the number of degenerating motor neurons varies according to the 
segment, the rostral (C1-C3) region is the most severely affected, but at all times, cervical 
motor neurons displayed the same trend of neurodegeneration [Junier, 1994]. 
Using a retrograde labeling of the median nerve motor neurons it has been observed that about 
50% of the motor neurons area disappeared in six weeks old mice [Pollin, 1990] and a 
measurement performed in the abducens nucleus revealed a 31% of motor neuron loss in 
wobbler mice at 4-5 weeks of age compared to healthy littermates. 
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Although the loss of cervical motor neuron is the most striking marker of neurodgeneration in 
the wobbler mouse, other subpopulations of motor neurons are affected. In the abducens 
nucleus, degenerating motor neurons displayed a loss of Nissl staining in cell bodies but were 
rarely vacuolated [LaVail, 1987]. In the motor nuclei of the brainstem the extent of motor 
neuron loss is much less important than in the cervical spinal cord. In the facial motor nucleus, 
only 15% of motor neurons have disappeared in 5 week-old wobbler mice [Coulpier, 1996]. 
The measurement of motor neurons was performed in cranial nuclei of wobbler mice at two 
stages of the disease, at the presymptomatic phase (P21), and an intermediate phase of the 
disease (6 weeks of age). A significant decrease of hypoglossal motor neurons was reported 
both in early symptomatic (25%) and in 6 week-old wobbler mice (28%) compared to age- 
matched control mice. A decrease of trigeminal motor neurons number (13 %) was observed in 
the symptomatic phase [Haenggeli, 2002]. 
During the progression of symptoms, features of degeneration, other than vacuoles, were 
observed both in spinal and in cortical motor neurons. 
53.1.2 Cytology 
The characteristics of affected motor neurons in the wobbler mice are atypical. Vacuoles 
earliest appear in the cell body and become increasingly large and numerous until they 
completely pervade the soma [Duchen, 1968]. Their composition is not yet determined; they 
are not electron-dense but result empty. Moreover other ultrastuctural alterations like the 
presence of tubular structures and an increased number of lysosomes are detectable in affected 
motor neurons [Andrews, 1974; Biscoe, 1982]. 
Some vacuolated motor neurons can be still found in aged wobbler mice, but the frequency is 
very low [Duchen, 1968; Junier, 1994]. 
Large and medium-sized motor neurons in "stabilized" wobbler mice (4 to 6 months of age) 
showed a modified neurite arborization, characterized by shorter and thinner dendrites and a 
reduction in the density of the dendritic spines. 
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5.3.2 Axons 
Two weeks after the birth, cervical ventral-roots nerves and the mean axons number in the 
median and ulnar nerves, the nerves that are later most severely interested to denervation, are 
similar in wobbler mice and in control littermates [Mitsumoto, 1982]. At the 3`d week of age 
some intramuscular nerve trunks contain fragmented axons, and many pre-terminal axons 
present a fine sprouting and innervate more than one muscle fiber but first degenerating 
myelinated fibers appear only at the end of third week of age. The absence of an early axonal 
alteration indicates that the wobbler motor neuron degeneration primarily affects the perikaryon 
of motor neurons (primary neuropathy) and that the axonal alteration is delayed compared to 
the cell body degeneration (secondary axonopathy) [Mitsumoto, 1982]. 
At the beginning of the symptomatic stage, when alterations of perykaria are evident, 
morphological alteration of axons, described at the presymptomatic stage, become amplified. 
The thin, beaded axons sprout and the number of motor nerve terminals are lowered 
[Mitsumoto, 1990; Duchen, 1968]. The number of large-diameter fibers is greatly reduced and 
this process of axonal alteration is maintained over the entire period of symptoms progression 
[Lewkowicz, 1979]. Signs of axonal degeneration are also reported to be associated with a 
reduced diameter of the myelin sheaths and even a loss of myelin leading to the presence of 
non-myelinated fibers of large diameter. 
In contrast, by experiments of quantitative hystomorphometry, we have observed that in 
median nerve of twelve week-old wobbler mice, corresponding to the end of the clinical 
progression, no significant reduction in the thickness of myelin sheaths fiber was found. 
Although a significant decrease in the total number of myelinated fibers (49%), a higher 
percentage of altered myelinated fibers and a marked reduction of the myelinated fiber area 
(65%), were seen. This result suggests that, in spite of a relevant process of axonal 
degeneration, demyelinaton does not seem a feature of wobbler motor neuron disease (Bigini 
and De Angelis 2000 unpublished). 
The morphological abnormalities observed in the axons originating from cervical spinal cord 
motor neurons are always accompanied by an alteration of axonal transport system, likely 
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related to the accumulation of abnormal neurofilaments already observed in the 
presymptomatic period. At the symptomatic phase the amount of proteins transported by slow 
axonal transport, fast anterograde transport and slows retrograde transport is notably reduced 
[Mitsumoto, 1990]. In spite of these apparent abnormalities, the axons maintain their 
regenerative properties in response to a crush or a cut, thus showing a slower and less effective 
process than in healthy mice [Mitsumoto, 1985]. Axonal collateral sprouting is often observed 
and could partially compensate for the functional consequences of the neuronal loss [Blondet, 
1992; Duchen, 1968]. 
5.3.3 Muscles 
Changes in the muscle structure are not detectable in the presymptomatic. The atrophy occurs 
in the same progressive manner as motor neuron degeneration. Atrophy is particularly relevant 
in muscles of the head, neck, shoulders and forelimbs. The muscles of the proximal portion of 
the forelimb, particularly biceps muscles, are more severely affected than those located in the 
distal position. On the other hand, the trunk and hind legs muscles are not affected [Blondet, 
1992; Duchen, 1968]. 
In symptomatic wobbler mice the weight of the injured muscles is decreased, as well as the 
total number of muscle fibers [LaVail, 1987]. Atrophied muscle are first located at the 
periphery of the muscle fascicles, and gradually form clusters of abnormal fibers. These 
abnormalities of muscle fibers are characterized by a reduction in their diameter, an 
enlargement of sarcolemmal nuclei with prominent nucleoli often located in the central position 
and a reduction in the length of the post junctional membrane [Mitsumoto, 1982]. 
The muscles of symptomatic wobbler mice display a mixture of normal and affected areas, the 
size of the muscle fibers and end plates are significantly decreased and this reduction cannot be 
exclusively related to the reduced rate of growth that occurs during the evolutionary phase 
[Mitsumoto, 1996; Lewkowicz, 1979]. Alterations of neuromuscular synapses have been 
detected during both the evolutionary phase and the phase of plateau, after the 12`h week of age. 
At the end of the progression of symptoms, about 90% of the neuromuscular junctions 
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proximally connected to cervical motor neurons are deprived of the neuronal-cell adhesion 
molecule (N-CAM) and have a reduced acetylcholine esterase activity [Yung, 1994]. 
5.4 Pathological events and aetiology 
5.4.1 Glutamate-induced excitotoxicity 
As previously discussed, astrocytes play a fundamental role for the maintenance of glutamate 
extracellular levels under a toxic threshold in many areas of CNS [Danbolt, 2001 #469], and an 
excitotoxic effect due to a defective activity of the main glial glutamate transporters has been 
repeatedly considered as one of the most relevant components of various degenerative 
processes both in human and in animas [Rothstein, 1994; Cleveland, 2001]. 
In cultures of astrocytes obtained from the cervical spinal cord of 4 week-old wobbler mice 
higher levels of glutamate and glutamine were found in the extracellular medium. These 
abnormalities were accompanied by decreased intracellular levels of glutamate. Since this 
imbalance was demonstrated to be reversed by manipulation of glutamine concentration in the 
medium, the authors concluded that a deficit in the system of conversion glutamate/glutamine 
might play an important role in glial glutamate transporters activity and therefore in the 
glutamate-induced excitotoxity [Ait-Ikhlef, 2000]. 
Although astrocytosis in the cervical spinal cord of wobbler mice has been reported to involve 
selectively a population of astrocytes which is glutamine synthetase-negative, this abnormality 
in astroglial metabolism has not yet been confirmed by other in vivo studies. In addition, in the 
cervical spinal cord of symptomatic wobbler mice, the density of glutamate-binding sites, 
measured by experiments of autoradiography, was unaltered [Krieger, 1991]. 
To date, this body of evidence neither confirm nor confute the possible implication of 
glutamate-induced excitotoxicity in motor neuron degeneration that occurs in the wobbler 
mouse. For this reason a more detailed investigation about the role of glutamate, and above all 
AMPA-kainate-induced excitotoxicity will be developed in this thesis. 
5.4.2 Oxidative stress 
Evidence of oxidative damage has been reported in the cervical spinal cord of symptomatic 
wobbler mice. Histochemically, positive staining for nNOS, an enzyme which catalyzes the 
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formation of NO, is reported to be exclusively in pathologic conditions, such as axotomy, 
ventral root avulsion or during apoptosis. 
In the wobbler mouse motor neurons NOS induction was revealed by the nicotinamide adenine 
dinucleotide phosphate diaphorase (NADPH-diaphorase) diaphorase hystochemistry and nNOS 
immunoreactivity [Clowry, 1993; Clowry, 1996; Gonzalez Deniselle, 1999; Tsuzaka, 2001]. 
NADPH-diaphorase was found particularly increased in morphologically altered motor neurons 
and this trend increases during the clinical progression. 
Nonetheless this technique is currently used in different laboratories as a specific marker for 
nNOS induction, I did not find differences in NADPH levels in cervical motor neurons between 
wobbler and healthy littermates at different stages of the disease (Bigini and Barbera 2004 
unpublished). 
By immunohystochemical experiments,. we detected an overexpression of 4-hydroxynonenal- 
modified proteins, an indicator of lipid peroxidation, exclusively in the anterior horn of cervical 
spinal cord of symptomatic wobbler mice. This result further suggests a possible correlation 
between oxidative stress and motor neuron degeneration occurring in wobbler mice [Corvino, 
2003]. 
Another indirect evidence, suggesting the implication of oxygen radicals in the wobbler motor 
neuron progression derives from the beneficial effects produced by chronic treatments with 
different scavengers [Ikeda, 1995; Abe, 1997]. 
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5.4.3 Mitochondrial abnormalities 
As in ALS patients, mitochondria have been reported as preferential target in different models 
of motor neurodegeneration. Morphological alterations of mitochondria and reduced activity of 
complexes I and N of the mitochondrial respiratory enzymes were described in the 
presymptomatic phase in the murine model of fALS associated to the mutation of SOD1G93A 
transgenic mice [Browne, 1998; Bendotti, 2001]. 
In the cervical spinal motor neurons obtained from wobbler mice both light and electron 
microscopy observations have shown altered mitochondria with damaged cristae and a swelled 
shape [Gonzalez Deniselle, 2002]. 
By stimulating isolated mitochondria using pyruvate and malate as substrates consumption, it 
was observed that in mitochondria obtained from the brain of symptomatic wobbler mice, the 
oxygen consumption was lowered by 33% compared to healthy littermates. Moreover, 
incubating isolated mitochondria by using ascorbate and N, N, N, N'-tetramethyl-p- 
phenylenediamine the difference between wobbler and healthy littermates further increased by 
approximately reaching the 80%. According to these results the authors suggested that 
dysfunctional mitochondrial respiration occurring in the wobbler mouse brain and that this 
deficit could be mainly due to an impaired function of complex N [Xu, 2001]. 
A following study was carried out to compare the mitochondrial activity in the motor cortex 
and in the spinal cord. A significant decrease in mitochondrial complex III and IV and in 
respiration rates was found in the whole spinal cord of early symptomatic wobbler mice and a 
marked decrease in oxidative phosphorylation was seen both in spinal cord and in motor cortex 
of affected mice [Dave, 2003]. 
Although these results agree with the hypothesis of a decay of mitochondrial activity in 
symptomatic wobbler mice, both studies lack to selectively evaluate these parameters in the 
cervical spinal cord and do not provide an accurate analysis of each single mitochondrial 
complex. 
5.4.4 Neurofilament accumulation 
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Presymptomatic wobbler mice showed altered levels of mRNA for three neurofilament subunits 
NF-L, NF-M and NF-H [Pernas-Alonso, 1996]. As previously reported in section 1.2.2.1, 
excessive accumulation of proteins is a common of neurodegenerative diseases, and abnormal 
accumulation frequently occurs in motor neurons in patients with sporadic ALS [Carpenter, 
1968; Hirano, 1984]. In wobbler mice a significant increase of mRNA for neurofilaments was 
already reported in embryonic (E15) stage and remained higher compared to the healthy mice 
till 21 days old mice, the oldest time-point examined. Although in wobbler mice a marked 
increase in neurofilaments transcripts has been reported in embryonic stage no changes in 
proteins levels were observed by immunohystochemistry prior the 2nd week of age [Pemas- 
Alonso, 1996]. No alteration in neurofilament expression was detected in any other CNS area at 
this stage. Interestingly, as in other genetically unrelated pathologies leading to motor neuron 
death in animal models, the overexpression of neurofilaments and their consequent 
accumulation into the perikarya, represent a common event in the pathological evolution [Xu, 
1993; Cote, 1993]. This common feature further confirms the high sensitivity of neurofilament 
metabolism to a broad range of genetic insults occurring in motor neurons. An increase of 
mRNA levels of NF-H and NF-M has been reported in the stage between the onset of disease 
and the early symptomatic phase in the ventral horn of cervical spinal cord. By using an 
antibody (SMI31) directed against the NF-H/NF-H forms, I recently observed the presence of 
infra cytoplasmatic accumulation of neurofilaments in motor neurons of 4 week-old wobbler 
mice (Bigini 2003 unpublished). 
5.4.5 Intracellular aggregates and/or failure of protein folding 
Neurofilaments are not the unique proteins accumulate in the cell body of motor neurons during 
the progression of the disease. The presence of the protein inclusions, often conjugated with 
ubiquitin, is an usual phenomenon in different pathologies including ALS, Alzheimer's disease, 
Parkinson's disease and several neurological syndromes caused by an expansion of poly- 
glutamine tract [Braak, 2000; Lansbury, 2000]. These observations have led to the suggestion 
that altered chaperone activity may contribute to increase in misfolded proteins and 
accumulation of ubiquinated conglomerates in the cell body, thus producing a dramatic 
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blockade of metabolic activities. In fact, chaperone activity guarantees the prevention of 
proteins misfolding and the correct maintenance of protein conformation and also promotes the 
ubiquitination and the consequent degradation of abnormal proteins by the proteasome 
complex. The possible link between the activity of chaperone proteins and the process of 
neuronal death is further supported by the evidence that experimental upregulation of the heat 
shock protein 70 (HSP70) and/or of members of the DNAJ/HSP40 co-chaperone family lowers 
the intracellular inclusions of altered proteins, and protects cellular models of the 
polyglutamine diseases and of ALS linked to SOD1 mutation [Stenoien, 1999]. HSP70 and 
DNAJ/HSP40 proteins act in a co-operative manner to prevent the accumulation of improperly 
folded proteins [Hayes, 1996]. In wobbler mice the accumulation of abnormal proteins, other 
than neurofilaments, has been reported in the cytoplasm of cervical motor neurons, and 
ubiquitin-immunopositive deposits have been observed at the end of the presymptomatic phase 
during the development of the disease [Andrews, 1974; Mitsumoto, 1982]. 
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5.4.6 Reactive gliosis 
As for other neurodegenerative diseases, reactive gliosis accompanies motor neuron 
degeneration progression in wobbler mice. The characteristic hallmarks of reactive gliosis, an 
increased expression of GFAP coupled with hypertrophied morphology are observed in the 
cervical spinal cord and in the brainstem obtained from symptomatic wobbler mice [Hantaz- 
Ambroise, 1994; Laage, 1988; Rathke-Hartlieb, 1999]. In the original strain (C57BL/Fa), 
reactive gliosis occurs as early as the onset of symptoms and progresses during the 
symptomatic phase also invading the whole gray matter and the anterior part of the anterior 
white matter. The age of maximal astogliosis was found to coincide with the peak of motor 
neuron loss and then is maintained after the evolutionary phase of the disease, thus persisting 
until the death of animals. 
According to the results obtained in C57BL/Fa, I observed a mild but significant increase of 
GFAP levels in the cervical homogenate obtained from 4`h week-old wobbler mice compared to 
healthy littermates, with a further increase in 12th week-old mutants, while no difference in the 
amount of GFAP was measured in the lumbar homogenates at both phases of clinical 
progression. No difference in GFAP levels were found by comparing the lumbar spinal cord 
homogenates obtained from the same animals [Bigini, 2001]. 
No signs of gliosis were observed in the brain areas that display occasional degenerating 
neurons, and our unpublished immunohystochemical observations have confirmed this 
biochemical result. By staining frontal cortex sections with GFAP, we have observed a very 
weak immunopositivity, both in the early and in the late symptomatic wobbler mice. Moreover 
the pattern of staining we observed in the frontal cortex of wobbler mice did not differ 
compared to the occipital cortex obtained from the same animals and from the frontal cortex of 
healthy littermates (Bigini and Barbera 2003 unpublished). 
Activated microglial cells were shown in the spinal region of wobbler mice from the 3rd week 
of age [Rathke-Hartlieb, 1999; Boillee, 2001]. At the end of the presymptomatic phase 
microglial cells are localized around affected motor neurons with their arborization disposed 
and organized to wrap ill motor neurons. Interestingly, in this phase of disease, an increase in 
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the number of microglial cells is not yet observed [Laage, 1988; Boillee, 2001]. During the 
symptomatic phase, in the cervical region, it is possible to note a marked microglial 
proliferation, mainly in the ventral region. The evidence that astrogliosis is not confined to the 
area of neurodegeneration, but rather extends to the dorsal part of the spinal cord, has suggested 
that astrocytes could themselves be a primary target of the disease and different in vivo 
experiments seem to support this hypothesis [Hantaz-Ambroise, 1994; Ait-Ilchlef, 
2000; Gonzalez Deniselle, 1999]. 
Like astrocytes, microglial response increases during the progression of motor neuron 
degeneration reaching a plateau at 10/12 weeks of age. Following the evolutionary phase a 
weak but progressive reduction was observed in the cervical spinal cord of wobbler mice. This 
decrease was first associated to a reduction of phagocytosis from microglial cells that are 
committed to remove motor neurons debris. However, despite the relevant process of 
microgliosis during the peak of motor neuronal loss, microglial cells scarcely display the 
typical rounded shape attributed to microglial cells engaged in phagocytosis [Boillee, 
2001; Streit, 1989; Raivich, 1999]. 
Gliosis is often accompanied by enhanced protease activities, possibly due to remodeling of 
tissue following brain injury [Lukes, 1999]. In the wobbler cervical spinal cord the expression 
of two metalloproteinases, MT1-MPP and disintegrin-like and metalloproteinase (ADAM8), is 
enhanced. These proteins are expressed both in activated astrocytes and in microglial cells 
[Schlomann, 2000; Rathke-Hartlieb, 2000]. The ability of TNFa to enhance the expression of 
ADAM8 in cultures of astrocytes from symptomatic animals indicates that glia may indeed be a 
target of this cytokine. 
A recruitment of lymphocytes is also observed in the cervical spinal cord region of 
symptomatic wobbler mice even if the BBB appears intact, these lymphocytes are scattered in 
the ventral horn and seem anatomically unrelated to motor neurons [Boillee, 2001]. 
A schematic representation of behavioural, hystological and biochemical abnormalities 
occurring during the symptoms progression in wobbler mice is shown in figure 5.1. 
128 
Chapter 5 The wvobbler mouse 
Paw abnormality + ++ +++ +++ 
Grip strenght 
ý(% 
10% 25% 65% 
EMG ) 
Clinical onset 
" 20 35 bu 
'10% 30% 50% 65% 
' Ns vacuolization 
ltitochondrial alterations ? + ++ 
GFAP + 
Cdllb 
1+ 
Ft+ 
+ 
+ 
+ 
++ 
+++ 
+++ 
++++ 
+++ 
++ 
Figure 5.1 Symptomatological, neuropathological and biochemical alterations occurring in 
wobbler mice during the evolution of the disease 
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5.5 Pharmacological trials 
The rapid progression of symptoms and the possibility to easily score the evolution of motor 
impairment make the wobbler mouse a valid tool to evaluate the efficacy of different 
pharmacological treatments. 
5.5.1. Growth factors 
In the last decade several pharmacological treatments were performed in wobbler mice in order 
to evaluate the capability of neurotrophins, to reducing clinical progression and to 
counteracting reducing the rate of motor neurons loss. 
5.5.1.1. BDNF and CNTF 
In 1994 Mitsumoto reported that the cotreatment with CNTF and BDNF promoted the survival 
of developing cervical spinal cord motor neurons in wobbler mice, but the administration of 
either factor alone showed to slow, but not to arrest, the progression of motor neuron 
dysfunction in wobbler mice [Mitsumoto, 1994]. Seven years later, a further investigations to 
better clarify the role of BDNF in the wobbler mouse motor neuron disease was carried out. In 
that study, to assess the role of endogenous BDNF, its immunoreactivity was determined by 
semi quantitative analysis. The cervical spinal cord of affected wobbler mice showed a 
significantly greater BDNF immunoreactivity compared to that of healthy littermates and the 
treatment further increased immunoreactivity in the affected cervical spinal cord motor 
neurons. In addition it was reported reported that exogenous BDNF treatment partially inhibited 
the increased NOS activity, measured by NADPH-diaphorase hystochemistry. They suggested 
that BDNF may be an important factor in halting nitric oxide (NO)-mediated motor neuron 
degeneration [Tsuzaka, 2001 ]. 
As in humans, the clinical and pharmacodynamic effects met-BDNF and met-free BDNF were 
compared by a clinical trial performed in early symptomatic wobbler mice. Both Met- and met- 
free BDNF improved grip strength and running time compared to vehicle. The plasmatic levels 
of BDNF did not differ between the two different BDNF groups. met-free BDNF exerted 
similar effects compared to met-BDNF in wobbler mice [Ishiyama, 2002]. 
5.5.1.2 IGF-1 
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Since recombinant human insulin-like growth factor-I (IGF-I) is considered to be a possible 
therapeutic agent for the ALS treatment (see section 1.4.3.4), a series of clinical trials were 
carried out in wobbler mice to determine the possible beneficial effect of IGF-I administration. 
The first study reported that IGF-I treated wobbler mice underwent a marked weight increase 
from 3 to 6 weeks of treatment compared to placebo treated wobbler mice. At the end of the 
treatment, grip strength was 40% higher in IGF-I treated versus placebo treated group. Mean 
muscle fiber diameter was increased in IGF-I treated mutants. However, in this study the 
muscle ChAT activity measured in the forelegs muscles and the number of spinal cord motor 
neurons were similar in both groups [Ikeda, 1995]. 
The role of IGF-I in decreasing the clinical progression in wobbler mice was further confirmed 
by treating early symptomatic mice with IGF-I and glycosaminoglycans - (GAGs). GAGs are 
constituents of proteoglycans, and the supplementation of GAGs promotes in vitro 
neuritogenesis and stimulates nerve regrowth and muscle reinnervation, mainly in correlation 
with an increase in trophic factor mRNA expression. 
Although each single treatment produced a significant protection compared to the vehicle- 
treated group, the effect of the combination treatment was significantly higher than that of the 
single drug. The treatment halted motor neuron loss and markedly reduced the decay of 
forelimb muscle morphometry and function [Gorio, 1998; Vergani, 1999]. Another positive 
effect, deriving from this pharmacological cocktail, was that the arrest of the progression of 
motor neuron disease was observed at low doses of IGF-I thus increasing the safety of possible 
treatment with a neurotorophic factor [Gorio, 2002]. 
5.5.1.3 T-588 and cardiotrophin 1 
R(-)-1-(benzo(b)thiophen-5y1)-2-[2(N, N-diethylamino)ethoxy]ethanol hydrochloride " (T-588) 
is a compound which has been shown to exhibit a wide range of neurotrophic effects both in 
vivo and in vitro [Iwasaki, 1989]. The chronic treatment with T-588 in symptomatic wobbler 
mice potentiated the grip strength, attenuated forelimb contracture and increased the weight of 
the biceps muscles. T-588-treated wobbler mice showed a delayed denervation, a lower degree 
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of muscle atrophy and higher activities of ChAT and lactate dehydrogenase in the biceps 
muscles [Ikeda, 2000]. 
Another neurotrophic agent, the cardiotrophin-1 (CT-1), was proposed for the treatment of 
wobbler mice. CT-1 treatment has been found to be effective in preventing deterioration in paw 
and walking position. Grip strength declined steadily in the vehicle group, whereas in the CT-1 
group it declined at-week 1 but increased thereafter to exceed baseline strength by 5% at week 
4. Running time was significantly improved in CT-1 treated wobbler micefaster with CT-1. 
Biceps muscle twitch tension, muscle weight, mean muscle fiber diameter, and intramuscular 
axonal sprouting were significantly greater with CT-1 treatment. Histochemistry revealed a 
trend to a modest increase in the number of immunoreactive motor neurons, as determined by 
both ChAT and c-Ret antibodies in CT-1-treated wobbler mice. 
The number of large myelinated motor axons significantly increased with treatment. The 
authors concluded that CT-1 exerts myotrophic effects as well as neurotrophic effects in this 
mouse model [Mitsumoto, 2001]. 
5.5.1.4 LIF 
Leukaemia inhibitory factor (LIF) is a cytokine that belongs to the group including CNTF, IL- 
6, CT-1, OM and IL-11 [Kurek, 1998] that has been shown to produce positive in vitro 
stimulating myoblast proliferation. For this reason the role of LIF as a possible neuroprotective 
agent was also investigated in the wobbler mouse. Subcutaneous injection of LIF significantly 
slowed progression of forelimb atrophy from the 2°d week up to the end of treatment. Although 
grip strength both in saline- and in LIF-treated animals decreased rapidly after 7 days, the LIF- 
treated group had a significant delay in reduction of strength after 4 weeks. Moreover, a 
significant reduction of biceps muscle weight loss was reported, and the mean diameter of 
muscle fibres and the percentage of denervated was significantly increased in LIF-treated 
compared to vehicles [Ikeda, 1995]. 
5.5.1.5 IL-6 
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Interleukin-6 (IL-6) is a multipotential cytokine that shares signal transduction pathways with 
CNTF and LIF. IL-6 triggers homodimerization of gp 130, whereas CNTF and LIF induce 
heterodimerization of gp130 and LIF receptor. The cotreatment with IL-6 and soluble IL-6 
receptor (slL-6R) improved symptomatic and neuropathological progression in wobbler mice. 
On the contrary IL-6 or slL-6R alone did not delay the progression of symptoms. These results 
indicated that the neuroprotective mechanism for IL-6/sIL-6R on wobbler mouse differs from 
that of CNTF or LIF alone thus suggesting that IL-6/sIL-6R complex may function on motor 
neurons through activation and homodimerization of gp130 [Ikeda, 1995]. 
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5.5.2 Antiglutamatergic agents 
The role of glutamate receptors mediated excitotoxicity has been evidenced in different animal 
models of motor neuron degeneration. In SOD1G93A mice and in mnd mice in vivo treatments 
with glutamate receptors antagonists are active both in improving motor efficiency and 
muscular strength and in prolonging the survival [Canton, 2001; Mennini, 1999; Van Damure, 
2003]. 
To test whether motor neuronal death in wobbler mouse syndrome was associated to the 
overstimulation of NMDAr, a treatment with the NMDAr antagonist (MK801), was carried out 
in wobbler mice just after birth or in early symptomatic phase. 
In the group of animals in which the treatment started four days after birth, MK801 (in doses of 
0.5/mg/kg/day) resulted highly toxic, whereas the group that initiated the treatment at 3/4 
weeks of age well tolerated a dose of 1 g/kg/day. In this latter group the treatment lasted for 8 
weeks. During that time both clinical progression and possible side effects, such as lethargy or 
ataxia, were monitored. Although the group treated from 4th to 12th week of age did no show 
side-effects, no significant difference in the body weight and in the progression of symptoms 
was reported by comparing in MK801-treated and saline-treated wobbler mice [Krieger, 1992]. 
5.5.3 Mitochondrial agents 
The implication of mitochondrial deficits in the evolution of wobbler mouse motor neuron 
syndrome was further confirmed by two distinct treatments in which energetic substrates were 
active in reducing clinical progression in wobbler mice. 
As previously described in SOD 1G93A transgenic mice [Klivenyi, 1999], the chronic treatment 
with creatine monohydrate potentiated grip strength, attenuated forelimb contracture and 
increased the weight of biceps muscles in early symptomatic wobbler mice. 
Mice treated with higher doses of creatine monohydrate showed delayed denervation atrophy of 
the biceps muscles and reduced degeneration of the spinal motor neurons. Creatine levels in 
biceps muscles were increased by approximately 20% following administration of higher-dose 
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creatine monohydrate. In comparison with vehicle, treatment with higher doses of creatine 
monohydrate improved behavioural performances and reduced atrophy and motor neuron loss. 
Thus, oral administration of creatine monohydrate delayed the progression of disease in 
wobbler mice [Ikeda, 2000]. 
More recently, an original approach, by treating early symptomatic wobbler mice with a 
hyperbaric oxygen therapy (HBOT), has been shown to produce positive effects. The rate of 
respiration for complex IV in mitochondria isolated from motor cortex was improved by 40% 
after HBOT and the onset and clinical progression resulted significantly delayed in HBOT 
treated wobbler mice. Neither hystopathological estimation nor measurement of mitochondrial 
activity in the cervical spinal cord was performed following this treatment [Dave, 2003]. 
5.5.4 Antioxidants 
In the wobbler mouse motor neuron disease few convincing clinical outcomes are, as yet, 
achieved by treating affected mice with molecules possessing antioxidant properties. 
A possible protective effect of a novel free radical scavenger, OPC-14117, on the progressive 
motor neuron death in wobbler mice was examined. The treatment with OPC-14117, improved 
the clinical parameters such as mortality, motor activity, and forelimb weakness in a dose- 
dependent manner. The treatment of wobbler mice with the drug reduced age-dependent 
increase of lipid peroxides in the spinal cord, and a supplement of the drug in the homogenate 
of spinal cord reduced the formation of lipid peroxides generated by an exogenous addition of 
ascorbate or xanthine/xanthine oxidase. These results suggest that OPC-14117 has a protective 
effect on the motor neuron death probably as a free radical scavenger, resulting in an 
improvement of clinical symptoms in wobbler mice [Abe, 1997]. 
The effects produced by a treatment with an antioxidant therapy in neuromuscular dysfunction 
were also evaluated by treating wobbler mice with lecithinized superoxide dismutase. In this 
study [Ikeda, 1995] the treatment improved the motor impairment by reducing muscle 
weakness and contracture of the forelimbs in this animal. Lecithinized superoxide dismutase 
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treatment also prevented denervation, muscle atrophy and delayed degeneration of spinal motor 
neurons in wobbler mice. 
A further study was conducted in early symptomatic wobbler mice with a non-selective NOS 
inhibitor, L-NAME, was carried out. The treatment with L-NAME potentiated grip strength and 
attenuated deformities in the forelimbs and arrested the loss of motor neurons. To a lesser 
extent, L-NAME-treated mice displayed slowed progression of disease. This study indicated 
that nNOS inhibitor may be a candidate for promising therapy in lower motor neuron disease or 
motor neuropathy [Ikeda, 1998]. 
Many others clinical trials with different types of pharmacological agents, such as steroid 
hormones, gangliosides, plasminogen activators, were reported to be active in reducing clinical 
progression and neuropathological alterations observed in the wobbler mouse motor neuron 
disease [Gonzalez Deniselle, 1997; Gonzalez Deniselle, 1999; Gonzalez Deniselle, 
2002; Gonzalez Deniselle, 2004; Blondet, 1992; Bose, 1999; Lisovoski, 1997]. However, despite 
these encouraging results in the wobbler mice, the clinical trials of some of these molecules in 
ALS patients had no significant effect (see chapter 1). 
5.6 Wobbler and apoptosis 
Although the animal models of human ALS allow to accurately characterize cell death 
processes by investigating the early events occurring in dying motor neurons, an unambiguous 
characterisation of cellular death occurring in cervical spinal cord motor neurons has not yet 
been documented both hystologically and ultrastucturally. 
The finding of motor neurons death in SOD1 transgenic provided inconclusive results. 
Although some authors reported the activation of apoptotic markers (caspase1 and caspase3) in 
the motor neurons of lumbar spinal cord, and a therapeutic effect after treatment with the 
antiapoptotic molecule zVAD-Fmk was also reported [Liu, 1996; Pasinelli, 2004] . Migheli et 
al. reported the absence of TUNEL staining in the same anatomical region, thus excluding 
apoptotic death [Migheli, 1999]. 
In the wobbler mouse the nature of motor neurons death has not been fully elucidated. An 
autolytic type of death has been described by Popper et al. In 4 week-old wobbler mice they 
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reported: 1) no evidence of inflammation and monocyte infiltration in the spinal cord, II) no 
DNA fragmentation (no motor neurons were labeled using TUNEL staining), III) vacuolisation 
of cell bodies and dense basophilic nuclei in the motor neurons and; N) increase of mRNA 
levels of testosterone repressed prostate message 2 (TRPM-2) in cervical spinal cord. However, 
the absence of TUNEL staining in the wobbler spinal cord may be due to a non-appropriate 
time point studied in this slowly progressing degenerative disease. Moreover the authors did 
not give details on the effective number of spinal cord sections analyzed and the region 
examined (cervical Vs lumbar) [Popper, 1997]. 
The protease-activated receptor 1 (PAR-1), a G-protein-coupled member of seven- 
transmembrane domain superfamily, when coupled with thrombin, elicits a signaling pathway 
that leads to neural cell death. Salcedo et al. reported a fivefold greater level of PAR-1 mRNA 
in the spinal cord of wobbler mouse. This increase was greater in the cervical compared with 
the lumbar segment; it was also found that PAR-1 was already increased in wobbler cords at 
E12. However these data do not supply clear evidence that the increase in PAR1 generates a 
mechanism leading to apoptosis of cervical motor neurons. Since thrombin elevates the Ca++ 
after PAR-1 activation, up-regulation of PAR-1 may contribute both to apoptotic as well as to 
non-apoptotic neural death in wobbler mouse [Salcedo, 1998]. 
As previously reported, the most significant abnormality found in wobbler mice is the vacuolar 
neuronal degeneration accompanied by a loss in the number of motor neuron, starting from the 
third week of age. Blondet and co-workers observed, using TUNEL staining in spinal cord 
section, a massive DNA fragmentation in different cell types, including glial cell as well as 
motor neurons, before the appearance of clinical symptoms. After examination of spinal cord 
sections (C7-T3), 60% of motor neurons in the anterior horns exhibited TLJNEL positivity, 
specifically between P18-P21. The DNA fragmentation was clearly transient since the authors 
never observed similar features at later stages (P22, P26, P30 and P60). The same pattern of 
TUNEL positivity is reported in glial cells, astrocytes were individuated by double labelling 
using GFAP coupled to rhodamine. No chromatin condensation or apoptotic bodies were 
observed in TUNEL positive cells, including motor neurons and astrocytes. The authors do not 
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explain clearly the choice of the spinal cord region under studies and do not report the number 
of sections analyzed for each sample. Furthermore a so close time window of TUNEL 
positivity seems too short in this slowly degenerative disease. Although the authors report a 
astroglial TUNEL staining positivity closely in the P18-P22 wobbler spinal cord, it is difficult 
to explain as neuron and glia show this specific feature of cell death exclusively around this 
time. 
They argued that, in the narrow time window in which the positive TUNEL staining is seen in 
wobbler spinal cord, detrimental stimuli trigger an initial mechanism of DNA fragmentation 
without generating apoptosis. The failure of apoptotic pathway could be related to an efficient 
DNA repair mechanism, in fact a great percentage of these motor neurons survive this moment 
and are still present in old animals [Blondet, 2002]. 
The limitations to characterize correctly the type of cellular death in motor neuron diseases are 
linked both to the small number of cell and to the slow rate of neuronal death. In fact only a few 
cells out of many die at any given time making it difficult to determine whether the hallmarks 
of apoptosis are present. 
To better clarify the mechanism of motor neuronal death that occurs in the cervical motor 
neurons of wobbler mice, I have focused my attention on the evaluation of the possible role of 
apoptosis in the process of cell death, by exploiting both hystological and pharmacological 
approaches. 
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CHAPTER 6 
AIMS OF THE STUDY 
This study aims to verify, in in vitro and in vivo models of ALS, the role of apoptosis in motor 
neuron death. In addition, I tested a possible link between apoptosis and the occurrence of three 
different aetiopathological factors postulated to be involved in motor neuron degeneration in 
ALS patients: I) neurotrophic factors deficiency, II) glutamate-induced excitotoxicity and III) 
glial-induced neuroinflammation. 
To better characterize, at the single cell level, the possible interaction between these detrimental 
stimuli and apoptosis, in vitro studies, using primary cultures of rat embryo motor neurons were 
performed. 
In vitro studies 
In primary cultures of motor neurons I investigated: 
The toxic effect produced by chronic deprivation of trophic factors or chronic exposure 
to two glutamate agonists (AMPA and kainate) at the concentrations required to produce 50% 
of cell death (EC50) after 48 hours of treatment. 
The possible apoptotic involvement after excitotoxicity or serumBDNF deprivation, 
by evaluating the intrinsic apoptotic pathway at different steps (from mitochondrial PTP 
opening to DNA fragmentation). 
The possible protective and anti-apoptotic effect of EPO, a molecule that has been 
already reported to have anti-apoptotic and neuroprotective action in in vitro and in vivo models 
of neuronal death. 
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In vivo studies: 
After in vitro characterization I focused my attention on evaluating whether: I) these 
mechanisms were present in the affected region (cervical spinal cord) of early symptomatic 
wobbler mice and; II) they can produce a mechanism of death associated to apoptosis. 
This part of my study was mainly aimed to characterize: 
The possible involvement of neuroinflammation and apoptosis in cervical motor 
neuron degeneration, by evaluating microglial activation and overexpression of the extrinsic 
apoptotic pathway passing through TNF-a and TNFR 1 and caspase 8 activation. 
0 The potential role of glutamate-induced excitotoxicity, by verifying the expression and 
the activity of glutamate transporters and the expression and distribution of AMPAr subunits 
(G1uR 1-4) in the cervical spinal cord samples early symptomatic wobbler mice and healthy 
littermates. 
" The effects of chronic treatments with a selective AMPA antagonist (RPR 199900) and 
with riluzole in reducing the progression of symptoms and the neuropathological worsening 
occurring in wobbler mice. 
0 The possible involvement of mitochondria-dependent apoptosis in cervical motor 
neurons of wobbler mice by evaluating both mitochondrial activity and the main markers of 
apoptosis (caspase 9, -7 and -3, DNA fragmentation) and by performing a chronic treatment 
with EPO, a selective neuroprotective and antiapoptotic molecule that has been already shown, 
by in vitro experiments, to block neuronal apoptosis acting through mitochondria. 
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CHAPTER 7 
MATERIALS 
Reagents and materials that were utilized during this thesis are listed in the following pages: 
" (14 C) acetil-CoA, Amersham, Buckinghamshire, UK 
" (3H)-L-Glutamate, Amersham, US 
" 2-mercaptoetanole, SIGMA, Italy 
" ABC complex, Vector Laboratories, UK 
" Acetil CoA, SIGMA, Italy 
" Acetonitrile, SIGMA, Italy 
Alexa 488 goat anti-rabbit secondary antibody, Molecular Probes, US 
Alexa 546 goat anti-mouse secondary antibody, Molecular Probes, US 
0 Alu I, Genecraft, Germany 
0 AMPA, Tocris, Italy 
Analyser AIS software, Imagin Research St. Catherine's, Ontario, Canada 
Anti alpha-tubulin, SIGMA, Italy 
Anti-Epo antibody, Santa Cruz Biotechnology, CA, US 
Antimicin A, SIGMA, Italy 
Anti-mouse as secondary antibody, Amersham, US 
Ascorbate, SIGMA, Italy 
B27, Life Technologies, GIBCO, Italy 
BDNF, Amgen, US 
Biotinylated anti-mouse antibody, Vector Laboratories Inc., UK 
BSA, SIGMA, Italy 
Anti-Active capase 3 antibody, Promega, Italy 
Anti-Active caspase 7 antibody, Alexis Biochemical, UK 
Anti-Active caspase 8 antibody, Cell Signaling Technology, UK 
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" Anti-Active caspase 9 antibody, Alexis Biochemical, UK 
" Anti-CD 11 antibody, Serotech, UK 
" Anti-ChAT antibody, Chemicon, US 
" Choline Chloride, SIGMA, Italy 
" Cyclosporin A, SIGMA, Italy 
" Anti-Cytochrome C antibody, BP Biosciences, Italy 
" Diaminobenzidine, SIGMA, Italy 
" DMSO, SIGMA, Italy 
" DTNB, Wako Pure Chemical Industries, Tokyo, Japan 
" EDTA, Fluka Biochemical, Germany 
" EGTA, Acros, New Jersey, US 
" FCS, Life Technologies, US 
" Anti-GLAST antibody, Chemicon, US 
" Anti-GLT-1 antibody, Santa Cruz Biotechnology, US 
" Anti-G1uR1 antibody, Chemicon, US 
" Anti-G1uR2 antibody, Chemicon, US 
" Anti-GluR3 antibody, Santa Cruz Biotechnology, US 
" Anti-GluR4 antibody, Chemicon International, US 
" GraphPad Prism version 3. Oa for Macintosh, GraphPad Software, US 
" Grip-Strength transducer, Ugo Basile, Italy 
" HEPES, Eurobio, Italy 
" Hoechst 33258, SIGMA, Italy 
" Image Tool Software (UTHSCASA), US 
" Iodonitrotetrazolium Chloride, SIGMA, Italy 
" JC-1, Molecular Probes, Eugene, OR, US 
" Kainate, SIGMA, Milan, Italy 
" KCN, SIGMA, Italy 
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" Laminin, SIGMA, Milan, Italy 
" L-glutamic acid, SIGMA, Italy 
" L-Glutamine, Biochrom AG 
" Malate, SIGMA, Italy 
" Malonate, SIGMA, Italy 
" Mannitol, SIGMA, Italy 
" Monoclonal antibody IgG192 (kindly gift from Bruno Hivert. Marseille) 
" NADPH, SIGMA, Italy 
" NBT, SIGMA, Italy 
" N-dodecyl-D-maltoside, Calbiochem, Italy 
" Neurobasal Medium, Life Techonologies, GIBCO, Italy 
" NGS, Vector Laboratories, Germany 
" N-N-M-N-tetramethyl-P-phenylenediamide, SIGMA, Italy 
" OCT, Sakura Nihombashi, Tokio, Japan 
Olympus Fluoview Laser scanning, Japan 
" Orange Mitotracker, Molecolar Probes, US 
" Oxaloacetate, SIGMA, Italy 
" Oxigraph, Hansatech, Denmark 
" Paraformaldehyde, Merck, Darmstadt, Germany 
" PBS, Life Technologies, GIBCO, Italy 
" Penicillin, Seromed, Italy 
" Poly-DL-ornitine, SIGMA Italy 
" Propidium iodide, Molecular Probes, Eugene, OR, US 
" Restriction enzymes, GIBCO, Italy 
" Rotenone, SIGMA, Italy 
" Riluzole, Aventis-Pharma, France 
RPR119990, Aventis-Pharma, France 
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" Scintillation mixture, toluene scintillator, Packard, US 
" SMI-32, Sternberger Monoclonals Inc., US 
" Streptomicin, Seromed, Italy 
" Succinate, SIGMA, Italy 
" Sulphosalicylic acid, SIGMA, Italy 
" SYTO 59, Molecular Probes, US 
" Tetraphenylboron, SIGMA, Italy 
" TMPD, SIGMA, Italy 
" Anti-TNFR1 antibody, Hycult Biotechnology, The Netherlands 
" Anti-TNFR2 antibody, Hycult Biotechnology, The Netherlands 
" Anti-TNF-a antibody, Hycult Biotechnology, The Netherland 
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CHAPTER 8 
in vitro METHODS 
8.1 Primary cultures of motor neurons 
8.1.1 Animals 
Procedures involving animals were conducted in conformity with the institutional guidelines 
that comply with national (D. L. n. 116, G. U., suppl. 40, Feb. 18,1992) and international laws 
and policies (EEC Council Directive 86/609, OJL 358,1, Dec. 12,1987; NIH Guide for the 
Care and Use of Laboratory Animals, U. S. National Research Council, 1996). 
8.1.2 Motor neuron cultures 
Spinal cords were obtained from 15-day Sprague Dawley rat embryos. Meninges and other 
tissues (dorsal horn) were removed. The ventral horn was trypsinized and centrifuged through a 
4% BSA cushion for 10 min at 300 x g. Cells (representing mixed neuron/glia culture) were 
seeded at a density of 20,000 cells/cm2 into 24 mm well plates precoated with poly-DL- 
ornithine and laminin, and containing complete culture medium (CCM) as follows: Neurobasal 
medium, B27 (2%), L-glutamine 0.5 mM, horse serum 2%, 2-mercaptoethanol 25 PM, 
glutamate 25 pM, penicillin and streptomycin 1%, BDNF 1 ng/ml. The same medium (without 
glutamate) was added to the cultures on fourth and sixth day in vitro. 
When indicated, motor neurons were further purified by immunopanning. The cells were added 
into a Petri dish coated with a monoclonal antibody IgG192 that recognizes the low affinity 
neurotrophin receptor (NGFRp75). Motor neurons were recovered by using an excess of 
monoclonal antibody and then collected by centrifugation through a BSA cushion as described 
above. The counted motor neurons were added at low density (2000 cells/cm) into 24-mm or 
35-mm well plates precoated with poly-DL-ornithine and laminin and containing CCM. For 
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immunofluorescence experiments cells were grown at similar densities on glass coverslips, 
precoated with poly-DL-ornithine and laminin. 
Neurobasal medium contains physiological concentrations of Ca++ (1.8 mM) and Mgr (0.8 
mM). 
8.1.3 Pharmacological treatments 
Cultures were treated on the sixth day in vitro (DIV 6) for 48 hrs. Aliquots ranging from 20 to 
50 pl of glutamate agonist solutions were added to each well, containing 1 ml of CCM without 
glutamate. Cell death was induced on sixth day in culture by incubation for 48 h with kainate (5 
)pM for mixed neuron/glia cultures and 50 pM for purified cultures), AMPA (1 pM for mixed 
glia/neurons cultures and 10 pM for purified cultures), as previously described [Comoletti, 
2001]. 
EPO (2.5 pmol/ml) or vehicle was added to the cultures in concomitance to, or 72 hours before 
the induction cell death (by addition of excitotoxins or serum/BDNF deprivation) or 
preincubated 72 h before. 
Cyclosporin A2 2 pM was added simultaneously with glutamate agonists and kept for 48 hours. 
8.2 Immunocytochemistry 
In the immunocytochemical experiments, for each type of antibody tested, the following 
procedure was adopted: at the end of each treatment the medium was discarded and the cells 
were fixed with paraformaldehyde 4% (w/vol) in PBS for 40 min. Following this common step, 
the various protocols of immunostaining differed depending on the type of antibody used. 
Immunocytochemical experiments were done by using two different methods of visualisation: 
I) fluorescent dyes coupled to a secondary antibody (immunofluorescence) or II) biotinylated 
secondary antibody that reacts with a third molecule in which both a molecule of avidin-biotin 
and molecules of horse-radish peroxidase are linked. The horseradish peroxidase (linked to the 
ABC complex) allows, in the presence of H202, diaminobenzidine oxidation with chromogenic 
reaction and a resulting brown staining product. More detailed descriptions of 
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immunocytochemical procedures are reported in the following sections. 
8.2.1 SMI 32 for non-phosphorylated neurofilaments 
For SMI 32 all the passages were conducted at room temperature. 
After fixation the cells were rinsed in 0.1 M PBS (pH 7.4) three times for 5 minutes and then 
permeabilized in a solution of PBS containing Triton X-100 (0.2%) and a blocking agent, FCS 
10% (vol/vol), to reduce non-specific reactions for 30 min. After permeabilization the cells 
were immediately incubated overnight with the anti-mouse monoclonal antibody SMI 32 
(1: 4000) in a solution of PBS and FCS (10%). Cells were then rinsed three times (5 minutes) 
and incubated with an anti-mouse secondary antibody. 
For immunofluorescence staining the secondary antibody was the Alexa-546 goat anti-mouse 
(the fluorophore used was a dye conjugated to rhodamine and having a? of absorption at 556 
nm and a ?, of emission at 573 nm -red fluorescence-). Cells were incubated for two hours in a 
solution of PBS containing the secondary antibody (1: 200), and FBS (3%). 
To avoid a decay of fluorescence, starting from the incubation of the secondary antibody, all 
steps were done in dark plates. 
After incubation with the secondary antibody the cells were rinsed three times in PBS and then 
the coverslips, where the cells are grown, were placed and mounted on glass slides. To preserve 
the fluorescence and allow a brighter signal in epifluorescence microscopy, or laser confocal 
scanning, few drops of fluor save agent were put between the side of the coverslip containing 
the cells and the glass slide. This procedure was used in all experiments in which fluorescent 
dyes were used. 
For avidin-biotin (ABC staining), after the incubation of SM132 and the three rinses in PBS, 
cells were incubated for 1 hour with a biotinylated anti-mouse antibody (1: 1000) in a solution 
of PBS containing FCS (5%). 
After incubation with the secondary antibody the cells were rinsed three times (5 min) and then 
incubated for 1 hour in a solution containing reagent A (avidin) and reagent B (biotinylated 
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horseradish peroxidase) with PBS 0.1 M pH 7.4 at final 1% concentration ( Triton X-100 was 
not used in this step). To increase the efficiency of staining, the A+B solution were prepared 30 
minutes before the incubation and maintained at 4 °C just until the incubation. 
After one rinse in PBS and two rinses in TBS 0.1 M pH 7.8-8.3, the cells were incubated for 
few minutes in TBS containing 0.5% DAB (w/V) and H202 (0.6 µl for 1 ml of solution, H202 
was added just before application). As DAB is a photosensitive molecule, the DAB was 
dissolved and stored in a dark vial until incubation. The steps involved in the process of 
staining enhancement by the ABC method are shown in figure 8.1. 
ABC method 
HRPO 
O-s avidin-biotin- 
i-ý HRPO complex 
biotin 
avidin 
antigen 
biotinylated 
secondary antibody 
(e. g., goat anti-rabbit) 
primary antibody ---- 
(e. g., rabbit anti-antigen) 
Figure 8.1 Schematic representation of events characterizing the immunoperoxidase process of 
immunohystochemistry with ABC method. Abbreviations: ABC, avidin-biotin conjugate 
complex; HRPO horseradish peroxidase. 
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8.2.2 EPO receptor 
After fixation and three rinses in 0.1 M PBS pH 7.4, the purified cultures were permeabilized 
with Triton X-100 (0.2%) for 30 minutes and blocked with FCS (10%) in PBS. Cells were 
incubated overnight at 4 °C with the rabbit polyclonal primary antibody, raised against anti-Epo 
receptor (1: 500), in absence or presence of an excess of blocking peptide (1: 50). Next steps 
were carried out at room temperature. Cells were washed three times and then incubated for 
two hours in a solution of PBS containing biotinylated anti-rabbit (1: 200) and FCS (1%). The 
following steps were identical to the SM132 protocol (ABC kit method). 
8.2.3 GluR 1-4 
Before the incubation with the specific antibody directed against the four different subunits of 
the AMPAr, the same experimental procedure was used. 
After fixation, purified cultures were washed three times in 0.1 M PBS pH 7.4, and then 
incubated in a solution of PBS containing Triton X-100 (0.4%) for 30 minutes at 4 °C. A 
further incubation in PBS and Triton X-100 (0.1%) and FBS (3%) for 15 minutes at 4 °C was 
then performed. 
GluRI 
The cells were incubated overnight at 4 °C in a solution of PBS containing an anti-rabbit 
polyclonal antibody raised against GluR-1 (1: 500), Triton X-100 (0.1%) and FBS 3%. After 
incubation with the primary antibody, and two rinses in PBS at room temperature, cells were 
incubated for 2 hours at room temperature in a solution of PBS containing FBS (2%) and an 
Alexa-488 goat anti-rabbit secondary antibody (1: 1000) (the fluorophore used was a dye 
conjugated to fluorescein (mistakenly abbreviated by its commonly-used reactive 
isothiocyanate form (FITC)) having a% of absorption at 495 nm and a? of emission at 519 nm 
-green fluorescence-). 
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GIuR2 
The cells were incubated overnight at 4 °C in a solution of PBS containing an anti-mouse 
monoclonal antibody raised against G1uR-2 (1: 1000), Triton X-100 (0.1%) and FBS 3%. After 
incubation with the primary antibody and the following three rinses in PBS at room 
temperature, the cells were incubated 1 hour at room temperature in a solution of PBS 
containing an Alexa-488 goat anti-mouse secondary antibody (1: 2000) and FBS (4%). 
GluR3 
The cells were incubated overnight at room temperature in a solution of PBS containing an 
anti-goat polyclonal antibody raised against GluR-3 (1: 1000), Triton X-100 (0.1%) and FBS 
5%. After incubation with the primary antibody, and the following three rinses in PBS at room 
temperature, the cells were incubated 2 hours at room temperature in a solution of PBS 
containing an Alexa-488 mouse anti-goat secondary antibody (1: 1000) and FBS (3%). 
GluR4 
The cells were incubated overnight, the first two hours at room temperature and then at 4 °C, 
in a solution of PBS containing an anti-rabbit polyclonal antibody raised against GluR-4 
(1: 200), Triton X- 100 (0.1%) and FBS 1%. After incubation with the primary antibody, and 
three rinses in PBS at room temperature, the cells were incubated 2 hours at room temperature 
in a solution of PBS containing an Alexa-488 goat anti-rabbit secondary antibody (1: 500) and 
FBS (2%). 
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8.2.5 Active Caspase 3 and Caspase 9 
After fixation the cells were rinsed three times in 0.1 M PBS pH 7.4 and then permeabilized 
with Triton X-100 (0.1%) for 30 minutes and blocked with FCS (5%) in PBS. The incubation 
with the primary antibody against activated caspase 3 and 9 is described in the following 
paragraphs. 
3 Active caspase 
The cells were incubated for 36 hours, the first two hours at room temperature and then at 4 
°C, in a solution of PBS containing an anti-rabbit polyclonal antibody raised against the 
cleaved form of capase 3 (1: 100), Triton X-100 (0.05%) and FBS 1%. After incubation with the 
primary antibody, and three rinses in PBS at room temperature, the cells were incubated for 2 
hours at room temperature in a solution of PBS containing an Alexa-488 goat anti-rabbit 
secondary antibody (1: 500) and FBS (2%). 
Active caspase 9 
The cells were incubated overnight at 4 °C, in a solution of PBS containing an anti-rabbit 
polyclonal antibody raised against the cleaved form of capase 9 (1: 100), Triton X-100 (0.05%) 
and FBS 2%. After incubation with the primary antibody, and three rinses in PBS at room 
temperature, cells were incubated for 2 hours at room temperature, in a solution of PBS 
containing an Alexa-488 goat anti-rabbit secondary antibody (1: 1000) and FBS (4%). 
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8.2.5 Cytochrome-c 
For cytochrome-c immunostaining fixed cells were rinsed for three times in 0.1 M PBS pH 7.4 
and then preincubated for 15 minutes at room temperature in a solution of PBS containing FBS 
(10%). After three rinses in PBS the cells were permeabilized in a solution of PBS containing 
saponin (0.1%) for 15 minutes at room temperature and then incubated overnight at room 
temperature in a solution of PBS containing an anti-mouse monoclonal antibody raised against 
cytochrome-c (1: 100) and FBS (5%) according to the method previously described by Sanchez- 
Alcazar and colleagues [Sanchez-Alcazar, 2001]. 
8.3 Hoechst 33258 staining 
The cells were fixed overnight in Carnoy solution (3: 1 methanol/acetic acid) and stained with 
Hoechst 33258 (0.1 pg/ml in PBS) at room temperature for lh, then washed 10 times, 5 min 
each, with distilled water, air-dried overnight and covered with a glass coverslip. 
Cells were observed with an epifluorescence microscope (Zeiss, Germany) using a filter with 
an excitation wavelength of 365 nm (UV). 
8.4 Mito Tracker staining 
The cell-permanent Mito Tracker probe contains a mild thiolreactive chloromethyl moiety that 
appears to be responsible for keeping the dye associated to mitochondria penetration. To stain 
mitochondria, non-fixed cells were incubated with a submicromolar concentration of Mito 
Tracker (100 to 500 nM, depending on the intensity of the staining). Mito Tracker was 
previously dissolved in dimethyl sulfoxide (DMSO), to obtain a starting concentration 1 mM, 
and further diluted (1: 2 to 1: 10) and added at a ratio of 1: 1000 in the culture medium, 
maintained at 37 °C, to reach the nanomolar dilution required. 
The culture medium was removed and substituted, for about 30 minutes, with the medium 
containing the Mito Tracker at 37 °C. After incubation the cells were immediately fixed, 
following the procedure of fixation reported above (see paragraph 8.2), This rapid fixation is 
required to avoid that the Mito tracker probes, which passively diffuse across the plasma 
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membrane and accumulate into the mitochondria, diffuse after incubation. Because the Mito 
Tracker probes are retained into the mitochondria after permeabilization with detergents or 
organic solvents, they maintain their fluorescent staining even following the 
immunocytochemical experiments. 
For these experiments, an Orange-Mito Tracker probe was used. This probe has a? of 
absorption at 554 nm and a? of emission at 576 nm, and for this reason the same confocal 
microscope setting previously used for Alexa-546 fluorescent dyes, was adopted. 
8.5 Propidium Iodide and SYTO 59 staining 
The following experiments (sections 8.5,8.6 and 8.7) were performed in collaboration with 
Prof. Daniela Curti at the Department of Cellular & Molecular Physiological & 
Pharmacological Sciences, University of Pavia, Italy. 
Cells grown on glass coverslips were double stained with SYTO 59 (0.5 PM) and propidium 
iodide (PI, 10 Vg/ml). SYTO 59 is a red fluorescent dye excited with the 633 line of a He/Neon 
laser and propidium iodide is excited at 488 nm with an Argon laser. The pseudocolour blue 
was chosen for SYTO 59 to distinguish between the fluorescence emission of this dye and that 
of PI (red). The cells were incubated at 37 °C for 20 min with the fluorescent probes as 
previously described [225]. At the end of the incubation, the cells were washed and 
resuspended in fresh buffer. Laser scanning confocal images were acquired with a DMS IRBE 
SP2 (Leach) inverted microscope. 
8.6 Mitochondria transmembrane potential (ATM) 
The mitochondrial transmembrane potential was measured with the fluorescent probe 5,5', 6,6'- 
tetracloro-1,1', 3,3'-tetraetilbenzimidazol carbocianine QC-1). Cells were incubated at 37 °C for 
20 min with the fluorescent probe (3 pM). At the end of the incubation they were washed and 
resuspended in fresh buffer, then perfused with the same buffer in a 300 p1 chamber whose 
bottom is the coverslip where the cells were grown. JC-1 is excited at 488 nm with an Argon 
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laser and emits at 527 nm (green fluorescence, in monomeric form) and at 590 nm (red 
fluorescence, JC-1 aggregates representing energized mitochondria). A "shift" from red to 
green fluorescence is observed upon depolarisation of the mitochondria. To minimise any 
photobleaching, laser scanning confocal images were acquired at 0.8-1 pm interval on the z 
axis for each field with a DMS IRBE SP2 (Leica) inverted microscope and a 63x oil objective 
(NA 1.3). Calibration and quantification were performed with Image Tool software 
(UTHSCSA). Fluoresce intensity was expressed as the ratio of the fluorescence emission at 590 
nm and the total fluorescence emission at 590 and 527 nm (Fred/ Fred+F en). 
In some cases the cells were doubled stained with Hoechst 332588 (1 PM) and images were 
acquired with a sequential scanning program and an UV laser. 
8.7 Laser scanning confocal microscopy setting up 
For the double staining experiments (caspases/SMI 32 and Mito Tracker/cytochrome-c) the 
following setting of the laser scanning microscope (Olympus Fluoview microscope BX61 with 
confocal system FV500) was adopted. Dual excitation has been used, 488nm (LASER Ar) and 
543 (LASER He-Ne green). To select the appropriate emission wavelength from the 
fluorophore, an emission filter designed to allow only a well-defined spectrum of emitted light 
to reach the detector was used, thus rejecting any remaining stray excitation or scattered light 
rejected. The filter used was a 510-550 BP for Alexa 488 and 560-600 BP for Alexa 546 and 
orange-Mito Tracker -see section 8.4- (filter allows band of selected wavelengths to pass 
through, while rejecting all shorter and longer wavelength). The image acquisition was done 
with different setting of photomultiplier (PMT), voltage (increasing this value improves the 
sensitivity), offset (darkens the image at the ratio set during image acquisition) and gain 
(brightness the image at the ratio set during image acquisition). 
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8.8 Statistics 
Data are reported as mean values±S. D. and compared using ANOVA with Tukey's test. Dose- 
response curves were fitted accordingly to the four-parameter logistic equation: 
y--Bottom + (Top-Bottom) 
1+10 (logEC50X)Hdl slope 
which also gives an "asymptotic" standard error for each best-fit value. 
Calculations were performed using Prism version 3. Oa for Macintosh, Software, San Diego 
(CA, USA). 
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CHAPTER 9 
In vivo METHODS 
9.1 Genotyping 
In order to identify wr/wr homozigous mice in presymptomatic stage (2°d -3td week of age) a 
genotyping analysis was performed. An Alu I restriction polymorphism of a Cct 4 
amplification product was used for testing the allelic status at the wr locus. 
A small portion (0.5 cm) of the end segment of the tail was cut and digested overnight at 56 °C 
in 500 µl of lysis buffer (Puregene Genomic DNA Purification Kit for Mouse Tail Tissue, 
Gentra System) and 50 µg of Proteinase K (Gibco BRL). The following day, 500 µl of a mix 
1: 1 phenol-TRIS saturated: chloroform was added to each sample, shaking gently to obtain a 
homogeneous emulsion. The samples were centrifuged (12,000 rpm for 5 minutes) to obtain 
two separated phases: the supernatant contains the DNA, while the proteins form a layer 
between the phases. 
The supernatant was carefully transferred in 500 tl of isopropanol to precipitate the DNA. 
After precipitation DNA was withdrawn and dispensed in 100 p1 of Tris-EDTA solution (0.1 
mM pH 7.5) and incubated for 4 hours at 56 °C. The DNA amplification of the small portion of 
DNA containing the Alul restriction polymorphism was carried out by PCR. Cct4 diagnostic 
primers were purchased from Gibco BRL. The PCR reactions were performed as follows: 
initial denaturation step 4 min at 94 °C followed by 35 cycles of 30s 90 °C denaturation, 30s 
Tann, 64 °C, and 30s 72 °C polymerisation. Restriction enzymes were obtained from Gibco 
BRL. PCR products (4 p1) were digested in a total volume of 10 p1 with 10 U Alul for 1 hour at 
37 °C, separated by 2% agarose gel electrophoresis and stained with ethidium bromide. In this 
way it is possible to screen the wobbler and healthy littermates (both homozygotes and 
etherozygotes mice). One single band is associated to the amplified product from homozygous 
+/+ healthy mice, which show no polymorphism. Two lower band are associated the amplified 
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product from wr/wr mice, which present polymorphism in both alleles. Three bands are 
associated to the amplified product from wr/+ healthy mice (one from the wild type allele and 
two from the mutated alleles. 
9.2 Pharmacological treatments 
9.2.1 EPO treatment 
After the diagnosis of the disease at three weeks of age, 16 homozygous wobbler mice and 20 
healthy littermates were randomly assigned to one of four experimental groups: 
group 1: wobbler mice treated with EPO (10 animals); 
group 2: wobbler mice treated with vehicle (10 animals); 
group 3: control littermates treated with EPO (10 animals); 
group 4: control littermates treated with vehicle (10 animals). 
Animals were treated intraperitoneally, three times a week, with human recombinant 
erythropoietin (RhUEPO) at the dose of 4Units/g body weight (lU of EPO = 10 ng of protein) 
or with the same volume of saline solution (10 ml/kg body weight). 
All experimental groups included a similar number of male and female mice, since no sex- 
related differences in the evolution of the wobbler disease has been reported [Mitsumoto, 
1994]. 
Epo was a gift from Dragon Pharmaceuticals (Vancouver, BC, Canada). 
Animals were sacrificed at 12`h weeks of age. Five animals for each group were sacrificed by 
decapitation; blood was drowned for haematocrit determination. The cervical spinal cord and 
the biceps muscles were rapidly dissected, frozen in n-pentane at -45 °C and stored at -80 °C 
until analysis. The other animals belonging to the four experimental groups were transcardially 
perfused with 4% paraformaldehyde in PBS. 
Spinal cord and biceps muscles were removed, postfixed and cryopreserved by serial steps in 
sucrose solution. Samples were rapidly frozen in n-pentane at -45°C and stored at -80 °C until 
analysis. 
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9.2.2 RPR119990 treatment 
For RPR119990 treatment, after the diagnosis of the disease at three weeks of age, 20 wobbler 
mice and 20 healthy littermates were randomly assigned to one of four experimental groups: 
group 1: wobbler mice treated with RPR119990 (10 animals); 
group 2: wobbler mice treated with vehicle (10 animals); 
group 3: control littermates treated with RPR119990 (10 animals); 
group 4: control littermates treated with vehicle (10 animals). 
Mice were treated daily sub-cutaneously with 3 mg/kg of RPR119990 diluted in saline solution 
or with the same volume (10 ml/kg) of saline. Food (standard pellets) and water were supplied 
ad libitum. 
All experimental groups included a similar number of male and female mice, since no sex- 
related differences in the evolution of the wobbler disease has reported [Mitsumoto, 1994]. 
RPR119990 was kindly provided by Aventis-Pharma (Aventis Pharma Centre de Recherche de 
Paris, Vitry Sur Seine, Cedex, France). 
All mice receiving RPR119990 treatment were sacrificed at 12 weeks of age by transcardiac 
perfusion with 4% paraformaldehyde in PBS. Biceps muscles and spinal cord were rapidly 
dissected, post-fixed and cryoprotected. Samples were frozen in n-pentane at -45 °Cand stored 
at -80 °C until analysis. 
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9.2.3 Riluzole treatment 
For riluzole treatment, after the diagnosis of the disease at three weeks of age, 20 wobbler mice 
and 20 healthy littermates were randomly assigned to one of four experimental groups: 
group 1: wobbler mice treated with riluzole (10 animals); 
group 2: wobbler mice treated with vehicle (10 animals); 
group 3: control littermates treated with riluzole (10 animals); 
group 4: control littermates treated with vehicle (10 animals). 
Riluzole was administered in drinking water (final concentration: 150 pg/ml); the calculated 
dose for the treatment was 40 mg/kg/day. Vehicle-treated mice received tap water. Water 
consumption was calculated as 4 ml/animal/day and the volume needed was supplied by 
operators every two days, with addition of riluzole previously diluted in ethanol (0.05% of the 
final volume) for treated mice. Food (standard pellets) was supplied ad libitum. 
All experimental groups included a similar number of male and female mice, since no sex- 
related differences in the evolution of the wobbler disease has been reported [456]. 
Riluzole was kindly provided by Aventis-Pharma (Aventis Pharma Centre de Recherche de 
Paris, Vitry Sur Seine, Cedex, France). 
For each experimental group, five mice receiving riluzole treatment were sacrificed at 12 weeks 
of age by transcardiac perfusion with 4% paraformaldehyde in PBS. Immediately after 
perfusion, biceps muscles and spinal cord were rapidly dissected, post-fixed and cryoprotected. 
After freezing in n-pentane at -45 °C, biceps muscles and spinal cords were stored at -80 °C 
until analysis. 
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9.3 Behavioural scores recording 
Behavioural trials for wobbler mice were carried out twice a week, by the same operator 
blinded to treatments. The clinical progression of the disease was monitored using both 
quantitative measurements (running time and grip strength tests) and semi-quantitative score 
(paw abnormality and walking abnormality tests), according to previously described protocols 
[Kozachuk, 1987]. 
9.3.1 Paw and walking abnormality 
Description of the test: the massive loss of cervical spinal cord motor neurons that occurs in 
wobbler mice lead to progressive atrophy of the innervated muscles, in particular biceps 
muscles of the forelegs are severely affected. Symptoms become evident starting from the 
3`d/4`h week of age and worsen rapidly until the wobbler mice show severe motor impairment 
that impede to walk correctly. At the same time, the front paws show progressive retraction of 
digits and the adduction of the paws to the body. Both the paw abnormality and the walking 
abnormality tests are observational; the operator assigns a score to these parameters, scaled 
from 0 to 4, on the basis of the severity of abnormalities. 
The paw position is graded as follows: 
score 0: normal 
score 1: retracted digits 
score 2: curled digits 
score 3: curled wrists 
score 4: forelimb flexed to body 
The walking pattern is graded as follows: 
score 0: normal 
score 1: trembling (tremor without gait disturbance) 
score 2: wobbling (gait disturbance) 
score 3: curled paw walking 
score 4: jaw walking (no use of front paw). 
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9.3.2 Running time 
Description of the test: mice run over an inclined platform (75 cm long ramp inclined at one 
end to a height of 13 cm) stimulated with a gentle pressure on the tail (adverse stimulus). The 
running time is defined as the shorter time to reach the top of the platform from the bottom. 
Healthy mice rapidly improve their performances on the test until they reach the top of the 
platform in few seconds (1 to 3 sec. ). On the contrary, wobbler mice need longer time to reach 
the top of the platform. Moreover these animals show a marked worsening of their 
performances, due to the progressive muscular atrophy in the forelegs.. 
9.3.3 Grip strength. 
Description of the test: the mice are lifted by the tail and allowed to grasp with both forelegs to 
a horizontal bar, which is connected to a mechanoelectric transducer. The grip strength of the 
front paws is measured at the point when the mouse releases the horizontal bar as a result of a 
gentle traction applied by the operator. Healthy mice can record values higher than 100 grams, 
while values recorded by wobbler mice are very low (< 20 grams) and drastically reduced 
during symptoms progression. When animals are no longer able to grip the bar, grip strength is 
recorded as 0 grams. Values of grip strength were normalized dividing each value by body 
weight, in order to control for weight differences between wobbler and healthy mice. 
9.4 Haematocrit measurement 
Immediately after decapitation, few drops' of blood were collected in heparinated capillary 
tubes (soda lime glass Micro Haematocrit Tubes, ALC International) and centrifuged at 3500 
rpm for 20 min. at 20C°. Total and erythrocytes lengths were measured; the haematocrit value 
was calculated by dividing the particulate by total length and multiplying it by 100. For each 
sample, the mean of triplicate values was recorded. 
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9.5 Spinal cord perfusion and slice preparation 
To ensure an optimal quality of spinal cord tissues for hystochemical determinations, tissues 
were fixed following the transcardial perfusion method described below: 
" Before anaesthesia a peristaltic pump, including two boxes (the first one containing 0.1 M 
PBS, pH 7.4 at room temperature, and the other containing a solution of parformaldhheyde 4% 
dissolved in PBS at a pH ranging from 7.2-7.4) was prepared. This pump was connected to a 
25-gage needle. 
"A deep surgical anaesthesia was induced in mice by injecting intraperitoneally (IP) a 
solution of 0.6 g/Kg of chloral hydrate in saline (approx 150 µl for 20-g mouse). 
" The pupil closure was checked before starting the perfusion to ensure that the animals were 
completely anaesthetized by gently touching the eye with a plastic pipette. 
" When the animals were completely anaesthetized, the thorax was surgically opened, the 
diaphragm was cut and removed and the lateral part of thoracic cage was opened and directed 
to the back, by using a small clamp, in order to better penetrate into the beating hart (see figure 
9.1). 
" The 25-gage needle was then inserted in the left ventricle, closer to the aortic valves. This 
operation must be extremely accurate but, at the same time, fast. In fact, the absence of the 
diaphragm muscle activity and the consequent loss of respiration, may rapidly lead to an 
ischemic damage of the heart and a loss of blood circulation. 
" When the 25-gage needle was inserted into the left ventricle, the flux of PBS solution was 
opened and the auricle of the right atrium was cut. 
" The phase of washing tissues, to remove the blood cells was done by using about 15 ml of 
PBS for 20-g mouse and the phase of fixation was performed by using about 45 ml of fixative 
for a 20-g mouse 
" After perfusion, the vertebral column was removed and postfixed, three hours at 4 °C, in 
the same solution used to perfuse the mouse. 
" After fixation, samples were cryoprotected by three serial incubation at 4 °C, 2 hours each, 
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in a solution 0.1 M PBS, pH 7.4 containing increasing concentration of sucrose (10%, 20% and 
30%). This process removes water from tissues and prevents freezing artefacts. 
" After cryopreservation, samples were briefly dried and dipped in cooled isopentane (-35 °C 
to -45 °C). The time of immersion varies according to the type of tissue, its size and its shape. 
However it must be long enough to result in complete freezing but not so long to cause 
shrinkage or cracking of tissue. 
" Micrometric slices from 20 to 40 pm of thickness were obtained by sectioning the tissues 
using a microtone housed in a freezing chamber placed at a temperature of -20 °C. In order to 
avoid breaking of tissues during sectioning spinal cord samples must be previously embedded 
in a small cylinder of OCT 
Figure 9.1 Schematic representation of surgical procedures utilized to perfuse the animal 
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9.6 Immunohystochemistry 
For free floating immunohystochemistry, micrometric sections were placed in wells containing 
a buffered saline solution (PBS or TBS) and then rinsed three rinses (10 minutes each) to 
remove the OCT in solution. 
For this immunohystochemistry, the ABC method, already described in the chapter 8(see 
section 8.2.1), was utilized to visualize the immunoreactivity. 
9.6.1 ChAT 
After three rinses in TBS 0.1 M (pH 7.4) the sections were incubated for 1 hour at room 
temperature in TBS containing normal goat serum (10%), to avoid non-specific reactions. 
Then the sections were incubated, for the first two hours at room temperature and then at 4 °C, 
in TBS containing an anti-mouse monoclonal antibody directed against ChAT (1: 200) and 
NGS 3%. Since permeabilized tissues showed a non-specific staining, with a marked increase 
of staining in intemeurons and in fibers, in this study no permeabilization was performed. 
After three rinses in TBS the sections were incubated in a solution of TBS containing an anti- 
mouse secondary antibody (1: 200) and NGS (1%) for 2 hours at room temperature and then 
processed following the ABC method. 
9.6.2 CD 11b 
The sections were rinsed three times, 5 minutes each, in a solution of TBS 0.1 M (pH 7.4) and 
then incubated 30 minutes at room temperature in a solution of TBS containing Triton X-100 
(0.4%) and NGS (3%). A further incubation was done overnight at room temperature in TBS 
containing an anti-rat polyclonal antibody directed against the receptor CD l lb, that is 
selectively expressed in activated microglial cells (1: 100), Triton X-100 (0.2%) and NGS (2%). 
After three rinses in TBS the sections were incubated in a solution of TBS containing an anti- 
rat secondary antibody (1: 200) and NGS (2%) for 2 hours at room temperature and then 
processed following the ABC method. 
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9.6.3 TNF-a and TNF receptors 
The sections were incubated 1 hour at room temperature in a solution 0.1 M TBS pH 7.4 
containing NGS (10%) to reduce the non-specific staining, mainly due to cross-reaction of 
secondary antibodies. 
For TNF-a immunostaining the section were incubated overnight at room temperature in the 
following solution: TBS 0.1 M (pH 7.4) containing NGS (1%), Triton X- 100 (0.1 %) and 
primary antibody mouse monoclonal anti-human TNF-a (1: 50). After three rinses in a solution 
of TBS the sections were incubated for two hours at room temperature in TBS containing an 
anti-mouse biotinylated antibody (1: 100) and NGS (2%). 
For TNFRI and TNFR2 immunostaining the section were incubated overnight at room 
temperature in the following solution: TBS 0.1 M (pH 7.4) containing NGS (1%), Triton X-100 
(0.2 %) and anti-rat polyclonal antibody for TNFR1 (1: 100) or anti-rat polyclonal antibody 
TNFR2 (1: 25). After three rinses in TBS the sections were incubated two hours at room 
temperature in TBS containing an anti-rat biotinylated antibody (1: 100) and NGS (2%). 
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9.6.4 Active caspases 3,7,8 and 9 
Active caspase 3 
The sections were incubated in a solution containing PBS 0.1 M (pH 7.4) and FCS (10%) for 
24 hours at 4 °C, and, the following day, rinsed three times and further incubated in PBS and 
Triton X-100 (0.5 %) for 45 minutes at room temperature. 
These serial steps where then followed by an overnight incubation, at 4°C, in a solution 
containing PBS, an anti-rabbit polyclonal antibody raised against the cleaved form of capase 3 
(1: 100) and FCS (5%). After three rinses in PBS the sections were incubated with the 
secondary antibody in a solution of PBS containing a biotinylated anti-rabbit antibody (1: 100) 
and NGS (4%) for 2 hours at room temperature. 
Active caspase 7 
The sections were rinsed for three times in solutions of PBS 0.1 M (pH 7.4) containing 
increasing amounts of NGS (1%, 5%, and 10%). After a 30 minute incubation at room 
temperature in PBS containing Triton X-100 (0.5 %), the sections were incubated for 48 hours, 
at 4 °C, in PBS containing an anti-goat polyclonal antibody raised against the active form of 
caspase 7 (1: 50), Triton X-100 0.3% and NGS (5%). After three rinses in PBS the sections 
were incubated with the secondary antibody in a solution of PBS containing a biotinylated anti- 
goat antibody (1: 100) and NGS (4%) for 2 hours at room temperature. 
Active caspase 8 
The sections were rinsed three times in PBS pH (0.1 M) 7.4 and then preincubated in a solution 
of PBS and H202 (0.1%) for 15 minutes at room temperature. After three rinses in PBS and 
NGS (1%) the cells were incubated overnight at 4 °C in a solution containing anti-mouse 
monoclonal antibody directed against the activated form of caspase 8 (1: 50), Triton X-100 
(0.3%) and NGS (5%). After this incubation the cells were rinsed three times in PBS and then 
incubated for 1 hour at room temperature in a solution of PBS containing a biotinylated anti- 
mouse antibody (1: 200), Triton X-100 (0.2%) and NGS (3%). 
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Active caspase 9 
Following a preincubation for 2 hours at room temperature in a solution 0.1 M PBS (pH 7.4) 
containing NGS (5%) the sections were incubated overnight at 4 °C in PBS containing an anti- 
rabbit polyclonal antibody raised against the cleaved form of capase 9 (1: 100), Triton X-100 
(0.05%) and FBS (2%). After incubation with the primary antibody, and three subsequent 
rinses in PBS at room temperature, the sections were incubated 2 hours at room temperature in 
PBS containing an anti-rabbit secondary antibody (1: 200) and FBS (2%). 
9.6.5 G1uR 1-4 
Before incubation with the specific antibodies directed against the G1uR-1,2,4 subunits of 
AMPA receptor, the same experimental procedure was used. After three rinses in 0.1 M PBS 
(pH 7.4) containing FBS (5%) the sections were preincubated in PBS and then incubated in a 
solution of PBS containing Triton X-100 (0.5%) for 1 hour at room temperature. 
In addition, for GluR3 immunostaining, a preincubation in a solution of PBS and albumin 
(0.5%) for 24 hours at 4 °C, in order to reduce the non-specific staining, was required. 
GIuRI. 
The sections were incubated overnight at 4 °C in a solution of PBS containing an anti-rabbit 
polyclonal antibody raised against GluR-1 (1: 200), Triton X-100 (0.1%) and FBS 3%. After 
incubation with the primary antibody and three subsequent rinses in PBS at room temperature, 
the sections were incubated for 2 hours at room temperature in PBS containing an anti-rabbit 
secondary antibody (1: 200) and FBS (3%). 
GluR2 
The sections were incubated overnight, at 4 °C in 0.1 M PBS containing an anti-mouse 
monoclonal antibody raised against G1uR-2 (1: 1000), Triton X-100 (0.1%) and FBS 3%. After 
incubation with the primary antibody and three rinses in PBS at room temperature the cells 
were incubated for 1 hour at room temperature in PBS containing a biotinylated anti-mouse 
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secondary antibody (1: 2000) and FBS (4%). 
GluR3 
After three rinses in a solution 0.1 M PBS (pH 7.4) the sections were incubated overnight at 4 
°C in a solution of PBS containing an anti-goat polyclonal antibody raised against G1uR-3 
(1: 400), Triton X-100 (0.1%) and FBS (5%). After incubation with the primary antibody, and 
the following three rinses in PBS at room temperature, the cells were incubated for 2 hours at 
room temperature in a solution of PBS containing a biotinylated anti-goat secondary antibody 
(1: 200) and FBS (3%). 
GluR4 
The sections were incubated overnight, the first two hours at room temperature and the 
following time at 4 °C, in PBS containing an anti-rabbit polyclonal antibody raised against 
G1uR-4 (1: 50), Triton X-100 (0.2%) and FBS 1%. After incubation to primary antibody and 
three rinses in PBS at room temperature, the cells were incubated for 2 hours at room 
temperature in PBS containing an anti-rabbit secondary antibody (1: 100) and FBS (1%). 
9.6.6 BDNF 
For BDNF immunohystochemistry sections were pre-incubated 5 minutes at 4 °C in a solution 
0.1M TBS (pH 7.4) containing TritonX-100 (0.4%) and then 90 minutes in a solution 
containing TBS TritonX-100 (0.4%), C2H5OH (20%) and H202 (0.6%). The sections where 
then incubated for 45 minutes at room temperature in a solution of TBS containing TritonX- 
100 (0.4%) and FBS (10%). The sections were then incubated overnight at 4 °C in a solution of 
TBS containing a biotinylated anti-rabbit polyclonal antibody directed against BDNF (1: 1000), 
Triton-X100 (0.4%) and FBS (10%). After three rinses with TBS, sections were incubated for 
1 hour at room temperature with a secondary anti-rabbit antibody (1: 200) and FBS (10%). 
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9.6.7 EPOr 
The sections were rinsed three times in 0.1 M PBS (pH 7.4) at 4 °C and then incubated for 40 
minutes at 4 °C in a solution of PBS containing FBS (4%). The sections were then incubated 
overnight at 4 °C in PBS containing a rabbit polyclonal antibody directed against the c-terminal 
portion of receptor (1: 200) and FBS (10%). After incubation with the primary antibody the 
sections were rinsed with PBS, three times for 5 minutes, and then incubated for two hours at 
room temperature in PBS containing biotinylated anti-rabbit antibody (1: 200) and FCS (1%). 
In all immunohystochemical experiments the antibody visualization was carried out by reaction 
with 3-3'-diaminobenzidine (20 mg/ml in TBS 0.1 M (pH 7.8-8.3) in presence of 30% H202 (6 
µl/1 ml)), the time of incubation ranged from few seconds to 5 minutes, depending on the 
strength of chromogen action produced for each single type of antibody. After this step the 
sections were washed twice with 0.1M TBS pH 7.4, maintained in a solution of NaCl 0.9% and 
then air-dried and coverslipped with DPX mountant (BDH Laboratory) for light microscopy 
analysis. 
9.6.8 Densitometric analyses 
Complex I staining, GLUR1-4 subunits and BDNF immunostaining were evaluated by 
densitometric analysis of single motor neurons of the ventral horns. This study was carried out 
in sections of cervical spinal cord (C2-C6) of wobbler mice and healthy littermates. For each 
animal, 5 slides with 4 sections each were digitally acquired and analysed using the image 
analyser AIS software (Imaging Research, St. Catharine's, Ontario, Canada) after software 
calibration with appropriate grey scale. 
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9.7 Histological staining 
9.7.1 Nissl staining 
Nissl staining is a well-characterized method to stain neurons. This procedure of staining is 
particularly specific for neurons in spite of their abundant content of cytosoplasmatic 
ribonucleic acids, which are intensively stained with cresyl violet. 
Nissl staining was performed in sections of 30 µm of thick. The sections were obtained from 
perfused tissues of cervical spinal cord region. Nissl staining was done in wobbler mice at the 
presymptomatic, early symptomatic and late symptomatic stage and in healthy littermates. 
Serial sections, minimum 100, were processed to count the total number of motor neurons for 
each animal. At least 5 animals for each experimental group were utilized to compare the 
number of motor neuron in wobbler and healthy littermates. 
The sections were placed in gelatinated glasses slides and, to obtain a good adherence of 
sections to slide's surface, the slides were hold for 12 hours in a drier at 4 °C. 
The sections were then processed according to the protocol reported below: 
" Incubation of slides in H2O 1 minute 
" Incubation of slides in CZH5OH 70% 5 minutes 
" Incubation of slides in C2H50H 96% 5 minutes 
" Incubation of slides in C2H5OH 100% 5 minutes 
" Incubation of slides in xylene 5 minutes 
" Incubation of slides in C2H5OH 100% 5 minutes 
" Incubation of slides in C2H5OH 96% 5 minutes 
" Incubation of slides in C2HSOH 70% 5 minutes 
" Incubation of slides in H2O 1 minute 
" Incubation of slides in cresyl violet 0.5% 6 minutes (cresyl violet is diluted in H20+ 
C2H5OH 20%, the best condition of staining were obtained by keeping the sections in this 
solution for 3 minutes. 
" 10 rinses in H2O 
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" 10 rinses in CZH5OH 70% 
" Incubation of slides in C2H5OH 96% 3 minutes 
" Incubation of slides in CZH5OH 96% e acetic acid 3% 20-30 seconds (the acetic acid 
rapidly reduced the staining intensity cautions have to be used to avoid the complete loss of 
cresyl violet staining in neurons). Usually the time of immersion in this solution ranged from 
20" to 60". However the time of immersion was maintained constant when two different 
experimental groups were compared in the same experiment. 
" Incubation of slides in C2H5OH 100% 2 minutes (check that C2H5OH 100% does not 
strongly reduced the staining) 
" Incubation of slides in xylene 5 minutes 
9.7.2 IN Situ End Labelling (ISEL) colorimetric assay 
The in situ end-labelling (ISEL) method demonstrates DNA fragmentation, commonly regarded 
as a marker of apoptosis. This study was done in collaboration to Prof. A Migheli, Department 
of Anatomy, Pharmacology and Forensic Medicine, University of Torino, Italy. Deparaffinized 
sections, 5-10 gm of thickness, were digested in a mixture containing 0-2.5 pg/ml proteinase K 
for 15 min at room temperature. Alternative pre-treatment procedures were based on 
microwave oven heating (three 5-min cycles at 750 W). After quenching of endogenous 
peroxidase activity, sections were incubated in terminal deoxynucleotidyl transferase (TdT) 
buffer (25 mmol/liter Tris-HCI, 200 mmol/liter sodium cacodylate, 5 mmollliter cobalt 
chloride) for 5 minutes and then in TdT solution (20 U of TdT enzyme and 1 nmol of 
fluorescein-1 1-dUTP, in 100 pl of TdT buffer) for 2 hr at 37C. After washing in a solution 
containing 1x TBS, 0.3% Triton, and 2% BSA, the reaction was revealed incubating with anti- 
fluorescein sheep peroxidase-conjugated antibody (Boehringer-Mannheim) for 30 minutes at 
37 °C and then in diaminobenzidine solution. Sections were serially mounted on Superfrost 
slides for ISEL staining. Before ISEL staining the sections were stained by using the Nissl 
method. In this way it was possible to observe both the motor neuron morphology and possible 
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alterations in DNA morphology. 
9.7.3 Mitochondrial complex I staining 
Quantitative hystochemical determination of mitochondrial complex I activity in the spinal cord 
was performed according to Jung et al. [Kozachuk, 1987]. Briefly, sections (18 µm thickness) 
of spinal cord were incubated in 0.1 M Tris-HC1(pH 7.4), 0.14 mM NADH, 1.0 mg/ml nitro 
blue tetrazolium (NBT), antimycin A (2gg/ml), 84 mM malonate and 2mM KCN. 
Hystochemical reactions were performed by incubating the slides for 40 min at room 
temperature. Rotenone (60 µM), a specific inhibitor of complex I, was added in a group of 
sections as negative control. After incubation, the sections were repeatedly rinsed and then laid 
on gelatinised slides. The activity of complex I in individual motor neurons was quantified as 
optical intensity of fixed regions of interest. The high degree of vacuolisation that occurs in the 
motor neurons of 12 week-old wobbler mice may introduce a possible source of error in the 
quantification. For this reason only motor neurons presenting a good morphology were chosen 
and the level of optical density was reported as the mean value obtained from several adjacent 
sections. At least 10 motor neurons for each slice of the spinal cord ventral horn were examined 
for each animal. 
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9.8 Imunoblotting 
9.8.1 AMPA receptor subunits (G1uR 1-4) 
The study of immunoblotting for the AMPA receptor subunits GluR1-4 was done in 
collaboration with Dr. Fabrizio Gardoni, Department of Pharmacological Sciences, University 
of Milan, Italy. This study was performed by utilizing exclusively cervical spinal cord 
homogenates containing the fraction highly concentrated in pre and postsynaptic membranes 
and identified as postsynaptic density (PSD). To obtain PSD, the whole cervical spinal cord 
tissue was homogenized in ice-cold 0.32 M sucrose containing 1 mM Hepes, I mm M902.1 
mM NaHCO3,0.1mM phenylmethylsulfonyl fluoride, and a mixture of protease inhibitors 
(Complete, Roche Diagnostic, Milano) at pH 7.4 and centrifuged at 1,000 xg for 10 minutes. 
The supernatant was centrifuged at 3,000 xg for 15 minutes. The resulting pellet (containing 
mitochondria and synaptosomes) was resuspended in ice-cold 0.32 M sucrose containing 1 mM 
Hepes, 1 mM NaHCO3, and 0.1 mM phenylmethylsulfonyl fluoride (buffer B); overlaid on 
sucrose gradient (0.85 to 1.0 to 1.2 M); and centrifuged at 82,500 xg for 2 h. The fraction 
between 1.0 and 1.2 M was diluted with buffer B containing 1% Triton X-100, stirred at 4 °C 
for 15 minutes, and centrifuged at 82,500 xg for 30 minutes. The resulting pellet was 
resuspended, layered on a sucrose gradient (1.0 to 1.5 to 2.1 M), and centrifuged at 100,000 xg 
for 2h at 4 °C. The fraction between 1.5 and 2.1 M was removed and diluted with 150 mm KCl 
containing 1% Triton X-100. PSD were collected by centrifugation at 100,000 xg for 30 
minutes at 4 °C. 
Ten micrograms of PSD were then incubated overnight at 4 °C with the same antibodies 
utilized for immunocyto- and immunohystochemistry at the following concentrations, GluRl 
(1: 800), G1uR2 (1: 2000), G1uR3 (1: 3000) and GluR4 (1: 500) in a solution of 0.1 M PBS 
containing 200 mM NaCl, 10 mM EDTA, 10 mM Na2HPO4 and 0.1% SDS. 
The resulting proteins were resolved by SDS-PAGE, transferred onto polyvinylidene difluoride 
membranes, and blotted for 1 hour at room temperature in TBS containing 0.1%Tween 20 and 
5% low fat dry milk. Detection was performed by chemiluminescence (ECL) with horseradish 
peroxidase-conjugated secondary antibodies (1: 1500 dilution). 
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9.8.2 Glutamate transporters (GLAST and GLT1) 
The antibodies were tested in homogenates obtained from the cervical spinal cord of wobbler 
mice and healthy littermates. The concentrations of the primary antibodies were for GLT-1-Ab 
(1: 5000) and GLAST-Ab (1: 4000). 
The homogenates (about 5 micrograms for GLT-1,10 micrograms for GLAST) were subjected 
to SDS-polyacrylamide gel electrophoresis (8% polyacrylamide gel), transferred to 
nitrocellulose membrane, and reacted with polyclonal antibodies. 
The immunoreactive proteins were visualized with enhanced chemiluminescence (ECL, 
Amersham, US) using horseradish peroxidase-conjugated donkey antirabbit IgG (1: 2000). 
Blots were incubated concomitantly with anti ß-tubulin (1: 2000) using horseradish peroxidase- 
conjugated goat antimouse as secondary antibody (1: 2000). 
9.8.3 Densitometric measurement 
The expression levels of the analyzed markers were evaluated by densitometric analysis using 
the image analyser AIS software (Imaging Research, St. Catharine's, Ontario, Canada), after 
digital acquisition of films and software calibration with appropriate grey scale. Values of 
density for each marker were normalized for the density values of actin (data not shown) in the 
same blot. 
For quantitative evaluation of immunoreactivity, the optical densities were normalized to the 
optical density of ß tubulin in each animal. 
9.9 Glutamate determination in plasma 
These experiments were done in collaboration with Antonio Bastone at the Mario Negri 
Institute. Mice were killed by decapitation after overnight fasting, and blood samples were 
collected in heparinized tubes and diluted with 0.5% (w/v) sulphosalicylic acid solution (1: 125 
w/v). Samples were vigorously mixed and centrifuged. Aminoacid analysis was done on 50 pL 
supernatant fractions using a high performance aminoacid analyzer (AA Model 6300, Beckman 
Instrument Inc. Palo, CA), as previously described (Bartone A 1995). 
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9.10 13HJglutamate uptake 
These experiments were performed in collaboration with Dr. Marco Gobbi at the Mario Negri 
Institute. Animals were sacrificed by decapitation and the spinal cord were rapidly removed, 
pooled and homogenized with a Teflon/glass homogenizer, in 10 vols of ice-cold 0.32 M 
sucrose, containing 1 mM EDTA, pH 7.4. The homogenate was centrifuged at 1,000xg for 10 
minutes at 4 °C; the pellet was discarded and the supernatant (S1) used to obtain the classical 
crude synaptosomal preparation (P2) by centrifugation at 15,000xg for 30 minutes. 
For the determination of glutamate uptake, pellets from P2 were appropriately diluted in 0.32M 
sucrose, containing 1 mM EDTA, pH 7.4. (50 vols for P2). 100 pL of homogenates from these 
preparations were added to tubes containing 800 pL of Krebs-HEPES buffer (5 mM Tris, 10 
mIvi HEPES, 140 mM NaCl, 2.5 mM KCI, 1.2 mM K2HP04i 10 mM glucose, pH 7.3); NaCl 
was substituted with equimolar choline chloride for non-specific uptake evaluation. Tubes were 
mixed and bath-warmed at 37 °C for 5 minutes. The uptake assay was started by the addition of 
50 pL of 25nM [3H] glutamate (Amersham, specific activity: 56 Ci/mmol) after dilution with 
cold L-glutamate at a final total concentration of 5pM. Tubes were incubated at 37 °C for 5 min 
and the uptake reaction was stopped by filtration with ice-cold choline buffer (3x2 ml) on 
nitrocellulose filters (Millipore, pore diameter: 0.65 pm). Filters were collected and the 
remaining radioactivity was counted with a LKB 1214 Rack Beta liquid scintillation counter 
(counting efficiency is about 60%). L-glutamic acid was obtained from Sigma. [3H] glutamate 
uptake values were expressed as pmol/min/mg protein. 
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9.11 Mitochondrial activity 
The following experiments (sections 9.11.1 and 9.11.2) were performed in collaboration with 
Prof. Daniela Curti, Department of Cellular & Molecular Physiological & Pharmacological 
Sciences, University of Pavia, Italy. 
9.11.1 Oxygen consumption rate 
Q02 of somatic mitochondria in the tissue homogenate was measured by polarography with an 
oxygraph equipped with two thermostatic chambers set at 0.8 ml volume and 30° C and in a 
buffer of the following composition (in mM): KCl 110, mannitol 100, MOPS 20, glutamate 10, 
malate 1, EGTA 1, albumin 1.3 mg/ml, pH 7.0-7.2 (with HCl 1N). After the measurement of 
Q02 in resting condition (basal QO2), to stimulate ATP production and oxygen consumption 
ADP (200 pM) was added. The oxygen consumption rate through complexes I (NADH- 
ubiquinone reductase), II+ III and IV, was measured by using glutamate (10 mM) +malate 
(2.5mM), succinate (5mM) or artificial substrates (ascorbate 1.9 mM and N, N, N', N'- 
tetramethyl-p-phenylendiamine, TMPD, 1.5 mM) and inhibitors of the electron transfer chain 
(rotenone 4 pM; antimycin A 0.25 pM; KCN 5mM). Different substrates, cofactors and 
inhibitors were used to identify which step in the oxidative phosphorylation process was 
eventually impaired in the wobbler spinal cord. Q02 was expressed in nmoles 02/min/mg 
protein. 
9.11.2 Spectrophotometric assays 
Complex I was measured at 30 °C after two cycles of 20 s sonication (Misonix 2007) of the 
homogenate. The reaction mixture in a final volume of 1 ml was: 20 mM phosphate buffered 
solution (pH 7.5), 100 pM NADH, 1 mM KCN. The reaction was started by the addition of 50 
pM ubiquinone-1 and read at 340 nm against a blank containing all the components except the 
starter. After 2 minutes rotenone 10 pM was added and the inhibited rate observed for a further 
5 min. Complex I activity was calculated by subtracting from the overall rate, the rotenone non- 
178 
Chapter 9 In vivo methods 
inhibited rate. Succinate dehydrogenase activity was evaluated at 500 nm and 30° C. The 
reaction mixture contained: 100 mM triethanolamine (HC1), pH 8.3,0.5 mm EDTA, 2 mM 
KCN, 2 mM iodonitrotetrazolium chloride, 12 g/L Cremophor EL and 20 mM succinate, in a 
final volume of 1 ml. 
Cytochrome-c oxidase activity (complex IV) was assayed at 550 nm (30° C) incubating the 
sample with 0.2 M TRIS-HC1 buffer, pH 7.00; 0.1% n-dodecyl-D-maltoside and 25 mM 
reduced cytochrome-c. Cytochrome-c (50 mg) was reduced with ascorbate (15 mg) and eluted 
from PD-10 columns. The activity of citrate synthase (CS) was measured by the formation of 5- 
thio-2 nitrobenzoate from acetylcoA (100 pM), oxaloacetate (0.5 mM), 5,5'-dithiobis(2- 
nitrobenzoic acid) (0.2 mM DTNB) and Triton X-100 (0.5% ) at 412 nm. 
9.12 ChAT activity 
ChAT was assayed using the method of Fonnum [477]. Spinal cords and muscles were 
dissected and homogenized in 0.1 w/v medium containing 0.3% Triton X-100. One pL of tissue 
suspension was added to 10 pL of incubation mixture containing 0.2 mM labelled acetyl donor 
([14C] Specific Activity 47 mCi/mL), 0.25 M sodium phosphate buffer, 300 mM NaCl, 40 mM 
MgSO4,0.1 mM eserine phosphate, 8 mM choline chloride, 2% bovine serum albumin. 
Samples were vortexed and incubated for 10 min at 38 °C. After incubation, 9 pL of each 
sample was dispensed into vials containing 1250 pL of 0.25 M sodium phosphate buffer to stop 
the reaction, with 750 pL of kalignost (5 g of tetraphenylboron in 1000 mL of acetonitrile). 
Finally, the scintillation mixture (3 mL of toluene scintillator, Packard) was added. 
The vials were shaken slightly for 15 minutes and the radioactivity was counted using a liquid 
scintillation spectrometer LKB 1214 RACKBETA. 
The protein content was determined using the Peterson's modification of Lowry's method. 
ChAT activity was expressed as cpm/mg of tissue protein [337]. 
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9.13 Statistics. 
Data are shown as means ± S. D. Tukey's test analyses were used to compare biochemical and 
immunohystochemical values that are reported in chapter l land 12. Behavioural tests results 
were compared using the two-way Anova analysis, with the Bonferroni's post-test. Statistical 
analysis for biceps weight and number of motor neurons was done with the one-way Anova 
with Bonferroni's post-test. All statistical analyses were carried out using the GraphPad Prism 
version 4.00 for Windows. 
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CHAPTER 10 
In vitro RESULTS 
10.1 BDNF/serum withdrawal induces apoptosis in primary cultures motor neurons 
10.1.1 Introduction 
During development of CNS the correct cytological architecture of tissues is guaranteed by a 
mechanism in which the redundant number of neurons, generated in the early phases of 
neurogenesis, is drastically reduced. The massive death occurring in embryonic life is regulated 
by the presence of different trophic factors, and neurons that fail to establish proper connections 
with their respective postsynaptic targets activates an apoptotic program of death. This process 
of selection is well known as neurotrophic factor competition [Clarke, 1976; Bennet, 2002; Levi- 
Montalcini, 1987; Oppenheim, 1975]. 
Although neurotrophic factor competition is a typical phenomenon related to the development, 
a correlation between neurotrophic factors and neuronal death is also detectable in adult brain. 
A link between the decrease of neurotrophic support and neurodegenerative diseases has been 
found in different in vitro and in vivo models of Alzheimer's disease, Parkinson's disease, 
Hungtington's disease and ALS [Canu, 2003; Cattaneo, 2001; Collier, 2003; De Yebenes, 2003]. 
Since BDNF has been reported to be the neurotrophic factor responsible for motor neuron 
survival in different models of ALS [Ikeda, 1995; Mitsumoto, 1994; Mitsumoto, 
1994; Mitsumoto, 1999], in this study the vulnerability of embryonic rat spinal cord motor 
neurons chronically deprived (48 hours) of serum/BDNF was evaluated. 
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10.1.2 Experimental design 
The effects produced by serumBDNF deprivation were estimated both by measuring the rate of 
mortality, by SM132 positive cells counting, and by investigating the presence of two distinct 
markers of apoptosis, DNA fragmentation, by Hoechst 33258 nuclear staining, and caspase-3 
activation, by immunocytochemical staining using specific antibody directed against the 
cleaved form of caspase 3. 
The viability of motor neurons the number of fragmented nuclei and the number of activated 
caspases were counted across four sides of the cover slip. For each slide four different fields 
were counted and the mean used for statistical analysis. 
Other experiments were done following the procedures described in the chapter 8. 
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10.1.3 Results 
Cultures of motor neurons, chronically deprived of serumIBDNF, showed a significant decrease 
of cell viability compared to motor neurons growing in basal conditions (control cells). The 
counting of SM132 positive cells indicates that in mixed cultures the cell viability is reduced by 
40% after serum/BDNF deprivation, and this difference was significantly higher in purified 
cultures, see figure 10.1. The values of the mean of motor neurons survival after serum/BDNF 
deprivation, expressed as percentage compared to their respective controls normalized to 100, 
are reported in tables 10.1 and 10.2. 
CTR CTR- serumBDNF 
Motor neurons % SM132 positive cells 100±18.9 60±8.9** 
Table 10.1 Percentage of motor neurons viability in mixed glia/neurons cultures after 48 hours 
of serum and BDNF deprivation. ** p< 0.05 
CTR CTR- serumBDNF 
Motor neurons % SM132 positive cells 100±20 40±10*** 
Table 10.2 Percentage of motor neurons viability in purified cultures after 48 hours deprivation 
of serum and BDNF deprivation. *** p< 0.001 
Eighteen hours after serum/BDNF deprivation the percentage of apoptotic nuclei in purified 
motor neurons is significantly increased compared to control as revealed by DNA staining with 
Hoechst 33258 (see table 10.3). 
CTR CTR- serum/BDNF 
Fragmented nuclei % (Hoechst) 100±9.2 312±21.3*** 
Table 10.3 Percentage of fragmented nuclei in purified motor neurons after 18 hours of 
serum/BDNF deprivation; normalized to controls. *** p< 0.001 
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Representative nuclear staining is shown in figure 10.2. A marked increase of fragmented 
nuclei and the alteration of nuclear shape is evident in purified motor neurons following 
serum/BDNF deprivation, figure 10.2 (C, D) compared to control cells (Fig 10.2 A, B). 
Microphotographs at higher magnification clearly show as the nuclear integrity observed in 
control motor neurons (Fig 10.2 I) is lost after prolonged BDNF withdrawal (Fig 10.2 L). 
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Figure 10.1 SM132 staii; ing, iii I, 11. \,: J cultures of motor neurons. Scale bar 200 µm. In basal 
condition it is possible to observe a high percentage of cells with a good morphology (A). 
Serum and BDNF withdrawal drastically reduced the total number of SM132 positive cells (B), 
EPO alone produced a detectable growth of axons and dendrites (C) and significantly increased 
the total number of SM132 positive cells after serum and BDNF deprivation (D). 
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Figure 10.2 Hoechst staining in purified cultures of motor neurons. Scale bar, A, C, E, G 200 
µm; B. D, F, H 40 µm: 1, L 20 µm. In basal condition it is possibile to observe a high percentage 
of nuclei with a good morphology (A) and with a staining homogeneusly diffused in the whole 
surface (B and I). Serum and BDNF withdrawal drastically both reduced the total number (C) 
and the percentage of intact nuclei (D and L). EPO alone did not show marked differences 
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The apoptogenic role played by serumBDNF withdrawal in purified cultures of motor neurons 
was further confirmed by the marked increase of active caspase 3 positive motor neurons 
number. Six hours after serumBDNF deprivation, the number of caspase 3 positive motor 
neurons increased more than twofold compared to untreated cultures (se table 
CTR I CTR- serumBDNF 
Caspase 3 positive motor neurons (%) I 100±10.5 1 210±12.1*** 
Table 10.4 Percentage of active caspase 3 positive motor neurons in purified cultures after six 
hours of serum and BDNF deprivation; normalized to controls. *** p<0.005 . 
A representative microphotograph of motor neurons stained for activated caspase 3 in purified 
cultures in basal conditions is shown in figure 10.3 A. Few cells were positive and the staining 
was moderate and bordered on the cell body. On the contrary, an increased number of caspase 3 
positive motor neurons staining, and a more intense and distributed immunostaining was found 
in serum(BDNF deprived purified motor neurons (Fig 10.3 B). EPO treatment did not 
significantly reduced the number of caspase 3 positive cells compared to control (Fig 10.3 C) 
but greatly reduced the amount of caspase 3 motor neurons after 6 hours of serum and BDNF 
deprivation (Fig 10.3 D). 
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Figure 10.3 ActiNe caspase 3 immunostaining in purified cultures of motor neurons. Scale bar 
50 µm. In basal condition very few cells were positive against anti-active caspase 3 antibody 
(A). A marked increase of anti-active caspase 3 immunostaining was seen in purified 
motorneurons after 6 hours of serum and BDNF deprivation, in these cells it is easily detectable 
-- , hr immmmoreartivity is not only confined to the cytoplasm but it is also expanded at the 
;. _... ions and into the nucleus (B). EPO treatment produced a marked reduction in active 
, "A . ngce 4 motorneurons in purified cultures after six hours of serum and BDNF deprivation 
(C) 
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10.1.4 Discussion 
As previously reported in other primary cultures of neurons deprived of NGF, GDNF and other 
neurotrophins [Kaal, 1997; Ikeda, 1995], the results obtained in primary cultures of motor 
neurons clearly demonstrates that the deprivation of trophic factors produces toxic effects 
[Bennet, 2002]. The significant decrease of survival in primary cultures of motor neurons that 
are reported both in in vivo and in in vitro studies, have confirmed the role of BDNF in 
preventing cell death [Henderson, 1993; Yan, 1992]. 
In this study I found that embryo rat primary cultures of motor neurons are killed by chronic 
deprivation, 48 hours, of serum and BDNF, and that, in purified cultures, they are more 
vulnerable than in mixed glia/neurons cultures. This small, but notable increase of cell 
resistance, observed in mixed glia/neuron cultures, could be in part due to the fact that 
astrocytes express and release important survival factor, as GDNF and CNTF. Regarding the 
role of GDNF in motor neuron survival, is important to note that, in the earliest phase of 
neuronal development of mammalian and avian species, GDNF withdrawal produced an almost 
complete loss of developing motor neurons. For this reason, to better understand the role of 
neurotrophic factors withdrawal in inducing apoptosis in motor neurons, purified cultures were 
exclusively investigated. 
In addition, since the appearance of apoptotic markers is detectable earlier than motor neuron 
loss, and is not synchronous for each point of cell death pathway, the measurement of nuclear 
fragmentation was done 18 hours following serumBDNF deprivation and the rate of caspase-3 
activation was performed only after 6 hours from trophic factors starvation. 
The correlation between BDNF and motor neuron death in ALS patients has been widely 
investigated from the early 90s. The possible aetiopathological role of 
neurotrophic factors withdrawal in ALS and, especially, the possible contribution of BDNF 
supply to counteract motor neuron loss in patients, was tested both in in vivo models of motor 
neurodegeneration and by different clinical trials (see sections 1.4.3.1 and 5.5.1.1). The results 
obtained were controversial and inconclusive: in wobbler mice BDNF was active, whereas in 
ALS patients all treatments failed. 
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The different outcomes produced by BDNF treatments in wobbler mice and in ALS patients 
could not be related to difference in BDNF crossing the BBB, since evidence of a BBB 
disruption in the wobbler mouse is not reported. More relevant might be the fact in animals, the 
treatment started at the early stage of the disease. Moreover, no relevant evidence about the 
mechanisms of motor neuron protection of BDNF was reported. 
The results obtained from this study clearly demonstrates that in purified cultures of motor 
neurons, the deprivation of serum/BDNF leads to apoptosis. 
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10.2 Chronic treatments with AMPA and Kainate induce cell death in primary cultures of 
motor neurons by different mechanisms 
10.2.1 Introduction 
It has been previously reported that a chronic treatment for 48 hours with the three major 
glutamate agonists, AMPA Kainate and NMDA, produces a significant reduction of motor 
neuron viability in mixed glia/neuron cultures and that purified cultures of motor neurons are 
less vulnerable to glutamate agonists compared to motor neurons derived from mixed cultures 
[Comoletti, 2001]. In addition, both in purified and in mixed cultures a dose-response 
experiment for AMPA, kainate and NMDA were performed in order to obtain the concentration 
required to produce the 50% of cell death (EC50) after 48 hours of prolonged exposure for each 
excitotoxin [Comoletti, 2001 ]. 
In this study a more detailed characterization on the cell death mechanism(s) occurring in 
primary cultures of motor neurons exposed to excitotoxic stimuli was performed. 
In a previous study, I demonstrated that both AMPA and kainate toxicity was almost 
completely reversed by the co administration of a selective AMPA receptor antagonist, NBQX 
[Comoletti, 2001]. This result suggested that AMPA and kainate share the same receptor to 
activate embryo motor neuron death after excitotoxic exposure. For this reason a detailed study 
of the cell death pathway(s) elicited by AMPA and kainate, at the concentrations needed to 
produce their EC50 after 48 hours, was performed. Moreover immunocytochemical 
experiments with antibodies directed against GLUR1-4 subunits in purified cultures of motor 
neurons was carried out to correlate the excitotoxic effects with the expression of AMPAR 
subunits. Since mixed glia/neuron cultures are closer to the physiological condition compared 
to purified motomeurons cultures, I decided to investigate these mechanisms in mixed 
glia/neurons cultures. 
All the experiments were done following the procedures described in the chapter 8. 
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10.2.2 Results 
10.2.2.1 A11MPA receptor subunits expression 
A marked immunopositivity for G1uR1 was observed on cell bodies (fig 10.4A) with a more 
intense staining at the nuclear level (Fig 10.4 B). A low immunoreactivity for GIuRI was found 
along dendrites and axons, whereas stronger immunostaining was observed on the distal tract of 
axons and mainly at the synaptic endplate (Fig 10.4 C). 
Immunofluorescence for GIuR2 was found both in cell bodies and in their processes (Fig 10.5 
A, B). Marked GIuR 2 immunoreactivity was found in the distal part of axonal prolongation, 
which may correspond to the synaptic endplate (Fig 10.5 Q. In contrast to GluR1 
immunostaining, the nuclear area was unstained for GluR2 (Fig 10.5 D). 
In purified cultures an intense immunoreactivity for GluR3 was seen (Fig 10.6 A). Similarly to 
GIuR2, no nuclear staining was found but, interestingly, the nucleolus was stained using this 
antibody directed against GluR3 subunit (Fig 10.6 B). Dendrites and axons were positive for 
GluR3 immunostaining and a stronger immunopositivity was revealed at the branching points 
(Fig 10.6 C, D). 
In purified cultures of motor neurons the intensity of the G1uR4 immunostaining was markedly 
weaker compared to others subunits (Fig 10.7 A). G1uR4 immunostaining was mainly 
detectable on cell bodies and in correspondence to the axon hillock (Fig 10.7 B). In the colours- 
scaled microphotograph of figure 10.7 C, where red staining represents the highest signal 
intensity and blue the lowest intensity (background), it is possible note that GIuR4 positivity is 
more relevant in proximity to nuclear/cytoplasmic 
area than in the cell surface. Neurites and dendrites were almost completely unstained with the 
exception of the zone close to dendritic branches, where a modest but detectable staining was 
observed (Fig 10.7 D). 
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Figure 10.4 GluRI ilnmunostaining in purified cultures of motor neurons. Scale bar A, 100 
p. m; B 40 µm; C 25 µm. The pattern of GluR 1 staining is detectable both in the cell body and, 
in lesser extent, at the periphery (A). In the cell body G1uR1 it seems to be expressed in the 
membrane surface and in the cytoplasm (B), whereas in the ramifications of dendrites it results 
more concentrated in the growth cones (C). 
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Figure 10.5 GluR2 immunostaining in purified cultures of motor neurons. Scale bar, A-B 50 
µm; C-D 25 p. m. In lower magnification pictures (A and B) it is possible to note as GluR2 
immunoreactivity covers the whole network of neuronal connections, perikarya, axons and 
dendrites. Moreover, as for GluR1, its expression resulted stronger in the distal zones, maybe in 
correspondence to growth cones (B). A particular of sell body clearly shows as nuclear surface 
is rump leteb' "nstained for GIuR2 (C). 
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Figure 10.6 GiuR3 immunostaining in purified cultures of motor neurons. Scale bar, A100 gm; 
B 40 mm: C 50 gm; D 15 µm. In these cells GluR3 immunostaining is present both in cell 
bodies and in their arborizations (A). However, nuclear area is unstained with the exception of 
nucleolar zone (B). Neural network showed a milder but still evident immoreactivity for GIuR3 
(C) and , at 
higher magnification, it is possible to observe a synaptic zone highly positive for 
GIuR3 immunostaining (D). 
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Figure 10.7 GluR4 immunostaining in purified cultures of motor neurons. Scale bar, A 50 µm; 
B, 40 pm; C 100 µm; D 20 µm. GIuR4 immunoreactivity was greatly less intense compared to 
the other GIuR subunits tested. GluR4 showed a low and circumscribing staining in the body 
cell and axon hillock exclusively (A and B). In the colours-scaled microphotograph it is 
possible note that GluR4 positivity is more relevant in proximity to nuclear/cytoplasmic 
area than in the cell surface (C). Neurites and dendrites were almost completely unstained with 
the exception of the zone close to dendritic branches, where a modest but detectable staining 
",, as observed (D). 
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10.2.2.2 AMPA and kainate toxicity: time-course 
In order to select the appropriate time points to verify apoptotic markers, the time-course of 
AMPA- and kainate-induced motor neuron death was studied. After 6 hours of AMPA (1 µM) 
exposure a marked decrease of SM132 positive motor neurons (35 + 4% p<0.01) was found. 
After 6 hours, kainate (5 µM) lowered the percentage of SMI 32 positive cell only by 23 ±_3%, 
p<0.01. A clear difference (p<0.01) between AMPA and kainate toxicity was observed 18 h 
after treatment: AMPA produced about maximal effect (64 ± 5%, p<0.005) while kainate- 
induced motor neuron death was only 34 ± 3% (p<0.01). After 48 hours of incubation the 
toxicity induced by AMPA was not different from that obtained after 18 h, while kainate 
produced 58 + 5% motor neuron death. 
These data clearly shown that, a short treatment with AMPA 1 µM produces a stronger effect 
on motor neuron cell death compared to kainate 5 µM. However, while AMPA induces a severe 
motor neuron death in the first few hours of incubation, reaching a maximal cell death at about 
18 hours that is maintained until 48 hours, kainate produces a more modest and slower degree 
of motor neuron death, but progressively reduces the percentage of motor neurons even in the 
second half of treatment, from 18 to 48 hours, thus reaching similar levels of toxicity at the end 
of treatment (Fig 10.8). 
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Figure 10.8 Cell viability of motor neurons in mixed glia/neurons cultures 6,18,48 hours after 
incubation with AMPA 1 gM or kainate 5 µM. The mean number of viable motor neurons 
measured in control conditions are normalized to 100 %. The rate of viability is expressed as 
percentage compared to controls. *p<0.05 **p<0.001 (Student's t-test). 
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10.2.2.3 Nuclear fragmentation and membrane permeabilization 
Time course experiments allowed me to determine the appropriate times to verify apoptotic 
markers. To detect the possible involvement of apoptosis it was decided to stop the treatment 
after 6 hours to perform the immunocytochemical experiments for activated caspases 3 and -9, 
whereas 18 hours time point was used for DNA staining and mitochondrial transmembrane 
potential experiments. 
While kainate highly increased the percentage of fragmented nuclei, AMPA treatment, 
although drastically reducing the total number of SM132 positive cells, did not modify the 
percentage of fragmented nuclei in motor neurons. The mean values, expressed as the ratio 
between fragmented nuclei in SMI 32 positive cells and the total number of SMI 32 positive 
cells are reported in table 10.5. 
CTR CTR+kainate CTR+AMPA 
% (fragm. nuclei in SM132 + cells/ 
SM132 + cells) 
4.1±0.6 62.3±18.9*** 3.8±0.9 
Table 10.5 Percentage of the ratio between fragmented nuclei found in SM132 positve cells and 
the total number of SM132 positive cells (SM132 with fragmented nucleus/SM132) in mixed 
glia/neurons cultures exposed to AMPA or kainate. ***p<0.001. 
In order to detect if the kainate-induced motor neurons death was actually related to an 
apoptotic mechanism, double staining experiments using propidium iodide (PI) and SYTO 59, 
were performed (Fig 10.9 A-F). PI cannot penetrate the membrane of intact cells whereas 
SYTO 59 is a membrane permeable dye and stains nuclei. Necrotic cells exhibit cytoplasmic PI 
positivity (red) and nuclei that were both stained with PI and SYTO 59 positive (red+blue), 
whereas apoptotic cells were not PI positive and have condensed or fragmented nuclei stained 
with SYTO 59. Cells with regular sized nuclei stained with SYTO 59 represent healthy living 
cells. 
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In control cells the absence of PI positive cells is evident (fig 10.9 A). After 18 h of kainate 
exposure, several nuclei appeared condensed and fragmented; PI staining is absent or bordered 
the nuclear area (fig 10.9 C). In contrast, AMPA treatment produced massive PI staining in the 
whole cell and the nuclei resulted swollen and nucleic acids were scattered into the 
extracellular space (fig 10.9 E). 
Representative microphotographs showing a higher magnification of nuclear area in motor 
neurons (controls (B), kainate-treated (D), AMPA-treated (G)) stained for Syto 59 and PI, are 
shown in figure 10.9. 
These results evidenced that AMPA and kainate treated motor neurons undergo to a cell death 
process following two distinct morphologic patterns. Nuclear fragmentation, that was also 
quantitatively evaluated, and PI impermeability are the common features observed in kainate- 
treated motor neurons and suggest a process of death shared with apoptosis. On the other hand, 
the absence of nuclear fragmentation together with PI permeability and membrane disruption 
seems more likely to characterize a necrotic death or, at least, to exclude an apoptotic 
involvement in AMPA treated motor neurons. 
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figure 10.9 Syto59 (blue) and I'1 (red) double staining in purified cultures of motor neurons. 
Scale bar, A, C, E, G 40 µm. B, D, F, 11 12.5 p. m. Control cells exhibited a typical nuclear 
staining without either PI entry and DNA fragmentation (A and B). Kainate treated cells 
underwent to a massive DNA fragmentation and nuclear shrinkage thus remaining impermeable 
to PI (C and D). AMPA treated motorneurons showed a massive PI penetration accompanied 
by a nuclear enlargement (E and F). EPO completely counteracted the effect produced by 
kainate treatment (G and H). 
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10.2.2.4 Capase 3 and caspase 9 activation 
To further confirm the selective involvement of apoptosis in motor neurons treated with 511M 
kainate, but not with 1µM AMPA, immucytochemical experiments were performed using 
antibodies directed against the active form of caspase 3 and -9, the two caspases mainly 
involved in the cell death-signaling cascade active during apoptosis. 
Mixed glia/neuron cultures, exposed to different conditions, were double-stained using specific 
antibodies against SM132 (Fig 10.10 A, C, E, G) and the activated form of caspase 3 (Fig 10.10 
B, D, F, H). Under basal conditions SMI 32 positive motor neurons showed a regular shape and 
size and very few activated caspase 3 positive cells were present (Fig 10.10 A, B). After 6 
hours of treatment kainate significantly reduced the number of SMI 32 positive motor neurons 
and increased the number of cells expressing active caspase 3 cells (Fig 10.10 E, F), (Table 
10.6). 
Six hours after AMPA treatment the number of SMI 32 positive cells was reduced to a greater 
extent than after kainate treatment, and the remaining cells showed marked swelling. However, 
the amount of activated caspase 3 positive cells was very low, suggesting that a non-apoptotic 
mechanism of cell death is involved (Fig. 10.10 C, D), (Table 10.7). 
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i: igure 10.10 Double ittuuuusiaiiºi, ig, SM1132 (red A-H, C, E, G) - caspase 3 (green B, D, F, 
H), in mixed glia/neurons cultures. Scale bar 50 µm. At the basal conditions SM132 positive 
neurons (A) resulted almost completely unstained for anti-active caspase 3 antibody (B). 
AMPA treatment produced a marked alteration of SM132 positive neurons morphology but did 
not increase the active caspase 3 immunoreactivity (D). On the other hand kainate produced 
both a shrinkage of SM132 positive neurons (E) and a intense activation of active caspase 3 
immunostaining (F). EPO treatment partially reverted the effects of kainate (G and H). 
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The quantification of active caspase 3 positive motor neurons in these different conditions, 
expressed as percentage of the total number of SMI 32 positive cells, is reported in the table 
10.6. 
CTR CTR+kainate CTR+AMPA 
% (caspase 3 positive cells in SM132 
positive cells/ SM132 positive cells) 
2.8±0.7 8.8±1.6** 2.3±0.6 
Table 10.6 The percentage of SM132 positive cells which expressed active caspase 3 in mixed 
glia/neuron cultures exposed to AMPA or kainate. **p<0.005. 
Similarly to caspase 3, kainate-treatment increases the number of activated caspase 9 positive 
motor neurons (Fig 10.11 E, F) over the control condition (Fig. 10.11 A, B), but not in AMPA- 
treated cells (Fig. 10.11 C, D). 
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Figure 10.11 Double immunostaining, SM132 (red A, C, E, G )- caspase 9 (green B, D, F, H ), 
in mixed glia/neurons cultures. Scale bar 50 µm. At the basal conditions SM132 positive 
neurons (A) resulted almost completely unstained for anti-active caspase 9 antibody (B). 
AMPA treatment produced a marked alteration of SM132 positive neurons morphology but did 
not increase the active caspase 9 immunoreactivity (D). Kainate produced both a shrinkage of 
SM132 positive neurons (E) and a intense activation of active caspase 9 immunostaining (F). 
EPO treatment completely reverted the effects of kainate (G and H). 
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The measurement of active caspase 9 positive cells, expressed as percentage of the total number 
of SMI 32 positive cells, is significantly increased in kainate treated motor neurons compared 
to the control. AMPA treatment, thus producing a marked decrease in SMI 32 positive cells, 
did not increase the number of caspase 9 positive cells (see table 10.7). 
CTR CTR+kainate CTR+AMPA 
% (caspase 9 positive cells in SM132 
positive cells/ SM132 positive cells) 
2.3±0.4 20.6±1.6*** 1.9±0.2 
Table 10.7 The percentage of SM132 positive cells which expressed active caspase 3 in mixed 
glia/neuron cultures exposed to AMPA or kainate ***p<0.001. 
A more detailed pattern of distribution of activated caspases 3 and 9 proteins in SMI-32 
positive cells is shown in figure 10.12 A-D. In these figures at higher magnification, it is 
possible to observe as SM132 and active caspases 3/9 staining present a different pattern of 
distribution. While SMI 32 immunostaining (Fig. 10.12 A, C) is clearly detectable both in cell 
body and in neuronal arborizations and its distribution is homogenous and diffuse, active 
caspase 3/9 (Fig 10.12 B, D) immunostaining is mainly concentrated on the cytoplasm and is 
characterized by small areas in which immunopositivity is stronger compared to the rest of 
cytosol. 
The results of the immunostaining for activated caspases 3 and 9 further confirm the hypothesis 
that, while kainate induces an apoptotic pathway of cell death, AMPA produces a process of 
death unrelated to apoptosis. 
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Figura10.12 Double immunostaining, SM132 (red A, C) - caspase 3 (B) and -9 (D) (green), in 
mixed glia/neurons cultures. Scale bar, 20. tm. SM132 antibody clearly shows a pattern of 
staining in which it is possible to observe the expression of not-phosphorylated neurofilaments 
both in the cell body and in the peripheral emergences of neuron (A and Q. A different pattern 
of staining can be observed by processing the same cells with active caspase 3 (B) and -9 (D). 
Both caspases produced an immunoreactivity bordered in the cytoplasmic area. The 
immunoreactivity for active caspases is characterized by several perinuclear spots having a 
more intense brightening staining. 
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10.2.3 Discussion 
In this study a model of excitotoxicity, where a comparable toxicity is induced in primary rat 
spinal motor neuron cultures by low concentrations of kainate or AMPA has been further 
investigated [Comoletti, 2001]. 
Before starting the experiments to evaluate the types of cell death associated to AMPA and 
kainate, the expression of four AMPAr subunits was investigated in purified cultures of motor 
neurons. The results revealed that, already at the embryonic E-14, rat motor neurons express the 
four AMPAr subunits [Carriedo, 1995], but the specific localization and distribution varies 
among each subunit. This result clearly demonstrate that all AMPAr subunits are expressed on 
motor neurons and also suggests that this receptor can mediate excitotoxic stimuli induced by 
glutamatergic agonists AMPA and kainate. In addition, electrophysiological recordings and 
experiments Co'+ uptake measurements (see section 4.2.2.1) demonstrated that: I) in embryo rat 
motor neurons, AMPAr are functionally active and; II) motor neurons showing a strong 
immunopositivity for GluR2 are permeable to Ca . These results 
indicated that, despite the 
abundant expression of GluR2, a subset of AMPAr expressed in the cell surface of embryo rat 
motor neurons lack of G1uR2 that allows the AMPA/kainate mediated Ca++ influx. 
Time course measurement, performed in this study, suggests that, in this experimental 
condition, AMPA and kainate possess two different kinetics of death. While kainate produces a 
slow but long lasting trend of toxicity, AMPA rapidly reduces the motor neuron survival but 
this effect becomes smaller after 18 hours of treatment. On the basis of previous findings 
obtained in cerebellar and cortical neurons [Nicotera, 1997; Leist, 1997], in which necrosis was 
characterized as a fast and acute process while apoptosis requires a lower but more prolonged 
time of exposure to toxic agents, the different slopes of motor neuron death produced by 
AMPA and kainate suggested two distinct patterns of death. 
The activation of the apoptotic pathway by kainate is clearly demonstrated by DNA 
fragmentation, nuclear condensation and activation of caspases 3 and 9. On the contrary, 
AMPA does not activate apoptotic motor neuron death, as indicated by active caspases 
immunocytochemistry and the double staining experiments using propidium iodide (PI) and 
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SYTO 59. The lack of DNA fragmentation and caspases activation, together with a marked 
nuclear swelling and cellular permabilization observed after AMPA treatment, clearly indicate 
a necrotic-like mechanism of motor neuron death. 
In this experimental condition, AMPA and kainate act on the same receptor, as indicated by the 
fact that NBQX, a selective antagonist of the AMPA subtype of glutamate receptor, inhibits the 
motor neuron death induced by both AMPA and kainate [Comoletti, 2001]. Thus the 
differences observed in the cell death processes induced by two agonists are somewhat 
surprising. An important difference may be due to the different behaviour of AMPA and 
kainate in stimulating AMPA receptor. In fact, while AMPA (like glutamate) is a strongly 
desensitizing receptor agonist, kainate is a weakly desensitizing AMPA receptor agonist 
[Vandenberghe, 2000]. According to this electrophysiological evidence it is possible to 
hypothesize an intense, but short-lasting Cä + entry after AMPA treatment, capable of 
triggering necrotic motor neurons death, and a longer-lasting influx of Ca , under 
kainate 
stimulation, that may induce apoptosis. 
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10.3 EPO selectively protects primary cultures of motor neurons from apoptotis 
10.3.1 Introduction 
In addition to promoting hematopoiesis [Semenza, 1991], EPO has protective effects in 
different in vitro and in vivo models of neurodegeneration. Although the molecular mechanisms 
involved in EPO activity are still not fully understood, several studies have shown that EPO 
acts by protecting neurons that are committed to die by apoptosis [Semenza, 1991]. In this 
study it has been already demonstrated that primary cultures of spinal motor neurons undergo 
apoptotic death if deprived for 48 hours of serum and BDNF (see section 10.1). The selective 
induction of apoptosis 'produced by serum/BDNF deprivation is therefore a valid tool' to 
evaluate the possible protective and anti-apoptotic role of EPO in. primary motor neurons. 
Purified cultures were used to assess the effectiveness of EPO. 
Excitotoxicity has been shown to play an important role in neurodegenerative diseases 
comprising ALS [Rothstein, 1995; Mennini, 2004], mainly through activation of the 
AMPA/kainate receptors [Van Den Bosch, 2000]. In the section 10.2 it has been shown that, 
after exposure of motor neuron cultures for 48 h to equipotent concentration of glutamate 
agonists inducing about 50% cell death, Kainate induced apoptosis while AMPA reduced the 
viability via a non-apoptotic mechanism. The different processes of death elicited by. the two 
excitotoxins not only allows to further verify the role of EPO as anti-apoptotic agent on motor 
neurons but also to evaluate if its protective effect could be observed also in other types of 
neuronal death. 
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10.3.2 Results 
103.2.1 EPO receptor is expressed in embryo rat spinal cord motor neurons 
Immunocytochemical experiments, performed both in purified and in mixed glia/neurons motor 
neurons showed a high immunopositivity for EPOr (Fig. 10.13 A). The staining was present on 
cell bodies and arborizations, and seems to be located both in the membrane and in the cytosol 
(Fig. 10.13 B). To assess if a repeated EPO treatment modifies the expression or the 
distribution of EPOr on motor neurons, purified cultures were treated with EPO (2.5 pmolml) 
for 5 days. The staining revealed no difference in the intensity and distribution of EPO 
receptors in EPO-treated cells compared to vehicle-treated cells (not shown). These results 
indicate that EPO treatment, under. these experimental conditions, did not induce down- or up- 
regulation of its receptor. To evaluate the specificity of this antibody, the same 
immunocytochemical staining was repeated in cultures that had been pre-treated with an excess 
(20x) of the specific blocking peptide. As shown in figure 10.13 C, this procedure almost 
completely eliminated the EPOr immunostaining, thus confirming the selectivity of this 
antibody directed against EPOr. 
This result first demonstrates that E-14 embryo rat motor neurons already express the EPOr in 
their cell surface. 
10.3.2.2 Serum/BDNF deprivation and EPO 
As shown in section 10.1.3,48 hours of serumBDNF deprivation, significantly reduced motor 
neuron viability. In motor neurons deprived of serumBDNF, EPO (2.5 pmol/ml), pre-incubated 
for 72h and then added again during serumBDNF withdrawal, completely reversed this 
toxicity (see table 10.8). 
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Figure 10.13 EPOr immunostaining :A mixed glia/neurons cultures; B purified cultures of 
motor neurons; C mixed glia/neurons cultures after incubation with a selective blocking agent 
of the antibody anti EPOr together with primary antibody. Scale bar, A, C 200 µm. B, 40 µm. 
As clearly shown in figure A EPOr is already expressed at the embryo stage and its distribution 
is not only confined into the cell bodies but it is also localized in their arborizations. The 
highest magnification (B) reveals the immunoreactivity of the perikaryon and in cell 
membrane. The specificity of antibody is confirmed by the lack of staining obtained by adding 
a blocking peptide together with the antibody (C). 
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CTR CTR-serumBDNF CTR+EPO CTR- 
serumBDNF+EPO 
Motor neurons % 100±6.2 68.6±5.5** 121.3±9.8 107.2±4.9 
SM132 positive cells 
Table 10.8 Protective effect of EPO treatment on percentage of motor neurons survival in 
purified cultures after deprivation of serum and BDNF; normalized to controls. ** p< 0.005 
As shown in section 10.1.3 the percentage of apoptotic nuclei in purified motor neurons 18 
hours after serumBDNF deprivation significantly increased compared to controls. EPO 
reduced the percentage of apoptotic nuclei in serum/BDNF-deprived cells (see table 10.9). 
CTR CTR+EPO CTR- serumBDNF CTR- 
serumBDNF+EP 
0 
Fragmented nuclei % 100119.3 77.3112.1 338.2+26.4*** 86.2±8.0 
(Hoechst) 
Table 10.9 Protective effect of EPO in reducing the percentage of fragmented nuclei in purified 
motor neurons after 18 hours of serumBDNF deprivation; normalized to controls. *** p< 
0.001 
In addition, the increase in the number of active caspase 3 positive motor neurons (see section 
10.1.3), was completely reverted by the EPO treatment (see table 10.10). 
CTR CTR+EPO CTR- serumBDNF CTR- serumBDNF+EPO 
Caspase 3 positive 
motor neurons 
100±9.6 82.9±10.9 277±22.3*** 126±14.9 
Table 10.10 Protective effect of EPO in reducing the percentage of active caspase 3 positive 
motor neurons in purified cultures after six hours of serum and BDNF deprivation; normalized 
to controls. ** p< 0.005 
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Representative microphotographs showing the effect of EPO, both alone and following 
serumBDNF deprivation, in reducing nuclear fragmentation and caspase 3 activation are 
shown in fig 10.2 E, F and G, H and in fig 10.3 C, D respectively. 
It is important to note that, in purified motor neuron cultures, 5 days treatment with EPO 
produced a clear neurotrophic effect, increasing the neurite outgrowth and the number (not 
shown) and differentiation of motor neurons (Fig 10.14 A) compared to control motor neurons 
(Fig. 10.14 B). It is likely that a similar effect is related to a decrease in spontaneous apoptosis. 
The reduction below control values of the percentage of apoptotic nuclei and of the number of 
active caspase 3 positive motor neurons further support this concept. 
II r% 
Chapter 10 In vitro results 
yp 
loý 
-Ab" 
It 
P 
t 
ýý 
Ißtº; 
P 
s` 
ý. 
ý, ` 
f 
Q, t', 
_ '[4 
It 
1R t' "'ý 'r7 ýº+-. RtýFw 
YdýPý'ryýýl. 
ý ý4 
* 11 
1a 
Figure 10.14 SM132 immunostaining in mixed glia/neurons cultures. Scale bar, 100 µm. 
Healthy motorneurons are shown in figure A. They have a high immunoreactivity for SM132 in 
the cell body and also presented a weaker immunostaining in their small peripheral processes 
(axon and dendrites). EPOr treatment (5 days) clearly induced a growing of neuronal 
arborizations and developing of neuronal network. On the other hand, the size of the cell body 
does not seem increased in EPO-treated cultures. 
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10.3.2.3 EPO protects motor neurons exposed to kainate but not to AMPA 
In order to evaluate whether the role of EPO on motor neuron protection was exclusively 
related to its anti-apoptotic component or may be also extended to other processes of death, the 
effect of EPO in preventing motor neuron loss in glialneurons cultures exposed to AMPA or 
kainate was compared. 
EPO significantly reduced the mortality of SM132-positive neurons in mixed glialneuron 
cultures following 48 hours to 5 µM Kainate exposure but did not rescue motor neurons upon 1 
µM of AMPA exposure (see table 10.11). 
CTR CTR+kainate CTR+kainate CTR+AMPA CTR+AMPA 
+EPO +EPO 
% of SM132 100±8.1 43.5±. 3*** 82.4±8.7 39.4±5.2*** 43.1±10.2*** 
positive cells 
Table 10.11 Effect of EPO on SM132 positive cell survival in mixed glia/neuron cultures 
exposed for 48 hours to kainate or AMPA. The values are expressed as percentage of mean 
number of cells measured in control wells (normalized to 100). ***p<0.001; *p<0.05 
EPO alone significantly increased cell viability (128 ± 38% p<0.02). The effect of EPO in basal 
condition further confirms the neurotrophic properties of this compound. 
The same EPO concentration protected motor neurons from kainate toxicity even if added 
simultaneously with kainate (without preincubation) or only during the 72 h pre-treatment (cell 
viability in control cells 100.0 ± 7.1% ; in kainate treated cells 54.2±8.7% p<0.01; in kainate 
treated cells +EPO 86.9±12.2 % n. s. ). However, the maximum protective effect was obtained 
when EPO was present both in pre-treatment and during kainate exposure. 
In order to exclude a potential, glia-mediated effect of EPO in motor neuron protection (either 
by activating glial factors or by reducing the toxicity of glial cells following exposure to 
excitotoxins) the action of EPO was also tested on purified motor neurons exposed for 48 hours 
to kainate 50 µm. A similar protection in purified cultures was found, indicating a direct action 
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of EPO on motor neurons (cell viability in control cells 100.0± 5.1%; in kainate treated cells 
43.5±4.3% p<0.01; in kainate treated cells+EPO 74.6±2.7%). 
In order to discriminate the molecular mechanism(s) underlying the protection of EPO on 
motor neurons exposed to kainate, the anti-apoptotic effect of EPO was then examined in detail 
by evaluating it at different points of apoptotic cascade. 
10.3.2.4 EPO reduces nuclear fragmentation in kainate treated motor neurons 
The anti-apoptotic effect of EPO against SM132 positive cells in mixed glia/neurons cultures 
exposed to kainate for 18 hours was first evaluated by measuring the number of fragmented 
nuclei by Hoechst 33258 staining. The quantification of the mean number of fragmented nuclei, 
in EPO treated cultures exposed to AMPA or kainate and expressed as percentage of the ratio 
between fragmented nuclei in SM132 positive cells and the total number of SM132 positive 
cells, is shown in table 10.12. 
CTR CTR+ CTR+kainate CTR+ CTR+AMPA 
kainate +EPO AMPA +EPO 
% (fragm. nuclei in 3.3±0.9 76.2±8.9*** 4.4±1.1 3.9±0.6 2.3±0.3 
SM132 + cells/ SM132 + 
cells) 
Table 10.12 Effect of EPO on DNA fragmentation in SM132 positive cells. The experiments 
were carried out in mixed glia/neurons cultures exposed to AMPA or kainate. The values are 
expressed as the percentage of the ratio between the number of SMI 32 positive cells showing 
nuclear fragmentation and the total number of SMI 32 positive cells. 
As expected, EPO did not influence the percentage of fragmented nuclei in motor neurons 
exposed to AMPA, further confirming that apoptosis is not involved in motor neuron death 
process induced by AMPA. 
In figure 10.9 G, H it is possible to observe that, after kainate exposure, EPO treatment 
maintains the nuclear morphology, and the pattern of syto 59 staining resulted similar to control 
cells. In contrast to kainate, EPO did not modify the morphology of motor neurons exposed to 
AMPA (not shown). 
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10.3.2.5 EPO inhibits caspases 3 and 9 activation in kainate treated motor neurons 
The selective protection exerted by EPO in cultures of motor neurons by inhibiting the kainate- 
induced apoptosis was further confirmed by detecting steps earlier than DNA fragmentation. 
EPO treatment completely reverted the effects produced by kainate exposure (6 hours) by 
reducing the number of active caspase 3 positive cells and increasing the number of SMI 32 
positive cells. In addition, EPO showed its anti-apoptotic effect also by reducing the natural cell 
death occurring in our culture condition, i. e. by reducing the number of caspase 3 SMI-32 
positive cells compared to control. On the other hand, EPO did not modify the effect produced 
by AMPA (see table 10.13). 
CTR CTR+ CTR+kainate CTR+ CTR+AMPA 
kainate +EPO AMPA +EPO 
% (caspase 3 positive cells in 
SM132 positive cells/ SM132 2.7±0.3 10.9±0.5*** 2.9±0.4 2.5±0.3 2.9±1.3 
positive cells) 
Table 10.13 Effect of EPO in reducing the percentage of active caspase 3 SM132 positive cells 
in mixed glia/neurons cultures exposed to kainate. The values as expressed as percentage of the 
ratio between active caspase 3 positive cells found in SM132 positive cells and the total number 
of SM132 positive cells (SM132 cells showing caspase 3 positivity/SM132) in mixed 
glia/neurons cultures exposed to AMPA or kainate. ***p<0.001 
Representative microphotographs showing the effect'of EPO in counteracting the activation of 
caspases 3 immunostaing in SM132 positive cells are reported in figure 10.10 G, H. 
Similarly, EPO treatment significantly decreased the number of activated caspase 9 SMI-32 
positive cells after 6 hours of exposure to kainate motor neurons and EPO alone reduced this 
number under control conditions (see table 10.14). 
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CTR CTR+ CTR+kainate CTR+ CTR+AMPA 
kainate +EPO AMPA +EPO 
% (caspase 9 positive cells in 3.5±0.7 20.5±3.5*** 4.7±1.2 1.5±0.7 2.7±0.6 
SM132 positive cells/ SM132 
positive cells) 
Table 10.14 Effect of EPO in reducing the percentage of active caspase 9 SM132 positive cells 
in mixed glia/neurons cultures exposed to kainate. The values as expressed as percentage of the 
ratio between active caspase 9 positive cells found in SM132 positive cells and the total number 
of SM132 positive cells (SM132 cells showing caspase 9 positivity/SM132) in mixed 
glia/neurons cultures exposed to AMPA or kainate. ***p<0.001 
Representative microphotographs showing the effect of EPO in counteracting the increase of 
immunopositivity in SM132 positive cells is reported in figure 10.11 G, H. 
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10.3.3 Discussion 
The present study demonstrates for the first time that, in the primary cultures of motor neurons, 
EPO counteracts the apoptotic cell death induced by kainate or serumBDNF deprivation, but is 
inactive on non-apoptotic cell death induced by exposure to AMPA under the same 
experimental conditions. 
In addition, EPO exerts its neuroprotective effect both when motor neurons are purified or 
maintained in mixed glia/neurons cultures, suggesting a direct effect of EPO on motor neurons 
rather than a modulator effect exerted via the glial cells. 
Furthermore, immunoreactive EPOr were detected in purified cultures of motor neurons, and 
did not show any down- or up- regulation after 5 days exposure to EPO treatment or following 
AMPA or kainate treatment. These findings are in agreement with previous studies reporting 
the presence of EPOr in human and rabbit spinal cord motor neurons. and offers the possibility 
to perform treatment with EPO also for chronic neurodegenerative diseases of the spinal cord, 
like ALS. 
Moreover, it is important to note the highest neuroprotective effect after kainate exposure was 
obtained after 72 hours pre-treatment + 48 hours treatment by EPO. However, partial protection 
is still obtained when EPO is present only during pre-treatment, or when EPO was added only 
during kainate exposure without pre-treatment. These data suggest that, while activation of 
survival kinases by EPO in hippocampal neurons is a rapid process [Siren, 2001] the 
neuroprotective effect in motor neurons takes longer time, possibly requiring induction of gene 
transcription. 
The effects of EPO in in vitro cellular models of excitotoxicity is somewhat controversial: 
protection is reported in cultured hippocampal and cortical neurons against glutamate exposure 
[Bernaudin, 1999] and in cortical neurons exposed to 
NMDA [Bernaudin, 1999]. However, another paper reports that EPO protects cortical neurons 
against AMPA-, but not glutamate- or NMDA-induced toxicity [Sinor, 2000]. The present data 
indicates that EPO protects against kainate but not AMPA in cultures of motor neurons. These 
discrepancies might be related to the type of death induced by: i) the different excitotoxins that 
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were utilized, ii) their concentration iii) the different time exposure and, iv) the different cell 
models used. 
The EPO concentration (2.5 pmol/ml) I used in this study is relatively high compared to those 
reported to be effective in other in vitro studies on primary neurons (0.3-1 pmol/ml). However, 
the concentrations of glutamate agonists required for motor neuron death are higher compared 
to other neuronal cultures [Siren, 2001]. 
The lack of caspase 3 and 9 activation in motor neurons exposed to kainate are treated with 
EPO, further confirms previous findings obtained in cortical neurons [Ruscher, 2002], and also 
indicates that EPO is capable of counteracting motor neuron apoptosis by inhibiting a step 
before caspases cascade cell signalling. For this reason, the upstream events of the intrinsic 
apoptotic pathway, i. e. the release of cytochrome-c, the mitochondrial membrane potential and 
the role of PTP, were then investigated. 
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10.4 EPO exerts its anti-apoptotic effect on primary cultures of motor neurons by 
inhibiting the mitochondrial depolarization produced by kainate treatment 
10.4.1 Introduction 
Both in death receptor- (extrinsic) or mitochondrion-dependent (intrinsic) apoptosis the 
recruitment and activation of adapter molecules is a key event to activate caspases and to 
propagate the apoptotic signalling pathways (see sections 2.2.1 and 2.2.2). In death receptor- 
mediated apoptosis, engagement of death receptors leads to the formation of the DISC 
containing death receptors, adaptor proteins, caspase 8 and 10. In mitochondrion-dependent 
apoptosis, the release of cytochrome-c into the cytosol results in the formation of apoptosome 
containing cytochrome-c, Apaf-l and caspase 9. 
Because neurotrophic withdrawal and glutamate-induced excitotoxicity appear more related to 
this latter process, and in view of the marked increase of caspase 9 positive cells that in kainate 
treated motor neurons (see section 10.2.2.4), the role of EPO in preserving mitochondrial 
activity was studied in purified cultures of motor neurons exposed to kainate or AMPA. 
All experiments were performed following the procedures described in chapter S. 
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10.4.2 Results 
10.4.2.1 Cytochrome-c release 
In purified cultured motor neurons, cytochrome-c release was detected by performing a double 
staining experiment with a mitochondrial dye (Mito Tracker) and an antibody directed against 
cytochrome-c. 
Cultures of purified motorneurons were treated with 50 tM kainate for 4 hours; this 
concentration was utilized since it has an equipotent effect in inducing motor neuron death as 
kainate 5 gm in mixed glia/neurons cultures after 48 hours of treatment [Comoletti, 2001]. 
In contrast to AMPA treated motor neurons, in which a loss of mitochondrial integrity and a 
consequent loss of cytochrome-c immunoreactivity is already detectable after 4 hours of 
treatment (Fig 10.15 C, D), both in control and in kainate treated cells mitochondrial integrity 
was seen (Fig 10.15 A, E). However, in a large percentage (quantification not done) of kainate 
treated motor neurons, cytochrome-c staining did not overlap with mitochondria, but 
homogenously diffused throughout the whole cytoplasm (Fig 10.15 B. D). EPO treatment 
markedly reduced the spreading of cytochrome-c staining, in almost all motor neurons exposed 
to kainate and treated with EPO (Fig 10.15 G, H). 
This evidence supports the hypothesis that kainate produces apoptosis by modifying 
mitochondrial activity and thus allowing the caspase-cascade activation by cytochrome-c 
release and consequent apotosome formation. 
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Figure 10.15 Double staining, Mito tracker (red A, C, E, G) and cytochrome-c antibody 
(green B, D, F, H), in purified cultures of motor neurons. Scale bar, 15 µm. A representative 
pattern of intra-mitochondrial localization of cytochrome-c in motorneurons exposed to the 
basal conditions is shown in figure A and B. In control cells it is in fact possible to observe a 
clear overlapping between red -mitochondrial- staining (A) and green -cytochrome c- 
immunostaining (B). In contrast, AMPA treated motorneurons showed a collapse of 
mitochondria (C) with a dispersion of cytochrome-c (D). Kainate treated motorneurons, thus 
Lk, lI, c, i1liegi ity (E) induced the release of cytochrome-c in the cytoplasm 
(F, ). EPO treatment markedly counteracted the effects produced by kainate (G and H). 
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10.4.2.2 Mitochondrial membrane potential 
In order to verify if EPO counteracted the decay of mitochondrial activity caused during cell 
death, the functional expression of this organelle was analyzed by evaluating its state of energy 
and, indirectly, its AWM. 
Purified cultures of motor neurons were incubated with kainate (50 µM) or AMPA (10 µM) for 
18 h. AWM was measured with the fluorescent probe JC-1. A "shift" from red to green 
fluorescence was observed upon depolarisation of mitochondria (see section 8.6). Red staining 
is associated to energised mitochondria while green staining represents depolarized 
mitochondria. 
The quantitative measurement of AWM in control, kainate and AMPA treated motor neurons, 
with or without EPO, is expressed as degree of mitochondrial energisation (ratio between red 
fluorescence intensity, Fled at 590 nm, and green fluorescence intensity, FIgreen at 527 nm). 
Compared to control cells, kainate exposure significantly reduced the AWM while AMPA did 
not. EPO treatment reversed the depolarizing effect produced by kainate but did not increase 
the AWM in AMPA treated motor neurons. The levels of mitochondrial energisation in control 
and in treated cells are reported in table 10.15 
CTR CTR+kainate CTR+kainate CTR+AMPA CTR+AMPA 
+EPO +EPO 
% of mitochondrial 48.8±4.3 33.4±0.5** 45.5±3.2 45.011.0 48.2±7.0 
energisation 
(FI,. e/ FI,. d + FIgo) 
Table 10.15 Effect of EPO on mitochondrial energistaion levels, expressed as % FIred/ FIrc + 
FIgreCn, in purified cultures of motor neurons exposed to kainate or AMPA. ** p<0.01 
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In figure 10.16 representative laser scanning confocal images of cells loaded with JC1 (3 µM) 
and Hoechst 33258 (1 µM) are shown. A high percentage of red stained mitochondria were 
found in control condition (Fig 10.16 A) while kainate treatment drastically reduced the 
number of red stained mitochondria and consequently increased the green component (Fig 
10.16 E). Motor neurons exposed to kainate and treated with EPO maintained a high rate of 
energized (red) mitochondria thus suggesting that mitochondrial depolarization and 
mitochondrial PTP opening are both prevented by EPO administration (Fig 10.16 G). AMPA 
treatment, while significantly reducing the total number of cells, did not cause an evident 
decrease in the ratio between red stained and green stained mitochondria (Fig 10.16 C). 
Microphotographs of these cells at higher magnification are presented in figure 10.16 B, D, F, 
H. 
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Figure 10.16 Purified cultures of motor neurons stained using the mitochondrial dye JC-1 and 
the nuclear dye Hoechst 33258. Mitochondrial transmembrane potential was measured with the 
fluorescent probe JC-1. A "shift" from red to green fluorescence is observed upon 
depolarization of mitochondria. Hoechst staining was used to reveal the nuclei of motor 
neurons. Scale bar, A, C, E, G, 40 µm. B, D, F, 1120 µm. 
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10.4.2.3 AMPA, kainate and the mitochondrial PTP 
To better clarify the possible involvement of mitochondrial PTP in kainate-induced apoptotic 
pathway, the effect of cyclosporin A2, an anti-apoptotic agent that binds to the PTP and 
maintains it in a closed position, was measured on SMI-32 cell viability in mixed 
neuron/cultures exposed to AMPA 1 µm or kainate 5µm. 
Treatment with cyclosporin A2 (2 µM, added simultaneously with either one of the glutamate 
agonists), prevented the decrease of SM132 positive cell viability induced by kainate, but not by 
AMPA. Cyclosporin A2 alone showed a clear Neuroprotective action by reducing the natural 
death occurring under basal conditions. The number of SMI 32 positive cells in cultures not 
exposed to excitotoxins and treated with cyclosporin was significantly higher compared to 
untreated cultures (see table 10.18). 
CTR CTR+ CTR+kainate CTR+kainate CTR+AMPA CTR+AMPA 
cyclosporin +cyclosporin +cyclosporin 
% of SM132 100±16.1 137.1±12.600 43.5±. 3*** 97.6±19.2 53.6±13.3*** 63.4±7.2*** 
positive cells 
Table 10.17 Effect of cyclosporin A2 (on motor neurons survival in mixed glia/neuron cultures 
exposed for 48 hours to kainate or AMPA. The values are expressed of percentage of controls 
and normalized to 100. °°p<0.05 ***p<0.001 
It is of interest to note that cyclosporin A2 slightly hyperpolarises the mitochondrial inner 
membrane (not shown). The selective protection of cyclosporin A2 against kainate, but not 
against AMPA implies that this effect is related not only to the increased number of cells but 
also to prevention the of mitochondrial depolarization induced by kainate. 
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10.4.3 Discussion 
EPO significantly antagonizes the kainate-induced apoptosis, by decreasing both the release of 
cytochrome-c and mitochondrial depolarization. It is worth mentioning that a slight, but 
significant, reduction in mitochondrial depolarization was also observed 
after AMPA treatment. In this condition, however, EPO did not prevent the decay of 
mitochondrial AWM. 
To investigate whether the selective effect of EPO, after kainate exposure, was related to an 
anti-apoptotic mechanism passing through the inhibition of the PTP opening, the effect of a 
treatment with a well documented inhibitor, like cyclosporin A2 was tested [Chang, 2002], 
against the chronic exposure to AMPA or kainate. Like EPO, cyclosporin A2 protected motor 
neurons against kainate treatment but not against AMPA. The selective protection of 
cyclosporin A2 after kainate treatment suggests that kainate generates a cascade of events that 
have as a target the mitochondrial transition pore, while AMPA affects a different pathway in 
which the inhibition of the mitochondrial PTP does not seem to play a relevant role. 
Unfortunately, the relative low amount of protein that can be obtained from purified cultures of 
motor neurons did not allow me performing a quantitative measurement by western blot 
analyses. 
Specific inhibitors of MAPK and PI3K largely abolish the EPO-induced protection against 
hypoxia-induced cell death in rat hippocampal neurons [Siren, 2001]. Since PI3K 
phosphorylation produces its anti-apoptotic effect by phosporylating and inactivating BAD and 
consequently reducing the mitochondrial PTP opening, and EPO has been reported to induce a 
mechanism that increase the phosphorylation of BAD [Siren, 2001], it has been hypothesized 
that this mechanism may be involved in the selective anti-apoptotic neuroprotection exerted by 
EPO. Unfortunately, it was impossible to verify the mechanism of action of EPO upstream the 
mitochondrial PTP regulation because of the high motor neurons toxicity of the PI3K 
(LY984002) and MAP-K (PD98059) inhibitors over the period of time required for my studies 
(5 days of treatment). 
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Notwithstanding this experimental limitation, this study demonstrates that: I) motor neurons 
undergoing to apoptosis, induced both by kainate exposure and/or serum/BDNF deprivation, 
are protected by EPO and; II) this protective mechanism is selectively active in counteracting a 
mechanism of death associated to the mitochondrion-dependent apoptosis. 
A schematic representation of the motor neuron death pathways elicited by both AMPA 5 µm 
and kainate 1µm in mixed glia/neurons cultures is reported in figure 10.17. 
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Figure 10.17 Motor neuron pathways activated following chronic exposure (48 hours) with 
kainate 5 pm and AMPA I pm, in mixed glia/neurons cultures. While AMPA induces a fast 
pattern of death unrelated to apoptosis, kainate activated an intrinsic pattern of death passing 
through mitochondria 1) and leading to the release of cytochrome-c 2), caspases activation 3-4), 
DNA fragmentation of 5) and apoptotic death 6). 
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CHAPTER 11 
MECHANISMS OF MOTOR NEURON DEATH IN THE CERVICAL SPINAL 
CORD OF WOBBLER MICE 
11.1 Motor neurons loss: time course in wobbler mice 
11.1.1 Introduction 
As described in Chapter 1, the main clinical and hystopathological feature of ALS is the 
degeneration of the spinal motor neurons: in the latest stages of the disease the total amount of 
motor neurons is reduced by 70 % [Munsat, 1988]. Although various studies were performed to 
clarify the type of cellular death that occurs in this pathology, the results are still controversial 
and the mechanisms involved are poorly understood. The studies carried out from autopsy 
samples do not allow analysis the early stage of cellular death, thus the use of alternative 
models is needed in order to detect the different steps of motor neuron degeneration. The 
wobbler mouse is a model of motor neuron disease characterized by an early and selective 
vulnerability of cervical spinal cord motor neurons [Duchen, 1968; Bradley, 1984]. Although in 
wobbler mice several histological and morphological studies have elucidated the main 
alterations occurring in these motor neurons, the mechanisms involved in motor neuron death 
are poorly understood and the aetiology is still unclear (see chapter 5). 
Since the use of animal models of diseases is still object of argument, mainly because of their 
dissimilarities respect to human diseases, it is important to exploit these models by 
investigating the features of the diseases that cannot be evaluated in human samples for ethical 
reasons and to allows studying the early pathological events. 
This chapter describes studies aimed at understanding why and how, in the wobbler mouse, 
cervical motor neurons motor die. 
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For this reason the possible involvement of two aetiological factors suggested in ALS, glial- 
induced neuroinflammation and glutamate induced-excitotoxicity were investigated as possible 
contributors to the motor neuron degeneration occurring in wobbler mice. 
This study was achieved: 1) by investigating the presence of main markers related to these 
detrimental processes; 2) by evaluating if the propagation of these stimuli could generate 
apoptotic cell death. 
11.1.2 Experimental design 
To characterize the rate of motor neurons death from presymptomatic to late symptomatic 
phase, cell counting was performed before starting the investigation of the different cell death 
pathways. This measurement was made at three different ages: 3`d week of age, corresponding 
to the presymptomatic phase (P19-P21), 5th week of age, corresponding to early symptomatic 
phase (P30-P34), and 12'h week of age, corresponding to late symptomatic phase (P60-P66). In 
each experimental group the mean number of motor neurons measured in wobbler mice was 
compared to the number found in healthy littermates. 
The measurement was done in the region of spinal cord selectively affected, the cervical region. 
The number of motor neurons for each single animal was calculated by measuring the total 
number of motor neurons obtained by analysing 100 sections (30 µm of thickness). 
For each experimental group, the values of motor neurons were reported as mean of cells 
counted for each animal, the mean values of motor neurons in wobbler mice was expressed as 
percentage of the mean values obtained in healthy littermates and normalized to 100. 
The number of animals was five for early symptomatic and late symptomatic groups, and three 
for presymptomatic group. 
All experiments were done following the procedures described in the chapter 9. 
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11.1.3 Results 
11.1.3.1 Genotyping 
In mice with genetic background as NFR/wr a polymorphism on the Cct4 gene generates a new 
restriction site on the DNA sequence (intrastrain Restriction Fragment Length Polymorphism, 
RFLP) that is recognized and cleaved by the restriction enzyme A/uI. It is known that this 
mutation is closely related to the mutation on the locus wr that generates mutant alleles on the 
chromosome 11 [Rathke-Hartlieb, 1999]. The identification of mice genotype is based on the 
presence of this linkage. 
The fragment of DNA that is amplified by PCR from the Cct4 gene has a length of 394 bp. 
Homozygous healthy mice (+/+) displayed only a single DNA band of this length. 
Heterozygous healthy mice (wr/+) show one band of 394 bp, corresponding to the wild type 
allele of Cct4, and two bands respectively of 209 and 165 bp, produced by restriction of the 
mutated Cct4 allele. Homozygous wobbler mice (wr/wr) showed only the two bands at 209 and 
165 bp, since both alleles are mutated and no wild type alleles are present. 
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Figure 11.1 Polymorphism at the Cct4 locus as detected by PCR. Cct4 based diagnosis of the 
allelic status at the wr locus applied to a litter wr/+ X wr/+. Alul (see section 5.1) digested 
PCR products. Lanes 3,5,6,7 correspond to homozigous healthy mice (+/+). Lanes 1,2,4,8 
correspond to heterozygous healthy mice (wr/+). Lane 4 corresponds to homozygous wobbler 
mouse (wr/wr). 
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11.1.3.2 Motor neurons counting 
The rate of motor neuron loss in the cervical spinal cord of wobbler mice can be estimated by 
using different criteria. Original studies, performed both by counting the number of motor 
neurons by Nissl staining [Duchen, 1968; Bradley, 1984; Mitsumoto, 1985] or by utilizing a 
more advanced technique in which a retrograde tracer fluorogold system for labelling a 
subpopulation of motor neurons [Haenggeli, 2002], produced similar results. All these 
measurements were done using a non stereological approach. After genotyping, the number of 
cervical motor neurons, measured in the most rostral tract, C2-C3 to C5-C7, was performed. 
Abnormalities in cervical motor neurons of wobbler mice were already reported at the 
presymptomatic stage [Blondet, 2002; Mitsumoto, 1982], however no significant difference was 
found by counting the cells both using Nissl staining (% of healthy motor neurons in control 
mice 100.0 13.5; in wobbler mice 96,5 f 6,3 n. s) and ChAT immunostaining (% of healthy 
motor neurons in control mice 100.0 ± 9.7; in wobbler mice 92,5 ± 11.4). 
Two weeks later, at 5`h week of age, both Nissl and ChAT staining confirmed the previous 
evidence of a marked decrease in the cervical motor neurons number occurring in wobbler 
mice. Moreover, Nissl and ChAT methods reproduced the same rate of death, thus confirming 
the reliability of both techniques. The values found are the following: Nissl staining (% of 
healthy motor neurons in control mice 100.0 ± 2.7; in wobbler mice 61.4 ± 8.2 p<0.001), ChAT 
immunostaining (% of healthy motor neurons in control mice 100.0 f 11.7; in wobbler mice 
58.3 ± 13.3 p<0.001). 
During the progression of symptoms a further decrease in motor neurons was found. At the 12`h 
week of age, the cervical number of motor neurons calculated by Nissl staining was 
significantly lower (% of healthy motor neurons in control mice 100.0 ± 2.1; in wobbler mice 
37.6 ± 12.5 p<0,001). Interestingly, at this stage of the disease ChAT immunostaining revealed 
a more marked decrease of cervical motor neuron number, compared to the same group 
analyzed using Nissl staining, (% of healthy motor neurons in control mice 100.0 ± 12.6; in 
wobbler mice 26.9 ± 13.0 p<0,001), although the two means were not statistically different. 
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Representative microphotographs of the pattern of staining observed by Nissl and ChAT 
experiments in sections of cervical spinal cord are shown in figures 11.2 and 11.3 respectively. 
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Figure 11.2 Representative microphotographs showing the pattern of Nissl staining in cervical 
spinal cord sections of healthy mice and affected wobbler mice, at three different stages of the 
disease. In the anterior horn (lamina IX) motorneurons are easily detectable as they have 
intense positivity for cresyl violet. They are motor neurons. During clinical progression (B-D) 
motor neurons number decreases and the strength of staining is markedly reduced. Scale 
bar 
200 µm 
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Figure 11.3 Representative microphotographs showing ChAT immunostaining in the cervical 
spinal cord sections of healthy mice and affected wobbler mice, at three different stages of the 
disease. In the anterior horn (lamina IX), ChAT staining is observed in healthy mice (A) and 
presymptomatic wobbler mice (B). During symptom progression the number of ChAT positive 
cells is progressively diminished (C-D). Interestingly, in figure C, it is possible to observe a 
marked alteration in ChAT positive cells morphology (such as the loss of typical shape, the 
lack of immunopositivity in arborizations and a reduced intensity of staining) rather than a 
relevant number loss. These features of motor neurons alterations at the early symptomatic 
phase will be more evident in figure 11.5. Scale bar 200 gm 
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Higher magnification microphotographs clearly showed the progressive neuronal degeneration 
occurring in the cervical spinal cord motor neurons of wobbler mice. In the anterior horn 
(lamina IX lateral column) large neurons which are strongly labelled for cresyl violet are easily 
detectable as motor neurons. Few motor neurons obtained from the cervical spinal cord of 
wobbler mice are shown in figure (11.4 A). In these cells it is possible to note an intense 
positivity for the cresyl violet both in the cell body and in their arborizations. During the 
presymptomatic stage Nissl stained motor neurons did not show relevant signs of abnormality, 
compared to control motor neurons (Fig 11.4 B). At 5'h week of age, marked alterations of 
motor neurons were easily detected (Fig 11.4 C), with a decreased motor neuron density and a 
strong reduction in the shape and strength of the staining. 
In figure 11.4D, a typical "wasted area" observed in the cervical anterior horns of 12 week-old 
wobbler mice is shown. Both the decrease in motor neurons number and the profound 
cytological alterations in the few remaining cells clearly indicate a stage of advanced 
degeneration. 
Four microphotographs showing the ChAT immunostaining in lamina IX of cervical motor 
neurons in healthy mice and in wobbler mice at the three stages of the disease are shown in 
figure 11.5 A-D. Similar differences can be noted regarding the pattern of staining from Nissl 
and ChAT. 
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Figure 11.4 Representative microphotographs showing cervical motor neurons stained by 
Nissl method. In presymptomatic wobbler mouse (B), motor neurons do not differ from 
unaffected mice (A) either as morphology or as Nissl staining distribution. In early 
symptomatic mice (C) a marked alteration of motor neurons is clearly detectable. In this phase 
of the disease, dying motor neurons show morphological alterations and present a reduced 
intensity of staining, likely due to vacuolization processes. At the end stage of the disease the 
few motor neurons remaining have completely lost their identity (D). Nissl staining clearly 
reveals the entity of damage in this late phase of the disease. Scale bar 50 gm. 
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Figure 11.5 Representative microphotographs showing ChAT positive cells in the anterior 
horn of the cervical spinal cord, lamina IX, in healthy and affected wobbler mice, at three 
different stages of the disease. In the presymptomatic wobbler mouse (B) ChAT positive cells 
are similar (as number, shape, size and staining intensity) to healthy mice (A). In 5 week-old 
wobbler mice (C), lamina IX presents ChAT positive neurons with reduced staining on their 
arborizations and an altered morphology. Moreover, a significant reduction in ChAT positive 
cell number is already detectable at this phase of the disease. At the 12`h week of age, ChAT 
positive cells in the cervical spinal cord of wobbler mice are almost completely disappeared 
(D). Scale bar 60 gm. 
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Motor neuron death progression in wobbler mice is reported in figure 11.6. 
Rate of motor neuron loss in the cervical spinal cind of vioh61e r mice 
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Figure 11.6 Percentage of motor neurons loss in the cervical region (C2-C7) of wobbler mice 
after 3,5,11-12 weeks of life. The mean number of motor neurons measured in control 
conditions are normalized to 100. The rate of viability is expressed as percentage compared to 
controls. ***p<0.0001 (Student's t test). 
11.1.4 Discussion 
This first series of study was planned to confirm the progression of motor neuron loss 
observed in the cervical spinal cord of wobbler mice from the 3`d/4`h to the 10`h/12`h 
week of life and also to evaluate the range of time in which the rate of cell loss is 
higher. In this time-course analysis I observed that: 1) in presymptomatic stage (P 18- 
P21), although a small trend of decrease is observed, any statistical difference in 
cervical motor neuron number is not seen by comparing wobbler mice and healthy 
littermates; II) in the early stage of clinical progression, 3 weeks of age, a conspicuous 
reduction of cervical motor neurons, about 40%, is found in wobbler mice and; III) in 
the late phase of disease progression, 6 to 12 week of age, the rate of motor neuron loss 
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11.1.4 Discussion 
This first series of study was planned to confirm the progression of motor neuron loss observed 
in the cervical spinal cord of wobbler mice from the 3rd/4`h to the 10`h/12th week of life and also 
to evaluate the range of time in which the rate of cell loss is higher. In this time-course analysis 
I observed that: I) in presymptomatic stage (P 18-P21), although a small trend of decrease is 
observed, any statistical difference in cervical motor neuron number is not seen by comparing 
wobbler mice and healthy littermates; II) in the early stage of clinical progression, 3 weeks of 
age, a conspicuous reduction of cervical motor neurons, about 40%, is found in wobbler mice 
and; III) in the late phase of disease progression, 6 to 12 week of age, the rate of motor neuron 
loss is markedly diminished compared to the early phase, in this period only a 20% of motor 
neurons is lost. 
The results emerging from this analysis are particularly relevant for my following studies. 
Because of the difficulties in investigating the possible involvement of apoptosis in in vivo 
models of chronic neurodegenerative diseases (see section 2.3), a clear indication of the peak of 
motor neuron loss in this model is required. My observation clearly indicates that, the narrow 
range of time from the 4th to the 5`h week of age is the most reliable period to investigate about 
the cell death mechanisms in cervical motor neurons of wobbler mice. 
In several neurological human disorders, including ALS, is postulated that the clinical onset is 
detectable after a large percentage of neurons have already disappeared. Genotyping 
experiments allowed me to test whether a few days before clinical onset characterization of 
motor neuron symptoms in wobbler mice, a reduction in motor neurons was already in 
progress. Since in mnd mice a loss of ChAT immunoreactivity has been reported without any 
apparent loss of motor neurons and a loss in ChAT activity has been repeatedly reported in the 
cervical region of wobbler mice [Mennini, 2004; Bigini, 2001], I performed my cell counting 
both by measuring the total number of cholinergic neurons in cervical sections of spinal cord 
(ChAT immunostaining) and by using Nissl staining. No differences were seen between Nissl 
staining and ChAT immunostaining, both in total number of motor neurons and in the rate of 
motor neuron death. Thus, the results obtained by Nissl and ChAT staining, demonstrated the 
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reliability of both procedures to perform motor neurons counting in the cervical region of 
wobbler mice. 
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11.2 Neuroinflammation and apoptosis 
11.2.1 Introduction 
Although glial-induced neuroinflammation has been postulated as an pathological mechanism 
in wobbler mice (see section 5), the actual correlation between neuroinflammation and motor 
neuron disease is not yet fully established, reporting an increased expression of two 
metalloproteinases that seem to be enhanced by increasing TNF-a levels, are available 
[Schlomann, 2000; Rathke-Hartlieb, 2000]. 
Immunohystochemical experiments, therefore, were performed to ascertain if microglia, TNF-a 
and TNFRI proteins are over expressed in the cervical spinal cord of 4 week old wobbler mice 
compared to their respective healthy littermates. In addition, since the coupling to TNF- 
a/TNFRI often leads to the activation of an extrinsic apoptotic cell death pathway (see section 
2.2.1.1), the possible activation of caspase 8 was evaluated. 
11.2.2 Experimental design 
The time-course of motor neuron loss, allowed me to determine the time at which the motor 
neuron death peaked, i. e. from the 3`a to the 5t` week of age, with about 50% motor neurons 
death. For this reason the age of animals utilized in the following experiments ranged from P24 
to P28. 
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11.2.3 Results 
11.2.3.1 Microglial staining 
CDl lb immunohystochemistry revealed a marked increase in microglial cells in the wobbler 
mice compared to healthy littermates. In 4 week-old wobbler mice the pattern of expression of 
CD11b in the cervical spinal cord was markedly increased in the whole grey matter without 
immunoreactivity in the white matter (Fig 11.7 A). Unaffected littermates showed a very weak 
CD11b immunoreactivity (Fig 11.7 B). In the cervical anterior horn of wobbler mice is 
interesting to note that activated microglial cells, which are easily detectable for their loss of 
arborizations and their rounded shape, are mainly concentrated in lamina IX in the proximity of 
the lateral and central column motor neurons. In that zone they cluster and seem to cover dying 
motor neurons (Fig 11.7C B). 
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Figure 11.7 Representative microphotographs showing activated microglia staining in the 
cervical region of early symptomatic wobbler mice (B) and healthy littermates (A), revealed by 
an anti CDl lb antibody. In affected mice a marked increase of CDI lb immunopositivity is 
detectable in the whole gray matter. However, mainly in anterior horns, in correspondence to 
lateral and central columns of motor neurons, a strong immunopositivity of activated microglia 
cells is exclusively detectable in affected mice (C). In the latter case microglial cells, 
completely lose their ramified morphology and acquire a globular shape. More likely they 
cover and wrap dying motor neurons that have released chemoattractant factors. Scale bar, A-B 
200 µm. C 60 µm. 
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11.2.3.2 TNF-a immunostaining 
As for CDl lb immunostaining, the sections of cervical spinal cord from 4 week-old control 
mice resulted almost completely unstained for TNF-a (Fig. 11.8 A). Immunopositivity for 
TNF-a was instead found in the grey matter of age-matched wobbler mice (Fig 11.8 B), mainly 
in large sized neurons of the anterior horn, presumably motor neurons (Fig 11.8 C). Such 
marked increase of TNF-a immunoreactivity in motor neurons might be explained by the fact 
that an active phenomenon of TNF-a uptake was induced in injured cells or, more likely, that 
activated microglial cells, wrapping damaged motor neurons, release a high amount of this 
cytokine. 
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Figure 11.8 Representative microphotographs showing the pattern of staining for TNF-a in 
the anterior region of cervical spinal cord of control mice and early symptomatic wobbler mice. 
While the staining for TNF-a in the cervical region from healthy mice was almost completely 
absent (A), the sections obtained from wobbler mice showed a marked immunoreactivity for 
TNF-a, mainly in the proximity of lamina LX (B). A clear immunopositivity for TNF-a is 
detectable also in efferent fibers in the white matter (B). In that region neuronal staining (motor 
neurons) is clearly evident, but an intense positivity around neurons seems to suggest that other 
cells, likely astrocytes and microglia, are positive for TNF- a (C). Scale bar A-B 175 pm, C 50 
µm. 
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11.2.3.3 TNF receptors immunohystochemistry 
No immunoreactivity for TNFR-I in the cervical sections of healthy mice at 4 weeks of age was 
detected in the dorsal region, whereas an extremely weak and homogeneously scattered staining 
was observed in the ventral horn and exclusively in the grey matter (Fig. 11.9 A). In the ventral 
horn sections of age-matched wobbler mice, a small, but increased immunoreactivity for 
TNFR1 was found, mainly in cells in the ventral columns (lamina IX). At higher magnification, 
ventral horn neurons showed a pattern of immunoreactivity that was localized mainly, though 
not exclusively, in motor neurons (Fig. 11.9 Q. 
Immunohystochemistry for TNFR2 was also performed. However, in both experimental 
groups, the staining resulted almost undetectable (not shown). 
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Figure 11.9 Representative microphotographs showing the pattern of staining for TNFR I in 
the anterior region of cervical spinal cord of control mice and early symptomatic wobbler mice. 
In the cervical spinal cord of healthy mice the TNFR 1 immunoreactivity was very low and no 
difference was observed from the anterior horn and the other regions of the gray matter (A). 
Early symptomatic wobbler mice showed a marked immunopositivity for TNFR 1 in the 
anterior horn of the cervical spinal cord, this staining was particularly intense in the most 
anterior region of gray mater, in proximity of lamina IX (C). At higher magnification it is 
possible to note as, in the wobbler mice exclusively, TNFR I produces a diffuse staining, maybe 
related to glial cells, and a more intense positivity in the external surface of large sized body 
cells neurons (motor neurons), suggesting that only cell surface is positive for TNFRI staining. 
Scale bar, A-B magnification 175 µm. C 50 µm. 
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11.2.3.4 Active caspase 8 immunohystochemistry 
For these experiments, 50 sections for each animal, and 5 animals for each experimental group 
were processed by performing immunostaining experiments. Since co localization experiments 
by using secondary antibodies associated to fluororchrome gave a strong non-specific staining, 
100 serial sections were alternatively processed using an antibody directed against the active 
form of caspase 8 and against the antibody anti-ChAT (previously described, see sections 9.6.1 
and 1.1.3.2). 
Although a clear activation over expression of TNF-a and its cognate death receptor TNFRI 
has been shown in the cervical region of wobbler mice, no indication of caspase 8 activation 
was seen in either group. 
These results indicate that, in the cervical spinal cord of wobbler mice, the percentage of 
caspase positive motor neurons, expressed as ratio between caspase 8 positive neurons/ ChAT 
positive neurons, was extremely low and lower than those of healthy littermates. Moreover it is 
important to note that only 3 wobbler mice showed positive caspase 8 immunostaining and 
caspase 8 immunopositive motor neurons were also found in 2 healthy animals. 
The quantification of active caspase 8 motor neurons is reported in table 11.1. 
Animals (C2-C7) Ctr 1 Ctr 2 Ctr 3 Ctr 4 Ctr 5 Wr 1 Wr 2 Wr 3 Wr 4 Wr 5 
NO ChAT positive 1565 1622 1529 1662 1494 1102 998 1076 1029 992 
cells (50 sections) 
NO caspase 8 positive 3 0 0 4 0 1 0 2 1 0 
cells (50 sections) 
Table 11.1 ChAT and caspase 8 positive cells in the cervical spinal cord region of 4 week-old 
wobbler mice and healthy littermates 
A microphotograph of a representative section of a wobbler mouse spinal cord processed for 
caspase 8 is shown in figure 11.10 A, and a higher magnification microphotograph representing 
a "rare" motor neuron positive for the active form of caspase 8 is shown in figure 11.10 B. 
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Figure 11.10 A representative pattern of active caspase 8 immunostaining in the cervical 
spinal cord in early symptomatic wobbler mice is shown in the microphotograph (A). Although 
a weak and homogeneously diffused staining is detectable in the whole the gray matter, this 
represents a background due to a not specific reaction of the system of signal enhancing (ABC 
cholorimetric detection). One of the very rare motor neurons that are clearly found positive for 
caspase 8 in these sections is shown in B. In this case the staining observed into the motor 
neuron is markedly higher than the background. The pattern of distribution of staining, more 
intense on the periphery and weaker on the middle suggests that the immunopositivity for 
caspase 8 in this cell is bordered to the cytoplasm and excludes a nuclear staining. Scale bar, A 
400 µm. B 50 µm. 
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11.2.4 Discussion 
The main evidence emerging from this characterization is that: I) in 4 week-old wobbler mouse 
cervical spinal cord, and mainly in the anterior horn, microgliosis is accompanied by TNF-a 
and TNFR1 overexpression and; II) the reactive gliosis and the overproduction of this 
proinflammatory cytokine does not trigger an apoptotic pathway associated with caspase 8 
activation. These results further confirm the involvement of reactive gliosis already at the early 
phases of the disease [Boillee, 2001; Blondet, 1992] and represent the first evidence for the 
appearance of TNF-a and TNFRI, in association to microglial activation, in the affected region 
of the cervical spinal cord of wobbler mice. 
TNF-a is not merely a factor which is involved in regulation of immune response or which 
inhibits the tumour proliferation, but has been also correlated to various diseases of CNS. 
Elevated TNF-a levels were found in animal models of motor neuron diseases [Ghezzi, 
1998; Hensley, 2002; Hensley, 2003], and alteration of circulating levels of TNF-a has been also 
reported in the plasma of ALS patients [Poloni, 2000]. 
In vitro studies have strongly demonstrated that LPS-stimulated microglia is able to over 
express TNF-a, thus inducing apoptosis [Cheng, 2002; Nichols, 1998] and it has been reported 
that TNF-a has a detrimental action in the NSC-34 cell line co-cultured with an immortalized 
mouse microglial cell line (BV-2) stimulated with LPS [Hou, 2003; Woo, 2003]. On the 
contrary, in the absence of the stimulation with LPS, the dose of TNF-a required to produce the 
same effect is twenty fold higher. These data indicate that activated microglia secrete factor(s) 
that facilitate TNF-a mediated neuron death in vitro and it has been observed that LPS induced 
TNF-a acts through TNFR1 to modulate the expression of apoptotic genes and activate 
caspases-3 and -8 [He, 2002]. In addition, subcutaneous inoculation of LPS in TNFRI, TNFR2, 
and TNFRI+TNFR2 knockout mice have shown that TNFRI, but not TNFR 2 lead to an 
apoptotic neuronal death accompanied by a significant increase of caspase-8 and caspase-3 
activation [Pelagi, 2000; Heneka, 1998; De Simone, 2003]. 
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In vivo, the survival of injured motor neurons after axotomy has been examined in a line of 
transgenic mice that over express the soluble form of TNFR1 [Terrado, 2000]. The results 
indicate that the neutralization of endogenous TNF-a by means of over expression of the 
soluble receptor can decrease cell death of injured motor neurons, suggesting that this cytokine 
may play an important role in neuronal degeneration in the CNS following a lesion. 
Different hypotheses have been put forward suggesting both a beneficial or detrimental role of 
reactive astrocytosis and reactive microglia in the CNS [Eddleston, 1993]. It is well-known that 
once activated, astrocytes and microglia increase the expression of a large number of molecules 
that may have toxic effect (i. e. nitric oxide) or may directly support neuronal survival (some 
cytokines, neurotrophic factors). 
However, TNF also induces IL-6 [Benigni, 19961 and LIF [Ding, 1995], two cytokines that 
have neurotrophic activities, already demonstrated to be protective to reduce the clinical 
progression in the wobbler mouse, and whose receptors use the gp130 signal transducer 
[Mitsumoto, 1994]. 
In order to better investigate whether TNF-a/TNFR1 might induce motor neurodegeneration in 
wobbler mice, treatments with agents able to block this detrimental pathway (such as anti-TNF- 
a monoclonal antibodies, soluble TNFRs, TNFR1 receptor antagonist), are required. 
Although anti-TNF-a will reveal a link between the over expression of this cytokine and the 
death of motor neurons, a further treatment by using a caspase 8 inhibitor should be performed 
to clarify the possible involvement of this type of apoptotic pathway in the cervical motor 
neuron death. 
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11.3 Excitotoxicity and wobbler mouse motor neuron disease 
11.3.1 Introduction 
The role of glutamate-induced excitotoxicity in ALS and in different animal models of motor 
neuron degeneration has been previously reported in sections 1.3.2,4.2.2 and 5.4.1. Moreover, 
the mechanism of death induced by AMPA/Kainate overstimulation in primary neuron cultures 
(using Cam influx, proteases activation, mitochondrial damage, and, depending on the intensity 
of stimulus, caspases activation dependent- or energetic catastrophe dependent-cell death) has 
been widely described in the sections 2.2.2.3. 
It has been already- reported that the exposure to glutamate in neuronal cultures induces a rapid 
and massive pattern of death in a non-apoptotic manner, while more prolonged exposure to 
lowere concentration of glutamate generates apoptosis in neurons [Leist, 1997; Nicotera, 1997]. 
Although the possible involvement of glutamate-induced excitotoxicity in motor neuron 
degeneration was extensively investigated both in ALS patients and in almost all animal models 
of ALS, few and controversial results about excitotoxic involvement have been reported in the 
wobbler mouse [Ait-Ikhlef, 2000; Krieger, 1991; Tomiyama, 1994]. 
11.3.2 Experimental design 
To better evaluate the possible link between excitotoxicity and wobbler mice motor neuron 
degeneration, different experiments were carried out in this study: I) plasma levels of amino 
acids; II) glutamate in synaptosomes and glial fraction homogenates from the cervical spinal 
cord of wobbler mice and age-matched healthy littermates at 4 and 12 weeks of age; 111) 
immunohystochemistry and western blots to determine the levels of AMPA in the early 
symptomatic wobbler mice. 
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11.3.3 Results 
11.3.3.1 Glutamate determination in plasma 
The plasma levels of amino acids in wobbler and control mice at 4 and 12 weeks of ages (five 
animals for each group) are reported in table 11.2. In the control group, older animals (12 
weeks) higher plasma amino acids levels were found compared to younger mice (4 weeks). 
This increase was not restricted to glutamic acid, but involved all the amino acids (glycine, 
glutamine, isoleucine) analyzed. Wobbler mice also showed age-related increases of 
aminoacids levels (data not shown). 
Mean glutamic acid concentrations were no different in wobbler and control mice at any age. 
However, while isoleucine concentrations were similar in wobbler and control mice, 
concentrations of glutamate, glycine and glutamine tended to be lower in wobbler mice. 
However, not significant differences were found. 
Glutamic Acid Glycine Glutamine Isoleucine 
Ctr 4 weeks 53.1-140.7 372.6±442.0 208.5±197.4 59.5±58.8 
Wr 4 weeks 40.3±28.6 298.8±227.7 146.5±106.6 61.9±54.3 
Table 11.2. Amino acids concentrations in the plasma of wobbler mice and age matched 
healthy littermates. The values are expressed as mean ± S. D. 
11.3.3.2 Glutamate transporters 
This part of the study was designed to verify the possible role of glutamate transporters in 
wobbler mice, by comparing the levels of glutamate transporters (GLT-1 and GLAST) in the 
cervical spinal cord of control and wobbler mice, and Their functional expression by glutamate 
uptake activity. 
Representative immunoblot for glutamate transporters in 4 week-old wobbler mice and healthy 
Iittermates, are shown in figure 11.11. 
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Representative immunoblot for glutamate transporters in 4 week-old wobbler mice and 
healthy littermates, are shown in figure 11.11. 
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Figure 11.11 Representative immunoblot obtained for C-terminal GLTI and GLAST from 
homogenates of the cervical region of spinal cord in wobbler mice and healthy littermates at 4 
weeks of age. 
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No differences in immunoblot density were found for the GLT-1 protein measured with Ab 
raised against both the N- and the C- terminal; and for the GLAST protein (see table 11.3). 
GLT-1 (c-term) GLT-1 (n-term) GLAST 
Ctr 4 weeks (8) 100±18.1 100±22.2 100115.6 
Wr 4 weeks (7) 106.3±9.9 91.1±2 135.1±78 
Table 11.3. GLT-1 (C- and N- terminal) and GLAST protein levels in the cervical spinal cord 
homogenates obtained from 4 week-old wobbler mice and healthy littermates. The values are 
expressed as percentage of controls, (as mean ± S. D. ). 
In addition, the functional expression of glial and presynaptic glutamate transporters activity 
was measured in cervical spinal cord homogenates obtained from 4 week-old wobbler mice and 
healthy littermates. 
The [3H] glutamate uptake levels, measured in crude synaptosomal preparation (P2), are 
reported in table 11.4. The comparison between the samples obtained from wobbler mice and 
healthy littermates did not shown significant differences. 
[ H] glutamate activity in P2 
Ctr 4 weeks 227.1±9.3 
Wr 4 weeks 222.7±11.8 
Table 11.4. [3H] glutamate uptake in P2 obtained from 4 weeks aged cervical spinal cord 
homogenates from wobbler mice and healthy littermates (six animals for each group). (The 
numbers reported are the mean values expressed as pmol/min/mg protein f S. D. ). 
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11.3.3.3 AMPAr expression and localization 
G1uRI 
Representative microphotographs showing the immunostaining in the cervical spinal cord of 4 
week-old wobbler mice and healthy littermates are shown in figure (11.12 A, B). In both 
sections it is possible to observe a weak but homogenous staining in the whole the gray matter, 
whereas the white matter were almost unstained for G1uR1. No marked differences were seen 
between wobbler and healthy mice sections. 
Two microphotographs showing the distribution and the localization of G1uR1 staining in 
anterior horn neurons of cervical spinal are shown in figure 11.12. 
In order to obtain a semi-quantitative estimation of the G1uR1 expression in the anterior horn 
neurons, indirect measurements of immunostaining were performed by calculating the optical 
density for each single motor neuron. For this analysis, 20 cervical spinal cord sections (25 µm 
of thick) for each animal, 5 animals for each experimental group, and four different 
experimental groups (4 and 12 week-old wobbler mice and healthy littermates) were processed. 
The following procedure was also adopted to determine the immunostaining density for all the 
other three subunits. 
No significant differences in the mean levels of immunostaining density in wobbler mice, at 
both ages examed were found. The mean level of GluRI immunostaining density in cervical 
motor neurons is expressed as a percentage compared to their respective controls, normalized to 
100 (% GIuR1 immunostaining density control 4 weeks 100±4.2; wobbler 4 weeks 103±9.9 n. s) 
(% G1uR1 immunostaining density control 12 weeks 1001-4.9; wobbler 12 weeks 104±7.7 n. s). 
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Figure 11.12 Representative microphotographs showing GIuR I immunostaining in the 
cervical spinal cord region of healthy mice (A) and early symptomatic wobbler mice (B). 
G1uR1 immunostaining localization in motor neurons from the cervical spinal cord sections of 
healthy mice (C) and early symptomatic wobbler mice (D). 
Scale bar, A, B 200 gm. C, D 50 gm. 
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G1uR2 
Representative microphotographs showing the pattern of immunostaining for G1uR2 in the 
cervical spinal cord of 4 week-old wobbler mice are and healthy littermates are shown in figure 
11.13. In the section immunostained for G1uR2, an intense positivity is evident in the whole 
gray matter, and neurons, above all in the anterior horn, resulted more intensively stained. 
Marked differences between wobbler and control mice were not seen. 
The distribution and the localization of G1uR2 immunostaining in anterior horn neurons of the 
cervical spinal cord in 4 week-old wobbler mice and healthy littermates is shown in figure 
11.13. Motor neurons were intensively stained both in wobbler mice (Fig 11.13 B, D) and in 
healthy littermates (Fig 11.13 A, C). The values of G1uR2 immunostaining density measured in 
motor neurons in the younger experimental groups did not revealed any statistical difference 
between wobbler and control mice (% GluR2 immunostaining density control 4 weeks 
100±4.9; wobbler 4 weeks 109±7.7 n. s), a modest but significant decrease in G1uR2 
immunostaining density was instead observed in 12 weeks aged wobbler mice (% G1uR2 
immunostaining density control 12 weeks 100±9.4; wobbler 12 weeks 83.6±3.4 p<0.05). 
The reason of this decrease is unclear: it may be related to the process of cellular vacuolization 
that reduce the cellular density in wobbler mice motor neurons. 
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Figure 11.13 Representative microphotographs showing GluR2 immunostaining in the 
cervical spinal cord region of healthy mice (A) and early symptomatic wobbler mice (B). 
G1uR2 immunostaining localization in motor neurons from the cervical spinal cord sections of 
healthy mice (C) and early symptomatic wobbler mice (D). 
Scale bar, A, B 200 µm. C, D 50 pm. 
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GIuR3 
Cervical spinal cord sections showed a strong immunostaining for G1uR3 in the dorsal horn, 
both in wobbler (Fig 11.14 B) and in healthy littermates (Fig 11.14 A). 
However, by observing anterior horn at higher magnification, a strong immunopositivity for 
G1uR3 was found. No marked differences in localization, distribution and intensity for G1uR3 
staining were seen in motor neurons between wobbler mice (Fig 11.14 D) and healthy 
littermates (Fig 11.14 C). 
In both stages of the disease the immunodensity in wobbler mice, measured in motor neurons, 
did not statistically differ to age-matched healthy mice (% GluR3 immunostaining density 
control 4 weeks 100.017.8; wobbler 4 weeks 100.7123.7 n. s) (%G1uR3 immunostaining density 
control 12 weeks 100±9.1; wobbler 12 weeks 85.7±9.7 n. s). 
G1uR4 
As for GluR1 and GluR3, staining for G1uR4 was mainly localized in the dorsal region. A 
modest but detectable immunostaining was also observed in the anterior horns, but mainly in 
fibers rather than in cell bodies (fig 11.15 A, B). 
Motor neuron staining revealed a marked nuclear immunopositivity and a weaker signal in the 
periphery in unaffected (Fig 11.15 C) and diseased mice (Fig 11.15 C). No differences were 
determined by measuring the immunodensity in healthy and wobbler mice (% GluR4 
immunostaining density control 4 weeks 100.0±15.8 wobbler 4 weeks 83.9111.5 n. s) (%Glur4 
immunostaining density control 12 weeks 100.0±1.5; wobbler 12 weeks 99.0±0.9 n. s). 
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Figure 11.14 Representative microphotographs showing GIuR3 immunostaining in the 
cervical spinal cord region of healthy mice (A) and early symptomatic wobbler mice (B). 
GIuR3 immunostaining localization in motor neurons from the cervical spinal cord sections of 
healthy mice (C) and early symptomatic wobbler mice (D). 
Scale bar, A, B 200 µm. C, D 50 µm. 
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Figure 11.15 Representative microphotographs showing G1uR4 immunostaining in the 
cervical spinal cord region of healthy mice (A) and early symptomatic wobbler mice (B). 
G1uR4 immunostaining localization in motor neurons from the cervical spinal cord sections of 
healthy mice (C) and early symptomatic wobbler mice (D). 
Scale bar, A, B 200 µm. C, D 50 gm. 
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To confirm the qualitative observations obtained by immunohystochemistry and the semi 
quantitative data obtained by optical density measurements, a quantification (by 
immunoblott ing experiments) of all proteins was made in the ventral region of cervical spinal 
cord in 4 weeks wobbler mice and healthy littermates (5 animals for each group were utilized). 
No significant differences were found for other AMPA subunits (see table 
G1uR1 GIuR2 GIuR3 GIuR4 
Ctr 4 weeks 100±20.8 100±36.9 100±13.8 100±30.6 
Wr 4 weeks 107±0.3 89.9±19.5 121.1±20 111.3±37.4 
Table 11.5. GluR 1-4 protein levels in the cervical spinal cord homogenates (post synaptic 
densities) from 4 week-old wobbler mice and healthy littermates. The protein levels for each 
subunit are expressed as percentage compared to their respective controls normalized to 100 
and are reported as mean ± S. D. ** p<0.05 
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Representative immunoblotting of the G1uR 1-4 subunits is shown in figure 11.16. 
CTR WR 
G1uR1 
G1uR3 
G1uR4 
1 u1n 
iJ n: 
Figure 11.16 Representative immunoblot obtained for AMPA receptor subunits GIuR 1-4 
from homogenates of the cervical region (post synaptic densities) of spinal cord in wobbler 
mice and healthy littermates at 4 weeks of age. 
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11.3.4 Discussion 
The main evidence emerging from this investigation is that, in early symptomatic wobbler 
mice, glutamate-induced excitotoxicity does not seem to play a relevant role in inducing motor 
neuron death. Different mechanisms have been proposed to contribute to excitotoxic damage in 
ALS patients and in animal models of motor neuron degeneration. They included: I) increased 
amount of excitatory amino acids in plasma and CSF, II) reduced levels and/or decreased 
functional expression of glutamate transporters, III) glutamate hyper susceptibility of motor 
neurons due to an alterations, in the number or in electrophysilogical properties, of postsynaptic 
AMPAR. 
The majority of these parameters have been analyzed in this study and the comparison between 
wobbler mice and healthy littermates revealed: I) no difference in the amount of amino acids 
levels, II) no difference in the proteins level of the two main glial and presynaptic glutamate 
transporters expressed in the cervical spinal cord (GLT1, GLAST), and in glutamate uptake, 
and IV) no difference in the quantitative expression, distribution and localization of AMPA 
receptor subunits. 
These results clearly indicate that neither an overstimulation induced by a reduced glutamate 
uptake activity nor that produced by an increase of AMPA receptors and/or a decrease of 
G1uR2 expression, are involved. 
However, it is not yet possible to fully exclude this aetiological hypothesis. In fact, neither the 
electrophysiological properties of AMPA receptors nor the possible expression of the edited 
form of G1uR2 (the Ca++ permeable conformation) were investigated in this study. 
Alterations in such parameters may be responsible for making the AMPA receptor more 
vulnerable to physiological exposure to glutamate and therefore leading to motor neuron death. 
For this reason the effects of two pharmacological treatments, with a selective antagonist of 
AMPA receptors reported to be active in SOD1G93A mice [Canton, 2001], and with riluzole, a 
non selective antiexcitotoxic agents that is, the only FDA-approved drug for ALS treatment, 
were tested in early symptomatic wobbler mice and healthy littermates (see chapter 12). 
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1.4 Mitochondria and apoptosis 
11.4.1 Introduction 
The mechanisms of motor neuron degeneration in ALS are still unknown and the evidence for 
an apoptotic-like cell death is controversial (see section 2.3.3). Although animal models of ALS 
display remarkable differences with respect to human disease, they represent a useful tool to 
investigate the early processes leading to motor neuron death (see section 5.6). To verify the 
possible involvement of apoptosis and motor neurons death in the wobbler mouse, the pathway 
passing through mitochondria and activating caspases cascade cell signaling was investigated in 
this part of the study. 
11.4.2 Experimental design 
Before evaluating whether apoptotic markers were induced, a detailed characterization of the 
mitochondrial activity was carried out. Mitochondrial activity was measured in 4 week-old 
wobbler mice and healthy littermates by measuring the oxygen consumption rate and the 
activities of ETC complexes by spectrophotometric analysis, complex I activity was also 
determined using a quantitative hystochemical assay. 
Intrinsic apoptotic pathway mainly involves caspase 9, -3 and, in the CNS, caspase 7 (see 
section 2.2.5). For this reason immunohystochemical experiments with antibodies directed 
against the active form of these three caspases were carried out. A further investigation using 
ISEL staining to determine possible alterations of nuclear integrity was performed. These latter 
experiments were done by comparing cervical spinal cord of 4 week-old wobbler mice and 
healthy littermates. 
All experiments were done following the procedures described in the chapter 9. 
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11.4.3 Results 
11.4.3.1 Mitochondrial activity 
Mitochondria from early symptomatic wobbler mice showed a significant decrease in basal 
oxygen consumption (% Q02 control 4 weeks 100.0±2.1; wobbler 4 weeks 79.8±5.2 p<0.03) At 
4 weeks of age, mitochondrial enzymatic activities seemed to be lower in the cervical region, 
though a statistical significance was only found for complex I. When the respiratory enzyme 
activities were expressed as a ratio to citrate synthase (CS) activity, only complex I resulted to 
be significantly decreased (% activity complex I /CS, control 4 weeks 100.0±1.8; wobbler 4 
weeks 86.5±3.5 p<0.04). No differences were found in the lumbar spinal cord of the wobbler 
mice in comparison with controls (see Fig 11.17 A, B). 
Histochemical measurement of complex I activity in ventral horn motor neurons showed a 
significant decrease of staining intensity in the early symptomatic wobbler mice, the values are 
expressed as percentage respect to the controls (% of complex I, control mice 100±12.7; 
wobbler mice 65.7 ± 10.8% (p<0.05)). 
Representative microphotographs of complex I positive staining in the anterior horn of the 
cervical spinal cord are shown in Fig 11.18 A, B. 
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Figure 11.17. A representative diagram showing the oxygen consumption in the cervical spinal 
cord of control mice is represented in this figure. The different enzymatic activities (complex 
I-N) were estimated by adding specific blockers and/or uncouplers during the experiment, 
following the procedure described in the section (9.11.1). In the cervical spinal cord of wobbler 
mice the activity recorded by oxygraphy resulted significantly lower compared to control mice. 
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Figure 11.18 Hystochemical determination of complex I activity evaluated in the cervical 
spinal cord of wobbler mice and healthy littermates. Complex I staining is proportional to the 
amount of substrate reduced (NADH) by complex I and the consequent activation of a 
colorimetric reaction following the oxidation of the nitro blue tetrazolium (blue staining). In the 
upper microphotograph a representative distribution of staining in the cervical spinal cord 
region is shown (A). It is possible to note as motor neurons appear highly immunopositive for 
this staining procedure. The cellular localization of complex I staining clearly shows an intense 
positivity into the cytoplasm with a lack of staining in the nucleus. Scale bar, A 200 µm. B 40 
µm. 
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11.4.3.2 Active caspase 3, -7 and -9 immunohystochemistry 
Mitochondria alterations can often generate the release of cytochrome-c and the consequent 
formation of apoptosome and procaspase 9 cleavage [Ferraro, 2003]. Caspase 9 activation can 
furthermore propagate this process by recruiting caspases 3 and 7 by hierarchical activation 
[Slee, 1999]. 
To evaluate if mitochondrion-dependent apoptotic pathway might be related to motor neurons 
death in wobbler mice, the activated caspases 3,7 and 9 were investigated in 4 week-old 
wobbler mice and healthy littermates. 
For activated caspase 9, a very low number of positively stained motor neurons in the anterior 
horn of cervical spinal cord of early symptomatic wobbler mice were observed, and this value 
was not significantly higher than in healthy littermates. 
Animals (C2-C7) Ctr 1 Ctr 2 Ctr 3 Ctr 4 Ctr 5 Wr 1 Wr 2 Wr 3 Wr 4 Wr 5 
NO ChAT positive 1662 1589 1486 1536 1501 1076 834 1145 1201 894 
cells (50 sections) 
NO caspase 9 positive 2 3 1 0 4 0 2 2 3 1 
cells (50 sections) 
Table 11.6 ChAT and caspase 9 positive cells in the cervical spinal cord region of 4 weeks 
aged wobbler mice and healthy littermates. 
Immunohystochemical experiments in the cervical spinal cord of 4 week-old wobbler mice and 
healthy littermates for active caspases 7 and -3, revealed an extremely low number of positive 
cells for both caspases. The values of positive cells for caspase 7 and caspase 3 are reported in 
tables 11.7 and 11.8. 
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Animals (C2-C7) Ctr 1 Ctr Ctr 3 Ctr 4 Ctr 5 Wr Wr 2 Wr 3 Wr 4 Wr 5 
2 1 
NO ChAT positive 1539 1492 1631 1597 1533 973 1118 1206 1099 1149 
cells (50 sections) 
NO caspase 7 positive 0 3 0 0 2 2 0 1 0 2 
cells (50 sections) 
Table 11.7 ChAT and caspase 7 positive cells in the cervical spinal cord region of 4 weeks 
aged wobbler mice and healthy littermates 
Animals (C2-C7) Ctr Ctr 2 Ctr 3 Ctr 4 Ctr 5 Wr Wr 2 Wr 3 Wr 4 Wr 5 
1 1 
NO ChAT positive cells 1652 1432 1558 1601 1529 896 1024 1202 1155 1204 
(50 sections) 
NO caspase 3 positive 2 2 1 0 3 1 0 0 3 4 
cells (50 sections) 
Table 11.8 ChAT and caspase 3 positive cells in the cervical spinal cord region of 4 weeks 
aged wobbler mice and healthy littermates. 
Representative microphotographs showing sections of wobbler mice processed to caspase 9,7 
and 3 are reported in figure 11.18 (A-C). 
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Figure 11.19 Representative section of the cervical spinal cord in early symptomatic wobbler 
mice immunostained for active caspase 9 (A), active caspase 7 (B) and active caspase 3 (C) are 
shown here. Although a weak and homogeneously diffused staining is detectable in the whole 
gray matter in each section, this represents a background due to a not specific reaction of the 
system of signal enhancing (ABC colorimetric detection). Scale bar, 400 µm. 
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The pattern of immunostaining of active caspases 9,7 and 3 in motor neurons are 
shown in figure 11.19 (A-C). 
W il 4 weeks 
`VR 4 weeks 
Aý7. 
C 
Figure 11.20 Pattern of staining and cellular localization observed for the active caspase 9 
(A), capase 7 (B), and caspase 3 (C) in the cervical spinal cord motor neurons in wobbler mice. 
For each caspases no nuclear imniunopositivity was found. Scale bar, 20 µm. 
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11.4.3.3 ISEL staining 
DNA fragmentation was investigated in the cervical spinal cord of 4 week-old wobbler mice, 
and age healthy littermates, by staining the sections with cresyl violet and then performing an 
ISEL assay. 
Nissl staining revealed a marked vacuolar degeneration in the cervical spinal cord motor 
neurons in wobbler mice (Fig 11.20 A). 
Although ISEL reveals nuclear DNA strand breaks well before the appearance of an apoptotic 
morphology, ISEL positive cells were absent in all sections examined. No difference in nuclear 
morphology, were observed between wobbler and control mice (Fig 11.20 B). As a positive 
control, I processed for Nissl and ISEL staining cerebellar sections of 3 week-old weaver 
mouse, a model of neurodegeneration whose phenotype is associated with a missense mutation 
in the gene coding for the GIRK2 potassium channel, which produces a massive and selective 
loss of CGC form P1 to P21, exhibiting a strong nuclear staining for ISEL and a typical 
apoptotic morphology [Migheli, 2004]. As expected, cerebellar sections from 3 week-old 
weaver mice showed several neurons with an unaltered pattern of Nissl staining, purple 
staining, but intensively positive for ISEL, brown staining. (11.20 C, D). 
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Figure 11.21 Representative microphotograps showing a cervical spinal cord section (early 
symptomatic wobbler mice), processed for Nissl staining and ISEL staining (A-B). Dying 
motor neurons (arrows), clearly show morphological alterations but maintain their nuclear 
integrity and are not positive for ISEL staining. On the other hand, dying cerebellar neurons in 
3 week-old weaver mouse (C-D), are found highly positive for ISEL staining. Scale bar, A 100 
µm. B, 40 mm. C, 200 µm. D, 50 . im. 
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11.4.4 Discussion 
Many agents can trigger possible mitochondria-dependent apoptotic pathways (see section 
2.2.2.1 and 2.2.2.2), and, to make a correlation between environmental alterations and intrinsic 
apoptosis of cervical motor neurons in wobbler mice, Cam influx, through AMPAr stimulation, 
and neurotrophic factor withdrawal, must be considered. 
In chapter 10, it has been clearly shown that both BDNF deprivation and stimulation of AMPAr 
produce typical features of apoptosis and that the apoptotic process, induced by this excitotoxic 
stimulus, passes through mitochondria. 
Here, the mitochondrial activity was first investigated in the spinal cord of wobbler mice at 
early symptomatic phase. A decrease of the respiratory rate and activities of the mitochondrial 
enzymes were found in cervical spinal cord homogenates obtained from wobbler mice. Since 
these techniques for measuring respiratory rate and mitochondrial enzyme activities cannot 
distinguish between mitochondria deriving from neurons or from glial cells, the results maybe 
due to the reactive astrogliosis and motor neuron loss observed at this stage of the disease 
[Hantaz-Ambroise, 1994; Bigini, 2001]. However a decrease of complex I activity was also 
detectable when the activity of motor neurons was measured by hystochemical staining. 
Complex I is a critical site of mitochondria oxygen free radical (ROS) production. Even a small 
degree of enzyme inhibition seems sufficient to enhance ROS generation and chronic, low- 
grade complex I inhibition, induced by rotenone exposure, has been described to cause slight 
elevation in basal apoptosis. Complex I seems to participate in the regulation of PTP opening 
and the following propagation of apoptotic cell signaling [Chauvin, 2001; Fontaine, 
1999; Higuchi, 1998] and may therefore provide a link between mitochondria and the 
downstream pathway for cell death. 
In addition, it is important to note that in the lumbar spinal cord homogenates, obtained from 
the animals tested for cervical spinal cord mitochondria activities, by performing the same 
types of experiments, no differences were found both in oxygen consumption rate and in ETC 
complexes efficiency between affected and healthy mice (see appendix "Published papers 
arising from this thesis"). 
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The activation of caspases and the nuclear fragmentation in cervical spinal cord motor neurons 
of early symptomatic wobbler mice further investigated these aspects and the presence of signs 
indicative of apoptosis. 
A lowest percentage of motor neurons showed a positive staining for caspases 9, -7 and -3. 
Moreover, for each capsase, this percentage was not significantly higher than healthy 
littermates. In agreement with this result, no fragmented nuclei (ISEL positive) were found in 
the cervical motor neurons of both groups. 
The lack of caspases-associated apoptotic pathway, together with a loss of mitochondrial 
activity can be explained by a different mechanism of death in which mitochondria also play a 
relevant role. For instance, PTP has a role in regulating the fate of cells and in preventing or 
promoting apoptosis but also in contributing to enhance a necrotic cell death [Tatton, 1999]. If 
permeability transition pore can stimulate both primary necrosis and apoptosis, what makes the 
difference? 
It is possible that the bioenergetics and redox catastrophe (which would induce non-apoptotic 
cell death) and the activation of catabolic enzymes (caspases and nucleases) might compete 
with each other. Mitochondria are the main target of stress and their alterations could represent 
a trigger for distinct cell death pathways depending on the type of stress involved. This picture 
is compatible with the evidence that different agents can induce apoptosis at low doses, when 
permeability of the transition pore is induced smoothly and cells can activate caspases cascade 
cell signaling, and induce necrosis at higher doses, when permeability of transition pore is 
abruptly altered and the cell activate stronger pattern of death before cytochrome-c release- 
induced caspases cascade [Leist, 1997; Hirsch, 1997]. 
The concomitant observation of mitochondrial alterations in the absence of a caspases- 
associated apoptotic pathway could be generated by a methodological problem. Although the 
antibodies directed against the four different caspases that are utilized in this study have been 
found to work reliably in other conditions (see chapter 10), it is possible that a so low number 
of caspases positive cells might be due to the low probability to find a cell undergoing 
apoptotic process. 
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For this reason the immunohystochemical experiments a very high number of cells, 100 
sections for each animal and 5 animals for each experimental group), and were performed at a 
time point (from the 4th to 5th week of age) when the more sustained loss of motor neurons was 
observed. 
To further exclude that intrinsic apotosis is involved in wobbler mouse motor neuron death, a 
pharmacological approach with EPO, a compound that have been shown to posses a selective 
antiapoptotic activity in primary cultures of motor neurons (see sections 10.3 and 10.4), was 
performed in early symptomatic wobbler mice. These data are reported in the next chapter. 
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CHAPTER 12 
PHARMACOLOGICAL TREATMENTS 
12.1 EPO fails to arrest neuromuscular impairment and motor neurons loss in wobbler 
mice 
12.1.1 Introduction 
In order to clarify the role of apoptosis in motor neuron degeneration occurring in the cervical 
spinal cord of wobbler mice, in addition to hystochemical characterization described in the 
Chapter 11, I investigated the effects of a chronic treatment with a selective anti-apoptotic 
compound (EPO) that had already been reported to be active in other forms of 
neurodegenerative diseases. Since treatments with EPO have demonstrated its protective role in 
reducing neuronal loss and in preventing the symptomatological worsening both in acute and in 
chronic neurological disorders (see section 2.4.2) and its selective anti-apoptotic effects in 
primary cultures of motor neurons exposed to kainate or deprived of serumBDNF have 
confirmed this role (see chapter 10), this agent was used in the experiments described in this 
chapter. 
Konishi et al. [Konishi, 1993] first demonstrated that some haematopoietic factors, including 
EPO, acted as neurotrophic factors on central cholinergic neurons, influencing their 
differentiation and regeneration. The anti-apoptotic mechanism of EPO that has been described 
in erythroid precursors was also observed in. Jak2 has been shown to trigger NF-kB, and the 
anti-apoptotic action of NF-k13 in neurons also involves activation of Akt! and BAD 
phosphorylation as well as BCL-xL up-regulation [Marti, 2004; Ruscher, 2002]. 
By characterizing the protective effect of EPO against oxygen/glucose deprivation-induced 
apoptosis of primary cortical neurons, Ruscher demonstrated that EPO produced its protection 
by activating a pathway involving Jak2 MAPK and PI3K. In fact, using specific inhibitors of 
these kinases, PD98059 and the LY984002, the protective effect of EPO was completely 
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prevented. These molecular mechanisms also included the activation of STAT5, Aktl, cysteine 
proteases, protein-tyrosine phosphatases, nuclear factor-KB [Ruscher, 2002]. 
Since PI3K activation produces an anti-apoptotic effect through BAD inactivation and the 
subsequent reduction of the ALFM by inhibition of the mitochondrial PTP opening [237], and 
EPO has been reported to induce BAD phosphorylation [330], it is possible to argue that EPO 
exerts its neuroprotective and anti-apoptotic effect by blocking and thus inhibiting the 
downstream steps (cytochrome-c release, caspases activation, nuclear fragmentation). The data 
obtained in red blood cells precursors (over expression of BCL-xL, an anti-apoptotic agent that 
acts blocking the mitochondrial PTP) [315], further confirm this suggestion. Interestingly, I 
observed the same evidence (i. e. block of iWM, inhibition of cytochrome-c release, and lack of 
mitochondrion-dependent apoptotic pathway) in primary cultures of motor neurons exposed to 
an apoptpgenic insult, as described in Chapter 10. 
12.1.2 Experimental design 
To detect whether EPO could produce a beneficial effect in slowing the neuromuscular deficit 
in the wobbler mouse, a group of wobbler mice was chronically treated, upon clear diagnosis at 
3 weeks of age, with rHuEPO until 12 weeks of age. To test the symptomatological 
progression, behavioural tests were done during the treatment. Biochemical and hystological 
experiments were carried in order to evaluate the treatment. All experiments were done 
according to the protocols reported in the chapter 9. 
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12.1.3 Results 
12.1.3.1 Behavioural scores 
Body weight 
As previously reported (see Chapter 5), the weight of wobbler mice was markedly lower 
compared to that asymptomatic littermates and the body weight increase is less marked in 
wobbler mice. Growth was more pronounced in the first period of treatment (from 3"d to 7`h 
week of age), in the last period of treatment, till 12th week of life, the rate of increase lowered. 
As shown in figure 12.1 A, EPO treatment did not produce effects on the rate of growth in 
wobbler mice. 
Paw abnormality and walking abnormality 
The semi quantitative studies (paw abnormality and walking abnormality) showed a similar 
trend by comparing EPO- and vehicle-treated wobbler mice (Fig 12.1 B, C). In both groups the 
scores of paw and walking abnormality showed a rapid worsening in the first period of 
treatment, markedly increasing from the 3rd to the 7`h week of age, at the 12`h week of age the 
values of the degree of paw and walking abnormality was similar. During the treatment, healthy 
mice treated with EPO did not show any abnormality both in paw and in walking compared to 
untreated mice. 
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Grip strength and running time 
In both EPO- and vehicle-treated mice, grip strength homogeneously declined during the 
treatment without any significant difference between the two groups (Fig 12.2 B). In order to 
avoid any possible interference due to the gain of body weight data of the grip strength were 
normalized by dividing each measurement by body weight before comparisons were made 
(data not shown): no difference in the scores and the degree of worsening was found in either 
normalized or raw data. 
The running time trials did not shown any significant difference between EPO- and vehicle- 
treated wobbler mice (Fig 12.2 A). In both groups a progressive decay was detected from the 
3`d to the 12`h week of age. 
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Figure 12.2 Behavioural tests in wobbler mice treated with rHuEPO at the dose of 4000 
unit/kg/day, i. p. three times a week from the 4th to the 12th week of age. Panel A: running 
time; panel B: grip strength. Each point represents the mean ± SD of 10 mice for each 
experimental group. 
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12.1.3.2 Neuropathological estimation 
Nissl motor neurons counting and biceps weight 
The number of cervical motor neurons in vehicle-treated wobbler mice at the end of treatment 
(12th week of age) was significantly smaller than that in control littermates and EPO treatment 
did not produce difference in motor neurons number in healthy mice. In addition, EPO. 
treatment did not reduce the rate of motor neuron loss occurring during the progression of 
symptoms, as no differences were seen between EPO-treated and vehicle-treated wobbler mice 
(see table 12.1). 
CTR vehicle CTR EPO Wr vehicle Wr EPO 
Motor neurons % 100±1.7 98.2±1.0 34.5+3.4*** 35.9±3.8*** 
Table 12.1 Nissl positive motor neurons in the cervical region, 50 sections for each animal 
were processed, of wobbler mice and healthy littermates after chronic treatment with EPO or 
saline (vehicle). The values are expressed as percentage compared to their respective controls 
normalized to 100 and are reported as means ± S. D. 
Consistent with the loss of cervical motor neurons during the clinical progression, the biceps 
weight of wobbler mice, considered, as the most reliable measurement to evaluate the degree of 
atrophy, was significantly lower compared to healthy littermates. Both in healthy and in 
affected mice EPO treatment did not modified the biceps weight (see table 12.2). 
CTR vehicle CTR EPO Wr vehicle Wr EPO 
Weight 
(milligrams) 
32±6.8 34.1±8.3 9.0±3.1*** 7.9±2.6*** 
Table 12.2 Biceps weight of wobbler mice and healthy littermates after chronic treatment with 
EPO or saline (vehicle). The values are reported as means ± S. D. ***p<0.001 
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ChAT activity 
Total ChAT activity was measured in the spinal cord of wobbler mice (EPO and vehicle- 
treated) and littermates at 12 weeks of age. ChAT activity in the cervical region of wobbler 
mice was similar between EPO and vehicle-treated wobbler mice, but was significantly reduced 
compared to control mice, where EPO-treated mice group showed a slight trend of increase 
respect to vehicle treated healthy littermates (see table 12.3). 
CTR vehicle CTR EPO Wr vehicle Wr EPO 
Chat activity (% vehicle control) 100±10.2 113.6±16 69.2±13.9* 70.3±18.5* 
Table 12.3 ChAT activity measured in the cervical spinal cord homogenates of EPO and 
vehicle treated wobbler mice and healthy littermates. The values are expressed as percentage 
compared to their respective controls normalized to 100 and are reported as means ± S. D. 
*p<0.01 
12.1.3.3 EPOr immunohystochemistry 
Representative microphotographs showing the cervical spinal cord immunostaining for EPOr 
after chronic treatment with EPO are reported in figure 12.3. The staining in the whole cellular 
body of spinal cord neurons indicates a clear expression of EPOr also in the adult healthy mice 
(Fig 12.3 A). A comparison between the staining of EPOr in the cervical spinal cord of controls 
and wobbler mice did not show any difference between the two groups (Fig 12.3 B). The 
experiment carried out after chronic treatment did not reveal a loss of immunopositivity in 
spinal cord sections from EPO chronically treated mice. A higher magnification 
microphotograph of cervical motor neurons in healthy mice chronically treated with EPO, 
which had been stained for EPOr antibody, is shown in figure 12.3 C. 
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Figure 12.3 Representative microphotographs showing the pattern of staining and the 
distribution of EPOr antibody in the cervical spinal cord section of chronically treated healthy 
(A) and wobbler mice (B). After 9 weeks of treatment with rHuEPO EPOr immupositivity was 
maintained in almost all neurons, not exclusively motor neurons, in the cervical spinal cord and 
did not seem to be decreased compared to untreated animals (not shown). Interestingly, a 
marked immunopositivity in correspondence of the nuclear region was found both in EPO 
treated than in vehicle treated mice (C). Scale bar, A-B 400 gm. C, 50 µm. 
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12.1.3.4 Haematocrit measurement 
Both in healthy and in affected animals chronic treatment with rHuEPO significantly increased 
the red blood percentage from values lower than 50% to values close to 70% (see table 12.4). 
CTRvehicle CTR EPO Wr vehicle Wr EPO 
Haematocrit (%) 45.3±4.2 73±6.0** 47.8±1.2 63.2±4.9** 
Table 12.4 Haematocrit values measured in wobbler mice and healthy littermates after chronic 
treatment with EPO or saline (vehicle). The values are reported as means ± S. D. **p<0.005 
The increased levels of haematocrit levels in EPO treated mice confirmed the haematopoietic 
activity of this compound. 
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12.1.4 Discussion 
These results indicate that EPO is not effective in vivo in reducing motor impairment and motor 
neuron loss in wobbler mice. Since EPO is reported to be active in different in vitro and in vivo 
models of neurodegeneration, and it can be considered a selective anti-apoptotic agent, the lack 
of efficacy in the wobbler mouse suggest that apoptosis is not involved [Chong, 2002; Martinez- 
Estrada, 2003; Agnello, 2002; Siren, 2001; Villa, 2003; Digicaylioglu, 2001; Sadamoto, 
1998; Bemaudin, Nissenson, 1992; Kawakami, 2001; Sinor, 2000]. 
However, it is important to consider that EPO has been mainly utilized in acute models of 
neurodegeneration. Due to its effect of increasing blood red cells percentage chronic treatment 
with EPO can induce side effects related to cardiovascular alterations. Also in the present 
study, the mice treated with EPO for 9 weeks had high haematocrit values compared to vehicle 
treated mice. Thus I cannot exclude that this cardiovascular effect could have masked a 
beneficial neuroprotective action of EPO [Smith, 1991 ]. 
In addition, the receptor by which EPO exerts its neuroprotective effects is not clearly 
identified. However, very recent studies indicate that the haematopoietic and the 
neuroprotective effect can be dissociated, since compounds that do not bind to the EPO 
receptor yet are fully tissue protective. It is hypothesized that EPOr interacts with the common 
beta receptor (CD131), the signal-transducing subunit shared by GMCSF, IL3 and IL5. 
Therefore further studies using EPO derivatives lacking the haematopoietic effect are planned 
in order to verify the possible anti-apoptotic effect in wobbler mice. 
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12.2 Riluzole, unlike the AMPA antagonist RPR119990, reduces motor impairment and 
partially prevents motor neurons death in the wobbler mouse 
12.2.1 Introduction 
Glutamate-induced excitotoxicity is considered to play an important role leading to cell death in 
several neurodegenerative diseases, such as amyotrophic lateral sclerosis (ALS), Alzheimer's 
disease, and ischemia (see 1.3.2). 
The link between excitotoxic damage and ALS is highlighted in several studies which have 
shown alterations of glutamatergic transmission. A significant increase of glutamate levels in 
cerebrospinal fluid, plasma and serum was reported in patients affected by sporadic ALS 
[Bastone, 1995; Plaitakis, 1987; Rothstein, 1990; Shaw, 1995] and decreased levels of glutamate 
were found in post-mortem tissues from ALS patients [Perry, 1987]. As reported by Rothstein, 
the high extracellular levels of glutamate were probably due to a selective loss of the glial 
glutamate transporters EAAT2 in the motor cortex and spinal cord of ALS patients [Rothstein, 
1995; Bristol, 1996]. This decrease of EAAT2 was correlated with a reduced glutamate uptake 
found in synaptosomes prepared from brain and spinal cord of sporadic ALS patients 
[Rothstein, 1992]. 
AMPA-mediated excitotoxicity has been implicated in neuronal loss in ALS, where motor 
neurons seem to be selectively vulnerable to the Can-dependent injury mediated by these 
receptors [Carriedo, 1996; Carriedo, 2000; Laslo, 2001; Rothstein, 1993; Rothstein, 
1996; Takuma, 1999; Vandenberghe, 2000; Williams, 1997]. AMPAr that contain the edited 
GluR2 subunit show low Cam permeability, because this subunit carries an arginine residue in a 
position occupied by glutamine in the other subunits, that are unedited [Burnashev, 
1992; Hume, 1991; Pellegrini-Giampietro, 1997; Washbum, 1997]. Recent studies suggest that 
the same neuron can express different sub-populations of AMPAr with non-fixed stoichiometry 
of GluR2lnon-G1uR2 subunits [Petralia, 1997; Vandenberghe, 2001; Wenthold, 1996]. Moreover 
the ratio of G1uR2 to non-G1uR2 subunits can vary in different neuronal populations, and may 
change in pathological conditions [Pellegrini-Giampietro, 1992; Pollard, 1993; Prince, 1995]. 
Therefore, although the mechanisms are not fully understood, the selective vulnerability of 
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motor neurons in ALS might result from a predominant expression of highly Cam-permeable 
AMPAr or from the lack of the GluR2 subunit in this cell type. The role of glutamate receptors- 
mediated excitotoxicity has been shown in vivo in animal models of motor neuron 
degeneration. In particular in SOD1G93A transgenic mice and mnd mice, it has been 
demonstrated that treatment with AMPA antagonists can show neuroprotective properties 
[Canton, 2001; Bendotti, 2002; Mennini, 1999; Van Damme, 2003]. 
Several clinical trials have been undertaken in ALS using anti-excitotoxic agents [Blin, 
1992; Eisen, 1993; Gredal, 1997; Hollander, 1994; Miller, 1996; Tandan, 1996]. However none of 
these drugs had beneficial effects in prolonging survival or in decreasing the rate of clinical 
decline in ALS patients. The only pharmacological strategy that provided a modest increase in 
survival followed was that with riluzole [Bensimon, 1994; Lacomblez, 1996; Miller, 2003]. The 
mechanism of action of riluzole is complex, since the drug is able to alter glutamatergic 
transmission both pre- and postsynaptically, to inhibit the activity of protein kinase C and to 
interact with a variety of ion channels [Doble, 1996; Huang, 1997; Martin, 1993; Noh, 2000; Xu, 
2001; Zona, 19981. Riluzole inhibits responses mediated by NMDA and AMPAr, by an indirect 
mechanism not fully clarified [Couratier, 1994; Doble, 1996; Kretschmer, 1998]. Experimental 
evidence suggests that riluzole also inhibits presynaptic glutamate release [Doble, 1992; Martin, 
1993] and it has been shown that the mechanism is dependent on the reduction of Ca -influx 
mediated by P/Q-type calcium channels, probably through a G-protein signalling pathway 
[Wang, 2004]. 
Riluzole was previously tested in SOD1G93A and SOD1G37R transgenic mice, and has also 
shown neuroprotective properties in these animal models of ALS, both alone and in association 
with other drugs [Gurney, 1996; Gurney, 1998; Kriz, 2003; Snow, 2003]. 
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12.2.2 Experimental design 
To investigate if the efficacy of riluzole is linked to its anti-glutamatergic activity or if different 
mechanisms could be involved, a chronic treatment with riluzole wobbler mice was performed 
and compared with that of the selective competitive AMPAr antagonist, RPR119990. Since it 
was reported that BDNF was increased in motor neurons of wobbler mice [Tsuzaka, 2001] and 
that riluzole was able to enhance the production of neurotrophins [Mizuta, 2001; Katoh-Semba, 
2002], 1 have also investigated the effect of riluzole treatment on BDNF levels in wobbler mice. 
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12.2.3 Results 
12.2.3.1 Behavioural scores. 
Body weight 
As previously reported, in wobbler mice the mean body weight is lower compared to that of 
healthy littermates; this feature is characteristic of the animal model. No significant differences 
in the growth rate were noted during the treatment with riluzole or with RPR119990 between 
treated and untreated mice (Fig 12.4 A, B). 
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Figure 12.4 Body weight recording in wobbler mice treated with: riluzole (40 mg/kg/day in the 
drinking water) -panel A- and; RPR 1199900 (3 mg/Kg/day, i. p. ) -panel B, Each point 
represents the mean of 10 mice for each experimental group. 
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Paw abnormality and walking abnormality 
Vehicle-treated wobbler mice showed a rapid worsening of symptoms, as already described for 
this disease. Treatment with riluzole had a beneficial effect in improving the paw (Fig 12.5 A) 
and the walking abnormality scores (Fig 12.6 A); the statistical analysis showed that the overall 
treatment had a significant effect on improving the semi-quantitative scores for riluzole-treated 
wobbler mice (p< 0.005 wobbler riluzole vs. wobbler vehicle for the overall treatment for both 
semi-quantitative tests (two-way Anova)). On the contrary, RPR1 19990 treatment had no effect 
in improving the semi-quantitative scores, as the animals showed a rapid worsening in the first 
period of treatment and a progression of impairment that was not affected by treatment (Fig 
12.6 A, B). Values for paw and walking abnormality were not significantly different between 
RPR119990 and vehicle-treated wobbler mice. Healthy mice treated with riluzole or 
RPR119990 did not show paw or walking abnormalities when compared to vehicle-treated 
mice. 
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Figure 12.5 Paw abnormality tests performed in wobbler mice treated with: riluzole (40 
mg/kg/day in the drinking water) -panel A- and, RPR 1199900 (3 mg/Kg/day, i. p. ) -panel B- 
. 
Each point represents the mean ± SD of 10 mice for each experimental group. **p<0.05 
Vs. wobbler vehicle (two-way anova). 
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Figure 12.6 Walking abnormality tests performed in wobbler mice treated with: riluzole (40 
mg/kg/day in the drinking water) -panel A- and; RPR 1199900 (3 mg/Kg/day, i. p. ) -panel B- 
. 
Each point represents the mean ± SD of 10 mice for each experimental group. **p<0.05 
Vs. wobbler vehicle (two-way anova). 
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Grip strength and running time. 
For the confirmation of grip strength values, data were normalized by dividing the absolute 
values by body weight before comparisons were made No difference was seen by comparing by 
comparing normalized and raw data. Both the running time (Fig 12.7 A) and the grip strength 
scores (Fig 12.8 A) in wobbler mice were improved by riluzole treatment (p< 0.001 wobbler 
riluzole vs. wobbler vehicle for the overall treatment (two-way Anova)). The decline of grip 
strength and running time was less marked for riluzole-treated mice compared to vehicle- 
treated wobbler mice. This trend was particularly evident starting from the 3`d week of 
treatment, when in riluzole-treated wobbler mice a stabilization of symptoms was observed. 
The overall treatment effect was statistically significant for both the quantitative scores. On the 
contrary, in RPR119990-treated and vehicle-treated wobbler mice, the normalized grip strength 
declined in parallel during the treatment, without any significant difference between the two 
groups. In the same way, the running time trials did not showed significant differences between 
RPR119990 and vehicle-treated wobbler mice (Fig 12.8 A, B) by comparing normalized and 
raw data. 
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Figure 12.7 Running time measurements performed in wobbler mice treated with: riluzole (40 
mg/kg/day in the drinking water) -panel A- and; RPR 1199900 (3 mg/Kg/day, i. p. ) -panel 13- 
. 
Each point represents the mean ± SD of 10 mice for each experimental group. **p<0.05 
Vs. wobbler vehicle (two-way anova). 
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Figure 12.8 Grip strength measurements performed in wobbler mice treated with: riluzole (40 
mg/kg/day in the drinking water) -panel A- and; RPR 1199900 (3 mg/Kg/day, i. p. ) -panel 13- 
. 
Each point represents the mean ± SD of 10 mice for each experimental group. **p<0.05 
Vs. wobbler vehicle (two-way anova). 
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12.2.3.3 Neuropathological estimation 
Nissl motor neurons counting and biceps weight 
The number of cervical motor neurons in vehicle-treated wobbler mice was significantly 
decreased compared to control littermates (see table 12.5). However, the number of motor 
neurons in riluzole-treated wobbler mice was significantly higher compared to vehicle-treated 
wobbler mice (p<0.05); the number of motor neurons was respectively reduced by 57% and 
70%, compared to vehicle-treated control mice. 
CTR vehicle CTR riluzole Wr vehicle Wr riluzole 
Motor neurons % 100±3.2 102.3±3.3 30.3±3.1 43.7±2.4* 
Table 12.5 Nissl positive motor neurons in the cervical region, 50 sections for each animal 
were processed, of wobbler mice and healthy littermates after chronic treatment with riluzole or 
saline (vehicle). The values are expressed as percentage compared to their respective controls 
normalized to 100 and are reported as means ± S. D. *p<0.01 (from riluzole treated wobbler 
mice and vehicle treated wobbler mice) 
On the contrary, there were no differences between RPR119990-treated and vehicle-treated 
wobbler mice (see table 12.6). 
CTR vehicle CTR RPR119990 Wr vehicle Wr RPR119990 
Motor neurons % 10015.6 103.3±3.4 36.3±2.9 31.9±5.1 
Table 12.6 Nissl positive motor neurons in the cervical region, 50 sections for each animal 
were processed, of wobbler mice and healthy littermates after chronic treatment with 
RPR119990 or saline (vehicle). The values are expressed as percentage compared to their 
respective controls normalized to 100 and are reported as means ± S. D. 
Consistent with the reduced loss of cervical motor neurons after riluzole treatment, the degree 
of atrophy, measured by biceps weight, was significantly lower in riluzole-treated wobbler 
mice compared to vehicle-treated wobbler mice (see table 12.7). 
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CTR vehicle CTR riluzole Wr vehicle Wr riluzole 
Weight 
(milligrams) 
36.2±5.0 33.5±4.3 7.6±0.9 13.1±2.6** 
Table 12.7 Biceps weight of wobbler mice and healthy littermates after chronic treatment with 
riluzole or saline (vehicle). The values are reported as means ± S. D. **p<0.005 (from riluzole 
treated wobbler mice and vehicle treated wobbler mice) 
Contrary to riluzole, RPRI 19990 treatment did not modify the biceps weight in wobbler and 
healthy mice (see table 12.8). 
CTR vehicle CTR RPR119990 Wr vehicle Wr 
RPR119990 
Weight 28,9±7.2 32.8±6.7 8.0±1.2 7.3±0.7 
(milligrams) 
Table 12.8 Biceps weight of wobbler mice and healthy littermates after chronic treatment with 
RPR119990 or saline (vehicle). The values are reported as means ± S. D. 
ChAT activity 
ChAT activity in the cervical spinal cord of wobbler mice was reduced by about 35% compared 
to control mice. However, in wobbler mice riluzole treatment significantly increased ChAT 
activity by about 70% compared to vehicle-treated wobbler mice (p<0.001). 
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12.2.3.3 BDNF immunostaining 
BDNF immunoreactivity in wobbler mice (Fig 12.9 B) was higher than in control mice (Fig 
12.9 A); riluzole treatment further increased BNDF immunostaining in motor neurons of the 
ventral horn in wobbler mice (Fig 12.9 D), as it did in healthy controls (Fig 12.9 Q. 
309 
Chapter 12 Pharmacological treatments 
A 
C. 
00 
Iwo 
r ýyE 5. R 
eý 
- 
-4 
A 
. 
1-T.: 
iýýiyz-, 
ý 
., ý 
WR 
.ý 
." 
t1 
^, re 
wr"t; _ " 4"rß, r' 
'xa 
wý, 
r"` P 
j, 
r. t, 
ý "s ^ý Iflr 
"ý' 
r_ 
Figure 12.9 Representative microphotographs showing the pattern of BDNF immunostaining 
(distribution, localization and intensity of signal) in the cervical spinal cord of healthy mice 
treated with vehicle (A), healthy mice treated with riluzole (B), wobbler mice treated with 
vehicle(C), wobbler mice treated with riluzole (D). It is easily detectable as riluzole treatment 
increased the BDNF immunoreactivity both in healthy and in diseased mice. Moreover, it is 
also interesting to note that only wobbler mice (both groups) showed an intense 
immunopositivity in the most anterior part of the white matter, likely corresponding to efferent 
fibers (axons). Scale bar, 200 µm. 
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Statistical analysis of the densitometric values confirmed that BDNF immunodensity in 
riluzole-treated wobbler mice was significantly higher than in vehicle-treated wobbler mice 
(see table 12.9). 
CTR vehicle CTR riluzole Wr vehicle Wr riluzole 
BDNF immunodensity 
RODxPIXELS 
100±11.3 129.0±8.2* 100±3.9 118.9±3.1* 
Table 12.9 Percentage of BDNF immunodensity in motor neurons of wobbler mice and healthy 
littermates treated with riluzole compared to saline treated (vehicle) mice. The values are 
expressed as percentage compared to their respective controls normalized to 100 and are 
reported as means ± S. D. *p<0.05 
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12.2.4 Discussion 
The most relevant information emerging from this study is that chronic treatment with riluzole, 
started from the 4`h week of age, is effective in improving the motor impairment in wobbler 
mice. All behavioural scores used to describe the clinical worsening of the disease; paw and 
walking abnormality, running time and grip strength are significantly improved by treatment 
with riluzole. Ex vivo analyses showed that riluzole significantly decreases the loss of motor 
neurons that occurs in the cervical spinal cord of wobbler mice. Moreover riluzole partially 
reduced the muscular atrophy in the forelegs, which is a typical feature of the wobbler disease: 
weight of biceps muscles was significantly higher in riluzole-treated compared to vehicle- 
treated wobbler mice. 
Riluzole has previously been tested in transgenic SOD 1093A and SOD1037R mice. In these 
animal models of ALS, chronic treatment with riluzole, started before the onset of evident 
symptoms, was also effective in preserving the motor function [Gurney, 1996]; moreover, 
treatment with riluzole alone or in combination with other drugs delayed the onset of 
symptoms, with different effects on animal survival [Gurney, 1998; Kriz, 2003; Snow, 2003]. 
Although the mechanism of action was not investigated, the efficacy of riluzole in transgenic 
SOD 1093A mice seems to be due to its anti-glutamatergic activity. In fact it was reported that 
SODIG93A mice show a significant impairment in the glutamate uptake activity, linked to 
selective loss or inactivation of the main glutamate transporter GLT1 [Bendotti, 2001; Bruijn, 
1997; Dunlop, 2003]. In particular, the glutamate uptake in synaptosomes prepared from spinal 
cord of transgenic SOD1G93A rats was significantly enhanced after riluzole treatment, compared 
to untreated animals. 
It has been previously shown that in wobbler mice there are no changes in the levels of the 
glutamate transporters GLTI and GLAST in the cervical spinal cord, nor in uptake and in 
plasma levels of glutamate [Bigini, 2001]. These data suggest that removal of the released 
glutamate through glutamate transporters occurs normally in the wobbler mice; thus ' it is 
unlikely that the effects of riluzole observed here are related to its interaction with the processes 
involved in glutamate removal. 
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Together with a mechanism linked to the interaction with glutamate transporters, which might 
reduce excitotoxicity by lowering the extracellular glutamate concentration, riluzole might also 
interact indirectly with postsynaptic receptors that are known to trigger neurodegeneration 
following overstimulation. 
Treatments with several AMPAr antagonists clearly demonstrated the involvement of 
glutamate receptor-mediated excitotoxicity in animal models of neurodegeneration. It has been 
previously reported as the treatment with NBQX significantly improved muscle strength 
performances and delayed the onset of clinical symptoms in the mnd mouse, an animal model 
characterized by progressive motor neuron dysfunction and functional impairment [Mennini, 
1999]. Significant delay in mortality was observed in transgenic SODIG93A transgenic mice 
after NBQX treatment [Van Damme, 2003]. The non-competitive AMPAr antagonist 
ZK187638 significantly decreased the symptoms of neuromuscular deficit and improved the 
motor behavioural impairment in both SOD1G93A and mnd mice, and extended the survival of 
SODIG93A transgenic mice [Bendotti, 2002]. In SODIG93A, the competitive AMPA antagonist 
RPR119990 was found to significantly improve muscle strength and to prolong survival of 
treated mice; it was also reported that the marked decrease of glutamate uptake observed in 
synaptosomes prepared from spinal cord of untreated SOD1G93A transgenic mice was 
significantly prevented by treatment with RPR119990 [Canton, 2001]. Taken together, these 
data confirm the neuroprotective role for AMPA antagonist drugs in these animal models of 
neurodegeneration. 
Little evidence is available about the involvement of glutamate receptors-mediated injury in 
motor neuronal loss in wobbler mice. It is unlikely that neurodegeneration of motor neurons is 
linked to NMDA receptor activation, since treatment of wobbler mice with the non-competitive 
NMDA receptor antagonist MK801 was completely ineffective in delaying the progression of 
the disease [Krieger, 1992]. 
My results clearly indicate that treatment of wobbler mice with the competitive AMPA 
antagonist RPRI 1990 has no effect on the onset and the progression of the disease. Both semi- 
quantitative and quantitative behavioural trials show no difference between treated and 
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untreated wobbler mice. Moreover, the motor neuronal loss is not reduced by treatment with 
RPR119990. In the same way, the muscular atrophy of the forelegs is not reduced by the 
treatment, since no differences are seen in the weight of biceps muscles between treated and 
untreated wobbler mice. It is possible to conclude that RPR119990 is unable to improve the 
progression of symptoms in wobbler disease. These data, together with our previous findings, 
strongly support the conclusion that there is no involvement of glutamate receptor-mediated 
excitotoxicity in the motor neuronal death observed in the wobbler mouse and that the 
glutamatergic transmission is probably not altered in this animal model of neurodegeneration. 
Thus the wobbler mouse can be considered to be a useful animal model of neurodegeneration to 
investigate other. processes leading to motor neuronal death in the absence of glutamate- 
mediated excitotoxicity. 
These conclusions also imply that riluzole, which is effective in improving the motor 
impairment and in partially preventing motor neuronal loss in the wobbler disease, probably 
acts via a different mechanism that does not involve glutamatergic transmission. In some 
experimental models it was demonstrated that riluzole increases the expression of neurotrophic 
factors. Cultured mouse brain astrocytes showed enhanced levels of BDNF, GDNF and NGF 
after treatment with riluzole [Mizuta, 2001]; moreover it was reported that repeated injections 
with riluzole in rats produced persistent increases of BDNF levels in hippocampus, enthorinal 
cortex and hypothalamus [Katoh-Semba, 20021. These evidence indicate that riluzole could 
exert a neuroprotective action by increasing the production of neurotrophic factor, since it has 
been shown that neurotrophins, in particular BDNF, prevent cell death in several experimental 
models, including the wobbler mouse [Henderson, 1993; Mitsumoto, 1999; Yan, 1992; Peluffo, 
1997]. Ikeda et al. reported that treatment with BDNF significantly slowed the neuronal 
degeneration and the impairment of the motor function in wobbler mice [Ikeda, 1995]. It was 
also shown that BDNF expression was significantly increased in the ventral spinal cord of 
wobbler mice, both at early and advanced stages of the disease [Tsuzaka, 2001]. Probably, the 
increased expression of BDNF can be considered as a compensatory mechanism activated to 
counteract cell processes that are involved in the motor neurons neurodegeneration. 
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This study confirmed a significant increase in the BDNF immunoreactivity in motor neurons of 
wobbler mice; moreover, it has been shown that riluzole treatment produced a further increase 
in BDNF levels in degenerating cells, associated with a significant decrease in the number of 
motor neurons lost in treated wobbler mice. The mechanism underlying this up-regulation of 
BDNF is not fully clear; recently it was suggested that the blockade of sodium channels 
mediated by riluzole can stimulate BDNF synthesis, due to low levels of ecto-adenosine 
[Katoh-Semba, 2002]. 
The protective role of riluzole is further confirmed by ChAT activity measurement. In the 
cervical spinal cord of riluzole-treated wobbler mice I observed a significant increase in the 
ChAT activity compared to vehicle-treated wobbler mice. This result not only . supports the 
evidence that in riluzole-treated mice a higher number of motor neurons are spared but also 
indicates that the cholinergic activity is preserved compared to vehicle-treated wobbler mice. 
In conclusion, this study clearly shown that riluzole has a neuroprotective effect on motor 
neuron degeneration in wobbler mice, by improving motor behaviour of treated mice and 
partially reducing the muscular atrophy in the forelegs. This neuroprotective effect seems to be 
mediated by a mechanism of action not involving anti-glutamatergic activity suggested for 
riluzole in ALS patients and in other animal models of neurodegeneration, but that is likely to 
be linked to the increase in the synthesis of the neurotrophic factor BDNF. 
Whether this effect of riluzole also contributes to its protective effect in ALS patients clearly 
deserves further investigation. 
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CHAPTER 13 
APOPTOSIS AND MOTOR NEURON DISEASE: A LESSON FROM 
CELLULAR AND ANIMAL MODELS OF ALS 
The aim of my thesis was to evaluate possible apoptotic processes induced by 
aetiopathological factors that are relevant to ALS, such as neurotrophic factors 
starvation, glutamate-induced excitotoxicity and glial-induced neuroinflammation, and to 
confirm the presence of these mechanisms in an animal model of ALS, the wobbler 
mouse. 
Some of the aetiopathological factors that are associated with ALS and are able to trigger 
apoptosis include (see Chapters 1 and 2): I) deficit of trophic factors which maintain the 
neuronal integrity by inhibiting the induction of the mitochondria-dependent apoptotic 
pathway, passing through cytochrome-c release, apoptosome formation and induction of 
caspases cascade cell signalling leading to DNA fragmentation [Swerdlow, 1998; 
Swerdlow, 2000; Borthwick, 1999; Green, 1998; Luo, 1998; Wadia, 1998; Mignotte, 
1998; Gorman, 2000; Guegan, 2001; Mitsumoto, 1994; Mitsumoto, 1999]; 
II) glutamate-induced excitotoxicity, that generates a modest but prolonged 
overstimulation of postsynaptic glutamate receptors, lower motor neurons in this case, 
accompanied by an increased Ca influx [Shaw, 1997; Rothstein, 1994; Nicotera 
1997; Ankarcrona, 1995; Mitchell, 1994; Hassinger 1995; Steinonen, 1999; Rothstein, 
1990; Petralia 1997] ; III) mechanisms of neuroinflammation with an overproduction of 
proinflammatory cytokines, in particular TNF-a, that are expressed by activated 
microglial cells. These, once released, can interact with death receptors (or TNF-family 
receptors) that are expressed on the motor neuron surface and can trigger an apoptotic 
pathway involving an even larger number of adapter molecules, leading to procaspase 8 
cleavage and caspase 3 activation [Raivich, 1999; Turner, 2004; Streit, 1989; Duchen, 
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1968; Cheng, 2002; De Simone, 2003]. Data suggesting a possible involvement of these 
factors in the wobbler mouse motor neurons death and in other animal models of ALS 
were summarized in Chapters 3 and 5 [Streit, 1988; Zona, 1998; Riviere, 1998; Mennini, 
2002; Vance, 1997; Bertamini, 2002; Wong, 1995; Howland, 2002; Tsuzaka, 2001; Xu, 
2001; Dave, 2003; Hantaz-Hambroise, 1994; Gonzalez Deniselle, 1999; Laage, 
1988; Bigini, 2001; Mitsumoto, 1994; Mennini, 1999; Krieger, 1992; Pasinelli, 2004; 
Mitsumoto, 1994; Hensley, 2002; Tomiyama, 1994; Bendotti, 2001]. 
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13.1 Neurotrophic factors starvation and apoptosis 
As far as the role of neurotrophic factors, and their involvement in the wobbler mouse 
motor neuron disease, are concerned, it has been shown that, although a significant 
increase of BDNF levels occurs in the affected region of the wobbler spinal cord, 
treatments with BDNF, and others neurotrophins, protect motor neurons and delay the 
progression of symptoms [Mitsumoto, 1994]. The increased expression of basal BDNF 
might thus be considered as a compensatory effect, and exogenous neurotrophins could 
play a relevant role in the survival of cervical motor neurons in treated mice [Tsuzaka, 
2001 ]. Unfortunately, treatments of ALS patients with neurotrophins are ineffective, 
possibly because in contrast to animal models they are initiated when a clear pathology is 
already present [ALS CNTF GROUP, 1999]. 
While apoptosis is easily detectable in in vitro condition, in vivo the cells undergoing 
apoptosis are rapidly removed and the time window to observe apoptotic markers is very 
narrow. In addition, it is difficult to study the role of apoptosis in chronic diseases, 
because the mechanism of cell death is in operation over several weeks. For this reason, 
this process was studied in the time window in which the greatest percentage of motor 
neurons are dying, (i. e. in wobbler mice from the 4th to the 5th week of life). 
Before characterizing these mechanisms in the wobbler mouse, however, the action of 
BDNF withdrawal at the single cell level was evaluated in a cellular model, the primary 
cultures of rat embryo motor neurons. As expected [Henderson, 1993], toxic effects were 
observed following a chronic (48 hours) deprivation of serum+BDNF in these primary 
cultures. Furthermore, by comparing the toxicity produced by BDNF deprivation in 
mixed glia/neurons and in purified cultures a significant higher resistance to trophic 
factors withdrawal (60% _vs. 
40% of viability) in mixed cultures was detected. This can 
be due to the fact that the astrocytes can supply trophic factors, as GDNF, which can 
partially counteract the detrimental effects caused by the lack of BDNF [Mitsumoto, 
1999]. 
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The cell death induced by BDNF deprivation in purified cultures was associated with a 
higher percentage of fragmented nuclei and a marked activation of the activated form of 
caspase 3. In addition, EPO treatment significantly increased cell viability in BDNF- 
deprived motor neurons and, at the same time, markedly decreased the percentage of 
cells with nuclear fragmentation and the number of active caspase 3 positive cells. 
BDNF is known to produce its anti-apoptotic effect by inhibiting the activation and the 
translocation from the cytosol to the mitochondrion, of different pro-apoptotic agents, 
such as BID, BAK, BAX, that mainly act by opening PTP [Yuan, 1995; Whitfield, 
2001; Sanchez, 2001; Sartorius, 2001]. The PTP opening induces mitochondrial 
depolarization and thus produces decay in mitochondrial efficiency [Tatton, 1999]. A 
reduced mitochondrial activity has been described, but these measurements had been 
obtained in brain regions that are not strictly associated to the affected areas of the 
wobbler motor neuron disease, such as the cerebral cortex and the whole spinal cord [Xu, 
2001]. In addition, only few and controversial data are available on the activity of the 
ETC enzymatic complexes [Dave, 2003], which have been documented to be particularly 
vulnerable to mitochondrial depolarization [Chauvin, 2001; Fontaine, 1999; Higuchi, 
1998]. 1 was able to show that both oxygen consumption and enzymatic activities were 
significantly lower in the cervical region of early symptomatic wobbler mice. On the 
other hand, no difference was found by comparing the same parameters of mitochondrial 
activity in the lumbar tract of wobbler mice and healthy littermates. 
A detailed morphological characterization may be more reliable to elucidate the degree 
of mitochondrial alteration occurring in cervical motor neurons of wobbler mice. In a 
recent ultrastructural study [Gonzalez Deniselle, 2004] a massive vacuolization of 
mitochondria with the rupture of inner/outer mitochondrial membranes and the 
disruption of cristae has been reported in 10 week-old wobbler mice. However, as clearly 
demonstrated in a series of study in SOD1G93A mice, morphological abnormalities in 
mitochondria occur earlier than symptoms onset [Bendotti, 2001], and a morphological 
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analysis at a time when 70% of the cells have already died and the remaining ones are 
highly vacuolized and altered, is somewhat questionable. 
The first steps in mitochondrion-dependent apoptosis are the release of cytochrome-c 
into the cytosol and the apoptosome formation. In the lumbar motor neurons of early 
symptomatic SOD 1093A mice a homogeneously diffused staining for cytochrome-c and a 
clear activation of caspase 9 has been reported. The presence of immunopositivity for 
both markers may indicate a clear link between cytochrome-c release and caspase 9 
activation in this process of motor neuron degeneration. Cytochrome-c immunostaining, 
however, cannot be taken as strong evidence of an active release of cytochrome-c from 
intact mitochondria if it is not supported by an ultrastructural investigation of 
immunogold staining (cyotochrome-c antibody) or double staining co localization with a 
marker that detects mitochondria integrity, as reported in my in vitro experiment with 
Mito Tracker (Chapter 10). For this reason, the caspases cascade cell signalling was 
directly evaluated by performing immunohystochemical experiments with antibodies 
against the activated form of caspases 3, -7 and -9, and a hystochemical assay (ISEL) 
was used to determine nuclear fragmentation. To decrease any bias due to the low 
probability of finding apoptotic motor neurons, a large number of cells were evaluated 
(about 1500 motor neurons for each animal in healthy tissues and 1150 in affected 
regions) and at least 5 animals for each antibody were used. An extremely small number 
(<0.1%) of motor neurons were positively stained for the three caspases and no ISEL 
positive nuclei was detected. In addition, no differences were seen by comparing the 
percentage of active caspases 3, -7 and -9 in the cervical motor neurons of wobbler mice 
and healthy littermates. It is difficult to explain why a similar number of active caspases 
positive motor neurons in both experimental groups were observed, and a significant 
decrease was observed in older healthy mice when comparing the percentage of active 
caspases-positive motor neurons at 4 and 12 weeks of age (data not shown). It might be 
that the few caspases-positive motor neurons observed at the 5`h week of life are 
undergoing a physiological apoptosis, possibly as the latest effect of the developmental 
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reduction of neuron number, rather than a pathological process associated to the disease. 
However, although the sensitivity and the specificity of antibodies was already tested 
both on primary cultures and in other in vitro models of apoptosis, it is not possible to 
exclude a false negative result, particularly as we are dealing with a process of chronic 
neurodegeneration. - 
To further exclude the possibility that motor neurons death in wobbler mice occurs by 
apoptosis , the effects of a chronic treatment with EPO, an anti-apoptotic agent that I 
have previously shown to inhibit mitochondrion dependent apoptosis by blocking 
cytochrome-c release and mitochondrial PTP opening (see section 10.4), was studied in 
early symptomatic wobbler mice. EPO treatment failed to delay the progression of the 
symptoms and did not reduce the rate of motor neurons loss and the biceps atrophy. This 
finding further support the notion that in the wobbler mouse motor neuron disease the 
mitochondrion-dependent apoptotic pathway is not involved in the process of motor 
neuron death. 
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13.2 Glutamate-induced excitotoxicity and apoptosis 
Another aetiological mechanism that has been suggested to play a relevant role in motor 
neurons death in ALS patients is glutamate-induced excitotoxicity [Shaw, 1997; Kato, 
2000; Hentati, 1994; Hadano, 2001; Kanekura, 2004; Choi, 1987; Rothstein, 
1993; Rothstein, 1994]. In the last decade, many experimental results obtained from 
autoptic samples have shown a reduced level and a decreased efficiency of glutamate 
transporters (that could decrease glutamate clearance in the synaptic cleft) [Rothstein, 
1994; Rothstein, 1995], a post translational mutation of G1uR2 AMPAr subunit (that 
would render the AMPA receptors more permeable to Cam) [Takuma, 1999; Pellegrini- 
Giampietro, 1997; Laslo, 2001] and increased levels of excitatory aminoacids in the 
plasma and liquor of ALS patients [Haenggeli, 2002]. These findings support the 
hypothesis that alterations in the glutamatergic system might be the primary source of 
motor neuron damage in ALS patients. In addition, similar changes in the glutamate 
system have been reported in different animal models of motor neuron degeneration 
[Casciola-Rosen, 1994; Mennini, 1999]. 
In contrast to acute processes of excitotoxicity, such as ischemia/riperfusion, in which a 
rapid and strong glutamatergic overstimulation is often associated to a massive Ca{`' 
influx [Howland, 2002; Gredal, 1997], in a chronic process of neurodegeneration, such as 
ALS, glutamatergic overstimulation is associated with a mild but prolonged 
glutamatergic overstimulation [Pellegrini-Giampietro, 1992]. Indeed, in cerebellar 
granule cells cultures exposed to glutamate, the mechanisms of cell death depends on the 
intensity of stimulation, with high doses of glutamate inducing a fast process of necrotic 
death, and a lower but more prolonged application of this neurotransmitter producing a 
slower death with the typical features of apoptosis [Nicotera, 1997]. Since the latter 
mechanism of death seems to be more correlated to the process that could occur in ALS, 
the effects of chronic AMPAr stimulation in primary cultures of motor neurons was 
studied using AMPA and kainite, as they are known to induce two different mechanisms 
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of death. While AMPA treatment induced a rapid decay of motor neurons survival and a 
plateau phase in the second part of the treatment and did not show apoptotic features, 
kainate produced a clear apoptotic pattern, with a slower kinetic of death and a marked 
increase of nuclear fragmentation and caspases 3 and -9 activation. 
Whether such mechanism of death involved the mitochondrion-dependent cell death was 
further evaluated by measuring the release of cytochrome-c, the mitochondrial 
depolarization, and the protective effect of a pharmacological agent that inhibits the PTP 
opening, cyclosporin A2. The results of the chronic treatment with kainate confirm the 
hypothesis that mitochondrion plays a key role in this mechanism of apoptosis. 
Moreover, the different mechanism of death produced by AMPA and kainate exposure 
on primary cultures of motor neurons allowed evaluating if EPO treatment is selective 
active against apoptosis or showed a broader spectrum of action. EPO was found to 
selectively rescue motor- neurons exposed to kainate and was ineffective on AMPA- 
treated motor neurons. This evidence further confirms the anti-apoptotic effects exerted 
by EPO, and is also supported by the ability of EPO to inhibit caspases 3/9 activation, 
cytochrome-c release and mitochondrial depolarization in motor neurons chronically 
exposed to kainate. 
The lack of any difference in the EAA plasma levels, the expression and activity of 
glutamate transporters, and the expression and the localization of AMPAr subunits (GluR 
1-4) between early symptomatic wobbler mice and healthy littermates does not 
completely rule out an involvement of glutamate overstimulation in the wobbler mouse 
motor neurons disease, since an increased Ca' permeability, due to modifications of 
G1uR2 subunit, was not investigated in this work. In order to clarify the role of AMPAr 
in motor neuron death occurring in wobbler mice a chronic treatment with a selective 
AMPA antagonist (RPR 119990) was performed. However, no beneficial effect in the 
motor performance, as well as in the survival rate and atrophy of motor neurons, was 
seen in early symptomatic wobbler mice after 9 weeks of treatment with RPR 119990, a 
compound that has been shown to be active in SOD1G93A mice. All together, therefore, 
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these behavioural, biochemical and hystochemical findings suggest that glutamate- 
induced excitotoxicity is not involved in the pathogenesis occurring in cervical motor 
neurons of wobbler mice. 
Together with an altered glutamate metabolism in CNS samples obtained from ALS 
patients, the link between ALS and excitotoxicity is supported by the evidence that 
riluzole, a non selective anti-excitotoxic compound, slightly but significantly reduces 
the clinical progression in ALS patients, such that clinical trials which do not include 
riluzole treatment in the "placebo group" are considered unethical and deleterious. 
Indeed, in contrast to the lack of action of RPR119990, riluzole significantly reduced 
motor impairment, with a stabilization of symptoms in the second half of the. treatment, 
and a marked decrease of motor neurons loss and biceps atrophy in wobbler mice. This 
finding opens a new perspective about the mechanism of riluzole protection in motor 
neuron disease, like scavenger effects, increase in trophic factors and/or stimulation of 
neurogenesis. In view of these results, therefore, the wobbler mouse should be 
considered as a useful tool to investigate the mechanism(s) of motor neuron death that 
are unrelated to excitotoxicity but sensitive to the reference drug riluzole. 
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13.3 Glial-induced neuroinflammation and apoptosis 
A marked increase of activated microglial cells, particularly close to degenerating areas, 
and a clear expression of TNF-a and its cognate receptor for the induction of apoptosis 
(TNFRI) were observed in the cervical region of early symptomatic wobbler mice. 
However, an extremely low number of active caspase 8 and -3 positive motor neurons 
were found in these tissues. These data suggest that TNF-a can contribute to motor 
neuron death by activating alternative mechanisms of damage. Regarding the 
involvement of TNF-a and TNFRI and in motor neuron disorders, it is important to note 
that an even larger expression of TNF-a and TNFR1 has been recently reported in the 
anterior horn, and that this expression parallels the symptoms- progression in the mnd 
mouse, a model of motor impairment in which motor neuron death is lacking [Mennini, 
2004, Ghezzi, 1998]. Further experiments to clarify the possible role of TNF-a and its 
receptors in wobbler mice motor neurons death should include treatments with agents 
able to block this detrimental pathway (such as anti-TNF-a monoclonal antibodies, 
soluble TNF-a receptor, TNFR1 receptor antagonist). These experiments alone, 
however, will not elucidate the possible link between microglial and TNF-a activation 
and extrinsic apoptotic pathway induction, because detrimental action of TNF-a might 
be dissociated to apoptosis. Thus, treatment with specific caspase 8 inhibitors would be 
required. 
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In summary, this study suggests that apoptosis is not involved in the process of death 
leading to the loss of about the 70% of motor neurons in the cervical spinal cord region 
of the wobbler mouse. Future studies, aimed at investigating alternative pathways of 
death, such as autophagic cell death, will be fundamental to answer this important 
question which is of great relevance for finding new therapeutic strategies for ALS 
patients. 
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